US4419340A
(en)
*
|
1969-03-24 |
1983-12-06 |
University Of Delaware |
Controlled release of anticancer agents from biodegradable polymers
|
US3993073A
(en)
*
|
1969-04-01 |
1976-11-23 |
Alza Corporation |
Novel drug delivery device
|
US3993071A
(en)
*
|
1971-09-09 |
1976-11-23 |
Alza Corporation |
Bioerodible ocular device
|
US3981303A
(en)
*
|
1971-09-09 |
1976-09-21 |
Alza Corporation |
Bioerodible ocular device
|
US3960150A
(en)
*
|
1971-09-09 |
1976-06-01 |
Alza Corporation |
Bioerodible ocular device
|
US3986510A
(en)
*
|
1971-09-09 |
1976-10-19 |
Alza Corporation |
Bioerodible ocular device
|
BE793246A
(fr)
*
|
1971-12-30 |
1973-06-22 |
Xerox Corp |
Procede d'encapsulation
|
US3962414A
(en)
*
|
1972-04-27 |
1976-06-08 |
Alza Corporation |
Structured bioerodible drug delivery device
|
US4351337A
(en)
*
|
1973-05-17 |
1982-09-28 |
Arthur D. Little, Inc. |
Biodegradable, implantable drug delivery device, and process for preparing and using the same
|
US3991766A
(en)
*
|
1973-05-31 |
1976-11-16 |
American Cyanamid Company |
Controlled release of medicaments using polymers from glycolic acid
|
US3914402A
(en)
*
|
1973-06-14 |
1975-10-21 |
Alza Corp |
Ophthalmic dosage form, for releasing medication over time
|
US4001388A
(en)
*
|
1973-06-14 |
1977-01-04 |
Alza Corporation |
Ophthalmological bioerodible drug dispensing formulation
|
US3976071A
(en)
*
|
1974-01-07 |
1976-08-24 |
Dynatech Corporation |
Methods of improving control of release rates and products useful in same
|
US4054138A
(en)
*
|
1974-12-30 |
1977-10-18 |
Louis Bucalo |
Implants for acting on living beings
|
US3982537A
(en)
*
|
1974-12-30 |
1976-09-28 |
Louis Bucalo |
Dynamic implants and method for implanting the same
|
US4076798A
(en)
*
|
1975-05-29 |
1978-02-28 |
American Cyanamid Company |
High molecular weight polyester resin, the method of making the same and the use thereof as a pharmaceutical composition
|
US4011312A
(en)
*
|
1975-06-25 |
1977-03-08 |
American Home Products Corporation |
Prolonged release drug form for the treatment of bovine mastitis
|
US4115544A
(en)
*
|
1976-08-18 |
1978-09-19 |
Alza Corporation |
Ocular system made of bioerodible esters having linear ether
|
HU174057B
(hu)
*
|
1976-09-17 |
1979-10-28 |
Richter Gedeon Vegyeszet |
Sostav dlja pokrytij obespechivajuhhij uregulirovannuju otdachy aktivnogo vehhestva biologicheski aktivnykh preparatov i sposob poluchenija takikh preparatov s uregulirovannoj otdachej aktivnogo vehhestva
|
US4328204A
(en)
*
|
1977-03-02 |
1982-05-04 |
Ethicon, Inc. |
Absorbable polymer-drug compounds and method for making same
|
WO1978000011A1
(en)
*
|
1977-06-07 |
1978-12-21 |
Garching Instrumente |
Form of implant medicament and preparation process
|
CH644768A5
(de)
*
|
1977-08-25 |
1984-08-31 |
Sandoz Ag |
Verfahren zur herstellung von mikrokugeln.
|
US4186189A
(en)
*
|
1977-09-28 |
1980-01-29 |
Ethicon, Inc. |
Absorbable pharmaceutical compositions based on poly(alkylene oxalates)
|
US4148871A
(en)
*
|
1977-10-11 |
1979-04-10 |
Pitt Colin G |
Sustained subdermal delivery ofdrugs using poly(ε-caprolactone) and its copolymers
|
DE2843963A1
(de)
*
|
1978-10-09 |
1980-04-24 |
Merck Patent Gmbh |
Im koerper resorbierbare geformte masse auf basis von kollagen und ihre verwendung in der medizin
|
US4159322A
(en)
*
|
1978-06-26 |
1979-06-26 |
A. H. Robins Company, Inc. |
Anticoccidium implants
|
GB2026862A
(en)
*
|
1978-08-04 |
1980-02-13 |
Robins Co Inc A H |
Filaricide implants containing diethylcarbamazine
|
US4272398A
(en)
*
|
1978-08-17 |
1981-06-09 |
The United States Of America As Represented By The Secretary Of Agriculture |
Microencapsulation process
|
US4585651A
(en)
*
|
1978-10-17 |
1986-04-29 |
Stolle Research & Development Corporation |
Active/passive immunization of the internal female reproductive organs
|
CA1143289A
(en)
*
|
1978-10-17 |
1983-03-22 |
Lee R. Beck |
Microparticle drug delivery system
|
US4732763A
(en)
*
|
1978-10-17 |
1988-03-22 |
Stolle Research And Development Corporation |
Active/passive immunization of the internal female reproductive organs
|
US4622244A
(en)
*
|
1979-09-04 |
1986-11-11 |
The Washington University |
Process for preparation of microcapsules
|
US4331652A
(en)
*
|
1979-09-12 |
1982-05-25 |
Eli Lilly And Company |
Controlled release parasitic formulations and method
|
AR221964A1
(es)
*
|
1979-09-12 |
1981-03-31 |
Lilly Co Eli |
Dispositivo para rumiantes
|
US4293539A
(en)
*
|
1979-09-12 |
1981-10-06 |
Eli Lilly And Company |
Controlled release formulations and method of treatment
|
US4333919A
(en)
*
|
1979-09-12 |
1982-06-08 |
Eli Lilly And Company |
Growth promotant controlled release formulations and method of treatment
|
US4273920A
(en)
*
|
1979-09-12 |
1981-06-16 |
Eli Lilly And Company |
Polymerization process and product
|
AU534665B2
(en)
*
|
1979-09-12 |
1984-02-09 |
Eli Lilly And Company |
Method
|
US4384975A
(en)
*
|
1980-06-13 |
1983-05-24 |
Sandoz, Inc. |
Process for preparation of microspheres
|
US4389330A
(en)
*
|
1980-10-06 |
1983-06-21 |
Stolle Research And Development Corporation |
Microencapsulation process
|
US4675189A
(en)
*
|
1980-11-18 |
1987-06-23 |
Syntex (U.S.A.) Inc. |
Microencapsulation of water soluble active polypeptides
|
PH19942A
(en)
*
|
1980-11-18 |
1986-08-14 |
Sintex Inc |
Microencapsulation of water soluble polypeptides
|
DE3045135A1
(de)
*
|
1980-11-29 |
1982-06-09 |
Sandoz-Patent-GmbH, 7850 Lörrach |
Pharmazeutische kompositionen enthaltende bioabbaubare polymere
|
GB2091554B
(en)
*
|
1981-01-13 |
1984-09-12 |
Mitsui Toatsu Chemicals |
Rod like moulded drug
|
US5366734A
(en)
*
|
1981-02-16 |
1994-11-22 |
Zeneca Limited |
Continuous release pharmaceutical compositions
|
IE52535B1
(en)
*
|
1981-02-16 |
1987-12-09 |
Ici Plc |
Continuous release pharmaceutical compositions
|
DE3360633D1
(en)
*
|
1982-02-12 |
1985-10-03 |
Unitika Ltd |
Anti-cancer device
|
US4532123A
(en)
*
|
1982-03-04 |
1985-07-30 |
Battelle Development Corporation |
Dual Microcapsules and process for their preparation
|
WO1983003061A1
(en)
*
|
1982-03-04 |
1983-09-15 |
Battelle Development Corp |
Dual microcapsules
|
US4637905A
(en)
*
|
1982-03-04 |
1987-01-20 |
Batelle Development Corporation |
Process of preparing microcapsules of lactides or lactide copolymers with glycolides and/or ε-caprolactones
|
DE3378250D1
(en)
*
|
1982-04-22 |
1988-11-24 |
Ici Plc |
Continuous release formulations
|
DE3218151A1
(de)
*
|
1982-05-14 |
1983-11-17 |
Akzo Gmbh, 5600 Wuppertal |
Mikroporoese, pulverfoermige polylactide und verfahren zu deren herstellung
|
DE3218150C2
(de)
*
|
1982-05-14 |
1986-09-25 |
Akzo Gmbh, 5600 Wuppertal |
Wirkstoff enthaltender Körper für die Langzeitabgabe sowie Verfahren zu dessen Herstellung
|
US5248700A
(en)
*
|
1982-05-14 |
1993-09-28 |
Akzo Nv |
Active agent containing solid structures for prolonged release of active agents
|
US4530840A
(en)
*
|
1982-07-29 |
1985-07-23 |
The Stolle Research And Development Corporation |
Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents
|
AT382076B
(de)
*
|
1982-10-15 |
1987-01-12 |
Chemie Linz Ag |
Verfahren zur herstellung von presslingen mit retardierter wirkstofffreisetzung
|
US4523591A
(en)
*
|
1982-10-22 |
1985-06-18 |
Kaplan Donald S |
Polymers for injection molding of absorbable surgical devices
|
US4550449A
(en)
*
|
1982-11-08 |
1985-11-05 |
Johnson & Johnson Products Inc. |
Absorbable bone fixation device
|
US4539981A
(en)
*
|
1982-11-08 |
1985-09-10 |
Johnson & Johnson Products, Inc. |
Absorbable bone fixation device
|
FR2537980B1
(fr)
*
|
1982-12-17 |
1986-12-19 |
Sandoz Sa |
Derives d'acides hydroxycarboxyliques oligomeres, leur preparation et leur utilisation
|
CA1196864A
(en)
*
|
1983-06-10 |
1985-11-19 |
Mattheus F.A. Goosen |
Controlled release of injectable and implantable insulin compositions
|
CH656884A5
(de)
*
|
1983-08-26 |
1986-07-31 |
Sandoz Ag |
Polyolester, deren herstellung und verwendung.
|
CH661206A5
(fr)
*
|
1983-09-23 |
1987-07-15 |
Debiopharm Sa |
Procede pour la preparation d'un medicament destine au traitement de maladies hormonodependantes.
|
JPS60100516A
(ja)
*
|
1983-11-04 |
1985-06-04 |
Takeda Chem Ind Ltd |
徐放型マイクロカプセルの製造法
|
US4530920A
(en)
|
1983-11-07 |
1985-07-23 |
Syntex (U.S.A.) Inc. |
Nonapeptide and decapeptide analogs of LHRH, useful as LHRH agonist
|
FR2557459B1
(fr)
*
|
1984-01-02 |
1986-05-30 |
Lhd Lab Hygiene Dietetique |
Matrice inerte a base de polycaprolactone pour administration orale d'un medicament, et procede de preparation de la forme galenique comprenant cette matrice
|
US4578384A
(en)
*
|
1984-02-15 |
1986-03-25 |
The United States Of America As Represented By The Secretary Of The Army |
Polylactic-polyglycolic acids combined with an acidic phospholipid-lysozyme complex for healing osseous tissue
|
DE3855510T2
(de)
*
|
1984-03-06 |
1997-02-06 |
United States Surgical Corp |
Ein Verfahren zur Herstellung von zwei-Phasen-Zusammensetzungen für absorbierbare chirurgische Ausrüstungen
|
USRE40786E1
(en)
|
1984-03-16 |
2009-06-23 |
The United States Of America As Represented By The Secretary Of The Army |
Vaccines against intracellular pathogens using antigens encapsulated within biodegradable-biocompatible microspheres
|
US6217911B1
(en)
|
1995-05-22 |
2001-04-17 |
The United States Of America As Represented By The Secretary Of The Army |
sustained release non-steroidal, anti-inflammatory and lidocaine PLGA microspheres
|
US6309669B1
(en)
|
1984-03-16 |
2001-10-30 |
The United States Of America As Represented By The Secretary Of The Army |
Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix
|
US4659693A
(en)
*
|
1984-04-30 |
1987-04-21 |
Syntex (U.S.A.) Inc. |
N,N'-dialkyl substituted guanidino amino acyl residue substituted GRF-analog peptides
|
GB8416234D0
(en)
*
|
1984-06-26 |
1984-08-01 |
Ici Plc |
Biodegradable amphipathic copolymers
|
DE3428640A1
(de)
*
|
1984-08-03 |
1986-02-06 |
Akzo Gmbh, 5600 Wuppertal |
Mikroporoese, pulverfoermige polylactide
|
US4880635B1
(en)
*
|
1984-08-08 |
1996-07-02 |
Liposome Company |
Dehydrated liposomes
|
US4666704A
(en)
*
|
1985-05-24 |
1987-05-19 |
International Minerals & Chemical Corp. |
Controlled release delivery system for macromolecules
|
GB8609537D0
(en)
*
|
1986-04-18 |
1986-05-21 |
Ici Plc |
Polyesters
|
ATE97929T1
(de)
*
|
1986-05-15 |
1993-12-15 |
Hoechst Ag |
Biologisch abbaubare polymere fuer depotzubereitungen mit kontrollierter wirkstoffabgabe.
|
US5160745A
(en)
*
|
1986-05-16 |
1992-11-03 |
The University Of Kentucky Research Foundation |
Biodegradable microspheres as a carrier for macromolecules
|
US4962091A
(en)
*
|
1986-05-23 |
1990-10-09 |
Syntex (U.S.A.) Inc. |
Controlled release of macromolecular polypeptides
|
US4744365A
(en)
*
|
1986-07-17 |
1988-05-17 |
United States Surgical Corporation |
Two-phase compositions for absorbable surgical devices
|
US4758435A
(en)
*
|
1986-08-11 |
1988-07-19 |
American Cyanamid Company |
Estradiol implant composition and method for preparation
|
US4981696A
(en)
*
|
1986-12-22 |
1991-01-01 |
E. I. Du Pont De Nemours And Company |
Polylactide compositions
|
DE3700128A1
(de)
*
|
1987-01-03 |
1988-07-14 |
Hoechst Ag |
Biologisch abbaubare poly- (hydroxyalkyl)- aminodicarbonsaeure-derivate, verfahren zu ihrer herstellung und verwendung derselben fuer depotzubereitungen mit kontrollierter wirkstoffabgabe
|
DE3701625A1
(de)
*
|
1987-01-21 |
1988-08-04 |
Boehringer Ingelheim Kg |
Perorale arzneimittelzubereitung mit verzoegerter wirkstofffreigabe
|
DE3710175A1
(de)
*
|
1987-02-12 |
1988-08-25 |
Hoechst Ag |
Mehrteilige implantierbare arzneizubereitung mit langzeitwirkung
|
AU606383B2
(en)
*
|
1987-03-06 |
1991-02-07 |
Research Triangle Institute |
Polymer blends for selective biodegradability
|
DE3712095A1
(de)
*
|
1987-04-10 |
1988-10-20 |
Lentia Gmbh |
Bindemittelfreies granulat mit verzoegerter wirkstoffabgabe
|
FR2618674B1
(fr)
*
|
1987-07-30 |
1990-06-15 |
Ire Celltarg Sa |
Microparticules comportant un polymere biodegradable controlant la liberation d'un principe actif antimalarique, compositions pharmaceutiques en comprenant et procede de preparation
|
US4897268A
(en)
*
|
1987-08-03 |
1990-01-30 |
Southern Research Institute |
Drug delivery system and method of making the same
|
US5212154A
(en)
*
|
1987-08-14 |
1993-05-18 |
Akzo N.V. |
Preparation for treating complications in diabetes
|
GB2209937B
(en)
*
|
1987-09-21 |
1991-07-03 |
Depiopharm S A |
Water insoluble polypeptides
|
AU2810189A
(en)
*
|
1987-10-30 |
1989-05-23 |
Stolle Research & Development Corporation |
Low residual solvent microspheres and microencapsulation process
|
DE3738228A1
(de)
*
|
1987-11-11 |
1989-05-24 |
Hoechst Ag |
Verfahren zur herstellung von bioabbaubaren mikrokapseln wasserloeslicher peptide und proteine sowie nach diesem verfahren erhaltene mikrokapseln
|
DE3744329A1
(de)
*
|
1987-12-28 |
1989-07-06 |
Schwarz Pharma Gmbh |
Verfahren zur herstellung einer mindestens einen wirkstoff und einen traeger umfassenden zubereitung
|
WO1989007451A1
(en)
|
1988-02-10 |
1989-08-24 |
Abbott Laboratories |
Reduced size lhrh analogs
|
US4902515A
(en)
*
|
1988-04-28 |
1990-02-20 |
E. I. Dupont De Nemours And Company |
Polylactide compositions
|
US5444113A
(en)
*
|
1988-08-08 |
1995-08-22 |
Ecopol, Llc |
End use applications of biodegradable polymers
|
US5180765A
(en)
*
|
1988-08-08 |
1993-01-19 |
Biopak Technology, Ltd. |
Biodegradable packaging thermoplastics from lactides
|
US5502158A
(en)
*
|
1988-08-08 |
1996-03-26 |
Ecopol, Llc |
Degradable polymer composition
|
US6323307B1
(en)
|
1988-08-08 |
2001-11-27 |
Cargill Dow Polymers, Llc |
Degradation control of environmentally degradable disposable materials
|
US5424346A
(en)
*
|
1988-08-08 |
1995-06-13 |
Ecopol, Llc |
Biodegradable replacement of crystal polystyrene
|
DE3826915A1
(de)
*
|
1988-08-09 |
1990-02-15 |
Henkel Kgaa |
Neue werkstoffe fuer den knochenersatz und knochen- bzw. prothesenverbund
|
US4990336A
(en)
*
|
1989-02-08 |
1991-02-05 |
Biosearch, Inc. |
Sustained release dosage form
|
US5116964A
(en)
|
1989-02-23 |
1992-05-26 |
Genentech, Inc. |
Hybrid immunoglobulins
|
US6797270B1
(en)
*
|
1989-03-16 |
2004-09-28 |
Center For Blood Research, Inc. |
Functional derivatives of the intercellular adhesion molecule ICAM-1 in anti-viral therapy
|
US5491131A
(en)
*
|
1989-04-14 |
1996-02-13 |
Applied Research Systems Ars Holding Nv |
Somatostatin-active polypeptide composition
|
HU221294B1
(en)
*
|
1989-07-07 |
2002-09-28 |
Novartis Ag |
Process for producing retarde compositions containing the active ingredient in a polymeric carrier
|
US5232707A
(en)
*
|
1989-07-10 |
1993-08-03 |
Syntex (U.S.A.) Inc. |
Solvent extraction process
|
US5268178A
(en)
*
|
1989-09-25 |
1993-12-07 |
The Board Of Regents, The University Of Texas System |
Biodegradable antibiotic implants and methods of their use in treating and preventing infections
|
EP0423484B1
(de)
*
|
1989-10-16 |
1993-11-03 |
PCD-Polymere Gesellschaft m.b.H. |
Pressling mit retardierter Wirkstofffreisetzung
|
FR2654337B1
(fr)
*
|
1989-11-15 |
1994-08-05 |
Roussel Uclaf |
Nouvelles microspheres injectables biodegradables procede de preparation et suspensions injectables les renfermant.
|
DE4002736A1
(de)
*
|
1990-01-31 |
1991-08-01 |
Hoechst Ag |
Biologisch abbaubare polymere, verfahren zu ihrer herstellung und verwendung derselben fuer depotzubereitungen mit kontrollierter wirkstoffabgabe
|
FR2663224B1
(fr)
*
|
1990-06-14 |
1995-01-20 |
Applicationes Farmaceuticas Sa |
Forme galenique parenterale.
|
FR2663223B1
(fr)
*
|
1990-06-14 |
1994-12-02 |
Af Aplicaciones Far Lab |
Forme galenique parenterale.
|
CA2046830C
(en)
*
|
1990-07-19 |
1999-12-14 |
Patrick P. Deluca |
Drug delivery system involving inter-action between protein or polypeptide and hydrophobic biodegradable polymer
|
US6353030B1
(en)
*
|
1990-08-01 |
2002-03-05 |
Novartis Ag |
Relating to organic compounds
|
US5149543A
(en)
*
|
1990-10-05 |
1992-09-22 |
Massachusetts Institute Of Technology |
Ionically cross-linked polymeric microcapsules
|
US5562099A
(en)
*
|
1990-10-05 |
1996-10-08 |
Massachusetts Institute Of Technology |
Polymeric microparticles containing agents for imaging
|
DE4041563A1
(de)
*
|
1990-12-22 |
1992-06-25 |
Sanol Arznei Schwarz Gmbh |
Verfahren zur herstellung wirkstoffhaltiger mikropartikel aus hydrolytisch abbaubaren polymeren
|
US6228954B1
(en)
|
1991-02-12 |
2001-05-08 |
United States Surgical Corporation |
Blends of glycolide and/or lactide polymers and caprolactone and/or trimethylene carbonate polymers and absorabable surgical devices made therefrom
|
US5320624A
(en)
*
|
1991-02-12 |
1994-06-14 |
United States Surgical Corporation |
Blends of glycolide and/or lactide polymers and caprolactone and/or trimethylene carbonate polymers and absorbable surgical devices made therefrom
|
US5153002A
(en)
*
|
1991-03-04 |
1992-10-06 |
University Of Montreal |
Biocompatible gradient controlled release implant
|
AU8303691A
(en)
|
1991-04-24 |
1992-12-21 |
United States Of America, As Represented By The Secretary Of The Army, The |
Oral-intestinal vaccines against diseases caused by enteropathogenic organisms using antigens encapsulated within biodegradable-biocompatible microspheres
|
EP0514790A2
(de)
*
|
1991-05-24 |
1992-11-25 |
Hoechst Aktiengesellschaft |
Polykondensate, die Weinsäurederivate enthalten, Verfahren zu ihrer Herstellung und Verwendung derselben
|
HU222501B1
(hu)
*
|
1991-06-28 |
2003-07-28 |
Endorecherche Inc. |
MPA-t vagy MGA-t tartalmazó nyújtott hatóanyag-felszabadulású gyógyászati készítmény és eljárás előállítására
|
ZA924811B
(en)
*
|
1991-06-28 |
1993-12-29 |
Endorecherche Inc |
Controlled release systems and low dose androgens
|
WO1993004732A1
(en)
|
1991-09-09 |
1993-03-18 |
The Government Of The United States Of America, As Represented By The Secretary Department Of Health And Human Services |
Methods and devices for treating hemophilia and aids
|
US6063910A
(en)
*
|
1991-11-14 |
2000-05-16 |
The Trustees Of Princeton University |
Preparation of protein microparticles by supercritical fluid precipitation
|
US6005067A
(en)
*
|
1992-01-24 |
1999-12-21 |
Cargill Incorporated |
Continuous process for manufacture of lactide polymers with controlled optical purity
|
US5247059A
(en)
*
|
1992-01-24 |
1993-09-21 |
Cargill, Incorporated |
Continuous process for the manufacture of a purified lactide from esters of lactic acid
|
US5247058A
(en)
*
|
1992-01-24 |
1993-09-21 |
Cargill, Incorporated |
Continuous process for manufacture of lactide polymers with controlled optical purity
|
US6326458B1
(en)
|
1992-01-24 |
2001-12-04 |
Cargill, Inc. |
Continuous process for the manufacture of lactide and lactide polymers
|
US5258488A
(en)
*
|
1992-01-24 |
1993-11-02 |
Cargill, Incorporated |
Continuous process for manufacture of lactide polymers with controlled optical purity
|
US5142023A
(en)
*
|
1992-01-24 |
1992-08-25 |
Cargill, Incorporated |
Continuous process for manufacture of lactide polymers with controlled optical purity
|
US6013853A
(en)
*
|
1992-02-14 |
2000-01-11 |
The University Of Texas System |
Continuous release polymeric implant carrier
|
US5876452A
(en)
*
|
1992-02-14 |
1999-03-02 |
Board Of Regents, University Of Texas System |
Biodegradable implant
|
FR2689400B1
(fr)
*
|
1992-04-03 |
1995-06-23 |
Inoteb |
Materiau pour prothese osseuse contenant des particules de carbonate de calcium dispersees dans une matrice polymere bioresorbable.
|
US5518730A
(en)
*
|
1992-06-03 |
1996-05-21 |
Fuisz Technologies Ltd. |
Biodegradable controlled release flash flow melt-spun delivery system
|
EP0586812B1
(en)
*
|
1992-07-13 |
2000-01-05 |
Nisshin Flour Milling Co., Ltd. |
Medicaments comprising glicentin as active ingredient
|
FR2693905B1
(fr)
*
|
1992-07-27 |
1994-09-02 |
Rhone Merieux |
Procédé de préparation de microsphères pour la libération prolongée de l'hormone LHRH et ses analogues, microsphères et formulations obtenues.
|
US5922340A
(en)
|
1992-09-10 |
1999-07-13 |
Children's Medical Center Corporation |
High load formulations and methods for providing prolonged local anesthesia
|
AU5296393A
(en)
*
|
1992-10-02 |
1994-04-26 |
Cargill Incorporated |
Paper having a melt-stable lactide polymer coating and process for manufacture thereof
|
US5338822A
(en)
*
|
1992-10-02 |
1994-08-16 |
Cargill, Incorporated |
Melt-stable lactide polymer composition and process for manufacture thereof
|
US6005068A
(en)
|
1992-10-02 |
1999-12-21 |
Cargill Incorporated |
Melt-stable amorphous lactide polymer film and process for manufacture thereof
|
AU5294893A
(en)
*
|
1992-10-02 |
1994-04-26 |
Cargill Incorporated |
A melt-stable lactide polymer fabric and process for manufacture thereof
|
EP0669128B1
(en)
*
|
1992-11-17 |
2000-01-05 |
Yoshitomi Pharmaceutical Industries, Ltd. |
Sustained-release microsphere containing antipsychotic and process for producing the same
|
TW333456B
(en)
*
|
1992-12-07 |
1998-06-11 |
Takeda Pharm Ind Co Ltd |
A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
|
US6387363B1
(en)
|
1992-12-31 |
2002-05-14 |
United States Surgical Corporation |
Biocompatible medical devices
|
US6221958B1
(en)
|
1993-01-06 |
2001-04-24 |
Societe De Conseils De Recherches Et D'applications Scientifiques, Sas |
Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
|
CA2114290C
(en)
*
|
1993-01-27 |
2006-01-10 |
Nagabushanam Totakura |
Post-surgical anti-adhesion device
|
US6124259A
(en)
*
|
1993-01-28 |
2000-09-26 |
Celtrix Pharmaceuticals, Inc. |
Method for treating ophthalmic disorders with IGFBP
|
US5340614A
(en)
*
|
1993-02-11 |
1994-08-23 |
Minnesota Mining And Manufacturing Company |
Methods of polymer impregnation
|
GB9310030D0
(en)
*
|
1993-05-15 |
1993-06-30 |
Scras |
Dry processed particles and process for the preparation of the same
|
US6939546B2
(en)
|
1993-05-21 |
2005-09-06 |
The United States Of America As Represented By The Secretary Of The Army |
Model for testing immunogenicity of peptides
|
US6440457B1
(en)
*
|
1993-05-27 |
2002-08-27 |
Alza Corporation |
Method of administering antidepressant dosage form
|
US6495343B1
(en)
|
1993-06-18 |
2002-12-17 |
The Salk Institute For Biological Studies |
Cloning and recombinant production of CRF receptor(s)
|
US6638905B2
(en)
*
|
1993-06-18 |
2003-10-28 |
The Salk Institute For Biological Studies |
Cloning and recombinant production of CFR receptor(s)
|
JPH08512056A
(ja)
*
|
1993-06-30 |
1996-12-17 |
ジェネンテク・インコーポレイテッド |
リポソームの製造法
|
JP3822232B2
(ja)
|
1993-08-30 |
2006-09-13 |
ベイラー・カレッジ・オブ・メディシン |
老化細胞由来dna合成阻害因子
|
US5500161A
(en)
*
|
1993-09-21 |
1996-03-19 |
Massachusetts Institute Of Technology And Virus Research Institute |
Method for making hydrophobic polymeric microparticles
|
US5339766A
(en)
|
1993-11-03 |
1994-08-23 |
Embrex, Inc. |
Method of introducing material into eggs during early embryonic development
|
EP0732933B1
(en)
*
|
1993-11-15 |
2002-10-09 |
Celtrix Pharmaceuticals, Inc. |
Use of igf-1 and igfbp-3 in the manufacture of a medicament for treating a renal disorder
|
DK0729357T3
(da)
*
|
1993-11-19 |
2005-06-06 |
Janssen Pharmaceutica Nv |
Mikroindkapslede 1,2-benzazoler
|
DE4406172C2
(de)
*
|
1994-02-25 |
2003-10-02 |
Sanol Arznei Schwarz Gmbh |
Polyester
|
DE4407898A1
(de)
*
|
1994-03-09 |
1995-09-14 |
Hoechst Ag |
Nanopartikel, enthaltend einen Wirkstoff und ein Polyketalweinsäureamid, Verfahren zu ihrer Herstellung und Verwendung derselben
|
US5877016A
(en)
|
1994-03-18 |
1999-03-02 |
Genentech, Inc. |
Human trk receptors and neurotrophic factor inhibitors
|
EP0754064B1
(en)
*
|
1994-04-08 |
2003-05-28 |
Atrix Laboratories, Inc. |
An adjunctive polymer system for use with medical device
|
US6855331B2
(en)
|
1994-05-16 |
2005-02-15 |
The United States Of America As Represented By The Secretary Of The Army |
Sustained release hydrophobic bioactive PLGA microspheres
|
US6447796B1
(en)
|
1994-05-16 |
2002-09-10 |
The United States Of America As Represented By The Secretary Of The Army |
Sustained release hydrophobic bioactive PLGA microspheres
|
US5708142A
(en)
|
1994-05-27 |
1998-01-13 |
Genentech, Inc. |
Tumor necrosis factor receptor-associated factors
|
DE4423131A1
(de)
*
|
1994-07-01 |
1996-01-04 |
Bayer Ag |
Neue hIL-4-Mutantenproteine als Antagonisten oder partielle Agonisten des humanen Interleukin 4
|
US5578662A
(en)
|
1994-07-22 |
1996-11-26 |
United States Surgical Corporation |
Bioabsorbable branched polymers containing units derived from dioxanone and medical/surgical devices manufactured therefrom
|
US6339130B1
(en)
*
|
1994-07-22 |
2002-01-15 |
United States Surgical Corporation |
Bioabsorbable branched polymers containing units derived from dioxanone and medical/surgical devices manufactured therefrom
|
US5595760A
(en)
*
|
1994-09-02 |
1997-01-21 |
Delab |
Sustained release of peptides from pharmaceutical compositions
|
AUPM897594A0
(en)
*
|
1994-10-25 |
1994-11-17 |
Daratech Pty Ltd |
Controlled release container
|
US6093697A
(en)
*
|
1994-11-07 |
2000-07-25 |
The University Of Virginia Patent Foundation |
Synthetic insulin mimetic substances
|
US5660817A
(en)
*
|
1994-11-09 |
1997-08-26 |
Gillette Canada, Inc. |
Desensitizing teeth with degradable particles
|
US7033608B1
(en)
|
1995-05-22 |
2006-04-25 |
The United States Of America As Represented By The Secretary Of The Army |
“Burst-free” sustained release poly-(lactide/glycolide) microspheres
|
US5674888A
(en)
*
|
1995-06-07 |
1997-10-07 |
University Of California |
Method for the treatment of a trabecular meshwork whose cells are subject to inhibition of cell division
|
US5641502A
(en)
*
|
1995-06-07 |
1997-06-24 |
United States Surgical Corporation |
Biodegradable moldable surgical material
|
US5599535A
(en)
*
|
1995-06-07 |
1997-02-04 |
Regents Of The University Of California |
Methods for the cyto-protection of the trabecular meshwork
|
MX9700850A
(es)
|
1995-06-09 |
1997-09-30 |
Euro Celtique Sa |
Formulaciones y metodos para proporcionar anestesia local prolongada.
|
US5955574A
(en)
|
1995-07-13 |
1999-09-21 |
Societe De Conseils De Recherches Et D'applications Scientifiques, S.A. |
Analogs of parathyroid hormone
|
US5925351A
(en)
*
|
1995-07-21 |
1999-07-20 |
Biogen, Inc. |
Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
|
US6020473A
(en)
*
|
1995-08-25 |
2000-02-01 |
Genentech, Inc. |
Nucleic acids encoding variants of vascular endothelial cell growth factor
|
US7005505B1
(en)
|
1995-08-25 |
2006-02-28 |
Genentech, Inc. |
Variants of vascular endothelial cell growth factor
|
DE19537415A1
(de)
*
|
1995-10-09 |
1997-04-10 |
New Standard Gmbh |
Micro Wirkstoff-Perlen
|
US5942253A
(en)
*
|
1995-10-12 |
1999-08-24 |
Immunex Corporation |
Prolonged release of GM-CSF
|
SE505146C2
(sv)
*
|
1995-10-19 |
1997-06-30 |
Biogram Ab |
Partiklar för fördröjd frisättning
|
US5968543A
(en)
*
|
1996-01-05 |
1999-10-19 |
Advanced Polymer Systems, Inc. |
Polymers with controlled physical state and bioerodibility
|
US7888466B2
(en)
|
1996-01-11 |
2011-02-15 |
Human Genome Sciences, Inc. |
Human G-protein chemokine receptor HSATU68
|
US5980945A
(en)
*
|
1996-01-16 |
1999-11-09 |
Societe De Conseils De Recherches Et D'applications Scientifique S.A. |
Sustained release drug formulations
|
US6004572A
(en)
*
|
1996-01-25 |
1999-12-21 |
Triangle Laboratories, Inc. |
Time release delivery system
|
IE960308A1
(en)
*
|
1996-04-23 |
1997-11-05 |
Kinerton Ltd |
Sustained release ionic conjugate
|
EP1479707A3
(en)
*
|
1996-04-23 |
2005-05-18 |
Ipsen Manufacturing Ireland Limited |
Biodegradable polyesters and method for their preparation
|
FR2748205A1
(fr)
|
1996-05-06 |
1997-11-07 |
Debio Rech Pharma Sa |
Compositions pharmaceutiques pour la liberation controlee de principes actifs insolubles
|
US6100071A
(en)
|
1996-05-07 |
2000-08-08 |
Genentech, Inc. |
Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
|
US5792477A
(en)
|
1996-05-07 |
1998-08-11 |
Alkermes Controlled Therapeutics, Inc. Ii |
Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent
|
US5766877A
(en)
*
|
1996-05-10 |
1998-06-16 |
Amgen Inc. |
Genes encoding art, an agouti-related transcript
|
AU733867B2
(en)
|
1996-06-24 |
2001-05-31 |
Euro-Celtique S.A. |
Methods for providing safe local anesthesia
|
US5756651A
(en)
*
|
1996-07-17 |
1998-05-26 |
Chronopol, Inc. |
Impact modified polylactide
|
US6159462A
(en)
*
|
1996-08-16 |
2000-12-12 |
Genentech, Inc. |
Uses of Wnt polypeptides
|
US5851984A
(en)
*
|
1996-08-16 |
1998-12-22 |
Genentech, Inc. |
Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides
|
US5985830A
(en)
*
|
1996-09-16 |
1999-11-16 |
Dalhousie University |
Use of IGF-I for the treatment of kidney disorders
|
US6046187A
(en)
*
|
1996-09-16 |
2000-04-04 |
Children's Medical Center Corporation |
Formulations and methods for providing prolonged local anesthesia
|
CN1539970A
(zh)
|
1996-10-25 |
2004-10-27 |
�Ϻ���ͨ��ѧ |
嗜中性白细胞因子α
|
ES2221019T3
(es)
|
1996-10-31 |
2004-12-16 |
Takeda Chemical Industries, Ltd. |
Preparacion de liberacion mantenida.
|
US6156728A
(en)
|
1996-11-01 |
2000-12-05 |
Genentech, Inc. |
Treatment of inner ear hair cells
|
US6593290B1
(en)
|
1996-11-01 |
2003-07-15 |
Genentech, Inc. |
Treatment of inner ear hair cells
|
US6919373B1
(en)
|
1996-11-12 |
2005-07-19 |
Alza Corporation |
Methods and devices for providing prolonged drug therapy
|
US7390891B1
(en)
|
1996-11-15 |
2008-06-24 |
Amgen Inc. |
Polynucleotides encoding a telomerase component TP2
|
US5919656A
(en)
*
|
1996-11-15 |
1999-07-06 |
Amgen Canada Inc. |
Genes encoding telomerase protein 1
|
US20020111603A1
(en)
*
|
1996-12-02 |
2002-08-15 |
Societe De Conseils De Recherches Et D'application |
Device for local administration of solid or semi-solid formulations and delayed-release formulations for proposal parental administration and preparation process
|
US7138511B1
(en)
|
1997-01-28 |
2006-11-21 |
The Regents Of The University Of California |
Nucleic acids, kits and methods for the diagnosis, prognosis and treatment of glaucoma and related disorders
|
US6171788B1
(en)
|
1997-01-28 |
2001-01-09 |
The Regents Of The University Of California |
Methods for the diagnosis, prognosis and treatment of glaucoma and related disorders
|
US6475724B1
(en)
*
|
1997-01-28 |
2002-11-05 |
The Regents Of The University Of California |
Nucleic acids, kits, and methods for the diagnosis, prognosis and treatment of glaucoma and related disorders
|
US6126919A
(en)
*
|
1997-02-07 |
2000-10-03 |
3M Innovative Properties Company |
Biocompatible compounds for pharmaceutical drug delivery systems
|
US5945126A
(en)
*
|
1997-02-13 |
1999-08-31 |
Oakwood Laboratories L.L.C. |
Continuous microsphere process
|
DE69829891T2
(de)
|
1997-04-07 |
2005-10-06 |
Genentech, Inc., South San Francisco |
Anti-VEGF Antikörper
|
ES2349559T3
(es)
|
1997-04-07 |
2011-01-05 |
Genentech, Inc. |
Anticuerpos anti-vegf.
|
AU737106B2
(en)
*
|
1997-04-18 |
2001-08-09 |
Biogen, Inc. |
Type II TGF-beta receptor/immunoglobulin constant region fusion proteins
|
DE69841994D1
(de)
|
1997-05-30 |
2010-12-23 |
Human Genome Sciences Inc |
32 Humane sekretierte Proteine
|
US6867181B1
(en)
|
1997-06-02 |
2005-03-15 |
Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. |
Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
|
US6663899B2
(en)
|
1997-06-13 |
2003-12-16 |
Genentech, Inc. |
Controlled release microencapsulated NGF formulation
|
FR2764514B1
(fr)
|
1997-06-13 |
1999-09-03 |
Biopharmex Holding Sa |
Implant injectable en sous-cutane ou intradermique a bioresorbabilite controlee pour la chirurgie reparatrice ou plastique et la dermatologie esthetique
|
US6113947A
(en)
*
|
1997-06-13 |
2000-09-05 |
Genentech, Inc. |
Controlled release microencapsulated NGF formulation
|
IL129951A0
(en)
*
|
1997-07-02 |
2000-02-29 |
Euro Celtique Sa |
Prolonged anesthesia in joints and body spaces
|
US6342220B1
(en)
|
1997-08-25 |
2002-01-29 |
Genentech, Inc. |
Agonist antibodies
|
US6635443B1
(en)
|
1997-09-17 |
2003-10-21 |
Human Genome Sciences, Inc. |
Polynucleotides encoding a novel interleukin receptor termed interleukin-17 receptor-like protein
|
JP2003533164A
(ja)
|
1997-10-29 |
2003-11-11 |
ジェネンテック・インコーポレーテッド |
Wnt−1誘導分泌ポリペプチド:WISP−1,−2及び−3
|
IL135607A0
(en)
|
1997-10-29 |
2001-05-20 |
Genentech Inc |
Wnt-1 inducible genes
|
ATE233097T1
(de)
|
1997-11-07 |
2003-03-15 |
Chiron Corp |
Verfahren zur herstellung von igf-i formulierungen mit verzögerter freisetzung
|
US7192589B2
(en)
|
1998-09-16 |
2007-03-20 |
Genentech, Inc. |
Treatment of inflammatory disorders with STIgMA immunoadhesins
|
CA2310892A1
(en)
*
|
1997-11-21 |
1999-06-03 |
Human Genome Sciences, Inc. |
Chemokine alpha-5
|
US8088386B2
(en)
|
1998-03-20 |
2012-01-03 |
Genentech, Inc. |
Treatment of complement-associated disorders
|
ES2288649T3
(es)
|
1997-11-21 |
2008-01-16 |
Genentech, Inc. |
Antigenos tipo a-33 y sus utilizaciones farmacologicas.
|
EP1947119A3
(en)
|
1997-12-12 |
2012-12-19 |
Genentech, Inc. |
Treatment of cancer with anti-erb2 antibodies in combination with a chemotherapeutic agent
|
KR100289471B1
(ko)
*
|
1998-01-19 |
2001-09-17 |
김충섭 |
휀타닐계마취제의이식형서방성제제
|
KR19990065921A
(ko)
*
|
1998-01-19 |
1999-08-16 |
김충섭 |
항생제의서방성제제
|
US5906979A
(en)
*
|
1998-01-27 |
1999-05-25 |
Insmed Pharmaceuticals, Inc. |
Compositions and methods for treating metabolic diseases characterized by hyperandrogenism and/or anovulation and/or infertility
|
EP2050762A3
(en)
|
1998-03-10 |
2009-07-08 |
Genentech, Inc. |
Human cornichon-like protein and nucleic acids encoding it
|
US20030180368A1
(en)
*
|
1998-03-14 |
2003-09-25 |
Cenes Drug Delivery Limited |
Production of microparticles
|
DK1064382T3
(da)
|
1998-03-17 |
2008-12-08 |
Genentech Inc |
Homologe polypeptider til VEGF og BMP1
|
EP1093457B8
(en)
|
1998-03-19 |
2011-02-02 |
Human Genome Sciences, Inc. |
Cytokine receptor common gamma chain like
|
EP1941905A1
(en)
|
1998-03-27 |
2008-07-09 |
Genentech, Inc. |
APO-2 Ligand-anti-her-2 antibody synergism
|
US7157083B2
(en)
*
|
1998-04-17 |
2007-01-02 |
Surrogate Pharmaceutical Pathways, Llc |
Compositions and methods for treating retroviral infections
|
ATE365800T1
(de)
|
1998-05-15 |
2007-07-15 |
Genentech Inc |
Therapeutische verwendungen von il-17 homologe polypeptide
|
EP3112468A1
(en)
|
1998-05-15 |
2017-01-04 |
Genentech, Inc. |
Il-17 homologous polypeptides and therapeutic uses thereof
|
US5973119A
(en)
|
1998-06-05 |
1999-10-26 |
Amgen Inc. |
Cyclin E genes and proteins
|
US7700353B2
(en)
*
|
1998-07-22 |
2010-04-20 |
E-P Therapeutics, Inc. |
Compositions and methods for inducing apoptosis in tumor cells
|
US20020172678A1
(en)
|
2000-06-23 |
2002-11-21 |
Napoleone Ferrara |
EG-VEGF nucleic acids and polypeptides and methods of use
|
US6344541B1
(en)
*
|
1998-09-25 |
2002-02-05 |
Amgen Inc. |
DKR polypeptides
|
CA2344049C
(en)
*
|
1998-10-09 |
2009-12-15 |
Biogen, Inc. |
Reversal of viral-induced systemic shock and respiratory distress by blockade of the lymphotoxin beta pathway
|
US6143314A
(en)
*
|
1998-10-28 |
2000-11-07 |
Atrix Laboratories, Inc. |
Controlled release liquid delivery compositions with low initial drug burst
|
US6270802B1
(en)
|
1998-10-28 |
2001-08-07 |
Oakwood Laboratories L.L.C. |
Method and apparatus for formulating microspheres and microcapsules
|
SI1135498T1
(sl)
|
1998-11-18 |
2008-06-30 |
Genentech Inc |
Variante protitelesa z višjo vezavno afiniteto vprimerjavi z izvirnimi protitelesi
|
EP1143953A3
(en)
*
|
1998-11-20 |
2002-02-06 |
Genentech, Inc. |
Method of inhibiting angiogenesis
|
US20030099682A1
(en)
*
|
1998-11-20 |
2003-05-29 |
Francis Moussy |
Apparatus and method for control of tissue/implant interactions
|
DE69918159T2
(de)
|
1998-11-20 |
2005-03-17 |
The University Of Connecticut, Farmington |
Verfahren und vorrichtung zur steuerung der gewebeimplantat-interaktionen
|
AUPP785098A0
(en)
|
1998-12-21 |
1999-01-21 |
Victor Chang Cardiac Research Institute, The |
Treatment of heart disease
|
EP1140173B2
(en)
|
1998-12-22 |
2013-04-03 |
Genentech, Inc. |
Vascular endothelial cell growth factor antagonists and uses thereof
|
CA2450402A1
(en)
|
1998-12-22 |
2000-06-29 |
Genentech, Inc. |
Methods and compositions for inhibiting cancer cell growth comprising pro224
|
US6194006B1
(en)
|
1998-12-30 |
2001-02-27 |
Alkermes Controlled Therapeutics Inc. Ii |
Preparation of microparticles having a selected release profile
|
US6498153B1
(en)
*
|
1998-12-31 |
2002-12-24 |
Akzo Nobel N.V. |
Extended release growth promoting two component composition
|
KR100887482B1
(ko)
|
1999-01-15 |
2009-03-10 |
제넨테크, 인크. |
효과기 기능이 변화된 폴리펩티드 변이체
|
US6303749B1
(en)
|
1999-01-29 |
2001-10-16 |
Amgen Inc. |
Agouti and agouti-related peptide analogs
|
US7708993B2
(en)
*
|
1999-02-03 |
2010-05-04 |
Amgen Inc. |
Polypeptides involved in immune response
|
US8624010B1
(en)
|
1999-02-03 |
2014-01-07 |
Steven K. Yoshinaga |
Nucleic acids encoding B7RP1
|
HUP0105337A3
(en)
*
|
1999-02-03 |
2011-01-28 |
Amgen Inc |
Polypeptides involved in immune response
|
US7435796B1
(en)
|
1999-02-03 |
2008-10-14 |
Amgen Inc. |
Antibodies which bind B7RP1
|
WO2000050620A2
(en)
|
1999-02-26 |
2000-08-31 |
Human Genome Sciences, Inc. |
Human endokine alpha and methods of use
|
EP2286792A1
(en)
|
1999-02-26 |
2011-02-23 |
Novartis Vaccines and Diagnostics, Inc. |
Microemulsions with an adsorbent surface, comprising a microdroplet emulsion
|
AU3770800A
(en)
|
1999-03-26 |
2000-10-16 |
Amgen, Inc. |
Beta secretase genes and polypeptides
|
US6306425B1
(en)
|
1999-04-09 |
2001-10-23 |
Southern Research Institute |
Injectable naltrexone microsphere compositions and their use in reducing consumption of heroin and alcohol
|
US6635249B1
(en)
*
|
1999-04-23 |
2003-10-21 |
Cenes Pharmaceuticals, Inc. |
Methods for treating congestive heart failure
|
US20040229779A1
(en)
*
|
1999-05-14 |
2004-11-18 |
Ramesh Kekuda |
Therapeutic polypeptides, nucleic acids encoding same, and methods of use
|
US20040023874A1
(en)
*
|
2002-03-15 |
2004-02-05 |
Burgess Catherine E. |
Therapeutic polypeptides, nucleic acids encoding same, and methods of use
|
US6974684B2
(en)
*
|
2001-08-08 |
2005-12-13 |
Curagen Corporation |
Therapeutic polypeptides, nucleic acids encoding same, and methods of use
|
US20040067490A1
(en)
*
|
2001-09-07 |
2004-04-08 |
Mei Zhong |
Therapeutic polypeptides, nucleic acids encoding same, and methods of use
|
CA2372994C
(en)
*
|
1999-06-04 |
2010-03-23 |
Alza Corporation |
Implantable gel compositions and method of manufacture
|
DE60043367D1
(de)
|
1999-06-15 |
2009-12-31 |
Genentech Inc |
Sekretierte und Transmembran-Polypeptide sowie Nukleinsäuren zu deren Kodierung
|
US20030166561A1
(en)
*
|
1999-06-18 |
2003-09-04 |
Cooper Garth J. S. |
Peptide
|
NZ515975A
(en)
|
1999-06-25 |
2004-01-30 |
Genentech Inc |
Anti-ErbB antibody-maytansinoid conjugates useful in the treatment of tumors characterised by the overexpression of an ErbB receptor
|
KR100850389B1
(ko)
|
1999-06-25 |
2008-08-04 |
제넨테크, 인크. |
인간화 항-ErbB2 항체 및 항-ErbB2 항체를 사용한치료 방법
|
EP1194555B1
(en)
|
1999-06-28 |
2012-09-26 |
Genentech, Inc. |
Methods for making apo-2 ligand using divalent metal ions
|
US7713739B1
(en)
*
|
2000-11-17 |
2010-05-11 |
Novartis Vaccines And Diagnostics, Inc. |
Microparticle-based transfection and activation of dendritic cells
|
EP1200140A1
(en)
*
|
1999-08-03 |
2002-05-02 |
Smith & Nephew, Inc. |
Controlled release implantable devices
|
PL202369B1
(pl)
|
1999-08-27 |
2009-06-30 |
Genentech Inc |
Zastosowanie przeciwciała skierowanego przeciw ErbB2, zastosowanie przeciwciała skierowanego przeciw ErbB oraz zestaw zawierający to przeciwciało
|
US20040214783A1
(en)
|
2002-05-08 |
2004-10-28 |
Terman David S. |
Compositions and methods for treatment of neoplastic disease
|
US7408047B1
(en)
*
|
1999-09-07 |
2008-08-05 |
Amgen Inc. |
Fibroblast growth factor-like polypeptides
|
US7459540B1
(en)
*
|
1999-09-07 |
2008-12-02 |
Amgen Inc. |
Fibroblast growth factor-like polypeptides
|
US7078382B1
(en)
|
1999-11-02 |
2006-07-18 |
Genentech, Inc. |
Modulation of eNOS activity and therapeutic uses thereof
|
US6495166B1
(en)
|
1999-11-12 |
2002-12-17 |
Alkermes Controlled Therapeutics Inc. |
Apparatus and method for preparing microparticles using in-line solvent extraction
|
US6705757B2
(en)
*
|
1999-11-12 |
2004-03-16 |
Alkermes Controlled Therapeutics, Inc. Ii |
Method and apparatus for preparing microparticles using in-line solvent extraction
|
US6331317B1
(en)
*
|
1999-11-12 |
2001-12-18 |
Alkermes Controlled Therapeutics Ii Inc. |
Apparatus and method for preparing microparticles
|
JP2004522404A
(ja)
|
1999-12-01 |
2004-07-29 |
ジェネンテック・インコーポレーテッド |
分泌及び膜貫通ポリペプチドとそれをコードしている核酸
|
ES2169980B1
(es)
|
1999-12-17 |
2003-11-01 |
Lipotec Sa |
Microcapsulas para la liberacion prolongada de farmacos.
|
EP1897945B1
(en)
|
1999-12-23 |
2012-01-18 |
Genentech, Inc. |
IL-17 homologous polypeptides and therapeutic uses thereof
|
IL150676A0
(en)
|
2000-01-13 |
2003-02-12 |
Genentech Inc |
NOVEL STRa6 POLYPEPTIDES
|
ES2267593T3
(es)
|
2000-02-16 |
2007-03-16 |
Genentech, Inc. |
Anticuerpos anti-april y celulas hibridomas.
|
US20030103978A1
(en)
|
2000-02-23 |
2003-06-05 |
Amgen Inc. |
Selective binding agents of osteoprotegerin binding protein
|
US6689747B2
(en)
*
|
2000-03-24 |
2004-02-10 |
Genentech, Inc. |
Use of insulin for the treatment of cartilagenous disorders
|
US7514239B2
(en)
|
2000-03-28 |
2009-04-07 |
Amgen Inc. |
Nucleic acid molecules encoding beta-like glycoprotein hormone polypeptides and heterodimers thereof
|
AU2001247616B2
(en)
|
2000-04-11 |
2007-06-14 |
Genentech, Inc. |
Multivalent antibodies and uses therefor
|
ES2484966T3
(es)
|
2000-04-12 |
2014-08-12 |
Novozymes Biopharma Dk A/S |
Proteínas de fusión de albúmina
|
EP2348047A1
(en)
|
2000-04-21 |
2011-07-27 |
New England Medical Center |
G protein coupled receptor (GPCR) agonists and antagonists and methods of activating and inhibiting GPCR using the same
|
AR023940A1
(es)
|
2000-05-03 |
2002-09-04 |
Eriochem Sa |
Procedimiento para la produccion de microcapsulas de liberacion prolongada de peptidos solubles en agua
|
EP1282443B1
(en)
|
2000-05-19 |
2009-09-02 |
Genentech, Inc. |
Gene detection assay for improving the likelihood of an effective response to an erbb antagonist cancer therapy
|
US6264987B1
(en)
|
2000-05-19 |
2001-07-24 |
Alkermes Controlled Therapeutics Inc. Ii |
Method for preparing microparticles having a selected polymer molecular weight
|
WO2001089500A2
(en)
*
|
2000-05-24 |
2001-11-29 |
Jordan Loyal Holtzman |
Agents and methods for increasing brain chaperonin levels
|
US6495164B1
(en)
*
|
2000-05-25 |
2002-12-17 |
Alkermes Controlled Therapeutics, Inc. I |
Preparation of injectable suspensions having improved injectability
|
US20040170665A1
(en)
*
|
2000-06-02 |
2004-09-02 |
Allergan, Inc. |
Intravitreal botulinum toxin implant
|
US20040033241A1
(en)
*
|
2000-06-02 |
2004-02-19 |
Allergan, Inc. |
Controlled release botulinum toxin system
|
US6306423B1
(en)
|
2000-06-02 |
2001-10-23 |
Allergan Sales, Inc. |
Neurotoxin implant
|
US20050214327A1
(en)
*
|
2000-06-02 |
2005-09-29 |
Allergan, Inc. |
Neurotoxin-containing suppositories and related methods
|
EP1294949A4
(en)
|
2000-06-15 |
2004-08-25 |
Human Genome Sciences Inc |
HUMAN TUMORNESCROSE FACTOR DELTA AND EPSILON
|
AU2001268363B2
(en)
|
2000-06-20 |
2006-08-17 |
Biogen Idec Inc. |
Treatment of B cell associated diseases
|
WO2001098543A2
(en)
*
|
2000-06-21 |
2001-12-27 |
Diadexus, Inc. |
Method of diagnosing, monitoring, staging, imaging and treating breast cancer
|
DK2042597T3
(da)
|
2000-06-23 |
2014-08-11 |
Genentech Inc |
Sammensætninger og fremgangsmåder til diagnose og behandling af sygdomme, der involverer angiogenese
|
CA2648051A1
(en)
|
2000-06-23 |
2002-01-03 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
|
WO2002000710A2
(en)
*
|
2000-06-28 |
2002-01-03 |
Amgen, Inc. |
B7-like molecules and uses thereof
|
WO2002000724A2
(en)
|
2000-06-28 |
2002-01-03 |
Amgen, Inc. |
Thymic stromal lymphopoietin receptor molecules and uses thereof
|
US20040023259A1
(en)
*
|
2000-07-26 |
2004-02-05 |
Luca Rastelli |
Therapeutic polypeptides, nucleic acids encoding same, and methods of use
|
EP2014303A2
(en)
|
2000-07-27 |
2009-01-14 |
Genentech, Inc. |
APO-2L receptor agonist and CPT-11 synergism
|
US6902734B2
(en)
|
2000-08-07 |
2005-06-07 |
Centocor, Inc. |
Anti-IL-12 antibodies and compositions thereof
|
UA81743C2
(uk)
|
2000-08-07 |
2008-02-11 |
Центокор, Инк. |
МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
|
US7288390B2
(en)
|
2000-08-07 |
2007-10-30 |
Centocor, Inc. |
Anti-dual integrin antibodies, compositions, methods and uses
|
KR100772950B1
(ko)
*
|
2000-08-07 |
2007-11-02 |
와꼬 쥰야꾸 고교 가부시키가이샤 |
젖산 중합체 및 이의 제조 방법
|
US6716932B2
(en)
|
2000-08-16 |
2004-04-06 |
Tyco Healthcare Group Lp |
High consistency absorbable polymeric resin
|
EP1309279A4
(en)
*
|
2000-08-17 |
2008-04-09 |
Tyco Healthcare |
US SUTURES AND COATINGS FROM RESORBABLE THERAPEUTIC GLASS
|
DE60136281D1
(de)
|
2000-08-24 |
2008-12-04 |
Genentech Inc |
Methode zur inhibierung von il-22 induziertem pap1
|
EP1944317A3
(en)
|
2000-09-01 |
2008-09-17 |
Genentech, Inc. |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
US6824822B2
(en)
*
|
2001-08-31 |
2004-11-30 |
Alkermes Controlled Therapeutics Inc. Ii |
Residual solvent extraction method and microparticles produced thereby
|
US6471995B1
(en)
*
|
2000-09-27 |
2002-10-29 |
Alkermes Controlled Therapeutics, Inc. Ii |
Apparatus and method for preparing microparticles using liquid-liquid extraction
|
WO2002026265A2
(en)
|
2000-09-29 |
2002-04-04 |
Schering Corporation |
Pegylated interleukin-10
|
US20040099976A1
(en)
*
|
2000-10-13 |
2004-05-27 |
Katsuto Otake |
Process for producing liposome and apparatus therefor
|
US7875585B2
(en)
|
2000-10-18 |
2011-01-25 |
Robert Sackstein |
Hematopoietic cell E-selectin / L-selectin ligand glycosylated CD44 polypeptide
|
DE10055742B4
(de)
*
|
2000-11-10 |
2006-05-11 |
Schwarz Pharma Ag |
Neue Polyester, Verfahren zu ihrer Herstellung und aus den Polyestern hergestellte Depot-Arzneiformen
|
US6989247B2
(en)
|
2000-11-28 |
2006-01-24 |
Celltech R & D, Inc. |
Compositions and methods for diagnosing or treating psoriasis
|
WO2002044364A2
(en)
|
2000-11-28 |
2002-06-06 |
Amgen Inc. |
Polypeptides involved in immune response
|
WO2002059145A1
(en)
*
|
2000-12-18 |
2002-08-01 |
Cubist Pharmaceuticals, Inc. |
Methods for preparing purified lipopeptides
|
IL156394A0
(en)
*
|
2000-12-18 |
2004-01-04 |
Cubist Pharm Inc |
Methods for preparing purified lipopeptides
|
US20060014674A1
(en)
|
2000-12-18 |
2006-01-19 |
Dennis Keith |
Methods for preparing purified lipopeptides
|
US20020114843A1
(en)
*
|
2000-12-27 |
2002-08-22 |
Ramstack J. Michael |
Preparation of microparticles having improved flowability
|
US6964849B2
(en)
|
2001-01-11 |
2005-11-15 |
Curagen Corporation |
Proteins and nucleic acids encoding same
|
US20040043928A1
(en)
*
|
2001-08-02 |
2004-03-04 |
Ramesh Kekuda |
Therapeutic polypeptides, nucleic acids encoding same, and methods of use
|
EP1370292A1
(en)
|
2001-01-31 |
2003-12-17 |
Idec Pharmaceuticals Corporation |
Use of cd23 antagonists for the treatment of neoplastic disorders
|
US20020159996A1
(en)
|
2001-01-31 |
2002-10-31 |
Kandasamy Hariharan |
Use of CD23 antagonists for the treatment of neoplastic disorders
|
US7087726B2
(en)
|
2001-02-22 |
2006-08-08 |
Genentech, Inc. |
Anti-interferon-α antibodies
|
EP1390067A1
(en)
*
|
2001-05-11 |
2004-02-25 |
Novartis AG |
Compositions for use in treating ige-associated disorders
|
GB0111628D0
(en)
*
|
2001-05-11 |
2001-07-04 |
Scancell Ltd |
Binding member
|
CA2975521A1
(en)
|
2001-05-30 |
2002-12-05 |
Genentech, Inc. |
Anti-ngf antibodies for the treatment of various disorders
|
US20070160576A1
(en)
|
2001-06-05 |
2007-07-12 |
Genentech, Inc. |
IL-17A/F heterologous polypeptides and therapeutic uses thereof
|
AUPR546801A0
(en)
|
2001-06-05 |
2001-06-28 |
Commonwealth Scientific And Industrial Research Organisation |
Recombinant antibodies
|
EP2000545B1
(en)
|
2001-06-20 |
2011-08-31 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of lung tumor
|
AU2002324447B2
(en)
|
2001-06-22 |
2006-06-29 |
Durect Corporation |
Zero-order prolonged release coaxial implants
|
WO2003002187A2
(en)
*
|
2001-06-26 |
2003-01-09 |
Photomed Technologies, Inc. |
Multiple wavelength illuminator
|
BRPI0210579B8
(pt)
|
2001-06-26 |
2021-05-25 |
Amgen Fremont Inc |
anticorpo e composição farmacêutica
|
AR034641A1
(es)
|
2001-06-29 |
2004-03-03 |
Takeda Pharmaceutical |
Composicion de liberacion controlada y metodo para producirla
|
CN1194688C
(zh)
*
|
2001-07-03 |
2005-03-30 |
山东绿叶制药股份有限公司 |
石杉碱甲及其衍生物或其盐的注射用缓释微球及其制备方法
|
US20030087274A1
(en)
*
|
2001-07-05 |
2003-05-08 |
Anderson David W. |
Therapeutic polypeptides, nucleic acids encoding same, and methods of use
|
US20040029790A1
(en)
*
|
2001-07-05 |
2004-02-12 |
Meera Patturajan |
Novel human proteins, polynucleotides encoding them and methods of using the same
|
GB0117057D0
(en)
*
|
2001-07-12 |
2001-09-05 |
Ferring Bv |
Pharmaceutical composition
|
AUPR673001A0
(en)
|
2001-07-31 |
2001-08-23 |
Prince Henry's Institute Of Medical Research |
Pregnancy-related enzyme activity
|
US20040030096A1
(en)
*
|
2001-08-02 |
2004-02-12 |
Linda Gorman |
Novel human proteins, polynucleotides encoding them and methods of using the same
|
KR20040019105A
(ko)
*
|
2001-08-03 |
2004-03-04 |
제넨테크, 인크. |
TACIs 및 BR3 폴리펩티드 및 이의 용도
|
EP1572887A4
(en)
|
2001-08-24 |
2008-12-24 |
Neuren Pharmaceuticals Ltd |
NEURAL REGENERATION PEPTIDES AND METHODS OF USE THEREOF IN THE TREATMENT OF CEREBRAL LESIONS
|
HU230373B1
(hu)
|
2001-08-29 |
2016-03-29 |
Genentech Inc |
Mitogén aktivitású Bv8-nukleinsavak és polipeptidek
|
US20040235068A1
(en)
*
|
2001-09-05 |
2004-11-25 |
Levinson Arthur D. |
Methods for the identification of polypeptide antigens associated with disorders involving aberrant cell proliferation and compositions useful for the treatment of such disorders
|
US20080085283A1
(en)
*
|
2001-09-05 |
2008-04-10 |
Levinson Arthur D |
Methods for the identification of polypeptide antigens associated with disorders involving aberrant cell proliferation and compositions useful for the treatment of such disorders
|
GB0121709D0
(en)
*
|
2001-09-07 |
2001-10-31 |
Imp College Innovations Ltd |
Food inhibition agent
|
GB0122318D0
(en)
*
|
2001-09-14 |
2001-11-07 |
Novartis Ag |
Organic compounds
|
EP1487877B1
(en)
|
2001-09-18 |
2010-10-27 |
Genentech, Inc. |
Compositions and methods for the diagnosis of tumors
|
NZ532427A
(en)
*
|
2001-09-24 |
2008-07-31 |
Imp Innovations Ltd |
Modification of feeding behavior using PYY (peptide YY) and its agonists such as NPY (neuropeptide Y)
|
US20040186051A1
(en)
|
2001-10-02 |
2004-09-23 |
Kelley Robert F |
Apo-2 ligand variants and uses thereof
|
AR045702A1
(es)
|
2001-10-03 |
2005-11-09 |
Chiron Corp |
Composiciones de adyuvantes.
|
US20030199442A1
(en)
*
|
2001-10-09 |
2003-10-23 |
Alsobrook John P. |
Therapeutic polypeptides, nucleic acids encoding same, and methods of use
|
US7521053B2
(en)
|
2001-10-11 |
2009-04-21 |
Amgen Inc. |
Angiopoietin-2 specific binding agents
|
US7138370B2
(en)
|
2001-10-11 |
2006-11-21 |
Amgen Inc. |
Specific binding agents of human angiopoietin-2
|
MXPA04003291A
(es)
|
2001-10-12 |
2004-07-23 |
Schering Corp |
Uso de anticuerpos biespecificos para ragular respuestas inmunes.
|
US7349733B2
(en)
*
|
2001-11-02 |
2008-03-25 |
Ceramatel, Inc. |
Iontophoretic drug delivery systems
|
US20030119000A1
(en)
*
|
2001-11-05 |
2003-06-26 |
Jon Polansky |
Methods to screen and treat individuals with glaucoma or the propensity to develop glaucoma
|
US7741282B2
(en)
|
2001-11-13 |
2010-06-22 |
Genentech, Inc. |
ApO2 ligand/TRAIL formulations
|
CN100446809C
(zh)
*
|
2001-11-14 |
2008-12-31 |
阿尔扎有限公司 |
可注射的长效组合物
|
CN100374457C
(zh)
|
2001-11-14 |
2008-03-12 |
森托科尔公司 |
抗il-6抗体、组合物、方法和用途
|
AU2002348948A1
(en)
*
|
2001-11-30 |
2003-06-10 |
Pfizer Products Inc. |
Pharmaceutical compositions and methods for administering EP2 receptors selective agonists
|
WO2003060071A2
(en)
|
2001-12-21 |
2003-07-24 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
KR20080106369A
(ko)
|
2002-01-02 |
2008-12-04 |
제넨테크, 인크. |
종양의 진단 및 치료 방법 및 이를 위한 조성물
|
CA2472882A1
(en)
|
2002-01-10 |
2003-07-17 |
Imperial College Innovations Ltd |
Use of pyy and glp-1, or an agonist thereof, for the modification of feeding behaviour
|
US8058233B2
(en)
*
|
2002-01-10 |
2011-11-15 |
Oregon Health And Science University |
Modification of feeding behavior using PYY and GLP-1
|
US7662924B2
(en)
*
|
2002-02-22 |
2010-02-16 |
The Board Of Trustees Of The University Of Illinois |
Beta chain-associated regulator of apoptosis
|
AU2003217693A1
(en)
*
|
2002-02-22 |
2003-09-09 |
Board Of Trustees Of The University Of Illinois |
Beta chain-associated regulator of apoptosis
|
EP2388265A1
(en)
|
2002-02-22 |
2011-11-23 |
Genentech, Inc. |
Compositions and methods for the treatment of immune related diseases
|
US20090042291A1
(en)
*
|
2002-03-01 |
2009-02-12 |
Xencor, Inc. |
Optimized Fc variants
|
US20100311954A1
(en)
*
|
2002-03-01 |
2010-12-09 |
Xencor, Inc. |
Optimized Proteins that Target Ep-CAM
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
US7662925B2
(en)
|
2002-03-01 |
2010-02-16 |
Xencor, Inc. |
Optimized Fc variants and methods for their generation
|
JP4473117B2
(ja)
|
2002-03-13 |
2010-06-02 |
バイオジェン・アイデック・エムエイ・インコーポレイテッド |
抗αvβ6抗体
|
US7264822B2
(en)
*
|
2002-04-03 |
2007-09-04 |
Poly-Med, Inc. |
Conjugated drug-polymer coated stent
|
JP4761710B2
(ja)
|
2002-04-05 |
2011-08-31 |
アムジェン インコーポレイテッド |
選択的opgl経路インヒビターとしてのヒト抗opgl中和抗体
|
DK1501856T3
(da)
|
2002-04-10 |
2013-03-25 |
Genentech Inc |
Anti-HER2 antistofvarianter
|
US8030461B2
(en)
|
2002-04-15 |
2011-10-04 |
Chugai Seiyaku Kabushiki Kaisha |
Methods for constructing scDb libraries
|
JP2005536190A
(ja)
|
2002-04-16 |
2005-12-02 |
ジェネンテック・インコーポレーテッド |
腫瘍の診断と治療のための組成物と方法
|
WO2003090807A1
(en)
*
|
2002-04-24 |
2003-11-06 |
Poly-Med, Inc. |
Multifaceted endovascular stent coating for preventing restenosis
|
WO2003091424A1
(fr)
|
2002-04-26 |
2003-11-06 |
Chugai Seiyaku Kabushiki Kaisha |
Procede de criblage d'un anticorps agoniste
|
AU2002304965A1
(en)
|
2002-05-24 |
2003-12-12 |
Zensun (Shanghai) Sci-Tech.Ltd |
Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy
|
EP2305710A3
(en)
|
2002-06-03 |
2013-05-29 |
Genentech, Inc. |
Synthetic antibody phage libraries
|
CA2486270C
(en)
|
2002-06-05 |
2015-07-28 |
Genentech, Inc. |
Vegfr modulating agents and methods for liver growth and liver protection
|
AU2003243400B2
(en)
*
|
2002-06-07 |
2009-10-29 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
EP2500032A1
(en)
|
2002-06-24 |
2012-09-19 |
Genentech, Inc. |
APO-2 ligand/trail variants and uses thereof
|
AU2003280130B2
(en)
|
2002-06-28 |
2009-06-11 |
Centocor, Inc. |
Mammalian CH1 deleted mimetibodies, compositions, methods and uses
|
AU2003247806B2
(en)
|
2002-07-08 |
2009-11-12 |
Genentech, Inc. |
Compositions and methods for the treatment of immune related diseases
|
NZ596825A
(en)
|
2002-07-15 |
2013-06-28 |
Univ Texas |
Duramycin peptides and their use in imaging
|
JP5069843B2
(ja)
|
2002-07-15 |
2012-11-07 |
ジェネンテック, インコーポレイテッド |
抗ErbB2抗体を用いる処置に応答性である腫瘍を同定するための方法
|
KR20050116360A
(ko)
*
|
2002-07-25 |
2005-12-12 |
제넨테크, 인크. |
Taci 항체 및 그의 용도
|
US20050232995A1
(en)
|
2002-07-29 |
2005-10-20 |
Yam Nyomi V |
Methods and dosage forms for controlled delivery of paliperidone and risperidone
|
US20040142393A1
(en)
*
|
2002-08-01 |
2004-07-22 |
Cooper Garth James Smith |
Methods of use of compounds with preptin function
|
US20050271639A1
(en)
*
|
2002-08-22 |
2005-12-08 |
Penn Marc S |
Genetically engineered cells for therapeutic applications
|
US7438910B2
(en)
|
2002-09-06 |
2008-10-21 |
Amgen Inc. |
Therapeutic human anti-IL1-R1 monoclonal antibody
|
CA2497661A1
(en)
|
2002-09-11 |
2004-03-25 |
Genentech, Inc. |
Compositions and methods for the diagnosis of immune related diseases using pro71061
|
AU2003276874B2
(en)
|
2002-09-11 |
2009-09-03 |
Genentech, Inc. |
Novel compositions and methods for the treatment of immune related diseases
|
IL262513B
(en)
|
2002-09-11 |
2022-09-01 |
Genentech Inc |
Cleaning proteins
|
DE60335552D1
(de)
|
2002-09-11 |
2011-02-10 |
Genentech Inc |
Neue zusammensetzung und verfahren zur behandlung von immunerkrankungen
|
WO2004024097A2
(en)
|
2002-09-16 |
2004-03-25 |
Genentech, Inc. |
Compositions and methods for the treatment of immune related diseases
|
CA2499843A1
(en)
|
2002-09-25 |
2004-04-08 |
Genentech, Inc. |
Novel compositions and methods for the treatment of psoriasis
|
US20040062778A1
(en)
*
|
2002-09-26 |
2004-04-01 |
Adi Shefer |
Surface dissolution and/or bulk erosion controlled release compositions and devices
|
KR100960560B1
(ko)
|
2002-09-27 |
2010-06-03 |
젠코어 인코포레이티드 |
최적화된 Fc 변이체 및 그의 제조 방법
|
US20060147450A1
(en)
*
|
2002-10-04 |
2006-07-06 |
Shelton David L |
Methods for treating cardiac arrhythmia and preventing death due to cardiac arrhythmia using ngf antagonists
|
UA80447C2
(en)
*
|
2002-10-08 |
2007-09-25 |
|
Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
|
DE60335957D1
(de)
|
2002-10-08 |
2011-03-17 |
Rinat Neuroscience Corp |
Verfahren zur behandlung von postoperativen schmerzen durch verabreichung eines antikörpers gegen nervenwachstumsfaktor und diesen enthaltende zusammensetzungen
|
AU2003304238A1
(en)
|
2002-10-08 |
2005-01-13 |
Rinat Neuroscience Corp. |
Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody and compositions containing the same
|
US7335743B2
(en)
|
2002-10-16 |
2008-02-26 |
Amgen Inc. |
Human anti-IFN-γ neutralizing antibodies as selective IFN-γ pathway inhibitors
|
AU2003298607B9
(en)
|
2002-10-29 |
2011-08-04 |
Genentech, Inc. |
Compositions and methods for the treatment of immune related diseases
|
US20040086532A1
(en)
*
|
2002-11-05 |
2004-05-06 |
Allergan, Inc., |
Botulinum toxin formulations for oral administration
|
EP2364716A3
(en)
|
2002-11-08 |
2012-01-11 |
Genentech, Inc. |
Compositions and methods for the treatment of natural killer cell related diseases
|
WO2004047728A2
(en)
|
2002-11-26 |
2004-06-10 |
Genentech, Inc. |
Compositions and methods for the treatment of immune related diseases
|
ATE472556T1
(de)
|
2002-12-02 |
2010-07-15 |
Amgen Fremont Inc |
Gegen den tumor nekrose faktor gerichtete antikörper und deren verwendungen
|
PT1575517E
(pt)
*
|
2002-12-24 |
2012-05-28 |
Rinat Neuroscience Corp |
Anticorpos anti-ngf e métodos de utilização dos mesmos
|
US7569364B2
(en)
|
2002-12-24 |
2009-08-04 |
Pfizer Inc. |
Anti-NGF antibodies and methods using same
|
US9498530B2
(en)
|
2002-12-24 |
2016-11-22 |
Rinat Neuroscience Corp. |
Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
|
CA2511823A1
(en)
|
2002-12-30 |
2004-07-22 |
Amgen Inc. |
Combination therapy with co-stimulatory factors
|
US7060299B2
(en)
*
|
2002-12-31 |
2006-06-13 |
Battelle Memorial Institute |
Biodegradable microparticles that stabilize and control the release of proteins
|
GB0300571D0
(en)
*
|
2003-01-10 |
2003-02-12 |
Imp College Innovations Ltd |
Modification of feeding behaviour
|
WO2004065417A2
(en)
*
|
2003-01-23 |
2004-08-05 |
Genentech, Inc. |
Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
|
EP1592386A4
(en)
|
2003-01-24 |
2007-06-13 |
Elan Pharm Inc |
COMPOSITION AND METHOD FOR TREATING DEMYELINIZATION DISEASES AND PARALYSIS BY ADMINISTERING REMYELING AGENTS
|
CN101787073B
(zh)
|
2003-01-28 |
2013-12-25 |
艾恩伍德医药品股份有限公司 |
治疗胃肠病的方法和组合物
|
US7772188B2
(en)
|
2003-01-28 |
2010-08-10 |
Ironwood Pharmaceuticals, Inc. |
Methods and compositions for the treatment of gastrointestinal disorders
|
CN102993306B
(zh)
|
2003-02-01 |
2015-01-28 |
唐纳士公司 |
高亲和力抗人类IgE抗体
|
CA2516454A1
(en)
|
2003-02-19 |
2004-09-02 |
Rinat Neuroscience Corp. |
Methods for treating pain by administering a nerve growth factor antagonist and an nsaid and compositions containing the same
|
GB0304726D0
(en)
*
|
2003-03-01 |
2003-04-02 |
Ardana Bioscience Ltd |
New Process
|
US20090010920A1
(en)
*
|
2003-03-03 |
2009-01-08 |
Xencor, Inc. |
Fc Variants Having Decreased Affinity for FcyRIIb
|
US8388955B2
(en)
*
|
2003-03-03 |
2013-03-05 |
Xencor, Inc. |
Fc variants
|
JP4912144B2
(ja)
|
2003-03-12 |
2012-04-11 |
ジェネンテック, インコーポレイテッド |
造血促進のためのbv8及び/又はeg−vegfの使用
|
US9445901B2
(en)
*
|
2003-03-12 |
2016-09-20 |
Deger C. Tunc |
Prosthesis with sustained release analgesic
|
WO2004084823A2
(en)
|
2003-03-19 |
2004-10-07 |
Abgenix, Inc. |
Antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen and uses thereof
|
ZA200507757B
(en)
|
2003-04-04 |
2007-01-31 |
Genentech Inc |
High concentration antibody and protein formulations
|
CN1798838B
(zh)
|
2003-04-04 |
2012-01-04 |
洛桑大学 |
一种蛋白酶的抑制剂蛋白及其用途
|
PL1613350T3
(pl)
|
2003-04-09 |
2009-08-31 |
Genentech Inc |
Leczenie choroby autoimmunologicznej u pacjenta z nieodpowiednią odpowiedzią na leczenie inhibitorem TNFα
|
US7247711B2
(en)
|
2003-05-09 |
2007-07-24 |
Centocor, Inc. |
IL-23p40 specific antibody
|
DK1633784T3
(da)
|
2003-05-09 |
2011-10-24 |
Diadexus Inc |
OVR110 antistofsammensætninger og -anvendelsesfremgangsmåder
|
WO2004103390A2
(en)
|
2003-05-15 |
2004-12-02 |
Trustees Of Tufts College |
Stable analogs of peptide and polypeptide therapeutics
|
US7375076B2
(en)
*
|
2003-05-20 |
2008-05-20 |
The Regents Of The University Of Michigan |
Methods of reducing vascular permeability in tissue by inhibition of tissue plasminogen activator (tPA) and tPA inhibitors useful therein
|
WO2005000896A2
(en)
*
|
2003-05-30 |
2005-01-06 |
Genentech, Inc. |
Polypeptides that bind an anti-tissue factor antibody and uses thereof
|
EP2248829A1
(en)
|
2003-05-30 |
2010-11-10 |
Genentech, Inc. |
Treatment with anti-VEGF antibodies
|
US20050163775A1
(en)
*
|
2003-06-05 |
2005-07-28 |
Genentech, Inc. |
Combination therapy for B cell disorders
|
PT1631313E
(pt)
*
|
2003-06-05 |
2015-07-02 |
Genentech Inc |
Terapêutica de combinação para distúrbios de células b
|
JP2007526447A
(ja)
|
2003-06-06 |
2007-09-13 |
ジェネンテック・インコーポレーテッド |
HGFβ鎖とC−MET間の相互作用の調節
|
KR20140033239A
(ko)
*
|
2003-06-27 |
2014-03-17 |
암젠 프레몬트 인코포레이티드 |
상피 성장 인자 수용체의 결실 돌연변이체 지향 항체 및 그 용도
|
WO2005020886A2
(en)
*
|
2003-06-27 |
2005-03-10 |
New England Biolabs, Inc. |
Identification and use of cofactor independent phosphoglycerate mutase as a drug target
|
US7939058B2
(en)
*
|
2003-07-03 |
2011-05-10 |
University Of Southern California |
Uses of IL-12 in hematopoiesis
|
PT1641822E
(pt)
|
2003-07-08 |
2013-08-27 |
Genentech Inc |
Polipéptidos heterólogos il-17 a/f e suas utilizações terapêuticas
|
PL1648998T3
(pl)
|
2003-07-18 |
2015-03-31 |
Amgen Inc |
Specyficzne czynniki wiążące czynnik wzrostu hepatocytów
|
US8343513B2
(en)
|
2003-07-18 |
2013-01-01 |
Oakwood Laboratories, Llc |
Prevention of molecular weight reduction of the polymer, impurity formation and gelling in polymer compositions
|
JP2007501011A
(ja)
*
|
2003-08-01 |
2007-01-25 |
ジェネンテック・インコーポレーテッド |
制限多様性配列を有する結合型ポリペプチド
|
WO2005019258A2
(en)
|
2003-08-11 |
2005-03-03 |
Genentech, Inc. |
Compositions and methods for the treatment of immune related diseases
|
WO2005020933A2
(en)
*
|
2003-09-02 |
2005-03-10 |
University Of South Florida |
Nanoparticles for drug-delivery
|
CN1870893A
(zh)
|
2003-09-12 |
2006-11-29 |
特西卡股份有限公司 |
胰岛素样生长因子-1(igf-1)缺陷的治疗方法
|
US9714282B2
(en)
|
2003-09-26 |
2017-07-25 |
Xencor, Inc. |
Optimized Fc variants and methods for their generation
|
US8101720B2
(en)
|
2004-10-21 |
2012-01-24 |
Xencor, Inc. |
Immunoglobulin insertions, deletions and substitutions
|
UA89481C2
(uk)
|
2003-09-30 |
2010-02-10 |
Центокор, Инк. |
Еритропоетинові міметичні шарнірно-серцевинні міметитіла людини, композиції, способи та застосування
|
AU2003271174A1
(en)
|
2003-10-10 |
2005-04-27 |
Chugai Seiyaku Kabushiki Kaisha |
Double specific antibodies substituting for functional protein
|
EP2311945A1
(en)
|
2003-10-14 |
2011-04-20 |
Chugai Seiyaku Kabushiki Kaisha |
Bispecific antibodies substituting for functional proteins
|
WO2005037235A2
(en)
|
2003-10-16 |
2005-04-28 |
Imclone Systems Incorporated |
Fibroblast growth factor receptor-1 inhibitors and methods of treatment thereof
|
WO2005044188A2
(en)
|
2003-10-27 |
2005-05-19 |
Amgen Inc. |
Compositions and methods to modulate an immune response to an immunogenic therapeutic agent
|
WO2005040163A1
(en)
*
|
2003-10-28 |
2005-05-06 |
Dr. Reddy's Laboratories Ltd |
Heterocyclic compounds that block the effects of advanced glycation end products (age)
|
DK1682537T3
(da)
|
2003-11-05 |
2012-07-09 |
Sarcode Bioscience Inc |
Modulatorer af celleadhæsion
|
ME03330B
(me)
|
2003-11-05 |
2019-10-20 |
Roche Glycart Ag |
Cd20 antitijela sa povećanim afinitetom za vezivanje fc receptora i efektornom funkcijom
|
DE602004024921D1
(de)
|
2003-11-17 |
2010-02-11 |
Genentech Inc |
Zusammensetzungen und verfahren zur behandlung von tumoren hämatopoetischen ursprungs
|
US20050125914A1
(en)
*
|
2003-11-18 |
2005-06-16 |
Gerard Malle |
Hair shaping composition comprising at least one- non-hydroxide base
|
CN1914226B
(zh)
*
|
2003-11-25 |
2012-02-01 |
达纳-法伯癌症研究院有限公司 |
SARS-CoV抗体及其使用方法
|
US20050142133A1
(en)
*
|
2003-12-03 |
2005-06-30 |
Xencor, Inc. |
Optimized proteins that target the epidermal growth factor receptor
|
MXPA06006406A
(es)
|
2003-12-05 |
2007-03-21 |
Adnexus Therapeutics Inc |
Inhibidores de receptores de factor de crecimiento endotelial vascular tipo 2.
|
US20080220049A1
(en)
*
|
2003-12-05 |
2008-09-11 |
Adnexus, A Bristol-Myers Squibb R&D Company |
Compositions and methods for intraocular delivery of fibronectin scaffold domain proteins
|
DK1711531T3
(da)
|
2003-12-10 |
2012-04-30 |
Novimmune Sa |
Neutraliserende anti-TLR4/-MD-2-antistoffer og fremgangsmåder til anvendelse deraf
|
US7312320B2
(en)
|
2003-12-10 |
2007-12-25 |
Novimmune Sa |
Neutralizing antibodies and methods of use thereof
|
RU2006124743A
(ru)
|
2003-12-11 |
2008-01-20 |
Дженентек, Инк. (Us) |
СПОСОБЫ И КОМПОЗИЦИИ ДЛЯ ИНГИБИРОВАНИЯ ДИМЕРИЗАЦИИ И АКТИВАЦИИ с-Мет
|
MXPA06006985A
(es)
|
2003-12-19 |
2006-08-31 |
Genentech Inc |
Fragmentos de anticuerpo monovalente utiles como terapueticos.
|
EA200601220A1
(ru)
*
|
2003-12-23 |
2006-12-29 |
Ринат Ньюросайенс Корп. |
Анти-trkc антитела-агонисты и способы их применения
|
AU2005207998A1
(en)
*
|
2004-01-05 |
2005-08-11 |
Biotech Studio, Llc |
Biotherapeutics, diagnostics and research reagents
|
CN107090034B
(zh)
|
2004-01-07 |
2021-10-01 |
诺华疫苗和诊断公司 |
M-csf特异性单克隆抗体及其应用
|
JP2007517913A
(ja)
*
|
2004-01-13 |
2007-07-05 |
バソジェニックス ファーマシューティカルズ, インコーポレイテッド |
カルシトニン遺伝子関連ペプチドを投与することによって急性心筋梗塞を処置するための方法およびカルシトニン遺伝子関連ペプチドを含有する組成物
|
WO2005070444A2
(en)
*
|
2004-01-13 |
2005-08-04 |
Vasogenix Pharmaceuticals, Inc. |
Methods for treating acute myocardial infarction by calcitonin gene related peptide and compositions containing the same
|
EP1703895A2
(en)
*
|
2004-01-13 |
2006-09-27 |
Vasogenix Pharmaceuticals, Inc. |
Controlled release cgrp delivery composition for cardiovascular and renal indications
|
ES2687671T3
(es)
|
2004-01-30 |
2018-10-26 |
Shire Pharmaceuticals Ireland Limited |
Arilsulfatasa A recombinante para reducir los niveles de galatosil sulfátidos en un sujeto
|
US8778880B2
(en)
|
2004-02-02 |
2014-07-15 |
Ambrx, Inc. |
Human growth hormone modified at position 35
|
NZ584288A
(en)
|
2004-02-06 |
2011-10-28 |
Elan Pharm Inc |
Methods and compositions for treating tumors and metastatic disease
|
CA2555820C
(en)
|
2004-02-19 |
2016-01-19 |
Genentech, Inc. |
Cdr-repaired antibodies
|
JP2007523196A
(ja)
*
|
2004-02-20 |
2007-08-16 |
ライナット ニューロサイエンス コーポレイション |
Nt−4/5を用いて肥満または糖尿病を処置する方法
|
US20100028995A1
(en)
*
|
2004-02-23 |
2010-02-04 |
Anaphore, Inc. |
Tetranectin Trimerizing Polypeptides
|
US7422741B2
(en)
|
2004-03-05 |
2008-09-09 |
Vegenics Limited |
VEGFR-3 fusion proteins
|
WO2005090564A1
(ja)
|
2004-03-19 |
2005-09-29 |
Genomidea Inc. |
血管内皮増殖促進遺伝子
|
EP1729804A2
(en)
|
2004-03-19 |
2006-12-13 |
Amgen Inc. |
Reducing the risk of human and anti-human antibodies through v gene manipulation
|
AU2005229009A1
(en)
*
|
2004-03-23 |
2005-10-13 |
Amgen, Inc. |
Monoclonal antibodies specific for human OX40L (CD 134L)
|
SG151315A1
(en)
*
|
2004-03-31 |
2009-04-30 |
Centocor Inc |
Human glp-1 mimetibodies, compositions, methods and uses
|
MY162179A
(en)
|
2004-04-01 |
2017-05-31 |
Elan Pharm Inc |
Steroid sparing agents and methods of using same
|
US7794713B2
(en)
|
2004-04-07 |
2010-09-14 |
Lpath, Inc. |
Compositions and methods for the treatment and prevention of hyperproliferative diseases
|
KR20060135060A
(ko)
|
2004-04-07 |
2006-12-28 |
리나트 뉴로사이언스 코퍼레이션 |
신경성장인자 길항제의 투여에 의한 골암 통증의 치료방법
|
US20060034840A1
(en)
|
2004-04-08 |
2006-02-16 |
Agus David B |
ErbB antagonists for pain therapy
|
JP5030292B2
(ja)
|
2004-04-15 |
2012-09-19 |
アミリン・ファーマシューティカルズ,インコーポレイテッド |
ポリマーを基にした持続放出性装置
|
WO2005113003A2
(en)
*
|
2004-04-16 |
2005-12-01 |
Genentech, Inc. |
Method for augmenting b cell depletion
|
DE602005023976D1
(de)
|
2004-04-20 |
2010-11-18 |
Galapagos Nv |
Verfahren, zusammensetzungen und verbindungstests zur hemmung der amyloid-beta-proteinproduktion
|
WO2005103716A2
(en)
|
2004-04-27 |
2005-11-03 |
Galapagos N.V. |
Methods, agents, and compound screening assays for inducing differentiation of undifferentiated mammalian cells into osteoblasts
|
GB0410627D0
(en)
|
2004-05-12 |
2004-06-16 |
Scancell Ltd |
Specific binding members
|
EP1773881A4
(en)
*
|
2004-05-13 |
2008-08-06 |
Imclone Systems Inc |
Inhibition of macrophage-stimulating protein receptor (RON)
|
US20060292554A1
(en)
*
|
2004-05-18 |
2006-12-28 |
Genentech, Inc. |
Major coat protein variants for C-terminal and bi-terminal display
|
EP1598428A1
(en)
|
2004-05-18 |
2005-11-23 |
Georg Dewald |
Methods and kits to detect Hereditary angioedema type III
|
BRPI0510883B8
(pt)
|
2004-06-01 |
2021-05-25 |
Genentech Inc |
composto conjugado de droga e anticorpo, composição farmacêutica, método de fabricação de composto conjugado de droga e anticorpo e usos de uma formulação, de um conjugado de droga e anticorpo e um agente quimioterapêutico e de uma combinação
|
KR20130099228A
(ko)
|
2004-06-04 |
2013-09-05 |
제넨테크, 인크. |
다발성 경화증의 치료 방법
|
WO2005120462A2
(en)
*
|
2004-06-07 |
2005-12-22 |
Callisyn Pharmaceuticals, Inc. |
Biodegradable and biocompatible crosslinked polymer hydrogel prepared from pva and/or peg macromer mixtures
|
EP2270160A1
(en)
|
2004-06-14 |
2011-01-05 |
Galapagos N.V. |
Methods for identification, and compounds useful for the treatment of degenerative and inflammatory diseases
|
GT200500155A
(es)
|
2004-06-16 |
2006-05-15 |
|
Terapia del càncer resistente al platino
|
NZ551335A
(en)
|
2004-06-18 |
2010-03-26 |
Ambrx Inc |
Antibodies and fragments thereof comprising an non naturally encoded amino acid coupled to a linker
|
ES2427046T3
(es)
|
2004-06-21 |
2013-10-28 |
Galapagos N.V. |
Métodos y medios para el tratamiento de la osteoartritis
|
EP2298896A1
(en)
|
2004-06-22 |
2011-03-23 |
The Board of Trustees of the University of Illinois |
Methods of inhibiting tumor cell proliferation with FOXM1 siRNA
|
CA3052445C
(en)
|
2004-07-10 |
2023-08-22 |
Kerry S. Campbell |
Genetically modified human natural killer cell lines
|
EP2940043A1
(en)
|
2004-07-15 |
2015-11-04 |
Xencor, Inc. |
Optimized fc variants
|
ME00226B
(me)
|
2004-07-15 |
2011-02-10 |
Medarex Llc |
Humana anti-ngf neutrališuća antitijela kao selektivni inhibitori ngf signalne kaskade
|
CN102641503A
(zh)
|
2004-07-20 |
2012-08-22 |
健泰科生物技术公司 |
血管生成素样4蛋白抑制剂,组合,以及其用途
|
BRPI0512396A
(pt)
|
2004-07-21 |
2008-03-11 |
Ambrx Inc |
polipeptìdeos biossintéticos utilizando aminoácidos codificados não naturalmente
|
PT1781264E
(pt)
|
2004-08-04 |
2013-10-16 |
Evonik Corp |
Métodos para o fabrico de dispositivis de administração e dispositivos para a mesma
|
ES2414460T3
(es)
|
2004-08-04 |
2013-07-19 |
Amgen Inc. |
Anticuerpos para Dkk-1
|
AU2005277384B2
(en)
|
2004-08-17 |
2011-11-17 |
The Johns Hopkins University |
PDE5 inhibitor compositions and methods for treating cardiac indications
|
US7393662B2
(en)
|
2004-09-03 |
2008-07-01 |
Centocor, Inc. |
Human EPO mimetic hinge core mimetibodies, compositions, methods and uses
|
DK1784426T3
(da)
|
2004-09-03 |
2012-03-12 |
Genentech Inc |
Humaniserede anti-beta7-antagonister og anvendelser deraf
|
US20100111856A1
(en)
|
2004-09-23 |
2010-05-06 |
Herman Gill |
Zirconium-radiolabeled, cysteine engineered antibody conjugates
|
PL1791565T3
(pl)
|
2004-09-23 |
2016-10-31 |
|
Modyfikowane cysteiną przeciwciała i koniugaty
|
WO2006037182A1
(en)
|
2004-10-06 |
2006-04-13 |
Agri-Biotech Pty Ltd |
Antibody production method
|
JP4852773B2
(ja)
|
2004-10-15 |
2012-01-11 |
国立大学法人三重大学 |
肝再生・修復制御剤
|
US7485468B2
(en)
|
2004-10-15 |
2009-02-03 |
Galapagos Bv |
Molecular targets and compounds, and methods to identify the same, useful in the treatment of joint degenerative and inflammatory diseases
|
PL1802334T3
(pl)
|
2004-10-21 |
2013-01-31 |
Genentech Inc |
Sposób leczenia wewnątrzgałkowych chorób neowaskularnych
|
WO2006052723A2
(en)
|
2004-11-04 |
2006-05-18 |
New England Medical Center Hospitals, Inc. |
G protein coupled receptor agonists and antagonists and methods of use
|
EP1817055B1
(en)
|
2004-11-10 |
2012-12-26 |
Diadexus, Inc. |
Ovr110 antibody compositions and methods of use
|
EP1817340B1
(en)
|
2004-11-12 |
2012-05-16 |
Xencor, Inc. |
Fc variants with altered binding to fcrn
|
US8546543B2
(en)
|
2004-11-12 |
2013-10-01 |
Xencor, Inc. |
Fc variants that extend antibody half-life
|
US8802820B2
(en)
|
2004-11-12 |
2014-08-12 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
US8367805B2
(en)
|
2004-11-12 |
2013-02-05 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
ATE492563T1
(de)
|
2004-11-17 |
2011-01-15 |
Amgen Inc |
Vollständige humane monoklonale antikörper gegen il-13
|
EP1817059A2
(en)
|
2004-12-01 |
2007-08-15 |
Genentech, Inc. |
Conjugates of 1,8-bis-naphthalimides with an antibody
|
AU2005314252B2
(en)
|
2004-12-06 |
2012-09-27 |
Siga Technologies, Inc. |
Compounds and methods for treating hemorrhagic fever viruses
|
AU2005319404B2
(en)
|
2004-12-20 |
2011-10-20 |
Amgen Fremont Inc. |
Binding proteins specific for human Matriptase
|
KR101017301B1
(ko)
|
2004-12-21 |
2011-02-28 |
메드임뮨 리미티드 |
앤지오포이에틴-2에 대한 항체 및 그의 용도
|
AU2005319518B2
(en)
*
|
2004-12-22 |
2010-09-09 |
Ambrx, Inc. |
Compositions of aminoacyl-tRNA synthetase and uses thereof
|
BRPI0516385B1
(pt)
|
2004-12-22 |
2021-07-20 |
Ambrx, Inc. |
Composto ou sal do mesmo contendo aminoácidos não naturais e polipeptídeos, métodos para produção e derivatização de um polipeptídeo
|
NZ584597A
(en)
|
2004-12-22 |
2011-09-30 |
Ambrx Inc |
Modified human growth hormone
|
WO2006073846A2
(en)
|
2004-12-22 |
2006-07-13 |
Ambrx, Inc. |
Methods for expression and purification of recombinant human growth hormone
|
CN103520735B
(zh)
|
2004-12-22 |
2015-11-25 |
Ambrx公司 |
包含非天然编码的氨基酸的人生长激素配方
|
ES2343746T3
(es)
|
2005-01-07 |
2010-08-09 |
Diadexus, Inc. |
Composiciones de anticuerpo ovr110 y metodos de uso.
|
EP1841454A4
(en)
*
|
2005-01-13 |
2009-07-22 |
Genentech Inc |
PROCESSING METHOD
|
TWI441646B
(zh)
|
2005-01-21 |
2014-06-21 |
Genentech Inc |
帕妥珠單抗(pertuzumab)用於製備治療人類病患癌症之藥物的用途
|
AU2006208286A1
(en)
|
2005-01-26 |
2006-08-03 |
Amgen Fremont Inc. |
Antibodies against interleukin-1 beta
|
US11246913B2
(en)
|
2005-02-03 |
2022-02-15 |
Intarcia Therapeutics, Inc. |
Suspension formulation comprising an insulinotropic peptide
|
EP1871805B1
(en)
|
2005-02-07 |
2019-09-25 |
Roche Glycart AG |
Antigen binding molecules that bind egfr, vectors encoding same, and uses thereof
|
DK1853718T3
(en)
|
2005-02-15 |
2015-11-09 |
Univ Duke |
ANTI-CD19 ANTIBODIES AND THEIR USE IN ONCOLOGY
|
WO2006089141A2
(en)
|
2005-02-18 |
2006-08-24 |
Dana-Farber Cancer Institute |
Antibodies against cxcr4 and methods of use thereof
|
CN101163503B
(zh)
|
2005-02-23 |
2013-05-08 |
健泰科生物技术公司 |
使用her二聚化抑制剂在癌症患者中延长病情进展前时间或存活
|
TW200714289A
(en)
*
|
2005-02-28 |
2007-04-16 |
Genentech Inc |
Treatment of bone disorders
|
US20060281680A1
(en)
|
2005-03-10 |
2006-12-14 |
Genentech, Inc. |
Methods and compositions for modulating vascular integrity
|
EP1871407A2
(en)
*
|
2005-03-31 |
2008-01-02 |
The University Of Chicago |
Compositions comprising wnt-3 peptide for modulating medial-lateral neuronal topographic maps
|
PT1876236E
(pt)
|
2005-04-08 |
2014-10-22 |
Chugai Pharmaceutical Co Ltd |
Anticorpos para substituição da função do factor de coagulação sanguínea viii
|
WO2006109045A2
(en)
|
2005-04-09 |
2006-10-19 |
Fusion Antibodies Limited |
Cathepsin s antibody
|
US20090054320A1
(en)
*
|
2005-04-20 |
2009-02-26 |
Protemix Discovery Limited |
Vesiculins
|
PA8672101A1
(es)
|
2005-04-29 |
2006-12-07 |
Centocor Inc |
Anticuerpos anti-il-6, composiciones, métodos y usos
|
JP5047947B2
(ja)
|
2005-05-05 |
2012-10-10 |
デューク ユニバーシティ |
自己免疫疾患のための抗cd19抗体治療
|
US20080009546A1
(en)
|
2005-05-06 |
2008-01-10 |
Chevron U.S.A. Inc. |
Diamondoid derivatives possessing therapeutic activity in the treatment of neurologic disorders
|
KR101443050B1
(ko)
|
2005-05-06 |
2014-09-22 |
지모제넥틱스, 인코포레이티드 |
Il-31 단클론성 항체 및 사용법
|
AU2006298519A1
(en)
*
|
2005-05-09 |
2007-04-12 |
Glycart Biotechnology Ag |
Antigen binding molecules having modified Fc regions and altered binding to Fc receptors
|
WO2006124627A2
(en)
*
|
2005-05-12 |
2006-11-23 |
Biogen Idec Ma Inc. |
Methods of treating conditions involving neuronal degeneration
|
CA2605508A1
(en)
*
|
2005-05-12 |
2006-11-23 |
Wisconsin Alumni Research Foundation |
Blockade of pin1 prevents cytokine production by activated immune cells
|
US8124084B2
(en)
|
2005-05-17 |
2012-02-28 |
University Of Connecticut |
Compositions and methods for immunomodulation in an organism using IL-15 and soluble IL-15Ra
|
PL2444079T3
(pl)
|
2005-05-17 |
2017-07-31 |
Sarcode Bioscience Inc. |
Kompozycje i sposoby leczenia chorób oczu
|
MX2007015058A
(es)
*
|
2005-06-03 |
2008-01-28 |
Ambrx Inc |
Moleculas de interferon humano mejoradas y sus usos.
|
EP2186402A1
(en)
|
2005-06-06 |
2010-05-19 |
Genentech, Inc. |
Knock-out animal models for novel genes and methods of use
|
KR101367544B1
(ko)
|
2005-06-10 |
2014-02-26 |
추가이 세이야쿠 가부시키가이샤 |
메글루민을 함유하는 단백질 제제의 안정화제, 및 그의이용
|
JP5224580B2
(ja)
|
2005-06-10 |
2013-07-03 |
中外製薬株式会社 |
sc(Fv)2部位特異的変異体
|
GB0511986D0
(en)
*
|
2005-06-13 |
2005-07-20 |
Imp College Innovations Ltd |
Novel compounds and their effects on feeding behaviour
|
CA2610839C
(en)
|
2005-06-14 |
2019-06-25 |
Amgen Inc. |
Self-buffering protein formulations
|
JP4931919B2
(ja)
|
2005-06-21 |
2012-05-16 |
ゾーマ テクノロジー リミテッド |
IL−1β結合抗体およびその断片
|
LT2452694T
(lt)
|
2005-06-30 |
2019-02-25 |
Janssen Biotech, Inc. |
Anti-il-23 antikūnai, kompozicijos, būdai ir panaudojimai
|
CN104072614B
(zh)
|
2005-07-08 |
2017-04-26 |
生物基因Ma公司 |
抗-αvβ6 抗体及其用途
|
EP2004695A2
(en)
|
2005-07-08 |
2008-12-24 |
Xencor, Inc. |
Optimized anti-ep-cam antibodies
|
JP5756588B2
(ja)
|
2005-07-15 |
2015-07-29 |
ミセル テクノロジーズ、インコーポレイテッド |
制御されたモルホロジーの薬剤粉末を含むポリマーコーティング
|
US20090062909A1
(en)
|
2005-07-15 |
2009-03-05 |
Micell Technologies, Inc. |
Stent with polymer coating containing amorphous rapamycin
|
CN101321783B
(zh)
*
|
2005-07-18 |
2015-08-26 |
安姆根有限公司 |
人抗-b7rp1中和抗体
|
EP1909812A4
(en)
|
2005-07-27 |
2009-11-25 |
Univ Florida |
SMALL CONNECTIONS FOR THE CORRECTION OF PROTEIN MISFAIRINGS AND USES THEREOF
|
EP2277916A3
(en)
*
|
2005-07-28 |
2011-04-27 |
Novartis AG |
Use of antibody to M-CSF
|
US8652469B2
(en)
*
|
2005-07-28 |
2014-02-18 |
Novartis Ag |
M-CSF-specific monoclonal antibody and uses thereof
|
KR20080039978A
(ko)
|
2005-08-11 |
2008-05-07 |
알피 마토씨안-로저스 |
자가면역 질병의 치료 및 진단용 tcr-v-베타 관련펩티드
|
AU2006280321A1
(en)
|
2005-08-15 |
2007-02-22 |
Genentech, Inc. |
Gene disruptions, compositions and methods relating thereto
|
DK1937824T3
(da)
*
|
2005-08-18 |
2013-04-02 |
Ambrx Inc |
Sammensætninger af tRNA og anvendelser deraf
|
SG192479A1
(en)
|
2005-08-26 |
2013-08-30 |
Roche Glycart Ag |
Modified antigen binding molecules with altered cell signaling activity
|
AU2006287562B2
(en)
|
2005-09-08 |
2012-05-10 |
Trustees Of Tufts College |
Stabilized GLP-1 analogs
|
CN106474118A
(zh)
|
2005-09-19 |
2017-03-08 |
诺伊罗纳森特公司 |
刺激神经形成和抑制神经元变性的方法和组合物
|
CA2625447C
(en)
|
2005-09-29 |
2015-06-09 |
Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. |
Compositions and methods for stimulating gastrointestinal motility
|
WO2007041635A2
(en)
|
2005-10-03 |
2007-04-12 |
Xencor, Inc. |
Fc variants with optimized fc receptor binding properties
|
NZ597082A
(en)
|
2005-10-13 |
2013-11-29 |
Human Genome Sciences Inc |
Methods and Compositions for Use in Treatment of Patients with Autoantibody Positive Diseases
|
CA2625773C
(en)
|
2005-10-14 |
2015-05-12 |
Fukuoka University |
Inhibition of interleukin-6 (il-6) receptor promotes pancreatic islet transplantation
|
KR101239051B1
(ko)
|
2005-10-21 |
2013-03-04 |
추가이 세이야쿠 가부시키가이샤 |
심장질환 치료제
|
EP1961065A4
(en)
|
2005-10-31 |
2009-11-11 |
Oncomed Pharm Inc |
COMPOSITIONS AND METHOD FOR DIAGNOSIS AND TREATMENT OF CANCER
|
WO2007117505A2
(en)
|
2006-04-05 |
2007-10-18 |
The Rockefeller University |
Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
|
EP1957099B1
(en)
|
2005-11-07 |
2015-03-25 |
The Rockefeller University |
Reagents, methods and systems for selecting a cytotoxic antibody or variant thereof
|
US8679490B2
(en)
|
2005-11-07 |
2014-03-25 |
Genentech, Inc. |
Binding polypeptides with diversified and consensus VH/VL hypervariable sequences
|
WO2007056448A2
(en)
*
|
2005-11-08 |
2007-05-18 |
Ambrx, Inc. |
Accelerants for the modification of non-natural amino acids and non-natural amino acid polypeptides
|
UA96139C2
(uk)
|
2005-11-08 |
2011-10-10 |
Дженентек, Інк. |
Антитіло до нейропіліну-1 (nrp1)
|
AU2006315580A1
(en)
|
2005-11-10 |
2007-05-24 |
Curagen Corporation |
Method of treating ovarian and renal cancer using antibodies against T cell immunoglobulin domain and mucin domain 1 (TIM-1) antigen
|
WO2007054623A2
(en)
*
|
2005-11-11 |
2007-05-18 |
Licentia Oy |
Mammalian hedgehog signaling inhiabitors
|
JP5398987B2
(ja)
|
2005-11-14 |
2014-01-29 |
セルミド リミテッド |
調節性t細胞の機能異常に基づく疾患の治療方法及び予防方法
|
AR056806A1
(es)
|
2005-11-14 |
2007-10-24 |
Amgen Inc |
Moleculas quimericas de anticuerpo rankl- pth/ pthrp
|
EA015526B1
(ru)
|
2005-11-14 |
2011-08-30 |
Ринат Ньюросайенс Корп. |
Антагонистические антитела против пептида, связанного с геном кальцитонина, и способы их применения
|
MY149159A
(en)
|
2005-11-15 |
2013-07-31 |
Hoffmann La Roche |
Method for treating joint damage
|
JP5134548B2
(ja)
|
2005-11-15 |
2013-01-30 |
アレイ バイオファーマ、インコーポレイテッド |
過剰増殖性疾患の処置のためのErbBI型受容体チロシンキナーゼ阻害剤としてのN4−フェニルキナゾリン−4−アミン誘導体および関連化合物
|
AR057582A1
(es)
|
2005-11-15 |
2007-12-05 |
Nat Hospital Organization |
Agentes para suprimir la induccion de linfocitos t citotoxicos
|
ES2547554T3
(es)
|
2005-11-16 |
2015-10-07 |
Ambrx, Inc. |
Métodos y composiciones que comprenden aminoácidos no naturales
|
WO2007056858A1
(en)
|
2005-11-18 |
2007-05-24 |
Glenmark Pharmaceuticals S.A. |
Anti-alpha2 integrin antibodies and their uses
|
JP2009516514A
(ja)
|
2005-11-21 |
2009-04-23 |
ジェネンテック・インコーポレーテッド |
新規遺伝子破壊、それらに関する組成物および方法
|
ES2618543T3
(es)
*
|
2005-11-23 |
2017-06-21 |
Genentech, Inc. |
Métodos y composiciones relacionados con ensayos de linfocitos B
|
JPWO2007061029A1
(ja)
|
2005-11-25 |
2009-05-07 |
学校法人慶應義塾 |
前立腺癌治療剤
|
EP2316483A1
(en)
|
2005-12-01 |
2011-05-04 |
The Provost Fellows And Scholars Of The College Of The Holy and Undivided Trinity Of Queen Elizabeth Near Dublin |
Compositions and methods relating to the treatment of cancer and infectious diseases
|
US20070213264A1
(en)
|
2005-12-02 |
2007-09-13 |
Mingdong Zhou |
Neuregulin variants and methods of screening and using thereof
|
EP1954719A2
(en)
|
2005-12-02 |
2008-08-13 |
Genentech Inc. |
Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to il-22 and il-22r
|
US8466263B2
(en)
*
|
2005-12-02 |
2013-06-18 |
Dana-Farber Cancer Institute, Inc. |
Carbonic anhydrase IX (G250) anitbodies
|
EP1973951A2
(en)
*
|
2005-12-02 |
2008-10-01 |
Genentech, Inc. |
Binding polypeptides with restricted diversity sequences
|
EP1957540B1
(en)
*
|
2005-12-02 |
2012-06-13 |
Genentech, Inc. |
Binding polypeptides and uses thereof
|
US8105601B2
(en)
*
|
2005-12-05 |
2012-01-31 |
The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin |
Compositions and methods for modulating an immune response
|
US8158588B2
(en)
*
|
2005-12-05 |
2012-04-17 |
Simon Delagrave |
Loop-variant PDZ domains as biotherapeutics, diagnostics and research reagents
|
CA2633956C
(en)
|
2005-12-13 |
2016-12-06 |
Olivia Raeber |
Binding proteins specific for insulin-like growth factors and uses thereof
|
JP5539649B2
(ja)
|
2005-12-13 |
2014-07-02 |
プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ |
細胞移植のための足場
|
ES2529065T3
(es)
*
|
2005-12-14 |
2015-02-16 |
Ambrx, Inc. |
Composiciones que contienen, procedimientos que implican y usos de aminoácidos no naturales y polipéptidos
|
ES2352205T3
(es)
|
2005-12-14 |
2011-02-16 |
Licentia Ltd. |
Usos de una proteína del factor neurotrófico.
|
EP2325208B1
(en)
|
2005-12-15 |
2017-09-20 |
Genentech, Inc. |
Polyubiquitin antibodies
|
BRPI0619853A2
(pt)
|
2005-12-15 |
2016-08-23 |
Astrazeneca Ab |
combinação, composição farmacêutica, e, métodos de antagonização da atividade biológica, de tratamento de angiogênese relacionada à doença em um mamífero e de tratamento de câncer em um mamífero
|
JP2009520023A
(ja)
|
2005-12-20 |
2009-05-21 |
セリュウサイエンス エイビー |
下肢静止不能症候群を治療及び診断するための方法及び組成物
|
KR101458728B1
(ko)
*
|
2005-12-22 |
2014-11-05 |
노파르티스 아게 |
옥트레오티드 및 2종 이상의 폴리락티드-코-글리콜리드 중합체를 포함하는 서방형 제제
|
US8138361B2
(en)
*
|
2005-12-28 |
2012-03-20 |
The Trustees Of The University Of Pennsylvania |
C-10 carbamates of taxanes
|
DK3219328T3
(da)
|
2005-12-29 |
2020-07-13 |
Janssen Biotech Inc |
Humane anti-il-23-antistoffer, sammensætninger, fremgangsmåder og anvendelser
|
EP2918283B1
(en)
|
2005-12-30 |
2018-01-31 |
Zensun (Shanghai) Science & Technology, Co., Ltd. |
Extended release of neuregulin for improved cardiac function
|
EP1973950B1
(en)
|
2006-01-05 |
2014-09-17 |
Genentech, Inc. |
Anti-ephb4 antibodies and methods using the same
|
RU2470665C2
(ru)
|
2006-01-05 |
2012-12-27 |
Новартис Аг |
Способы профилактики и лечения ракового метастаза и разрежения кости, связанного с раковым метастазом
|
JPWO2007083644A1
(ja)
|
2006-01-17 |
2009-06-11 |
ディナベック株式会社 |
新規タンパク質発現系
|
DK2264060T3
(da)
|
2006-01-26 |
2014-07-28 |
Recopharma Ab |
Sammensætninger og fremgangsmåder til inhibering af viral adhæsion
|
WO2007086490A1
(ja)
|
2006-01-27 |
2007-08-02 |
Keio University |
脈絡膜血管新生を伴う疾患の治療剤
|
US7756524B1
(en)
|
2006-01-31 |
2010-07-13 |
Nextel Communications Inc. |
System and method for partially count-based allocation of vocoder resources
|
CA2637707A1
(en)
*
|
2006-02-02 |
2007-08-09 |
Rinat Neuroscience Corporation |
Methods for treating obesity by administering a trkb antagonist
|
EP1988923A1
(en)
*
|
2006-02-02 |
2008-11-12 |
Rinat Neuroscience Corp. |
Methods for treating unwanted weight loss or eating disorders by administering a trkb agonist
|
EP1818395A1
(en)
|
2006-02-08 |
2007-08-15 |
Diatos |
Compositions and methods for treating lysosomal storage diseases
|
US20090221072A1
(en)
*
|
2006-02-15 |
2009-09-03 |
Chen Thomas T |
Compositions and methods for modulating cell differentiation
|
AU2007233263A1
(en)
|
2006-02-17 |
2007-10-11 |
Genentech, Inc. |
Gene disruptons, compositions and methods relating thereto
|
GB0604187D0
(en)
*
|
2006-03-02 |
2006-04-12 |
Fusion Antibodies Ltd |
Peptide and uses thereof
|
EP1999148B8
(en)
|
2006-03-06 |
2014-03-05 |
Medlmmune, LLC |
Humanized anti-cd22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
|
MX2008011220A
(es)
|
2006-03-07 |
2008-09-11 |
Array Biopharma Inc |
Compuestos de pirazol heterobiciclicos y metodos de uso.
|
US7504106B2
(en)
*
|
2006-03-14 |
2009-03-17 |
Boris Skurkovich |
Method and composition for treatment of renal failure with antibodies and their equivalents as partial or complete replacement for dialysis
|
AR059851A1
(es)
|
2006-03-16 |
2008-04-30 |
Genentech Inc |
Anticuerpos de la egfl7 y metodos de uso
|
US20090220504A1
(en)
|
2006-03-21 |
2009-09-03 |
Anan Chuntharapai |
Combinatorial therapy
|
KR101440634B1
(ko)
|
2006-03-24 |
2014-09-22 |
어레이 바이오파마 인크. |
글루코키나제 활성제로서의 2-아미노피리딘 유사체
|
US20100034819A1
(en)
*
|
2006-03-31 |
2010-02-11 |
Centocor Inc. |
Human epo mimetic hinge core mimetibodies, compositions, methods and uses for preventing or treating glucose intolerance related conditions on renal disease associated anemia
|
US8426387B2
(en)
*
|
2006-03-31 |
2013-04-23 |
Stephen Carper |
Treatments for cancer
|
EP2614839A3
(en)
|
2006-04-05 |
2015-01-28 |
Genentech, Inc. |
Method for using BOC/CDO to modulate hedgehog signaling
|
CA2648644C
(en)
|
2006-04-07 |
2016-01-05 |
Osaka University |
Muscle regeneration promoter
|
TW200813091A
(en)
|
2006-04-10 |
2008-03-16 |
Amgen Fremont Inc |
Targeted binding agents directed to uPAR and uses thereof
|
GB0620255D0
(en)
*
|
2006-10-12 |
2006-11-22 |
Fusion Antibodies Ltd |
Antibody and uses thereof
|
JP5796267B2
(ja)
*
|
2006-04-10 |
2015-10-21 |
フージョン アンティボディーズ リミテッド |
治療法
|
EP2010662A2
(en)
|
2006-04-19 |
2009-01-07 |
Genentech, Inc. |
Novel gene disruptions, compositions and methods relating thereto
|
TWI395754B
(zh)
|
2006-04-24 |
2013-05-11 |
Amgen Inc |
人類化之c-kit抗體
|
WO2007127175A2
(en)
|
2006-04-26 |
2007-11-08 |
F. Hoffmann-La Roche Ag |
Pharmaceutical compounds
|
EP2246354A1
(en)
|
2006-04-26 |
2010-11-03 |
F. Hoffmann-La Roche AG |
Thieno[3,2-d]pyrimidine derivative useful as PI3K inhibitor
|
PL2019657T3
(pl)
|
2006-04-26 |
2015-10-30 |
Micell Technologies Inc |
Powłoki zawierające wiele leków
|
WO2007127936A2
(en)
|
2006-04-27 |
2007-11-08 |
Pikamab, Inc. |
Methods and compositions for antibody therapy
|
US20070259820A1
(en)
*
|
2006-05-03 |
2007-11-08 |
The Regents Of The University Of Michigan |
Methods and reagents for activating heat shock protein 70
|
ES2429225T3
(es)
|
2006-05-17 |
2013-11-13 |
The Ludwig Institute For Cancer Research |
Anticuerpos anti VEGF-B para tratamiento o profilaxis de diabetes de tipo II o síndrome metabólico
|
WO2007139589A1
(en)
|
2006-05-26 |
2007-12-06 |
Bristol-Myers Squibb Company |
Sustained release glp-1 receptor modulators
|
SG172656A1
(en)
|
2006-05-30 |
2011-07-28 |
Genentech Inc |
Antibodies and immunoconjugates and uses therefor
|
US9274130B2
(en)
|
2006-05-31 |
2016-03-01 |
Lpath, Inc. |
Prevention and treatment of pain using antibodies to lysophosphatidic acid
|
JP2009538916A
(ja)
|
2006-05-31 |
2009-11-12 |
タリオン ファーマシューティカルズ インコーポレーテッド |
志賀毒素関連病状を治療するための方法、組成物、およびキット
|
US8796429B2
(en)
*
|
2006-05-31 |
2014-08-05 |
Lpath, Inc. |
Bioactive lipid derivatives, and methods of making and using same
|
US9274129B2
(en)
*
|
2006-05-31 |
2016-03-01 |
Lpath, Inc. |
Methods and reagents for detecting bioactive lipids
|
US9217749B2
(en)
*
|
2006-05-31 |
2015-12-22 |
Lpath, Inc. |
Immune-derived moieties reactive against lysophosphatidic acid
|
US7862812B2
(en)
|
2006-05-31 |
2011-01-04 |
Lpath, Inc. |
Methods for decreasing immune response and treating immune conditions
|
AU2007297869A1
(en)
|
2006-06-01 |
2008-03-27 |
Genentech, Inc. |
Crystal structure of CRig and C3b: CRig complex
|
US8124743B2
(en)
*
|
2006-06-01 |
2012-02-28 |
President And Fellows Of Harvard College |
Purification of a bivalently active antibody using a non-chromatographic method
|
MX2008015568A
(es)
|
2006-06-08 |
2009-01-13 |
Chugai Pharmaceutical Co Ltd |
Agentes para prevenir o tratar enfermedades inflamatorias.
|
GB0611405D0
(en)
|
2006-06-09 |
2006-07-19 |
Univ Belfast |
FKBP-L: A novel inhibitor of angiogenesis
|
UA95641C2
(en)
|
2006-07-06 |
2011-08-25 |
Эррей Биофарма Инк. |
Hydroxylated cyclopenta [d] pyrimidines as akt protein kinase inhibitors
|
SG173364A1
(en)
|
2006-07-10 |
2011-08-29 |
Biogen Idec Inc |
Compositions and methods for inhibiting growth of smad4-deficient cancers
|
JP5248494B2
(ja)
|
2006-07-11 |
2013-07-31 |
ユニバーシティ・オブ・メディシン・アンド・デンティストリー・オブ・ニュージャージー |
タンパク質、それをコードする核酸および関連する使用方法
|
CA2657385A1
(en)
|
2006-07-13 |
2008-01-17 |
Naoki Kimura |
Cell death inducer
|
US20080015546A1
(en)
*
|
2006-07-13 |
2008-01-17 |
Casas Jesus W |
Methods and formulations for optimal local delivery of cell therapy via minimally invasive procedures
|
WO2008011513A2
(en)
|
2006-07-19 |
2008-01-24 |
The Cleveland Clinic Foundation |
Compounds and methods of modulating angiogenesis
|
AU2007275654A1
(en)
|
2006-07-19 |
2008-01-24 |
The Trustees Of The University Of Pennsylvania |
WSX-1/p28 as a target for anti-inflammatory responses
|
JP5175729B2
(ja)
|
2006-07-21 |
2013-04-03 |
中外製薬株式会社 |
腎疾患治療剤
|
US20080038258A1
(en)
*
|
2006-07-21 |
2008-02-14 |
Amgen Inc. |
Polypeptides with Reduced Susceptibility to Oxidation and Methods of Making
|
WO2008014426A2
(en)
|
2006-07-28 |
2008-01-31 |
Children's Memorial Hospital |
Methods of inhibiting tumor cell aggressiveness using the microenvironment of human embryonic stem cells
|
CL2007002225A1
(es)
|
2006-08-03 |
2008-04-18 |
Astrazeneca Ab |
Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un
|
US8586716B2
(en)
|
2006-08-04 |
2013-11-19 |
Novartis Ag |
EPHB3-specific antibody and uses thereof
|
US9505823B2
(en)
*
|
2006-08-07 |
2016-11-29 |
TEV A Biopharmaceuticals USA, Inc. |
Albumin-insulin fusion proteins
|
EP2359808B1
(en)
|
2006-08-09 |
2013-05-22 |
Intarcia Therapeutics, Inc |
Osmotic delivery systems and piston assemblies
|
AR062223A1
(es)
|
2006-08-09 |
2008-10-22 |
Glycart Biotechnology Ag |
Moleculas de adhesion al antigeno que se adhieren a egfr, vectores que los codifican, y sus usos de estas
|
GEP20125612B
(en)
|
2006-08-18 |
2012-08-27 |
Novartis Ag |
Prlr-specific antibody and usage thereof
|
WO2008023077A2
(en)
*
|
2006-08-25 |
2008-02-28 |
The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth, Near Dublin |
Compositions and methods for modulating an immune response
|
KR101374983B1
(ko)
|
2006-08-28 |
2014-03-17 |
라 졸라 인스티튜트 포 앨러지 앤드 이뮤놀로지 |
길항성 인간 light-특이적 인간 모노클로날 항체를 포함하는 제약 조성물
|
DK2059533T3
(da)
|
2006-08-30 |
2013-02-25 |
Genentech Inc |
Multispecifikke antistoffer
|
CN101511348B
(zh)
*
|
2006-08-30 |
2012-04-18 |
国立大学法人九州大学 |
含有包封他汀类之纳米颗粒的药物组合物
|
KR101501660B1
(ko)
|
2006-09-01 |
2015-03-11 |
지모제넥틱스, 인코포레이티드 |
Il―31 단클론 항체의 가변 영역 서열 및 사용 방법
|
PT2061878E
(pt)
*
|
2006-09-08 |
2014-04-22 |
Ambrx Inc |
Supressor híbrido arnt para células de vertebrados
|
EP2069396B1
(en)
|
2006-09-08 |
2015-10-21 |
Ambrx, Inc. |
Modified human plasma polypeptide or fc scaffolds and their uses
|
US8420792B2
(en)
*
|
2006-09-08 |
2013-04-16 |
Ambrx, Inc. |
Suppressor tRNA transcription in vertebrate cells
|
US20100008910A1
(en)
|
2006-09-12 |
2010-01-14 |
John Chant |
Methods and compositions for the diagnosis and treatment of cancer
|
EP1905841A1
(en)
*
|
2006-09-25 |
2008-04-02 |
Max Delbrück Centrum für Molekulare Medizin (MDC) Berlin-Buch; |
Trex1 as a marker for lupus erythematosus
|
JP5105554B2
(ja)
|
2006-09-28 |
2012-12-26 |
メルク・シャープ・アンド・ドーム・コーポレーション |
癌を処置するためのペグ化il−10の使用
|
EA018260B1
(ru)
|
2006-09-29 |
2013-06-28 |
Онкомед Фармасьютикалз, Инк. |
Антитела к дельта-подобному лиганду 4 человека и их применение
|
US7833527B2
(en)
|
2006-10-02 |
2010-11-16 |
Amgen Inc. |
Methods of treating psoriasis using IL-17 Receptor A antibodies
|
EP2099467B1
(en)
|
2006-10-03 |
2017-05-10 |
University Of Medicine And Dentistry Of New Jersey |
Atap peptides, nucleic acids encoding the same and associated methods of use
|
EP2087113A2
(en)
*
|
2006-10-11 |
2009-08-12 |
Fusion Antibodies Limited |
Combination therapy
|
US7923011B2
(en)
*
|
2006-10-12 |
2011-04-12 |
Genentech, Inc. |
Antibodies to lymphotoxin-alpha
|
AU2007311137B2
(en)
*
|
2006-10-16 |
2013-06-20 |
The Salk Institute For Biological Studies |
Receptor(SSTR2)-selective somatostatin antagonists
|
US8691761B2
(en)
*
|
2006-10-16 |
2014-04-08 |
Jean E. F. Rivier |
Somatostatin receptor 2 antagonists
|
AU2007311052B2
(en)
*
|
2006-10-20 |
2014-01-16 |
Biogen Idec Ma Inc. |
Treatment of demyelinating disorders with soluble lymphotoxin-beta-receptor
|
US8338376B2
(en)
*
|
2006-10-20 |
2012-12-25 |
Biogen Idec Ma Inc. |
Compositions comprising variant LT-B-R-IG fusion proteins
|
AU2007313822A1
(en)
|
2006-10-27 |
2008-05-08 |
Lpath, Inc. |
Compositions and methods for treating ocular diseases and conditions
|
CN101679506B
(zh)
*
|
2006-10-27 |
2015-02-25 |
勒帕斯公司 |
用于结合鞘氨醇-1-磷酸的组合物和方法
|
DK2845866T3
(en)
|
2006-10-27 |
2017-07-10 |
Genentech Inc |
Antibodies and immunoconjugates and their applications
|
KR20090078364A
(ko)
|
2006-11-02 |
2009-07-17 |
제넨테크, 인크. |
인간화 항-d 인자 항체
|
EP2503341A3
(en)
|
2006-11-14 |
2012-10-03 |
Genentech, Inc. |
Modulators of Neuronal Regeneration
|
EP2727936B1
(en)
|
2006-11-22 |
2016-09-07 |
Bristol-Myers Squibb Company |
Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including IGF-IR
|
AU2007325283B2
(en)
|
2006-11-27 |
2012-08-30 |
Diadexus, Inc. |
Ovr110 antibody compositions and methods of use
|
AU2007329352B2
(en)
|
2006-12-07 |
2013-01-17 |
F. Hoffmann-La Roche Ag |
Phosphoinositide 3-kinase inhibitor compounds and methods of use
|
AU2007329307B2
(en)
|
2006-12-07 |
2012-08-02 |
Novartis Ag |
Antagonist antibodies against EphB3
|
MX2009006082A
(es)
|
2006-12-08 |
2009-08-18 |
Lexicon Pharmaceuticals Inc |
Anticuerpos monoclonales contra la proteina 3 similar a angiopoyetina (angptl3).
|
TWI428346B
(zh)
*
|
2006-12-13 |
2014-03-01 |
Imp Innovations Ltd |
新穎化合物及其等對進食行為影響
|
JP4564098B2
(ja)
|
2006-12-18 |
2010-10-20 |
武田薬品工業株式会社 |
徐放性組成物およびその製造法
|
TWI419904B
(zh)
|
2006-12-18 |
2013-12-21 |
Genentech Inc |
拮抗劑抗-notch3抗體及其用於預防及治療notch3相關疾病之用途
|
CN103143017A
(zh)
|
2006-12-19 |
2013-06-12 |
基因技术公司 |
用于辅助和新辅助疗法以及早期肿瘤的治疗的vegf特异性拮抗剂
|
KR20090091181A
(ko)
*
|
2006-12-20 |
2009-08-26 |
리나트 뉴로사이언스 코퍼레이션 |
자가면역 장애의 치료를 위한 티로신 수용체 키나아제 b 작용제
|
CA2673592C
(en)
|
2006-12-20 |
2014-03-25 |
Xoma Technology Ltd. |
Methods for the treatment of il-1.beta. related diseases
|
UY30820A1
(es)
*
|
2006-12-21 |
2008-07-03 |
Centocor Inc |
Uso de agonistas del receptor de glp-1 de accion prolongada para mejorar la sensibilidad a la insulina y los perfiles lipidicos
|
CN101711137B
(zh)
|
2007-01-08 |
2014-10-22 |
米歇尔技术公司 |
具有可生物降解层的支架
|
US11426494B2
(en)
|
2007-01-08 |
2022-08-30 |
MT Acquisition Holdings LLC |
Stents having biodegradable layers
|
ES2610474T3
(es)
|
2007-01-11 |
2017-04-27 |
Michael Bacher |
Diagnóstico y tratamiento de la enfermedad de Alzheimer y otras enfermedades neurodegenerativas causantes de demencia
|
CL2008000188A1
(es)
|
2007-01-23 |
2008-07-18 |
Chugai Pharmaceutical Co Ltd |
Agente para suprimir la reaccion de rechazo cronica que comprende como ingrediente activo un inhibidor de il-6; y uso del inhibidor de il-6.
|
US20080177219A1
(en)
*
|
2007-01-23 |
2008-07-24 |
Joshi Ashok V |
Method for Iontophoretic Fluid Delivery
|
EP2125013A4
(en)
*
|
2007-01-26 |
2010-04-07 |
Bioinvent Int Ab |
DLL4 SIGNALING INHIBITOR AND ITS USES
|
MX2009008104A
(es)
|
2007-02-02 |
2009-08-07 |
Amgen Inc |
Hepcidina, antagonistas de hepcidina y metodos de uso.
|
ATE516814T1
(de)
|
2007-02-02 |
2011-08-15 |
Bristol Myers Squibb Co |
10fn3 domain zur behandlung von krankheiten begleitet von unerwünschter angiogenese
|
US7834154B2
(en)
|
2007-02-09 |
2010-11-16 |
Genentech, Inc. |
Anti-ROBO4 antibodies and uses therefor
|
BRPI0807952A2
(pt)
|
2007-02-20 |
2014-06-10 |
Anaptysbio Inc |
Sistemas de hipermutação somática
|
CN101663407B
(zh)
|
2007-02-22 |
2017-08-08 |
健泰科生物技术公司 |
用于检测炎性肠病的方法
|
EP2899541A1
(en)
|
2007-03-02 |
2015-07-29 |
Genentech, Inc. |
Predicting response to a HER dimerisation inhbitor based on low HER3 expression
|
EP2136831B1
(en)
|
2007-03-02 |
2012-09-12 |
The Cleveland Clinic Foundation |
Anti-angiogenic peptides
|
US9610327B2
(en)
|
2007-03-06 |
2017-04-04 |
Amgen Inc. |
Variant activin receptor polypeptides, alone or in combination with chemotherapy, and uses thereof
|
US8501678B2
(en)
|
2007-03-06 |
2013-08-06 |
Atara Biotherapeutics, Inc. |
Variant activin receptor polypeptides and uses thereof
|
TW201718635A
(zh)
|
2007-03-06 |
2017-06-01 |
安美基公司 |
變異之活動素受體多肽及其用途
|
CL2008000719A1
(es)
|
2007-03-12 |
2008-09-05 |
Univ Tokushima Chugai Seiyaku |
Agente terapeutico para cancer resistente a agentes quimioterapeuticos que comprende un anticuerpo que reconoce hla de clase i como ingrediente activo; composicion farmaceutica que comprende dicho anticuerpo; y metodo para tratar cancer resistente a
|
US7960139B2
(en)
|
2007-03-23 |
2011-06-14 |
Academia Sinica |
Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
|
AU2008232937B2
(en)
|
2007-03-30 |
2012-09-27 |
Ambrx, Inc. |
Modified FGF-21 polypeptides and their uses
|
ES2520044T3
(es)
|
2007-03-30 |
2014-11-11 |
The Cleveland Clinic Foundation |
SDF-1 para su uso en el tratamiento de trastornos vasculares periféricos isquémicos
|
CN105688191A
(zh)
|
2007-04-23 |
2016-06-22 |
精达制药公司 |
促胰岛素释放肽的混悬制剂及其应用
|
US20130195881A1
(en)
|
2007-04-27 |
2013-08-01 |
Sanjaya Singh |
Potent, stable and non-immunosuppressive anti-cd4 antibodies
|
EP2076533B1
(en)
*
|
2007-05-02 |
2014-10-08 |
Ambrx, Inc. |
Modified interferon beta polypeptides and their uses
|
EP2703011A3
(en)
|
2007-05-07 |
2014-03-26 |
MedImmune, LLC |
Anti-icos antibodies and their use in treatment of oncology, transplantation and autoimmune disease
|
WO2008140026A1
(ja)
|
2007-05-11 |
2008-11-20 |
Bizen Chemical Co., Ltd. |
新規のロイコトリエン受容体アンタゴニスト
|
NZ555163A
(en)
|
2007-05-14 |
2010-05-28 |
Fonterra Co Operative Group |
Methods of immune or hematological enhancement, inhibiting tumour formation or growth, and treating or preventing cancer, cancer symptoms, or the symptoms of cancer treatments
|
PE20090387A1
(es)
|
2007-05-24 |
2009-04-28 |
Novartis Ag |
Formulacion de pasireotida
|
EP1994927A1
(en)
|
2007-05-24 |
2008-11-26 |
Chevron USA, Inc. |
Diamondoid derivatives possessing therapeutic activity in the treatment of viral disorders
|
EP1995227A1
(en)
|
2007-05-24 |
2008-11-26 |
Chevron USA, Inc. |
Spiro and other derivatives of diamondoids posessing therapeutic activity in the treatment of viral disorders
|
US9163091B2
(en)
*
|
2007-05-30 |
2015-10-20 |
Lpath, Inc. |
Compositions and methods for binding lysophosphatidic acid
|
WO2008150494A1
(en)
|
2007-05-30 |
2008-12-11 |
Xencor, Inc. |
Methods and compositions for inhibiting cd32b expressing cells
|
EP2164992B1
(en)
*
|
2007-05-30 |
2016-05-04 |
Lpath, Inc. |
Compositions and methods for binding lysophosphatidic acid
|
US7879802B2
(en)
|
2007-06-04 |
2011-02-01 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
|
US8969514B2
(en)
|
2007-06-04 |
2015-03-03 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
|
PE20090321A1
(es)
|
2007-06-04 |
2009-04-20 |
Genentech Inc |
Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica
|
US8034782B2
(en)
|
2008-07-16 |
2011-10-11 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
|
GB0710976D0
(en)
|
2007-06-07 |
2007-07-18 |
Bioalvo |
Am Screening method
|
LT2170390T
(lt)
*
|
2007-06-14 |
2019-01-10 |
Biogen Ma Inc. |
Natalizumabo antikūnų kompozicijos
|
PE20090368A1
(es)
*
|
2007-06-19 |
2009-04-28 |
Boehringer Ingelheim Int |
Anticuerpos anti-igf
|
JP2010538244A
(ja)
|
2007-06-20 |
2010-12-09 |
ガラパゴス・ナムローゼ・フェンノートシャップ |
骨及び関節の変性疾患の治療に有用な分子標的及び化合物並びにその同定方法
|
DK2170340T3
(en)
|
2007-06-21 |
2016-03-14 |
Neuronascent Inc |
Methods and compositions for Stimulating neurogenesis and inhibition of neuronal degeneration BY USING ISOTHIAZOLOPYRIMIDINONER
|
WO2009002401A2
(en)
|
2007-06-21 |
2008-12-31 |
President And Fellows Of Harvard College |
Scaffolds for cell collection or elimination
|
EP3127549B1
(en)
|
2007-06-22 |
2019-12-18 |
Children's Medical Center Corporation |
Methods and uses thereof of a fragment of saposin a
|
CA2691166A1
(en)
|
2007-06-27 |
2008-12-31 |
Liu Dongxu |
Polypeptides and polynucleotides for artemin and related ligands, and methods of use thereof
|
CN101802013B
(zh)
|
2007-07-16 |
2014-07-02 |
健泰科生物技术公司 |
人源化抗cd79b抗体和免疫偶联物及使用方法
|
DK2176296T3
(da)
|
2007-07-16 |
2012-05-21 |
Genentech Inc |
Anti-CD79B-antistoffer og immunkonjugater og anvendelsesfremgangsmåder.
|
EP3246045A1
(en)
|
2007-07-26 |
2017-11-22 |
Osaka University |
Therapeutic agents for ocular inflammatory disease comprising interleukin 6 receptor inhibitor as active ingredient
|
CN110372795A
(zh)
|
2007-08-02 |
2019-10-25 |
吉利德生物制剂公司 |
Lox和loxl2抑制剂及其应用
|
US8153112B2
(en)
*
|
2007-08-03 |
2012-04-10 |
Warsaw Orthopedic, Inc. |
Compositions and methods for treating cavity conditions
|
TW200916113A
(en)
|
2007-08-08 |
2009-04-16 |
Sod Conseils Rech Applic |
Method for inhibiting inflammation and pro-inflammatory cytokine/chemokine expression using a ghrelin analogue
|
PE20120259A1
(es)
|
2007-08-09 |
2012-04-04 |
Boehringer Ingelheim Int |
Anticuerpos anti-cd37
|
HUE037265T2
(hu)
|
2007-08-21 |
2018-08-28 |
Amgen Inc |
Humán c-fms antigént kötõ proteinek
|
EP3492488A1
(en)
*
|
2007-08-22 |
2019-06-05 |
The Regents of The University of California |
Activatable binding polypeptides and methods of identification and use thereof
|
EP2615113A3
(en)
|
2007-08-23 |
2013-11-13 |
Amgen Inc. |
Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
|
JOP20080381B1
(ar)
|
2007-08-23 |
2023-03-28 |
Amgen Inc |
بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
|
JP2010536844A
(ja)
|
2007-08-24 |
2010-12-02 |
オンコセラピー・サイエンス株式会社 |
癌の治療標的及び診断マーカーとしてのdkk1癌遺伝子
|
CN101835894A
(zh)
|
2007-08-24 |
2010-09-15 |
肿瘤疗法科学股份有限公司 |
Ebi3、dlx5、nptx1和cdkn3用作肺癌治疗和诊断的靶基因
|
LT2195023T
(lt)
|
2007-08-29 |
2018-06-25 |
Sanofi |
Humanizuoti anti-cxcr5 antikūnai, jų dariniai ir jų panaudojimas
|
AU2008295140A1
(en)
|
2007-09-05 |
2009-03-12 |
F. Hoffmann-La Roche Ag |
Combination therapy with type I and type II anti-CD20 antibodies
|
US7982016B2
(en)
|
2007-09-10 |
2011-07-19 |
Amgen Inc. |
Antigen binding proteins capable of binding thymic stromal lymphopoietin
|
US20090156488A1
(en)
|
2007-09-12 |
2009-06-18 |
Zensun (Shanghai) Science & Technology Limited |
Use of neuregulin for organ preservation
|
WO2009036209A2
(en)
|
2007-09-14 |
2009-03-19 |
Amgen Inc. |
Homogeneous antibody populations
|
KR20100068287A
(ko)
*
|
2007-09-17 |
2010-06-22 |
쁘레글렘 에스.아. |
폐경기 전 여성의 에스트로겐 의존성 질환의 치료
|
TW200918553A
(en)
|
2007-09-18 |
2009-05-01 |
Amgen Inc |
Human GM-CSF antigen binding proteins
|
CA2704711C
(en)
|
2007-09-24 |
2016-07-05 |
Genentech, Inc. |
Thiazolopyrimidine p13k inhibitor compounds and methods of use
|
EP2040075A1
(en)
|
2007-09-24 |
2009-03-25 |
Julius-Maximilians-Universität Würzburg |
Compounds and markers for surface-enhanced raman scattering
|
AR068566A1
(es)
*
|
2007-09-26 |
2009-11-18 |
Amgen Inc |
Proteinas fijadoras de antigeno de factor de crecimiento del tipo factor de crecimiento epidermico fijador de heparina
|
BRPI0817482B8
(pt)
|
2007-10-02 |
2021-05-25 |
Chugai Pharmaceutical Co Ltd |
uso de um anticorpo do receptor da interleucina-6 (il-6) no tratamento da doença do enxerto versus hospedeiro (gvhd)
|
GB2453589A
(en)
|
2007-10-12 |
2009-04-15 |
King S College London |
Protease inhibition
|
US20090098118A1
(en)
|
2007-10-15 |
2009-04-16 |
Thomas Friess |
Combination therapy of a type ii anti-cd20 antibody with an anti-bcl-2 active agent
|
EP2050764A1
(en)
|
2007-10-15 |
2009-04-22 |
sanofi-aventis |
Novel polyvalent bispecific antibody format and uses thereof
|
PL2233149T3
(pl)
|
2007-10-16 |
2016-08-31 |
Zymogenetics Inc |
Kombinacja przezbłonowego aktywatora i ligandu cyklofiliny (taci) oraz przeciwciała anty-cd20 do leczenia chorób autoimmunologicznych
|
CA2702984C
(en)
|
2007-10-19 |
2017-04-11 |
Sarcode Corporation |
Compositions and methods for treatment of diabetic retinopathy
|
US8361465B2
(en)
*
|
2007-10-26 |
2013-01-29 |
Lpath, Inc. |
Use of anti-sphingosine-1-phosphate antibodies in combination with chemotherapeutic agents
|
ME02101B
(me)
|
2007-10-30 |
2015-10-20 |
Genentech Inc |
Pročišćavanje antitijela hromatografijom izmjene katjona
|
MX2010004814A
(es)
|
2007-11-05 |
2010-08-10 |
Medimmune Llc |
Metodos para tratar esclerodermia.
|
CN102172395A
(zh)
|
2007-11-07 |
2011-09-07 |
健泰科生物技术公司 |
用于治疗微生物病症的组合物和方法
|
BRPI0820343A2
(pt)
|
2007-11-08 |
2017-08-22 |
Genentech Inc |
Anticorpos de antifator b e seus usos
|
WO2009062195A2
(en)
*
|
2007-11-09 |
2009-05-14 |
Anaphore, Inc. |
Fusion proteins of mannose binding lectins for treatment of disease
|
EP2614837A1
(en)
|
2007-11-09 |
2013-07-17 |
Affitech Research AS |
Anti-VEGF antibody compositions and methods
|
US20110033476A1
(en)
*
|
2007-11-12 |
2011-02-10 |
Theraclone Sciences Inc. |
Compositions and methods for the therapy and diagnosis of influenza
|
CN102089324B
(zh)
|
2007-11-12 |
2014-04-16 |
特罗科隆科学有限公司 |
用于对流行性感冒进行治疗以及诊断的组合物以及方法
|
CA2705582A1
(en)
|
2007-11-16 |
2009-05-22 |
The Rockefeller University |
Antibodies specific for the protofibril form of beta-amyloid protein
|
KR20100087330A
(ko)
|
2007-11-19 |
2010-08-04 |
제넨테크, 인크. |
종양 진행을 억제하기 위한 조성물 및 방법
|
WO2009067242A2
(en)
*
|
2007-11-20 |
2009-05-28 |
Imclone Llc |
Co-crystal of antibody 11f8 fab fragment and egfr extracellular domain and uses thereof
|
JP5547083B2
(ja)
*
|
2007-11-20 |
2014-07-09 |
アンブルックス,インコーポレイテッド |
修飾されたインスリンポリペプチドおよびそれらの使用
|
AR069393A1
(es)
*
|
2007-11-21 |
2010-01-20 |
Imclone Systems Inc |
Inhibicion del receptor para la proteina estimulante del macrofago (ron) y metodos para el tratamiento del mismo
|
TWI468417B
(zh)
|
2007-11-30 |
2015-01-11 |
Genentech Inc |
抗-vegf抗體
|
BRPI0821110B8
(pt)
|
2007-12-05 |
2021-05-25 |
Chugai Pharmaceutical Co Ltd |
anticorpo de neutralização de anti-nr10/il31ra, composição farmacêutica compreendendo o referido anticorpo e uso do mesmo
|
RU2596397C2
(ru)
|
2007-12-05 |
2016-09-10 |
Чугаи Сейяку Кабусики Кайся |
Терапевтическое средство от зуда
|
GB0723797D0
(en)
|
2007-12-05 |
2008-01-16 |
Immunosolv Ltd |
Method
|
WO2009079259A2
(en)
|
2007-12-06 |
2009-06-25 |
Dana-Farber Cancer Institute, Inc. |
Antibodies against influenza virus and methods of use thereof
|
CA2708251C
(en)
|
2007-12-07 |
2016-04-12 |
Zymogenetics, Inc. |
Humanized antibody molecules specific for il-31
|
EP2241333A1
(en)
|
2007-12-12 |
2010-10-20 |
National Cancer Center |
Therapeutic agent for mll leukemia and moz leukemia of which molecular target is m-csf receptor, and use thereof
|
AU2008338525B2
(en)
|
2007-12-14 |
2015-04-02 |
Juventas Therapeutics, Inc. |
Compositions and methods of promoting wound healing
|
CN106977601A
(zh)
|
2007-12-17 |
2017-07-25 |
辉瑞有限公司 |
间质性膀胱炎的治疗
|
WO2009086003A1
(en)
|
2007-12-20 |
2009-07-09 |
Xoma Technology Ltd. |
Methods for the treatment of gout
|
WO2009085952A1
(en)
|
2007-12-20 |
2009-07-09 |
Brookwood Pharmaceuticals, Inc. |
Process for preparing microparticles having a low residual solvent volume
|
US8414893B2
(en)
|
2007-12-21 |
2013-04-09 |
Amgen Inc. |
Anti-amyloid antibodies and uses thereof
|
CN105418762B
(zh)
|
2007-12-26 |
2019-11-05 |
Xencor公司 |
与FcRn结合改变的Fc变体
|
US8962806B2
(en)
|
2007-12-28 |
2015-02-24 |
Dana-Farber Cancer Institute, Inc. |
Humanized monoclonal antibodies and methods of use
|
EP2077281A1
(en)
|
2008-01-02 |
2009-07-08 |
Bergen Teknologioverforing AS |
Anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
|
US7914785B2
(en)
*
|
2008-01-02 |
2011-03-29 |
Bergen Teknologieverforing As |
B-cell depleting agents, like anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
|
US20090181068A1
(en)
|
2008-01-14 |
2009-07-16 |
Dunn Richard L |
Low Viscosity Liquid Polymeric Delivery System
|
US20090183503A1
(en)
*
|
2008-01-18 |
2009-07-23 |
Alberto Verdesi |
Exhaust apparatus
|
AR070141A1
(es)
*
|
2008-01-23 |
2010-03-17 |
Glenmark Pharmaceuticals Sa |
Anticuerpos humanizados especificos para el factor von willebrand
|
CA2711826C
(en)
|
2008-01-25 |
2018-02-27 |
Amgen Inc. |
Ferroportin antibodies and methods of use
|
TWI472339B
(zh)
|
2008-01-30 |
2015-02-11 |
Genentech Inc |
包含結合至her2結構域ii之抗體及其酸性變異體的組合物
|
MX351557B
(es)
|
2008-01-31 |
2017-10-19 |
Genentech Inc |
Anticuerpos anti-cd79b e inmunoconjugados y metodos de uso.
|
NZ602170A
(en)
|
2008-02-08 |
2014-03-28 |
Ambrx Inc |
Modified leptin polypeptides and their uses
|
TWI442932B
(zh)
*
|
2008-02-11 |
2014-07-01 |
Ferring Int Ct Sa |
以GnRH拮抗劑治療攝護腺癌的方法
|
WO2009102467A2
(en)
|
2008-02-13 |
2009-08-20 |
Intarcia Therapeutics, Inc. |
Devices, formulations, and methods for delivery of multiple beneficial agents
|
US9370558B2
(en)
|
2008-02-13 |
2016-06-21 |
President And Fellows Of Harvard College |
Controlled delivery of TLR agonists in structural polymeric devices
|
JP5690143B2
(ja)
|
2008-02-13 |
2015-03-25 |
プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ |
持続的細胞プログラミング装置
|
CN102007145A
(zh)
|
2008-02-14 |
2011-04-06 |
百时美施贵宝公司 |
基于结合egfr的工程化蛋白质的靶向治疗剂
|
JO2913B1
(en)
|
2008-02-20 |
2015-09-15 |
امجين إنك, |
Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
|
CN102015766B
(zh)
|
2008-03-10 |
2014-07-16 |
特罗科隆科学有限公司 |
用于对巨细胞病毒感染进行治疗以及诊断的组合物以及方法
|
MY163544A
(en)
|
2008-03-25 |
2017-09-29 |
Roche Glycart Ag |
Use of a type ii anti-cd20 antibody with increased antibody dependent cellular cytotoxicity (adcc) in combination with cyclophosphamide, vincristine and doxorubicine for treating non-hodgkin's lymphomas
|
EP3605088A1
(en)
|
2008-04-09 |
2020-02-05 |
Genentech, Inc. |
Compositions and methods for the treatment of immune related diseases
|
US20090258069A1
(en)
*
|
2008-04-15 |
2009-10-15 |
John Burnier |
Delivery of LFA-1 antagonists to the gastrointestinal system
|
US8080562B2
(en)
|
2008-04-15 |
2011-12-20 |
Sarcode Bioscience Inc. |
Crystalline pharmaceutical and methods of preparation and use thereof
|
GB0807018D0
(en)
*
|
2008-04-17 |
2008-05-21 |
Fusion Antibodies Ltd |
Antibodies and treatment
|
JP5608160B2
(ja)
|
2008-04-17 |
2014-10-15 |
ミセル テクノロジーズ、インコーポレイテッド |
生体吸収性の層を有するステント
|
CN102014957B
(zh)
|
2008-04-21 |
2014-12-10 |
奥德纳米有限公司 |
用于治疗耳部疾病和病况的耳用调配物
|
CR20170001A
(es)
|
2008-04-28 |
2017-08-10 |
Genentech Inc |
Anticuerpos anti factor d humanizados
|
JP2011523401A
(ja)
*
|
2008-04-29 |
2011-08-11 |
ワイス・エルエルシー |
炎症を治療するための方法
|
FI20080326A0
(fi)
|
2008-04-30 |
2008-04-30 |
Licentia Oy |
Neurotroofinen tekijä MANF ja sen käytöt
|
EP2816059A1
(en)
|
2008-05-01 |
2014-12-24 |
Amgen, Inc |
Anti-hepcidin antibodies and methods of use
|
BRPI0912003A2
(pt)
|
2008-05-06 |
2016-07-12 |
Genentech Inc |
afinidade de variantes de crig maturadas
|
WO2009136298A2
(en)
*
|
2008-05-09 |
2009-11-12 |
Recopharma Ab |
Compositions and methods for inhibiting shiga toxin and shiga-like toxin
|
US8093018B2
(en)
|
2008-05-20 |
2012-01-10 |
Otsuka Pharmaceutical Co., Ltd. |
Antibody identifying an antigen-bound antibody and an antigen-unbound antibody, and method for preparing the same
|
WO2009142773A2
(en)
|
2008-05-22 |
2009-11-26 |
Bristol-Myers Squibb Company |
Multivalent fibronectin based scaffold domain proteins
|
US20110076723A1
(en)
*
|
2008-05-23 |
2011-03-31 |
Samsung Electronics Co., Ltd. |
Antibody-peptide fused synergibody
|
JOP20190083A1
(ar)
|
2008-06-04 |
2017-06-16 |
Amgen Inc |
بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
|
JP2011522828A
(ja)
|
2008-06-04 |
2011-08-04 |
シナジー ファーマシューティカルズ インコーポレイテッド |
胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト
|
KR101665729B1
(ko)
|
2008-06-05 |
2016-10-12 |
국립연구개발법인 고쿠리츠간켄큐센터 |
신경침윤 억제제
|
ES2862923T3
(es)
|
2008-06-09 |
2021-10-08 |
Univ Muenchen Ludwig Maximilians |
Nuevos fármacos para inhibir la agregación de proteínas implicadas en enfermedades relacionadas con enfermedades neurodegenerativas y/o agregación de proteínas
|
WO2009150623A1
(en)
|
2008-06-13 |
2009-12-17 |
Pfizer Inc |
Treatment of chronic prostatitis
|
WO2009155565A1
(en)
|
2008-06-20 |
2009-12-23 |
Genentech, Inc. |
Triazolopyridine jak inhibitor compounds and methods
|
EP2138508A1
(en)
|
2008-06-26 |
2009-12-30 |
Helmholtz-Zentrum für Infektionsforschung GmbH |
Met agonists
|
AU2009262199B2
(en)
|
2008-06-27 |
2012-08-09 |
Amgen Inc. |
Ang-2 inhibition to treat multiple sclerosis
|
EP2899211A1
(en)
|
2008-07-08 |
2015-07-29 |
OncoMed Pharmaceuticals, Inc. |
Notch1 receptor binding agents and methods of use thereof
|
ES2630805T3
(es)
|
2008-07-14 |
2017-08-24 |
Polypid Ltd. |
Composición de vehículo de fármaco de liberación sostenida
|
ES2442024T3
(es)
|
2008-07-15 |
2014-02-07 |
Academia Sinica |
Matrices de glucano sobre portaobjetos de vidrio revestidos con aluminio de tipo PTFE y métodos relacionados
|
AR072804A1
(es)
|
2008-07-15 |
2010-09-22 |
Genentech Inc |
Conjugados derivados de antraciclina,proceso para su preparacion,composiciones farmaceuticas que los contienen y su uso como agentes antitumorales.
|
WO2011009096A1
(en)
|
2009-07-16 |
2011-01-20 |
Micell Technologies, Inc. |
Drug delivery medical device
|
US9486431B2
(en)
|
2008-07-17 |
2016-11-08 |
Micell Technologies, Inc. |
Drug delivery medical device
|
EP2306975A4
(en)
|
2008-07-21 |
2012-10-31 |
Otonomy Inc |
CONTROLLED RELEASE COMPOSITIONS MODULATING THE OTIC STRUCTURE AND MODULATING THE NATURAL IMMUNE SYSTEM AND METHODS OF TREATING OTIC DISORDERS
|
US8784870B2
(en)
|
2008-07-21 |
2014-07-22 |
Otonomy, Inc. |
Controlled release compositions for modulating free-radical induced damage and methods of use thereof
|
NZ600382A
(en)
*
|
2008-07-23 |
2013-11-29 |
Ambrx Inc |
Modified bovine G-CSF polypeptides and their uses
|
EP2172189A1
(en)
|
2008-10-01 |
2010-04-07 |
Novartis AG |
Pharmaceutical Compositions
|
EP2213307A1
(en)
|
2009-02-03 |
2010-08-04 |
Novartis AG |
Injectable depot formulations
|
WO2010019702A2
(en)
|
2008-08-12 |
2010-02-18 |
Oncomed Pharmaceuticals, Inc. |
Ddr1-binding agents and methods of use thereof
|
MX2011001506A
(es)
|
2008-08-14 |
2011-03-15 |
Genentech Inc |
Metodos para eliminar un contaminante utilizado cromatografia de membrana de intercambio de ion en desplazamiento de proteina indigena.
|
US20120128684A1
(en)
|
2008-08-25 |
2012-05-24 |
Burnham Institute For Medical Research |
Conserved Hemagglutinin Epitope, Antibodies to the Epitope and Methods of Use
|
US8790642B2
(en)
|
2008-08-29 |
2014-07-29 |
Genentech, Inc. |
Cross-reactive and bispecific anti-IL-17A/F antibodies
|
KR101432474B1
(ko)
|
2008-09-07 |
2014-08-21 |
글라이코넥스 인코포레이티드 |
항-연장된 ⅰ형 글라이코스핑고지질 항체, 이의 유도체 및 용도
|
KR20110051245A
(ko)
|
2008-09-10 |
2011-05-17 |
제넨테크, 인크. |
안구 혈관신생의 억제 방법
|
US8765376B2
(en)
|
2008-09-11 |
2014-07-01 |
Galapagos Nv |
Methods for identifying and compounds useful for increasing the functional activity and cell surface expression of CF-associated mutant cystic fibrosis transmembrane conductance regulator
|
TWI516501B
(zh)
|
2008-09-12 |
2016-01-11 |
禮納特神經系統科學公司 |
Pcsk9拮抗劑類
|
TW201438738A
(zh)
|
2008-09-16 |
2014-10-16 |
Genentech Inc |
治療進展型多發性硬化症之方法
|
CN102264763B
(zh)
|
2008-09-19 |
2016-04-27 |
米迪缪尼有限公司 |
定向于dll4的抗体及其用途
|
MX348657B
(es)
|
2008-09-26 |
2017-06-21 |
Ambrx Inc |
Microorganismos y vacunas dependientes de replicacion de aminoacidos no naturales.
|
AU2009296397B2
(en)
*
|
2008-09-26 |
2012-11-08 |
Ambrx Inc. |
Modified animal erythropoietin polypeptides and their uses
|
AU2009296246B2
(en)
|
2008-09-26 |
2015-07-30 |
Oncomed Pharmaceuticals, Inc. |
Frizzled-binding agents and uses thereof
|
EA032727B1
(ru)
|
2008-10-10 |
2019-07-31 |
Амген Инк. |
Мутантный резистентный к протеолизу полипептид fgf21 и его применение
|
JP2012504969A
(ja)
*
|
2008-10-10 |
2012-03-01 |
アナフォア インコーポレイテッド |
Trail−r1及びtrail−r2に結合するポリペプチド
|
TWI572359B
(zh)
|
2008-10-14 |
2017-03-01 |
建南德克公司 |
免疫球蛋白變異體及其用途
|
MX2011004306A
(es)
|
2008-10-22 |
2011-07-28 |
Genentech Inc |
Modulacion de degeneracion de axones.
|
US8871202B2
(en)
|
2008-10-24 |
2014-10-28 |
Lpath, Inc. |
Prevention and treatment of pain using antibodies to sphingosine-1-phosphate
|
AR073997A1
(es)
|
2008-10-29 |
2010-12-15 |
Wyeth Corp |
Formulaciones de moleculas de union a antigeno de dominio unico. metodo. kit
|
JP5848607B2
(ja)
|
2008-10-31 |
2016-01-27 |
ヤンセン バイオテツク,インコーポレーテツド |
フィブロネクチン3型ドメインに基づくスカフォールド組成物、方法及び使用
|
CA2742899A1
(en)
*
|
2008-11-06 |
2010-05-14 |
Glenmark Pharmaceuticals, S.A. |
Treatment with anti-alpha2 integrin antibodies
|
CN102272327B
(zh)
|
2008-11-07 |
2015-11-25 |
赛昆塔公司 |
通过序列分析监测状况的方法
|
US9506119B2
(en)
|
2008-11-07 |
2016-11-29 |
Adaptive Biotechnologies Corp. |
Method of sequence determination using sequence tags
|
US9365901B2
(en)
|
2008-11-07 |
2016-06-14 |
Adaptive Biotechnologies Corp. |
Monitoring immunoglobulin heavy chain evolution in B-cell acute lymphoblastic leukemia
|
US8628927B2
(en)
|
2008-11-07 |
2014-01-14 |
Sequenta, Inc. |
Monitoring health and disease status using clonotype profiles
|
US8748103B2
(en)
|
2008-11-07 |
2014-06-10 |
Sequenta, Inc. |
Monitoring health and disease status using clonotype profiles
|
US9528160B2
(en)
|
2008-11-07 |
2016-12-27 |
Adaptive Biotechnolgies Corp. |
Rare clonotypes and uses thereof
|
CA2744120A1
(en)
|
2008-11-17 |
2010-05-20 |
The Provost, Fellows, Foundation Scholars, And The Other Members Of Boar D, Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth, |
A vaccinia virus protein a46 peptide and use thereof
|
SI2752189T1
(sl)
|
2008-11-22 |
2017-02-28 |
F. Hoffmann-La Roche Ag |
Uporaba anti-vegf protitelesa v kombinaciji s kemoterapijo za zdravljenje prsnega raka
|
TWI496582B
(zh)
|
2008-11-24 |
2015-08-21 |
必治妥美雅史谷比公司 |
雙重專一性之egfr/igfir結合分子
|
PE20120206A1
(es)
|
2008-11-26 |
2012-03-09 |
Amgen Inc |
Variantes de polipeptidos receptores de activina iib
|
WO2010065572A1
(en)
|
2008-12-04 |
2010-06-10 |
The Salk Institute For Biological Studies |
Sstr1-selective analogs
|
UY32317A
(es)
*
|
2008-12-12 |
2010-07-30 |
Boehringer Ingelheim Int |
Anticuerpos anti-igf
|
US8691205B2
(en)
|
2008-12-17 |
2014-04-08 |
Merck Sharp & Dohme Corporation |
Mono- and di-PEG IL-10 production; and uses
|
CA2747248A1
(en)
|
2008-12-17 |
2010-07-15 |
Sharookh Kapadia |
Hepatitis c virus combination therapy
|
WO2010070136A2
(en)
|
2008-12-19 |
2010-06-24 |
Centre de Recherche Public de la Santé |
Novel caviidae allergens and uses thereof
|
WO2010075249A2
(en)
|
2008-12-22 |
2010-07-01 |
Genentech, Inc. |
A method for treating rheumatoid arthritis with b-cell antagonists
|
EP2367564A1
(en)
|
2008-12-22 |
2011-09-28 |
Universität Regensburg |
Norrin in the treatment of diseases associated with an increased tgf-beta activity
|
WO2010072740A2
(en)
|
2008-12-23 |
2010-07-01 |
Astrazeneca Ab |
TARGETED BINDING AGENTS DIRECTED TO α5β1 AND USES THEREOF
|
JO3382B1
(ar)
|
2008-12-23 |
2019-03-13 |
Amgen Inc |
أجسام مضادة ترتبط مع مستقبل cgrp بشري
|
WO2010075548A2
(en)
|
2008-12-23 |
2010-07-01 |
Genentech, Inc. |
Immunoglobulin variants with altered binding to protein a
|
US20110142836A1
(en)
*
|
2009-01-02 |
2011-06-16 |
Olav Mella |
B-cell depleting agents for the treatment of chronic fatigue syndrome
|
JP5851842B2
(ja)
|
2009-01-12 |
2016-02-03 |
サイトムエックス セラピューティクス, インク.CytomX Therapeutics, Inc. |
改変した抗体組成物、それを作製および使用する方法
|
EP2387627B1
(en)
|
2009-01-15 |
2016-03-30 |
Adaptive Biotechnologies Corporation |
Adaptive immunity profiling and methods for generation of monoclonal antibodies
|
KR101040396B1
(ko)
|
2009-01-20 |
2011-06-09 |
한올바이오파마주식회사 |
변형된 인간 트롬보포이에틴 폴리펩타이드 절편 및 그의 제조방법
|
US20120022000A1
(en)
|
2009-01-30 |
2012-01-26 |
Universite De Lausanne |
Use of a peptide in the treatment or prevention of metastasis
|
WO2010086828A2
(en)
|
2009-02-02 |
2010-08-05 |
Rinat Neuroscience Corporation |
Agonist anti-trkb monoclonal antibodies
|
MX2011008566A
(es)
|
2009-02-12 |
2011-11-29 |
Janssen Biotech Inc |
Composiciones supercontigo basadas en el dominio de fibronectina tipo iii, metodos y usos.
|
EP2396035A4
(en)
|
2009-02-12 |
2012-09-12 |
Human Genome Sciences Inc |
USE OF ANTAGONISTS OF PROTEIN STIMULATING LYMPHOCYTES B TO PROMOTE GRAFT TOLERANCE
|
WO2010092109A2
(en)
|
2009-02-13 |
2010-08-19 |
Novartis Ag |
Nucleic acid molecule of a biosynthetic cluster encoding non ribosomal peptide synthases and uses thereof
|
TW201031436A
(en)
*
|
2009-02-16 |
2010-09-01 |
Univ Nat Taiwan |
Pharmaceutical composition for inhalation delivery and fabrication method thereof
|
EP2398480A1
(en)
|
2009-02-19 |
2011-12-28 |
Galapagos N.V. |
Methods for identifying and compounds useful for the diagnosis and treatment of diseases involving inflammation
|
EP2398481A2
(en)
|
2009-02-19 |
2011-12-28 |
Galapagos N.V. |
Methods for identifying and compounds useful for the diagnosis and treatment of diseases involving inflammation
|
WO2010094734A2
(en)
|
2009-02-19 |
2010-08-26 |
Biofocus Dpi B.V. |
Methods for identifying and compounds useful for the diagnosis and treatment of diseases involving inflammation
|
GB0902916D0
(en)
|
2009-02-20 |
2009-04-08 |
Fusion Antibodies Ltd |
Antibody therapy
|
US8399219B2
(en)
|
2009-02-23 |
2013-03-19 |
Cytomx Therapeutics, Inc. |
Protease activatable interferon alpha proprotein
|
AP3069A
(en)
|
2009-02-27 |
2014-12-31 |
Siga Technologies Inc |
Thienopyridine derivatives for the treatment and prvention of dengue virus infection
|
JP5667094B2
(ja)
|
2009-03-10 |
2015-02-12 |
エムイーディー ディスカバリー エスエー |
好中球減少症の処置におけるセリンプロテアーゼ阻害剤の使用
|
US8536161B2
(en)
|
2009-03-12 |
2013-09-17 |
Genentech, Inc. |
Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents for the treatment of hematopoietic malignancies
|
JP2010210772A
(ja)
|
2009-03-13 |
2010-09-24 |
Dainippon Screen Mfg Co Ltd |
液晶表示装置の製造方法
|
SI3260136T1
(sl)
|
2009-03-17 |
2021-05-31 |
Theraclone Sciences, Inc. |
Humani imunodeficientni virus (HIV)-nevtralizirajoča protitelesa
|
CA2755640C
(en)
|
2009-03-20 |
2018-05-22 |
Genentech, Inc. |
Bispecific antibody with a single antigen-binding domain specific for both her3 and egfr
|
CA3018235C
(en)
|
2009-03-20 |
2021-01-12 |
Amgen Inc. |
Carrier immunoglobulins and uses thereof
|
KR101830024B1
(ko)
|
2009-03-25 |
2018-02-19 |
제넨테크, 인크. |
항-fgfr3 항체 및 그의 사용 방법
|
TWI504409B
(zh)
|
2009-03-25 |
2015-10-21 |
Genentech Inc |
新穎抗-α5β1抗體及其用途
|
EP2236139A1
(en)
|
2009-03-31 |
2010-10-06 |
F. Hoffmann-La Roche AG |
Combination therapy of erlotinib with an anti-IGF-1R antibody, which does not inhibit binding of insulin to the insulin receptor
|
AU2010230346A1
(en)
|
2009-03-31 |
2011-07-28 |
Roche Glycart Ag |
Treatment of cancer with a humanized anti-EGFR IgG1antibody and irinotecan
|
WO2010112569A1
(en)
|
2009-03-31 |
2010-10-07 |
Robert Zimmermann |
Modulation of adipose triglyceride lipase for prevention and treatment of cachexia, loss of weight and muscle atrophy and methods of screening therefor
|
AR075982A1
(es)
|
2009-03-31 |
2011-05-11 |
Roche Glycart Ag |
Terapia de combinacion de un anticuerpo afucosilado y una o mas de las citoquinas seleccionadas de gm- csf humano, m -csf humano y/o il-3 humano y composicion
|
US8993509B2
(en)
|
2009-03-31 |
2015-03-31 |
Robert Zimmerman |
Method for treatment of cachexia by administering inhibitors of adipose triglyceride lipase expression or activity
|
MX347978B
(es)
|
2009-04-01 |
2017-05-22 |
Genentech Inc * |
Uso de los anticuerpos anti-il-17a y anti-il-17f en el tratamiento de la resistentes a insulina.
|
AU2010236787A1
(en)
|
2009-04-01 |
2011-11-10 |
Genentech, Inc. |
Anti-FcRH5 antibodies and immunoconjugates and methods of use
|
WO2010120552A2
(en)
|
2009-04-01 |
2010-10-21 |
Micell Technologies, Inc. |
Coated stents
|
US8663930B2
(en)
|
2009-04-01 |
2014-03-04 |
Galapagos Nv |
Methods and means for treatment of osteoarthritis
|
BRPI1014089A2
(pt)
|
2009-04-02 |
2016-04-19 |
Roche Glycart Ag |
anticorpos multiespecíficos que compreendem anticorpos de comprimento completo e fragmentos fab de cadeia simples
|
US9297005B2
(en)
|
2009-04-13 |
2016-03-29 |
President And Fellows Of Harvard College |
Harnessing cell dynamics to engineer materials
|
JP5822822B2
(ja)
|
2009-04-17 |
2015-11-24 |
ニューヨーク ユニバーシティ |
Tnfファミリー受容体を標的とし、tnf作用を拮抗するペプチド、その組成物、方法および使用
|
WO2010121187A2
(en)
|
2009-04-17 |
2010-10-21 |
Micell Techologies, Inc. |
Stents having controlled elution
|
US9724337B2
(en)
*
|
2009-04-21 |
2017-08-08 |
University Of Kentucky Research Foundation |
AG-205 for the treatment of breast cancer
|
SG175305A1
(en)
*
|
2009-04-23 |
2011-11-28 |
Theraclone Sciences Inc |
Granulocyte-macrophage colony-stimulating factor (gm-csf) neutralizing antibodies
|
WO2010129304A2
(en)
|
2009-04-27 |
2010-11-11 |
Oncomed Pharmaceuticals, Inc. |
Method for making heteromultimeric molecules
|
CA2759888A1
(en)
*
|
2009-05-01 |
2010-11-04 |
Tine Kold Olesen |
Composition for the treatment of prostate cancer
|
JP2012525847A
(ja)
|
2009-05-05 |
2012-10-25 |
アムジエン・インコーポレーテツド |
Fgf21変異体およびその使用
|
PE20160718A1
(es)
|
2009-05-05 |
2016-08-03 |
Amgen Inc |
Polipeptidos mutantes fgf21
|
PE20160652A1
(es)
|
2009-05-05 |
2016-07-09 |
Novimmune Sa |
Anticuerpos que se unen a il-17f
|
TW201043221A
(en)
*
|
2009-05-06 |
2010-12-16 |
Ferring Int Ct Sa |
Kit and method for preparation of a Degarelix solution
|
JP2012527473A
(ja)
|
2009-05-20 |
2012-11-08 |
セラクローン サイエンシーズ, インコーポレイテッド |
インフルエンザの治療および診断のための組成物および方法
|
CA2761445A1
(en)
|
2009-05-27 |
2010-12-02 |
Genentech, Inc. |
Bicyclic pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use
|
EP2260857A1
(en)
|
2009-06-11 |
2010-12-15 |
Alfact Innovation |
Novel applications of HIP/PAP or derivatives thereof
|
WO2010144797A2
(en)
|
2009-06-12 |
2010-12-16 |
Vaccine Technologies, Incorporated |
Influenza vaccines with enhanced immunogenicity and uses thereof
|
WO2010146059A2
(en)
|
2009-06-16 |
2010-12-23 |
F. Hoffmann-La Roche Ag |
Biomarkers for igf-1r inhibitor therapy
|
IN2012DN00352A
(ja)
|
2009-06-16 |
2015-08-21 |
Bikam Pharmaceuticals Inc |
|
WO2010146511A1
(en)
|
2009-06-17 |
2010-12-23 |
Pfizer Limited |
Treatment of overactive bladder
|
MX2011013903A
(es)
|
2009-06-17 |
2012-05-08 |
Amgen Inc |
Polipeptidos quimericos y usos de los mismos.
|
KR20140146180A
(ko)
|
2009-06-25 |
2014-12-24 |
프레드 헛친슨 켄서 리서치 센터 |
적응 면역의 측정방법
|
EP2450055B1
(en)
|
2009-06-30 |
2018-01-03 |
Obshestvo S OgranichennoyOtvetstvennostiu"OncoMax" |
Method for suppressing renal tumor growth by blocking fibroblast growth factor receptor
|
US20110039787A1
(en)
*
|
2009-07-06 |
2011-02-17 |
Ferring International Center S.A. |
Compositions, kits and methods for treating benign prostate hyperplasia
|
WO2011004028A2
(en)
|
2009-07-10 |
2011-01-13 |
Innate Pharma |
Tlr3 binding agents
|
US20130029970A1
(en)
|
2009-07-10 |
2013-01-31 |
Ironwood Pharmaceuticals, Inc |
CB Receptor Agonists
|
KR20120106935A
(ko)
|
2009-07-13 |
2012-09-27 |
제넨테크, 인크. |
암의 치료를 위한 진단 방법 및 조성물
|
WO2011007353A1
(en)
|
2009-07-14 |
2011-01-20 |
Polypid Ltd. |
Sustained-release drug carrier composition
|
EP2460538B1
(en)
|
2009-07-31 |
2017-09-13 |
Shin Maeda |
Cancer metastasis inhibitor
|
WO2011014775A1
(en)
|
2009-07-31 |
2011-02-03 |
The Brigham And Women's Hospital, Inc. |
Modulation of sgk1 expression in th17 cells to modulate th17-mediated immune responses
|
WO2011014871A1
(en)
|
2009-07-31 |
2011-02-03 |
President And Fellows Of Harvard College |
Programming of cells for tolerogenic therapies
|
WO2011015573A1
(en)
|
2009-08-03 |
2011-02-10 |
Galapagos Nv |
Molecular targets and compounds, and methods to identify the same, useful in the treatment of neurodegenerative diseases
|
WO2011015572A1
(en)
|
2009-08-03 |
2011-02-10 |
Galapagos Nv |
Molecular targets and compounds, and methods to identify the same, useful in the treatment of neurodegenerative diseases
|
TWI409079B
(zh)
|
2009-08-14 |
2013-09-21 |
Roche Glycart Ag |
非典型岩藻醣化cd20抗體與苯達莫斯汀(bendamustine)之組合療法
|
CN102470172B
(zh)
|
2009-08-14 |
2014-09-24 |
罗切格利卡特公司 |
无岩藻糖基化cd20抗体与氟达拉滨和/或米托蒽醌的联合疗法
|
AU2010282282A1
(en)
|
2009-08-14 |
2012-03-01 |
Genentech, Inc. |
Biological markers for monitoring patient response to VEGF antagonists
|
TWI451875B
(zh)
|
2009-08-15 |
2014-09-11 |
建南德克公司 |
用於治療先前治療過之乳癌之抗-血管新生療法
|
WO2011024114A1
(en)
|
2009-08-25 |
2011-03-03 |
Ecole Polytechnique Federale De Lausanne (Epfl) |
Targeting extracellular matrix molecules for the treatment of cancer
|
AU2010286511B2
(en)
|
2009-08-28 |
2016-05-26 |
Juventas Therapeutics, Inc. |
SDF-1 delivery for treating ischemic tissue
|
EP3736338A1
(en)
|
2009-09-01 |
2020-11-11 |
F. Hoffmann-La Roche AG |
Enhanced protein purification through a modified protein a elution
|
WO2011028952A1
(en)
|
2009-09-02 |
2011-03-10 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
RU2012114094A
(ru)
|
2009-09-11 |
2013-10-20 |
Дженентек, Инк. |
Способ идентификации пациента с увеличенной вероятностью ответа на противораковый агент
|
RU2573915C2
(ru)
|
2009-09-16 |
2016-01-27 |
Дженентек, Инк. |
Содержащие суперспираль и/или привязку белковые комплексы и их применение
|
TW201118166A
(en)
|
2009-09-24 |
2011-06-01 |
Chugai Pharmaceutical Co Ltd |
HLA class I-recognizing antibodies
|
MX352878B
(es)
|
2009-09-28 |
2017-12-13 |
Intarcia Therapeutics Inc |
Establecimiento y/o terminacion rapidos de suministro de estado estable sustancial de farmaco.
|
PT2483278E
(pt)
|
2009-09-28 |
2014-03-05 |
Hoffmann La Roche |
Compostos de bezoxazepina inibidores de pi3k e a sua utilização no tratamento do cancro
|
BR112012006802A2
(pt)
|
2009-09-28 |
2020-08-18 |
F.Hoffmann-La Roche Ag |
composto, composição farmacêutica, método para tratar câncer, usos de um composto, kit e invenção
|
EP2305285A1
(en)
|
2009-09-29 |
2011-04-06 |
Julius-Maximilians-Universität Würzburg |
Means and methods for treating ischemic conditions
|
CA2776472A1
(en)
*
|
2009-10-01 |
2011-04-07 |
Evonik Degussa Corporation |
Microparticle compositions and methods for treating age-related macular degeneration
|
EP2305810A1
(en)
|
2009-10-02 |
2011-04-06 |
Technische Universität München |
miRNAs in the treatment of fibrosis
|
US20110195987A1
(en)
|
2009-10-05 |
2011-08-11 |
Thomas Najarian |
Treatment with cholinergic agonists
|
JP2013507124A
(ja)
*
|
2009-10-09 |
2013-03-04 |
アナフォア インコーポレイテッド |
Il−23rを結合するポリペプチド
|
TW201117824A
(en)
|
2009-10-12 |
2011-06-01 |
Amgen Inc |
Use of IL-17 receptor a antigen binding proteins
|
CA2777717C
(en)
*
|
2009-10-15 |
2021-05-25 |
Genentech, Inc. |
Chimeric fibroblast growth factors with altered receptor specificity
|
EP3072526B1
(en)
|
2009-10-16 |
2018-09-26 |
Oncomed Pharmaceuticals, Inc. |
Therapeutic combination and use of dll4 antagonist antibodies and anti-hypertensive agents
|
WO2011046457A1
(en)
|
2009-10-16 |
2011-04-21 |
Auckland Uniservices Limited |
Anti-neoplastic uses of artemin antagonists
|
US9068019B2
(en)
|
2009-10-19 |
2015-06-30 |
Hanall Biopharma Co., Ltd. |
Modified human tumor necrosis factor receptor-1 polypeptide or fragment thereof, and method for preparing same
|
WO2011049868A1
(en)
*
|
2009-10-19 |
2011-04-28 |
Genentech, Inc. |
Modulators of hepatocyte growth factor activator
|
US8378105B2
(en)
*
|
2009-10-21 |
2013-02-19 |
Sarcode Bioscience Inc. |
Crystalline pharmaceutical and methods of preparation and use thereof
|
ES2564207T3
(es)
|
2009-10-22 |
2016-03-18 |
F. Hoffmann-La Roche Ag |
Métodos y composiciones para modular la activación con hepsina de la proteína estimuladora de macrófagos
|
ES2534646T3
(es)
|
2009-10-22 |
2015-04-27 |
F. Hoffmann-La Roche Ag |
Anticuerpos anti-hepsina y métodos de uso de los mismos
|
RU2012120783A
(ru)
|
2009-10-22 |
2013-11-27 |
Женентек, Инк. |
Модуляция дегенерации аксона
|
WO2011056494A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
|
WO2011056497A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Activin receptor type iib compositions and methods of use
|
WO2011056502A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Bone morphogenetic protein receptor type ii compositions and methods of use
|
US8729058B2
(en)
|
2009-10-27 |
2014-05-20 |
Michael Zasloff |
Methods and compositions for treating and preventing viral infections
|
HUE041426T2
(hu)
|
2009-11-02 |
2019-05-28 |
Univ Washington |
Terápiás nukleáz-készítmények és eljárások
|
US20110165648A1
(en)
|
2009-11-04 |
2011-07-07 |
Menno Van Lookeren Campagne |
Co-crystal structure of factor D and anti-factor D antibody
|
WO2011057120A1
(en)
|
2009-11-05 |
2011-05-12 |
Genentech, Inc. |
Methods and composition for secretion of heterologous polypeptides
|
US8288381B2
(en)
|
2009-11-12 |
2012-10-16 |
Genentech, Inc. |
N-9 substituted purine compounds, compositions and methods of use
|
US8828990B2
(en)
|
2009-11-12 |
2014-09-09 |
Genentech, Inc. |
N-7 substituted purine and pyrazolopyrimine compounds, compositions and methods of use
|
CA2780761A1
(en)
|
2009-11-13 |
2011-05-19 |
Puget Sound Blood Center |
Factor viii t cell epitope variants having reduced immunogenicity
|
WO2011063277A1
(en)
|
2009-11-20 |
2011-05-26 |
Amgen Inc. |
Anti-orai1 antigen binding proteins and uses thereof
|
LT3279215T
(lt)
|
2009-11-24 |
2020-04-10 |
Medimmune Limited |
Tiksliniai surišantys agentai prieš b7-h1
|
WO2011066260A2
(en)
*
|
2009-11-25 |
2011-06-03 |
Michael Zasloff |
Formulations comprising aminosterols
|
AU2010324686B2
(en)
|
2009-11-30 |
2016-05-19 |
Genentech, Inc. |
Antibodies for treating and diagnosing tumors expressing SLC34A2 (TAT211 = SEQID2 )
|
US11377485B2
(en)
|
2009-12-02 |
2022-07-05 |
Academia Sinica |
Methods for modifying human antibodies by glycan engineering
|
JP2013512672A
(ja)
*
|
2009-12-02 |
2013-04-18 |
アムジエン・インコーポレーテツド |
ヒトFGFR1c、ヒトβ−クロト−、ならびにヒトFGFR1cおよびヒトβ−クロト−の両方に結合する結合タンパク質
|
US10087236B2
(en)
|
2009-12-02 |
2018-10-02 |
Academia Sinica |
Methods for modifying human antibodies by glycan engineering
|
US8491927B2
(en)
|
2009-12-02 |
2013-07-23 |
Nimble Epitech, Llc |
Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor
|
EP3778917A3
(en)
|
2009-12-04 |
2021-06-09 |
F. Hoffmann-La Roche AG |
Multispecific antibodies, antibody analogs, compositions, and methods
|
UA109888C2
(uk)
|
2009-12-07 |
2015-10-26 |
|
ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
|
WO2011071996A1
(en)
|
2009-12-08 |
2011-06-16 |
Ironwood Pharmaceuticals, Inc. |
Faah inhibitors
|
EP2509984B1
(en)
|
2009-12-09 |
2018-09-26 |
Auckland Uniservices Limited |
Fungicidal compounds and methods of their use
|
TWI505836B
(zh)
|
2009-12-11 |
2015-11-01 |
Genentech Inc |
抗-vegf-c抗體及其使用方法
|
EP3925670A1
(en)
|
2009-12-17 |
2021-12-22 |
Children's Medical Center, Corp. |
Saposin-a derived peptides and uses thereof
|
CN102753573A
(zh)
|
2009-12-21 |
2012-10-24 |
Ambrx公司 |
经过修饰的牛促生长素多肽和其用途
|
SG181769A1
(en)
|
2009-12-21 |
2012-07-30 |
Ambrx Inc |
Modified porcine somatotropin polypeptides and their uses
|
SG181905A1
(en)
|
2009-12-23 |
2012-07-30 |
Genentech Inc |
Anti-bv8 antibodies and uses thereof
|
GB0922553D0
(en)
|
2009-12-23 |
2010-02-10 |
Fusion Antibodies Ltd |
Prognostic marker
|
UY33110A
(es)
|
2009-12-23 |
2011-07-29 |
Ironwood Pharmaceuticals Inc |
Moduladores de CRTH2
|
EA027502B1
(ru)
|
2009-12-23 |
2017-08-31 |
Зиниммуне Гмбх |
Антитела против flt3 и способы их применения
|
WO2011082187A1
(en)
|
2009-12-30 |
2011-07-07 |
Genentech, Inc. |
Methods for modulating a pdgf-aa mediated biological response
|
EP2398488B1
(en)
|
2010-01-04 |
2018-11-14 |
Mapi Pharma Limited |
Depot system comprising glatiramer acetate
|
USRE49251E1
(en)
|
2010-01-04 |
2022-10-18 |
Mapi Pharma Ltd. |
Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
|
US8377885B2
(en)
|
2010-01-04 |
2013-02-19 |
Mapi Pharma Ltd. |
Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
|
WO2011085216A2
(en)
|
2010-01-08 |
2011-07-14 |
Ironwood Pharmaceuticals, Inc. |
Use of faah inhibitors for treating parkinson's disease and restless legs syndrome
|
TWI535445B
(zh)
|
2010-01-12 |
2016-06-01 |
安可美德藥物股份有限公司 |
Wnt拮抗劑及治療和篩選方法
|
MX2012008085A
(es)
|
2010-01-13 |
2012-09-12 |
Oncomed Pharm Inc |
Agentes de union notch1 y metodos de uso de los mismos.
|
BR112012017535A2
(pt)
|
2010-01-15 |
2019-09-24 |
Of Medicine And Dentistry Of New Jersey University |
uso de compostos de vanádio para cicatrização de osso
|
US8795726B2
(en)
|
2010-01-19 |
2014-08-05 |
Polypid Ltd. |
Sustained-release nucleic acid matrix compositions
|
EP2525792A1
(en)
|
2010-01-19 |
2012-11-28 |
Medizinische Universität Wien |
Pharmaceutical compositions comprising lignans and their derivatives for the medical management of angiogenesis and hypovascularity
|
WO2011089211A1
(en)
|
2010-01-22 |
2011-07-28 |
Synimmune Gmbh |
Anti-cd133 antibodies and methods of using the same
|
CA2788021A1
(en)
|
2010-01-27 |
2011-08-04 |
Children's Medical Center Corporation |
Pro-angiogenic fragments of prominin-1 and uses thereof
|
JP2013517782A
(ja)
|
2010-01-28 |
2013-05-20 |
ノヴォ・ノルディスク・ヘルス・ケア・アーゲー |
因子vii融合ポリペプチド
|
US11369498B2
(en)
|
2010-02-02 |
2022-06-28 |
MT Acquisition Holdings LLC |
Stent and stent delivery system with improved deliverability
|
US20130196960A1
(en)
|
2010-02-09 |
2013-08-01 |
Ironwood Pharmaceuticals, Inc. |
Cannabinoid Receptor Agonists
|
US20130178453A1
(en)
|
2010-02-09 |
2013-07-11 |
Ironwood Pharmaceuticals, Inc. |
Cannabinoid Agonists
|
EP2535057A2
(en)
|
2010-02-09 |
2012-12-19 |
Proyecto de Biomedicina Cima, S.L. |
Compositions for the treatment of infectious and tumoural diseases
|
EP2533859B1
(en)
|
2010-02-10 |
2016-04-06 |
Nayacure Therapeutics Ltd |
Pharmaceutical compositions for the treatment and prevention of cancer
|
SA111320200B1
(ar)
|
2010-02-17 |
2014-02-16 |
ديبيوفارم اس ايه |
مركبات ثنائية الحلقة واستخداماتها كمثبطات c-src/jak مزدوجة
|
WO2011101328A2
(en)
|
2010-02-18 |
2011-08-25 |
Roche Glycart Ag |
Treatment with a humanized igg class anti egfr antibody and an antibody against insulin like growth factor 1 receptor
|
JP5852968B2
(ja)
|
2010-02-19 |
2016-02-03 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
上皮膜タンパク質2(emp2)結合試薬および眼疾患治療におけるその使用
|
WO2011103375A1
(en)
|
2010-02-19 |
2011-08-25 |
Siga Technologies, Inc. |
Inhibitors and methods of inhibiting bacterial and viral pathogens
|
US8440651B2
(en)
|
2010-02-22 |
2013-05-14 |
F. Hoffmann-La Roche Ag |
Pyrido[3,2-d]pyrimidine PI3K delta inhibitor compounds and methods of use
|
TWI429453B
(zh)
|
2010-02-23 |
2014-03-11 |
Genentech Inc |
抗tat419抗體及其用途
|
CA3027824A1
(en)
|
2010-02-23 |
2011-09-01 |
Sanofi |
Anti-alpha2 integrin antibodies and their uses
|
MX2012009554A
(es)
|
2010-02-23 |
2012-11-23 |
Hoffmann La Roche |
Terapia anti-angiogenesis para el tratamiento del cancer ovarico.
|
US8298535B2
(en)
|
2010-02-24 |
2012-10-30 |
Rinat Neuroscience Corp. |
Anti-IL-7 receptor antibodies
|
US9155795B2
(en)
|
2010-02-26 |
2015-10-13 |
Anchor Therapeutics, Inc. |
CXCR4 receptor compounds
|
WO2011109398A2
(en)
|
2010-03-02 |
2011-09-09 |
President And Fellows Of Harvard College |
Methods and compositions for treatment of angelman syndrome and autism spectrum disorders
|
WO2011109834A2
(en)
|
2010-03-05 |
2011-09-09 |
President And Fellows Of Harvard College |
Enhancement of skeletal muscle stem cell engrafment by dual delivery of vegf and igf-1
|
WO2011112516A1
(en)
|
2010-03-08 |
2011-09-15 |
Ico Therapeutics Inc. |
Treating and preventing hepatitis c virus infection using c-raf kinase antisense oligonucleotides
|
KR20120138241A
(ko)
|
2010-03-11 |
2012-12-24 |
화이자 인코포레이티드 |
pH 의존성 항원 결합을 갖는 항체
|
JP2013525271A
(ja)
|
2010-03-12 |
2013-06-20 |
チルドレンズ メディカル センター コーポレーション |
免疫原およびそのスクリーニング方法
|
WO2011115804A1
(en)
|
2010-03-17 |
2011-09-22 |
Ironwood Pharmaceuticals, Inc. |
Sgc stimulators
|
EP2550018B1
(en)
|
2010-03-22 |
2019-02-27 |
F.Hoffmann-La Roche Ag |
Compositions and methods useful for stabilizing protein-containing formulations
|
TW201138821A
(en)
|
2010-03-26 |
2011-11-16 |
Roche Glycart Ag |
Bispecific antibodies
|
WO2011118804A1
(ja)
|
2010-03-26 |
2011-09-29 |
国立大学法人徳島大学 |
新規抗cd98抗体とその用途
|
WO2011119906A1
(en)
|
2010-03-26 |
2011-09-29 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
HUMAN POLYOMAVIRUS 6 (HPyV6) AND HUMAN POLYOMAVIRUS 7 (HPyV7)
|
JP2013523098A
(ja)
|
2010-03-29 |
2013-06-17 |
ザイムワークス,インコーポレイテッド |
強化又は抑制されたエフェクター機能を有する抗体
|
WO2011123719A2
(en)
|
2010-03-31 |
2011-10-06 |
Ironwood Pharmaceuticals, Inc. |
Use of faah inhibitors for treating abdominal, visceral and pelvic pain
|
EP2374816B1
(en)
|
2010-04-07 |
2016-09-28 |
Agency For Science, Technology And Research |
Binding molecules against Chikungunya virus and uses thereof
|
KR101464060B1
(ko)
|
2010-04-07 |
2014-11-20 |
에프. 호프만-라 로슈 아게 |
피라졸-4-일-헤테로사이클릴-카복사마이드 화합물 및 사용 방법
|
WO2011130332A1
(en)
|
2010-04-12 |
2011-10-20 |
Academia Sinica |
Glycan arrays for high throughput screening of viruses
|
US9517264B2
(en)
|
2010-04-15 |
2016-12-13 |
Amgen Inc. |
Human FGF receptor and β-Klotho binding proteins
|
EP2558864A1
(en)
|
2010-04-16 |
2013-02-20 |
Genentech, Inc. |
Fox03a as predictive biomarker for pi3k/akt kinase pathway inhibitor efficacy
|
EP2561068A1
(en)
|
2010-04-19 |
2013-02-27 |
Medizinische Universität Innsbruck |
Tmem195 encodes for tetrahydrobiopterin-dependent alkylglycerol monooxygenase activity
|
US10232092B2
(en)
|
2010-04-22 |
2019-03-19 |
Micell Technologies, Inc. |
Stents and other devices having extracellular matrix coating
|
RU2624027C2
(ru)
|
2010-04-23 |
2017-06-30 |
Дженентек, Инк. |
Получение гетеромультимерных белков
|
US8980253B2
(en)
|
2010-04-26 |
2015-03-17 |
Atyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of cysteinyl-tRNA synthetase
|
US8961960B2
(en)
|
2010-04-27 |
2015-02-24 |
Atyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of isoleucyl tRNA synthetases
|
RU2585489C2
(ru)
|
2010-04-27 |
2016-05-27 |
Рош Гликарт Аг |
КОМБИНИРОВАННАЯ ТЕРАПИЯ АФУКОЗИЛИРОВАННЫМ АНТИТЕЛОМ CD20 И ИНГИБИТОРОМ mTOR
|
AU2011248489B2
(en)
|
2010-04-28 |
2016-10-06 |
Pangu Biopharma Limited |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of alanyl tRNA synthetases
|
EP2563383B1
(en)
|
2010-04-29 |
2017-03-01 |
Atyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of valyl trna synthetases
|
JP6008838B2
(ja)
|
2010-04-29 |
2016-10-19 |
エータイアー ファーマ, インコーポレイテッド |
アスパラギニルtRNA合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
|
CN103096912A
(zh)
|
2010-05-03 |
2013-05-08 |
Atyr医药公司 |
与苯丙氨酰-α-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
|
JP5976638B2
(ja)
|
2010-05-03 |
2016-08-23 |
エータイアー ファーマ, インコーポレイテッド |
アルギニルtRNA合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
|
MA34291B1
(fr)
|
2010-05-03 |
2013-06-01 |
Genentech Inc |
Compositions et méthodes de diagnostic et de traitement d'une tumeur
|
CA2797978C
(en)
|
2010-05-03 |
2019-12-03 |
Atyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of methionyl-trna synthetases
|
BR112012027828A2
(pt)
|
2010-05-03 |
2016-08-09 |
Genentech Inc |
composição de matéria, artigo de fabricação e método de redução da viscosidade de uma formulação contendo proteína e de preparação de uma formulação aquosa contendo proteína
|
WO2011140267A2
(en)
|
2010-05-04 |
2011-11-10 |
Atyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of p38 multi-trna synthetase complex
|
GB201007531D0
(en)
|
2010-05-05 |
2010-06-23 |
Imp Innovations Ltd |
Composition
|
CN103038233B
(zh)
|
2010-05-07 |
2017-06-20 |
吉利德康涅狄格有限公司 |
吡啶酮和氮杂吡啶酮化合物及使用方法
|
EP3181692A1
(en)
|
2010-05-07 |
2017-06-21 |
Centre National De La Recherche Scientifique |
Ucp1 (thermogenin) - inducing agents for use in the treatment of a disorder of the energy homeostasis
|
CA2835489C
(en)
|
2010-05-10 |
2018-03-06 |
Chi-Huey Wong |
Zanamivir phosphonate congeners with anti-influenza activity and determining oseltamivir susceptibility of influenza viruses
|
WO2011141891A1
(en)
|
2010-05-12 |
2011-11-17 |
Debio Recherche Pharmaceutique S.A. |
Use of cycloundecadepsipeptide compounds
|
US8945541B2
(en)
|
2010-05-14 |
2015-02-03 |
Atyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-beta-tRNA synthetases
|
WO2011146574A1
(en)
|
2010-05-18 |
2011-11-24 |
Neumedicines, Inc. |
Il-12 formulations for enhancing hematopoiesis
|
WO2011146568A1
(en)
|
2010-05-19 |
2011-11-24 |
Genentech, Inc. |
Predicting response to a her inhibitor
|
US10335366B2
(en)
|
2010-05-31 |
2019-07-02 |
Laboratorios Farmacéuticos Rovi, S.A. |
Risperidone or paliperidone implant formulation
|
AU2011255203B2
(en)
|
2010-05-21 |
2016-01-21 |
Peptimed, Inc. |
Reagents and methods for treating cancer
|
US10350159B2
(en)
|
2010-05-31 |
2019-07-16 |
Laboratories Farmacéuticos Rovi, S.A. |
Paliperidone implant formulation
|
EP2394664B1
(en)
|
2010-05-31 |
2016-06-01 |
Laboratorios Farmaceuticos Rovi, S.A. |
Antipsychotic injectable depot composition
|
US10285936B2
(en)
|
2010-05-31 |
2019-05-14 |
Laboratorios Farmacéuticos Rovi, S.A. |
Injectable composition with aromatase inhibitor
|
WO2011150133A2
(en)
|
2010-05-26 |
2011-12-01 |
Bristol-Myers Squibb Company |
Fibronectin based scaffold proteins having improved stability
|
CN103096913B
(zh)
|
2010-05-27 |
2017-07-18 |
Atyr 医药公司 |
与谷氨酰胺酰‑tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
|
EP2578233B1
(en)
|
2010-05-28 |
2017-04-26 |
National Cancer Center |
Therapeutic agent for pancreatic cancer
|
WO2011149051A1
(ja)
|
2010-05-28 |
2011-12-01 |
中外製薬株式会社 |
抗腫瘍t細胞応答増強剤
|
PL2394663T3
(pl)
|
2010-05-31 |
2022-02-21 |
Laboratorios Farmaceuticos Rovi, S.A. |
Kompozycje do wstrzykiwania implantów biodegradowalnych in-situ
|
US10463607B2
(en)
|
2010-05-31 |
2019-11-05 |
Laboratorios Farmaceutics Rofi S.A. |
Antipsychotic Injectable Depot Composition
|
US10881605B2
(en)
|
2010-05-31 |
2021-01-05 |
Laboratorios Farmaceuticos Rovi, S.A. |
Methods for the preparation of injectable depot compositions
|
EP2575857B1
(en)
|
2010-06-01 |
2018-01-24 |
aTyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of lysyl-trna synthetases
|
WO2011153224A2
(en)
|
2010-06-02 |
2011-12-08 |
Genentech, Inc. |
Diagnostic methods and compositions for treatment of cancer
|
WO2011153243A2
(en)
|
2010-06-02 |
2011-12-08 |
Genentech, Inc. |
Anti-angiogenesis therapy for treating gastric cancer
|
WO2011153346A1
(en)
|
2010-06-03 |
2011-12-08 |
Genentech, Inc. |
Immuno-pet imaging of antibodies and immunoconjugates and uses therefor
|
EP2579892A2
(en)
|
2010-06-09 |
2013-04-17 |
Vaccine Technologies, Incorporated |
Therapeutic immunization in hiv infected subjects receiving stable antiretroviral treatment
|
CA2802635A1
(en)
|
2010-06-18 |
2011-12-22 |
Xiberscience Gmbh |
Peptides as active agents to stabilize biologic barriers
|
JP6029581B2
(ja)
|
2010-06-19 |
2016-11-24 |
メモリアル スローン−ケタリング キャンサー センター |
抗gd2抗体
|
PL3586826T3
(pl)
|
2010-06-24 |
2021-10-25 |
F. Hoffmann-La Roche Ag |
Kompozycje i sposoby stabilizowania preparatów zawierających białka
|
US9693954B2
(en)
|
2010-06-25 |
2017-07-04 |
President And Fellows Of Harvard College |
Co-delivery of stimulatory and inhibitory factors to create temporally stable and spatially restricted zones
|
BR112012033341B1
(pt)
|
2010-06-30 |
2022-08-23 |
Cyclerion Therapeutics, Inc |
Estimulantes de sgc
|
AU2011289831C1
(en)
|
2010-07-12 |
2017-06-15 |
Pangu Biopharma Limited |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-tRNA synthetases
|
WO2012009137A1
(en)
|
2010-07-12 |
2012-01-19 |
Ironwood Pharmaceuticals, Inc. |
Crth2 modulators
|
JP5913307B2
(ja)
|
2010-07-12 |
2016-04-27 |
コヴェックス・テクノロジーズ・アイルランド・リミテッド |
多機能性抗体複合体
|
US20130259830A1
(en)
|
2010-07-12 |
2013-10-03 |
Ironwood Pharmaceuticals, Inc. |
Crth2 modulators
|
CN103003279B
(zh)
|
2010-07-14 |
2015-09-23 |
弗·哈夫曼-拉罗切有限公司 |
对PI3K P110δ具有选择性的嘌呤化合物及其使用方法
|
WO2012009684A2
(en)
|
2010-07-16 |
2012-01-19 |
Micell Technologies, Inc. |
Drug delivery medical device
|
CN108314733A
(zh)
|
2010-07-16 |
2018-07-24 |
埃博灵克斯股份有限公司 |
修饰的单结构域抗原结合分子及其应用
|
US20120189618A1
(en)
|
2010-07-16 |
2012-07-26 |
Boehringer Ingelheim International Gmbh |
Superior efficacy of cd37 antibodies in cll blood samples
|
CA2804246A1
(en)
|
2010-07-19 |
2012-01-26 |
F. Hoffmann-La Roche Ag |
Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy
|
KR20130055647A
(ko)
|
2010-07-19 |
2013-05-28 |
에프. 호프만-라 로슈 아게 |
항암요법에 반응할 가능성이 증가된 환자를 확인하는 방법
|
NZ605438A
(en)
|
2010-07-22 |
2015-02-27 |
Harvard College |
Multiple input biologic classifier circuits for cells
|
EP3696195B1
(en)
|
2010-07-23 |
2024-02-14 |
Trustees of Boston University |
Anti-despr inhibitors as therapeutics for inhibition of pathological angiogenesis and tumor cell invasiveness and for molecular imaging and targeted delivery
|
CA2806252C
(en)
|
2010-07-29 |
2019-05-14 |
Xencor, Inc. |
Antibodies with modified isoelectric points
|
EP2600886A1
(en)
|
2010-08-02 |
2013-06-12 |
Université de Lausanne |
Use of a peptide enhancing the ability of radiation therapy to kill cancer cells
|
EP2603237A4
(en)
|
2010-08-12 |
2014-05-21 |
Theraclone Sciences Inc |
ANTI-HEMAGGLUTININE ANTIBODY COMPOSITIONS AND METHOD FOR THEIR USE
|
CA2808185A1
(en)
|
2010-08-13 |
2012-02-16 |
Genentech, Inc. |
Antibodies to il-1.beta. and il-18, for treatment of disease
|
ES2716241T3
(es)
|
2010-08-17 |
2019-06-11 |
Univ Geneve |
Isoformas de BARD1 en cáncer de pulmón y colorrectal y su uso
|
US9567386B2
(en)
|
2010-08-17 |
2017-02-14 |
Ambrx, Inc. |
Therapeutic uses of modified relaxin polypeptides
|
AU2011291943B2
(en)
|
2010-08-17 |
2015-01-22 |
Ambrx, Inc. |
Modified relaxin polypeptides and their uses
|
AR082693A1
(es)
|
2010-08-17 |
2012-12-26 |
Roche Glycart Ag |
Terapia de combinacion de un anticuerpo anti-cd20 afucosilado con un anticuerpo anti-vegf
|
CN103068846B9
(zh)
|
2010-08-24 |
2016-09-28 |
弗·哈夫曼-拉罗切有限公司 |
包含二硫键稳定性Fv片段的双特异性抗体
|
AU2011293294B2
(en)
|
2010-08-25 |
2016-03-24 |
Pangu Biopharma Limited |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Tyrosyl-tRNA synthetases
|
CA2812063A1
(en)
|
2010-08-30 |
2012-06-07 |
President And Fellows Of Harvard College |
Shear controlled release for stenotic lesions and thrombolytic therapies
|
PL3556396T3
(pl)
|
2010-08-31 |
2022-09-12 |
Theraclone Sciences, Inc. |
Przeciwciała neutralizujące ludzki wirus niedoboru odporności (hiv)
|
NZ607547A
(en)
|
2010-09-01 |
2015-06-26 |
Univ Jefferson |
Composition and method for muscle repair and regeneration
|
US9249123B2
(en)
|
2010-09-01 |
2016-02-02 |
Genentech, Inc. |
Pyridinones/pyrazinones, method of making, and method of use thereof
|
BR112013007499A2
(pt)
|
2010-09-01 |
2016-07-12 |
Genentech Inc |
piridazinonas - métodos de criação e usos
|
US8551479B2
(en)
|
2010-09-10 |
2013-10-08 |
Oncomed Pharmaceuticals, Inc. |
Methods for treating melanoma
|
US9616097B2
(en)
|
2010-09-15 |
2017-04-11 |
Synergy Pharmaceuticals, Inc. |
Formulations of guanylate cyclase C agonists and methods of use
|
US20130296183A1
(en)
|
2010-09-17 |
2013-11-07 |
President And Fellows Of Harvard College |
Functional genomics assay for characterizing pluripotent stem cell utility and safety
|
WO2012040518A2
(en)
|
2010-09-22 |
2012-03-29 |
Amgen Inc. |
Carrier immunoglobulins and uses thereof
|
AR083006A1
(es)
|
2010-09-23 |
2013-01-23 |
Lilly Co Eli |
Formulaciones para el factor estimulante de colonias de granulocitos (g-csf) bovino y variantes de las mismas
|
WO2012043533A1
(ja)
|
2010-09-28 |
2012-04-05 |
積水化学工業株式会社 |
抗ヒトccr7抗体、ハイブリドーマ、核酸、ベクター、細胞、医薬組成物、並びに、抗体固定化担体
|
NZ705124A
(en)
|
2010-10-01 |
2016-08-26 |
Biogen Ma Inc |
Interferon-beta for use as monotherapy or in combination with other cancer therapies
|
EP2624849A2
(en)
|
2010-10-04 |
2013-08-14 |
Centre National de la Recherche Scientifique (C.N.R.S.) |
Multivalent synthetic compounds as antibiotic treatment
|
LT2624873T
(lt)
|
2010-10-06 |
2020-03-10 |
President And Fellows Of Harvard College |
Įšvirkščiami, poras sudarantys hidrogeliai, skirti medžiagų pagrindo ląstelių terapijai
|
KR20140014077A
(ko)
|
2010-10-25 |
2014-02-05 |
리전츠 오브 더 유니버스티 오브 미네소타 |
교모세포종의 치료를 위한 치료 조성물
|
EP2633317A1
(en)
|
2010-10-25 |
2013-09-04 |
Genentech, Inc. |
Treatment of gastrointestinal inflammation and psoriasis a
|
EP2447276A1
(en)
|
2010-10-27 |
2012-05-02 |
Ferring B.V. |
Process for the manufacture of Degarelix and its intermediates
|
PT2632934T
(pt)
|
2010-10-27 |
2017-01-06 |
Ferring Bv |
Processo para o fabrico de degarelix e seus intermediários
|
EP2632951B1
(en)
|
2010-10-27 |
2017-08-02 |
Amgen Inc. |
Dkk1 antibodies and methods of use
|
SG10201508981YA
(en)
|
2010-11-01 |
2015-11-27 |
Peptimed Inc |
Compositions Of A Peptide-Based System For Cell-Specific Targeting
|
US9603894B2
(en)
|
2010-11-08 |
2017-03-28 |
President And Fellows Of Harvard College |
Materials presenting notch signaling molecules to control cell behavior
|
KR20200059320A
(ko)
|
2010-11-08 |
2020-05-28 |
제넨테크, 인크. |
피하 투여용 항―il―6 수용체 항체
|
JP5878546B2
(ja)
|
2010-11-09 |
2016-03-08 |
アイアンウッド ファーマシューティカルズ インコーポレイテッド |
sGC刺激剤
|
MY166429A
(en)
|
2010-11-17 |
2018-06-26 |
Chugai Pharmaceutical Co Ltd |
Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii
|
GB201019467D0
(en)
|
2010-11-17 |
2010-12-29 |
Biotecnol Sa |
Therapeutic agent
|
US9023791B2
(en)
|
2010-11-19 |
2015-05-05 |
Novartis Ag |
Fibroblast growth factor 21 mutations
|
PT2643019T
(pt)
|
2010-11-24 |
2019-04-23 |
Lexicon Pharmaceuticals Inc |
Anticorpos para notum pectinacetilesterase
|
EP2646440A4
(en)
|
2010-11-30 |
2014-06-18 |
Univ Johns Hopkins |
CYCLIC HYBRID LIBRARIES AND SCREENS FOR THIS
|
EP3208282A1
(en)
|
2010-11-30 |
2017-08-23 |
F. Hoffmann-La Roche AG |
Low affinity anti transferrin receptor and their use to transfer therapeutic scfv across the blood brain barrier
|
WO2012075581A1
(en)
|
2010-12-06 |
2012-06-14 |
Ym Biosciences Inc. |
Antibodies selective for cells presenting erbb2 at high density
|
KR20130088170A
(ko)
|
2010-12-16 |
2013-08-07 |
로슈 글리카트 아게 |
비푸코실화 cd20 항체와 mdm2 저해제와의 조합 치료
|
WO2012082997A1
(en)
|
2010-12-16 |
2012-06-21 |
F. Hoffmann-La-Roche Ag |
Tricyclic pi3k inhibitor compounds and methods of use
|
CA2817460A1
(en)
|
2010-12-17 |
2012-06-21 |
F. Hoffmann-La Roche Ag |
Substituted 6,6-fused nitrogenous heterocyclic compounds and uses thereof
|
US20140010812A1
(en)
|
2010-12-20 |
2014-01-09 |
Rockefeller University (The) |
Modulating agonistic tnfr antibodies
|
US9035022B2
(en)
|
2010-12-22 |
2015-05-19 |
Salk Institute For Biological Studies |
Cyclic CRF antagonist peptides
|
WO2012088254A1
(en)
|
2010-12-22 |
2012-06-28 |
Genentech, Inc. |
Autophagy inducer and inhibitor combination therapy for the treatment of neoplasms
|
AR084433A1
(es)
|
2010-12-22 |
2013-05-15 |
Ironwood Pharmaceuticals Inc |
Inhibidores de la faah y composiciones farmaceuticas que los contienen
|
WO2012088431A1
(en)
|
2010-12-23 |
2012-06-28 |
Ironwood Pharmaceuticals, Inc. |
Faah inhibitors
|
US8754037B2
(en)
|
2010-12-23 |
2014-06-17 |
Hanall Biopharma Co., Ltd. |
Modified human tumor necrosis factor receptor-1 polypeptide or fragment thereof, and method for preparing same
|
WO2012085111A1
(en)
|
2010-12-23 |
2012-06-28 |
F. Hoffmann-La Roche Ag |
Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
|
JOP20210044A1
(ar)
|
2010-12-30 |
2017-06-16 |
Takeda Pharmaceuticals Co |
الأجسام المضادة لـ cd38
|
WO2012092539A2
(en)
|
2010-12-31 |
2012-07-05 |
Takeda Pharmaceutical Company Limited |
Antibodies to dll4 and uses thereof
|
JP6289098B2
(ja)
|
2011-01-10 |
2018-03-07 |
ノビミューン エスアー |
抗tlr4抗体およびその使用法
|
AU2012206614A1
(en)
|
2011-01-12 |
2013-08-01 |
Innate Pharma |
TLR3 binding agents
|
EP2668207A4
(en)
|
2011-01-24 |
2015-06-10 |
Univ Singapore |
LIPOARABINOMANNANE ANTIGEN-BINDING PROTEINS HAVING A MANNOSIS FROM PATHOGENIC MYCOBACTERIAS
|
AU2012211014A1
(en)
|
2011-01-24 |
2013-05-02 |
National Research Council Of Canada |
Antibodies selective for cells presenting EGFR at high density
|
JO3755B1
(ar)
|
2011-01-26 |
2021-01-31 |
Ferring Bv |
تركيبات تستوستيرون
|
SI2667715T1
(sl)
|
2011-01-27 |
2017-11-30 |
Neuren Pharmaceuticals Limited |
Zdravljenje motenj avtističnega spektra z uporabo glicil-l-2-metilprolil-l-glutaminske kisline
|
WO2012106281A2
(en)
|
2011-01-31 |
2012-08-09 |
The General Hospital Corporation |
Multimodal trail molecules and uses in cellular therapies
|
BR112013019499B1
(pt)
|
2011-02-04 |
2023-01-10 |
Genentech, Inc. |
Proteína heteromultimérica variante ou anticorpo igg modificado, método para produzir uma proteína heteromultimérica variante ou anticorpo igg modificado, composição, método para preparar uma proteína heteromultimérica e proteína heteromultimérica variante
|
WO2012104824A1
(en)
|
2011-02-04 |
2012-08-09 |
Ecole polytechnique fédérale de Lausanne (EPFL) |
Therapeutic antibodies targeting app-c99
|
US10689447B2
(en)
|
2011-02-04 |
2020-06-23 |
Genentech, Inc. |
Fc variants and methods for their production
|
RU2440142C1
(ru)
|
2011-02-07 |
2012-01-20 |
Общество С Ограниченной Ответственностью "Онкомакс" |
Антитело, останавливающее или замедляющее рост опухоли (варианты), способ подавления роста опухоли, способ диагностики злокачественных образований
|
WO2012109329A2
(en)
|
2011-02-08 |
2012-08-16 |
Children's Medical Center Corporation |
Methods for treatment of melanoma
|
BR112013020329A2
(pt)
|
2011-02-09 |
2016-08-02 |
Hoffmann La Roche |
compostos heterocíclicos como inibidores da pi3-quinase
|
JP2014506580A
(ja)
|
2011-02-14 |
2014-03-17 |
セラクローン サイエンシーズ, インコーポレイテッド |
インフルエンザの治療および診断のための組成物および方法
|
US20120208755A1
(en)
|
2011-02-16 |
2012-08-16 |
Intarcia Therapeutics, Inc. |
Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
|
US8658171B2
(en)
|
2011-02-28 |
2014-02-25 |
Livzon Mabpharm Inc. |
Humanized anti-TNFα antibodies
|
CN102675460B
(zh)
|
2011-02-28 |
2015-08-19 |
珠海市丽珠单抗生物技术有限公司 |
抗肿瘤坏死因子α的人源化抗体
|
WO2012118903A2
(en)
|
2011-03-01 |
2012-09-07 |
Amgen Inc. |
Bispecific binding agents
|
RU2013141611A
(ru)
|
2011-03-10 |
2015-04-20 |
Дженентек, Инк. |
Лечение заболеваний с измененной барьерной функцией сосудов
|
BR112013023576A2
(pt)
|
2011-03-15 |
2016-12-06 |
Theraclone Sciences Inc |
composições e métodos para a terapia e diagnóstico de influenza
|
WO2012125775A1
(en)
|
2011-03-16 |
2012-09-20 |
Sanofi |
Uses of a dual v region antibody-like protein
|
MX2013010513A
(es)
|
2011-03-16 |
2013-10-07 |
Hoffmann La Roche |
Compuestos de alcohol 6,5-heterociclil-propargilico y usos de los mismos.
|
US9585930B2
(en)
|
2011-03-20 |
2017-03-07 |
Trustees Of Boston University |
Therapeutic agent for emphysema and COPD
|
BR112013024122A2
(pt)
|
2011-03-21 |
2019-09-24 |
Hoffmann La Roche |
compostos de benzoxazepina seletivos para p110 delta pi3k e métodos de uso
|
EP3184117B1
(en)
|
2011-03-22 |
2020-01-08 |
The Brigham And Women's Hospital, Inc. |
Compositions and their use in the treatment of cancer
|
KR102148063B1
(ko)
|
2011-03-31 |
2020-08-25 |
제넨테크, 인크. |
베타7 인테그린 길항제를 투여하는 방법
|
WO2012135779A1
(en)
|
2011-04-01 |
2012-10-04 |
Genentech, Inc. |
Combinations of akt and mek inhibitor compounds, and methods of use
|
MX2013011329A
(es)
|
2011-04-01 |
2014-03-12 |
Genentech Inc |
Combinaciones de compuestos inhibidores de akt y erlotinib y metodos de uso.
|
KR20140027211A
(ko)
|
2011-04-04 |
2014-03-06 |
유니버시티 오브 아이오와 리써치 파운데이션 |
백신 면역원성의 개선 방법
|
CN103619881B
(zh)
|
2011-04-07 |
2017-07-28 |
安姆根有限公司 |
新的egfr结合蛋白
|
CA2832581C
(en)
|
2011-04-08 |
2022-08-23 |
Yumei Xiong |
Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)
|
HUE033008T2
(hu)
|
2011-04-13 |
2017-11-28 |
Bristol Myers Squibb Co |
FC fúziós proteinek, amelyek tartalmaznak új linkereket
|
ES2601892T3
(es)
|
2011-04-21 |
2017-02-16 |
Mapi Pharma Limited |
Pentapolímero aleatorio para el tratamiento de enfermedades autoinmunes
|
AU2012249601A1
(en)
|
2011-04-26 |
2013-05-09 |
Genentech, Inc. |
Compositions and method for treating autoimmune diseases
|
US10647959B2
(en)
|
2011-04-27 |
2020-05-12 |
President And Fellows Of Harvard College |
Cell-friendly inverse opal hydrogels for cell encapsulation, drug and protein delivery, and functional nanoparticle encapsulation
|
US9675561B2
(en)
|
2011-04-28 |
2017-06-13 |
President And Fellows Of Harvard College |
Injectable cryogel vaccine devices and methods of use thereof
|
EP2701745B1
(en)
|
2011-04-28 |
2018-07-11 |
President and Fellows of Harvard College |
Injectable preformed macroscopic 3-dimensional scaffolds for minimally invasive administration
|
NZ616989A
(en)
|
2011-04-29 |
2016-03-31 |
Univ Washington |
Therapeutic nuclease compositions and methods
|
JP2014513128A
(ja)
|
2011-05-03 |
2014-05-29 |
ジェネンテック, インコーポレイテッド |
血管破壊剤とその使用
|
WO2012151474A2
(en)
|
2011-05-04 |
2012-11-08 |
Trustees Of Boston University |
Proton-motive force stimulation to potentiate aminoglycoside antibiotics against persistent bacteria
|
EP2705013B1
(en)
|
2011-05-04 |
2016-03-30 |
Balance Therapeutics, Inc. |
Pentylenetetrazole derivatives
|
MX2013013044A
(es)
|
2011-05-10 |
2014-02-20 |
Amgen Inc |
METODO PARA IDENTIFICAR COMPUESTOS QUE ESPECIFICAMENTE MODULAN LA INTERACCION DE FGFR1 Y ß-KLOTHO.
|
JOP20200043A1
(ar)
|
2011-05-10 |
2017-06-16 |
Amgen Inc |
طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
|
US9499593B2
(en)
|
2011-05-11 |
2016-11-22 |
Children's Medical Center Corporation |
Modified biotin-binding protein, fusion proteins thereof and applications
|
CA2836791A1
(en)
|
2011-05-20 |
2012-11-29 |
Benjamin Wolozin |
Identification of compounds that disperse tdp-43 inclusions
|
WO2012166903A1
(en)
|
2011-06-02 |
2012-12-06 |
President And Fellows Of Harvard College |
Methods and uses for ex vivo tissue culture systems
|
AU2012261848B2
(en)
|
2011-06-03 |
2017-06-15 |
President And Fellows Of Harvard College |
In situ antigen-generating cancer vaccine
|
US9574002B2
(en)
|
2011-06-06 |
2017-02-21 |
Amgen Inc. |
Human antigen binding proteins that bind to a complex comprising β-Klotho and an FGF receptor
|
WO2012170071A1
(en)
|
2011-06-06 |
2012-12-13 |
Elan Pharmaceuticas, Inc |
Mcam antagonists and methods of treatment
|
EA026121B1
(ru)
|
2011-06-14 |
2017-03-31 |
Бикам Фармасьютикалз, Инк. |
Опсин-связывающие лиганды, композиции и способы их использования
|
AU2012271329A1
(en)
|
2011-06-17 |
2013-12-19 |
Amgen Inc. |
Method of treating or ameliorating metabolic disorders using Clec-2
|
WO2013003112A1
(en)
|
2011-06-27 |
2013-01-03 |
The Jackson Laboratory |
Methods and compositions for treatment of cancer and autoimmune disease
|
LT2726092T
(lt)
|
2011-06-28 |
2019-10-10 |
Inhibrx, Lp |
Sulieti serpino polipeptidai ir jų panaudojimo būdai
|
AU2012275295B2
(en)
|
2011-06-28 |
2016-11-10 |
Inhibrx, Lp |
WAP domain fusion polypeptides and methods of use thereof
|
US10400029B2
(en)
|
2011-06-28 |
2019-09-03 |
Inhibrx, Lp |
Serpin fusion polypeptides and methods of use thereof
|
US20130090294A1
(en)
|
2011-06-28 |
2013-04-11 |
Alternative Innovative Technologies Llc |
Novel methods of use of hsp70 for increased performance or treatment of hsp70 related disorders
|
US20140227293A1
(en)
|
2011-06-30 |
2014-08-14 |
Trustees Of Boston University |
Method for controlling tumor growth, angiogenesis and metastasis using immunoglobulin containing and proline rich receptor-1 (igpr-1)
|
US10336992B2
(en)
|
2011-07-08 |
2019-07-02 |
Shire Human Genetic Therapies, Inc. |
Methods for purification of arylsulfatase A
|
JP2013023499A
(ja)
|
2011-07-14 |
2013-02-04 |
Pfizer Inc |
抗pcsk9抗体を用いた処置
|
CA2841360A1
(en)
|
2011-07-15 |
2013-01-24 |
Micell Technologies, Inc. |
Drug delivery medical device
|
US20130022551A1
(en)
|
2011-07-22 |
2013-01-24 |
Trustees Of Boston University |
DEspR ANTAGONISTS AND AGONISTS AS THERAPEUTICS
|
US20140234330A1
(en)
|
2011-07-22 |
2014-08-21 |
Amgen Inc. |
Il-17 receptor a is required for il-17c biology
|
WO2013017656A1
(en)
|
2011-08-02 |
2013-02-07 |
Medizinische Universität Wien |
Antagonists of ribonucleases for treating obesity
|
WO2013022855A1
(en)
|
2011-08-05 |
2013-02-14 |
Xencor, Inc. |
Antibodies with modified isoelectric points and immunofiltering
|
BR112014003296A2
(pt)
|
2011-08-12 |
2017-03-14 |
Hoffmann La Roche |
composto, composição farmacêutica, processo para a preparação de uma composição farmacêutica, método para o tratamento de uma doença ou distúrbio, conjunto para o tratamento de uma condição mediada pela quinase pim e utilização do composto
|
EP2745113B1
(en)
|
2011-08-16 |
2017-03-22 |
Evotec (München) GmbH |
Markers for susceptibility to an inhibitor of an src-family kinase
|
WO2013025939A2
(en)
|
2011-08-16 |
2013-02-21 |
Indiana University Research And Technology Corporation |
Compounds and methods for treating cancer by inhibiting the urokinase receptor
|
EP3348575A1
(en)
|
2011-08-16 |
2018-07-18 |
Emory University |
Jaml specific binding agents, antibodies, and uses related thereto
|
US9701731B2
(en)
|
2011-08-19 |
2017-07-11 |
Children's Medical Center Corporation |
VEGF-binding protein for blockade of angiogenesis
|
ES2610779T3
(es)
|
2011-08-23 |
2017-05-03 |
President And Fellows Of Harvard College |
Nanopartículas de péptidos y usos de las mismas
|
WO2013033069A1
(en)
|
2011-08-30 |
2013-03-07 |
Theraclone Sciences, Inc. |
Human rhinovirus (hrv) antibodies
|
MX2014002260A
(es)
|
2011-08-31 |
2014-08-18 |
Amgen Inc |
Factor de crecimiento de fibroblasto 21 para usar en el tratamiento de diabetes tipo 1.
|
US10385475B2
(en)
|
2011-09-12 |
2019-08-20 |
Adaptive Biotechnologies Corp. |
Random array sequencing of low-complexity libraries
|
WO2013039916A1
(en)
|
2011-09-12 |
2013-03-21 |
The United States Of America, Represented By The Secretary, Dept. Of Health And Human Services |
Compositions for and methods of treatment and enhanced detection of non-pituitary tumors
|
CA2849318C
(en)
|
2011-09-22 |
2019-11-12 |
Amgen Inc. |
Cd27l antigen binding proteins
|
PT2758073T
(pt)
|
2011-09-23 |
2019-02-01 |
Oncomed Pharm Inc |
Agentes de ligação a vegf/dll4 e utilizações dos mesmos
|
TWI593708B
(zh)
|
2011-09-26 |
2017-08-01 |
諾華公司 |
治療代謝病症之融合蛋白質
|
US9458214B2
(en)
|
2011-09-26 |
2016-10-04 |
Novartis Ag |
Dual function fibroblast growth factor 21 proteins
|
KR20140074964A
(ko)
|
2011-09-27 |
2014-06-18 |
에프. 호프만-라 로슈 아게 |
피라졸-4-일-헤테로사이클릴-카복사마이드 화합물 및 사용 방법
|
US10556949B2
(en)
|
2011-09-30 |
2020-02-11 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule inducing immune response to target antigen
|
DE102011114864A1
(de)
|
2011-10-05 |
2013-04-11 |
Acino Ag |
Verfahren zur Herstellung einer homogenen Pulvermischung und Verfahren zur Herstellung eines Implantats sowie Implantat
|
JP6310394B2
(ja)
|
2011-10-10 |
2018-04-11 |
ゼンコア インコーポレイテッド |
抗体を精製する方法
|
WO2013053076A1
(en)
|
2011-10-10 |
2013-04-18 |
Zensun (Shanghai)Science & Technology Limited |
Compositions and methods for treating heart failure
|
US10851178B2
(en)
|
2011-10-10 |
2020-12-01 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
US20140271657A1
(en)
|
2011-10-12 |
2014-09-18 |
Children's Medical Center Corporation |
Combinatorial compositions and methods of treating hemoglobinopathies
|
CA2851284A1
(en)
|
2011-10-13 |
2013-04-18 |
The Regents Of The University Of California |
Treatment of breast cancer with companion diagnostic
|
US8906860B2
(en)
|
2011-10-14 |
2014-12-09 |
The Board Of Trustees Of The University Of Illinois |
Methods and compositions inhibiting tumor cell proliferation
|
RU2014114849A
(ru)
|
2011-10-14 |
2015-11-20 |
Алтернатив Инновейтив Текнолоджиз Ллц |
Устойчивые к деградации производные белков теплового шока-70 (бтш70) и способы их применения (варианты)
|
WO2013056255A1
(en)
|
2011-10-14 |
2013-04-18 |
The Board Of Trustees Of The University Of Illinois |
Methods and compositions for inhibiting tumor cell proliferation
|
US10188772B2
(en)
|
2011-10-18 |
2019-01-29 |
Micell Technologies, Inc. |
Drug delivery medical device
|
WO2013058809A1
(en)
|
2011-10-19 |
2013-04-25 |
Bikam Pharmaceuticals, Inc. |
Opsin-binding ligands, compositions and methods of use
|
US9279159B2
(en)
|
2011-10-21 |
2016-03-08 |
Adaptive Biotechnologies Corporation |
Quantification of adaptive immune cell genomes in a complex mixture of cells
|
US20130122005A1
(en)
|
2011-10-27 |
2013-05-16 |
Paul Adam |
Anticancer combination therapy
|
EP2776051A4
(en)
|
2011-10-28 |
2015-06-17 |
Hoffmann La Roche |
THERAPEUTIC COMBINATIONS AND METHOD FOR THE TREATMENT OF MELANOMA
|
WO2013067029A2
(en)
|
2011-10-31 |
2013-05-10 |
Bristol-Myers Squibb Company |
Fibronectin binding domains with reduced immunogenicity
|
LT3091029T
(lt)
|
2011-10-31 |
2023-02-27 |
F. Hoffmann-La Roche Ag |
Anti-il13 antikūno kompozicijos
|
WO2013067264A1
(en)
|
2011-11-03 |
2013-05-10 |
Genentech, Inc. |
8-fluorophthalazin-1 (2h) - one compounds as inhibitors of btk activity
|
UA111756C2
(uk)
|
2011-11-03 |
2016-06-10 |
Ф. Хоффманн-Ля Рош Аг |
Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона
|
JP5808869B2
(ja)
|
2011-11-03 |
2015-11-10 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
二環式ピペラジン化合物
|
WO2013065017A2
(en)
|
2011-11-03 |
2013-05-10 |
Centre Hospitalier Universitaire Vaudois (C.H.U.V.) |
Platelet rich plasma (prp) and prominin-1 derived peptide stimulate lymphangiogenesis
|
WO2013067277A1
(en)
|
2011-11-03 |
2013-05-10 |
Genentech, Inc. |
Alkylated piperazine compounds as inhibitors of btk activity
|
US9243037B2
(en)
|
2011-11-10 |
2016-01-26 |
Trustees Of Boston College |
Gramicidin a mutants that function as antibiotics with improved solubility and reduced toxicity
|
RU2014116406A
(ru)
|
2011-11-11 |
2015-12-20 |
Ринат Ньюросайенс Корп. |
Антитела, специфичные к trop-2, и их применения
|
MX2014005957A
(es)
|
2011-11-16 |
2015-02-04 |
Amgen Inc |
Metodos para tratar trastornos relacionados con mutante viii de eliminacion de factor de crecimiento epidermico.
|
GR1007832B
(el)
|
2011-11-21 |
2013-02-14 |
Ιδρυμα Ιατροβιολογικων Ερευνων Ακαδημιας Αθηνων, |
Αδρανοποιητες της ακτιβινης και χρηση τους για την θεραπεια ασθενειων που σχετιζονται με παρεκκλινουσα ενεργοποιηση της "αμυντικης αποκρισης του ξενιστη"
|
WO2013078254A1
(en)
|
2011-11-22 |
2013-05-30 |
Array Biopharma Inc. |
Bicyclic heteroaryl derivatives as kinase inhibitors
|
US20130302274A1
(en)
|
2011-11-25 |
2013-11-14 |
Roche Glycart Ag |
Combination therapy
|
WO2013082000A1
(en)
|
2011-11-30 |
2013-06-06 |
Bikam Pharmaceuticals, Inc. |
Opsin-binding ligands, compositions and methods of use
|
WO2013081642A1
(en)
|
2011-12-01 |
2013-06-06 |
Bikam Pharmaceuticals, Inc. |
Opsin-binding ligands, compositions and methods of use
|
WO2013082511A1
(en)
|
2011-12-02 |
2013-06-06 |
Genentech, Inc. |
Methods for overcoming tumor resistance to vegf antagonists
|
EP2601941A1
(en)
|
2011-12-06 |
2013-06-12 |
Ludwig-Maximilians-Universität München |
Beta-O/S/N fatty acid based compounds as antibacterial and antiprotozoal agents
|
AU2012347540A1
(en)
|
2011-12-08 |
2014-06-26 |
Amgen Inc. |
Agonistic human LCAT antigen binding proteins and their use in therapy
|
CA2858070C
(en)
|
2011-12-09 |
2018-07-10 |
Adaptive Biotechnologies Corporation |
Diagnosis of lymphoid malignancies and minimal residual disease detection
|
EP2788500A1
(en)
|
2011-12-09 |
2014-10-15 |
F.Hoffmann-La Roche Ag |
Identification of non-responders to her2 inhibitors
|
US9499865B2
(en)
|
2011-12-13 |
2016-11-22 |
Adaptive Biotechnologies Corp. |
Detection and measurement of tissue-infiltrating lymphocytes
|
WO2013101509A2
(en)
|
2011-12-15 |
2013-07-04 |
Alternative Innovative Technologies Llc |
Hsp70 fusion protein conjugates and uses thereof
|
WO2013096516A1
(en)
|
2011-12-19 |
2013-06-27 |
Xoma Technology Ltd. |
Methods for treating acne
|
WO2013093868A1
(en)
|
2011-12-22 |
2013-06-27 |
Chuv, Centre Hospitalier Universitaire Vaudois |
Selective plasma activation for medical implants and wound healing devices
|
WO2013091903A1
(en)
|
2011-12-22 |
2013-06-27 |
Novo Nordisk A/S |
Anti-crac channel antibodies
|
WO2013096868A2
(en)
|
2011-12-22 |
2013-06-27 |
Children's Medical Center Corporation |
Saposin-a derived peptides and uses thereof
|
RU2014123030A
(ru)
|
2011-12-22 |
2016-02-20 |
Ринат Ньюросайенс Корп. |
Антагонистические антитела против человеческого рецептора гормона роста и способы их применения
|
IL267585B
(en)
|
2011-12-22 |
2022-09-01 |
Genentech Inc |
Ion exchange membrane chromatography
|
WO2013093693A1
(en)
|
2011-12-22 |
2013-06-27 |
Rinat Neuroscience Corp. |
Staphylococcus aureus specific antibodies and uses thereof
|
JP2015502397A
(ja)
|
2011-12-23 |
2015-01-22 |
ファイザー・インク |
部位特異的コンジュゲーションのための操作された抗体定常領域、ならびにそのための方法および使用
|
US9139564B2
(en)
|
2011-12-27 |
2015-09-22 |
Ironwood Pharmaceuticals, Inc. |
2-benzyl, 3-(pyrimidin-2-yl) substituted pyrazoles useful as sGC stimulators
|
WO2013101771A2
(en)
|
2011-12-30 |
2013-07-04 |
Genentech, Inc. |
Compositions and method for treating autoimmune diseases
|
US9884123B2
(en)
|
2012-01-03 |
2018-02-06 |
Invictus Oncology Pvt. Ltd. |
Ligand-targeted molecules and methods thereof
|
JP6413127B2
(ja)
|
2012-01-09 |
2018-10-31 |
コヴェックス・テクノロジーズ・アイルランド・リミテッド |
変異抗体およびそのコンジュゲーション
|
CN104520321A
(zh)
|
2012-01-09 |
2015-04-15 |
斯克利普斯研究所 |
超长互补决定区及其用途
|
EP2802601B1
(en)
|
2012-01-09 |
2019-11-13 |
The Scripps Research Institute |
Humanized antibodies with ultralong cdr3s
|
EP2804603A1
(en)
|
2012-01-10 |
2014-11-26 |
President and Fellows of Harvard College |
Beta-cell replication promoting compounds and methods of their use
|
US9512212B2
(en)
|
2012-01-11 |
2016-12-06 |
Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University |
Bispecific antibody fragments for neurological disease proteins and methods of use
|
CN104168899B
(zh)
|
2012-01-13 |
2017-04-05 |
通用医疗公司 |
麻醉剂化合物及其相关的使用方法
|
EP2802346B1
(en)
|
2012-01-13 |
2018-09-12 |
F.Hoffmann-La Roche Ag |
Biological markers for identifying patients for treatment with vegf antagonists
|
KR20140125803A
(ko)
|
2012-01-26 |
2014-10-29 |
암젠 인크 |
성장 분화 인자 15(gdf-15) 폴리펩타이드들
|
MX353190B
(es)
|
2012-01-30 |
2018-01-05 |
F Hoffmann La Roche Ag Star |
Derivados de isoquinolina y naftiridina.
|
KR102100388B1
(ko)
|
2012-02-06 |
2020-04-13 |
인히브릭스, 인크. |
Cd47 항체 및 그 사용 방법
|
CN104105711B
(zh)
|
2012-02-10 |
2018-11-30 |
弗·哈夫曼-拉罗切有限公司 |
单链抗体及其他异多聚体
|
EP2626066A1
(en)
|
2012-02-10 |
2013-08-14 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Combination therapy comprising selective VEGFR-2 inhibitors and MEK inhibitors
|
IN2014MN01642A
(ja)
|
2012-02-16 |
2015-07-03 |
Atyr Pharma Inc |
|
WO2013120980A1
(en)
|
2012-02-17 |
2013-08-22 |
F. Hoffmann-La Roche Ag |
Tricyclic compounds and methods of use therefor
|
CN104507473A
(zh)
|
2012-02-17 |
2015-04-08 |
奇尼塔四有限责任公司 |
用于治疗沙粒病毒感染的抗病毒药物
|
IN2014MN01887A
(ja)
|
2012-03-01 |
2015-07-10 |
Yeda Res & Dev |
|
US20150011471A1
(en)
|
2012-03-01 |
2015-01-08 |
Yeda Research And Development Co. Ltd. |
Regeneration of islet beta cells by hsp60 derived peptides
|
US10077478B2
(en)
|
2012-03-05 |
2018-09-18 |
Adaptive Biotechnologies Corp. |
Determining paired immune receptor chains from frequency matched subunits
|
EP2822936B1
(en)
|
2012-03-07 |
2021-09-08 |
The McLean Hospital Corporation |
Aminoquinoline derivatives and uses thereof
|
BR112014018964A2
(pt)
|
2012-03-13 |
2020-05-12 |
F. Hoffmann-La Roche Ag |
Anticorpo anti-vegf e uso de um anticorpo anti-vegf
|
MX2014010953A
(es)
|
2012-03-16 |
2014-10-13 |
Hoffmann La Roche |
Metodos para tratamiento de melanoma con inhibidores pak1.
|
EP2825191B1
(en)
|
2012-03-16 |
2019-08-28 |
University Health Network |
Soluble toso protein and its use in treating autoimmune disorders
|
EP2827884A4
(en)
|
2012-03-20 |
2015-09-16 |
Tufts College |
SILK RESERVOIRS FOR DRUG RELIEF
|
BR112014023517B1
(pt)
|
2012-03-22 |
2020-12-01 |
The Regents Of The University Of Michigan |
Usos de cloridrato de n-(2,6-bis(1-metiletil)fenil)-n-((1-(4-(dimetilamino)fenil)ciclopentil) metil)ureia para tratar distúrbios das células do córtex adrenal anormais
|
US9592289B2
(en)
|
2012-03-26 |
2017-03-14 |
Sanofi |
Stable IgG4 based binding agent formulations
|
RU2014136886A
(ru)
|
2012-03-27 |
2016-05-20 |
Дженентек, Инк. |
Диагностика и виды лечения, связанные с ингибиторами her3
|
EP2831117B1
(en)
|
2012-03-29 |
2017-11-01 |
NovImmune SA |
Anti-tlr4 antibodies and uses thereof
|
US9879012B2
(en)
|
2012-03-29 |
2018-01-30 |
Regents Of The University Of Colorado, A Body Corporate |
Click nucleic acids
|
SG10201509939PA
(en)
|
2012-03-30 |
2016-01-28 |
Genentech Inc |
Diagnostic methods and compositions for treatment of cancer
|
WO2013155346A1
(en)
|
2012-04-11 |
2013-10-17 |
The Regents Of The University Of California |
Diagnostic tools for response to 6-thiopurine therapy
|
WO2013155422A1
(en)
|
2012-04-12 |
2013-10-17 |
Ironwood Pharmaceuticals, Inc. |
Methods of treating alopecia and acne
|
US10130714B2
(en)
|
2012-04-14 |
2018-11-20 |
Academia Sinica |
Enhanced anti-influenza agents conjugated with anti-inflammatory activity
|
AU2013249366B2
(en)
|
2012-04-16 |
2018-02-01 |
President And Fellows Of Harvard College |
Mesoporous silica compositions for modulating immune responses
|
CA2871417C
(en)
|
2012-04-23 |
2021-08-31 |
Genefrontier Corporation |
Anti-human cd69 antibody, and use thereof for medical purposes
|
JP2015516980A
(ja)
|
2012-04-26 |
2015-06-18 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Cd37抗体とベンダムスチンとの併用
|
CN104540518A
(zh)
|
2012-04-27 |
2015-04-22 |
西托姆克斯治疗公司 |
结合表皮生长因子受体的可活化的抗体其使用方法
|
EA039663B1
(ru)
|
2012-05-03 |
2022-02-24 |
Амген Инк. |
Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств
|
WO2013166500A1
(en)
|
2012-05-04 |
2013-11-07 |
Dana-Farber Cancer Institute, Inc. |
Affinity matured anti-ccr4 humanized monoclonal antibodies and methods of use
|
MX354329B
(es)
|
2012-05-08 |
2018-02-27 |
Adaptive Biotechnologies Corp |
Composiciones y metodos para medir y calibrar el error de amplificacion en reacciones de pcr multiple.
|
JP2015517511A
(ja)
|
2012-05-16 |
2015-06-22 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Cd37抗体とice(イフォスファミド、カルボプラチン、エトポシド)の併用
|
WO2013171289A1
(en)
|
2012-05-16 |
2013-11-21 |
Boehringer Ingelheim International Gmbh |
Combination of cd37 antibodies with further agents
|
AR091069A1
(es)
|
2012-05-18 |
2014-12-30 |
Amgen Inc |
Proteinas de union a antigeno dirigidas contra el receptor st2
|
BR112014028838A2
(pt)
|
2012-05-21 |
2020-05-12 |
Genentech Inc |
Usos de um anticorpo, método para fazer um anticorpo e anticorpos
|
EP2666775A1
(en)
|
2012-05-21 |
2013-11-27 |
Domain Therapeutics |
Substituted pyrazoloquinazolinones and pyrroloquinazolinones as allosteric modulators of group II metabotropic glutamate receptors
|
EP2852584B1
(en)
|
2012-05-22 |
2018-02-28 |
F. Hoffmann-La Roche AG |
Substituted dipyridylamines and uses thereof
|
CN104718188B
(zh)
|
2012-05-22 |
2018-08-21 |
基因泰克公司 |
N-取代的苯甲酰胺类及其在治疗疼痛中的用途
|
WO2013177187A2
(en)
|
2012-05-22 |
2013-11-28 |
Massachusetts Institute Of Technology |
Synergistic tumor treatment with extended-pk il-2 and therapeutic agents
|
WO2013174947A1
(en)
|
2012-05-23 |
2013-11-28 |
Stemergie Biotechnology Sa |
Inhibitors of the activity of complex (iii) of the mitochondrial electron transport chain and use thereof
|
CN104379603B
(zh)
|
2012-05-31 |
2017-11-07 |
先天制药公司 |
Tlr3结合剂
|
BR112014029404A2
(pt)
|
2012-05-31 |
2017-06-27 |
Hoffmann La Roche |
compostos , composição farmacêutica, utilização de um composto, método para o tratamento ou profilaxia do cancêr e invenção
|
US9592266B2
(en)
|
2012-06-01 |
2017-03-14 |
Ferring B.V. |
Manufacture of degarelix
|
NZ702244A
(en)
|
2012-06-08 |
2017-06-30 |
Hoffmann La Roche |
Mutant selectivity and combinations of a phosphoinositide 3 kinase inhibitor compound and chemotherapeutic agents for the treatment of cancer
|
WO2014004676A1
(en)
|
2012-06-26 |
2014-01-03 |
Ironwood Pharmaceuticals, Inc. |
Use of faah inhibitors as neuroprotective agents in the cns
|
JP6242885B2
(ja)
|
2012-06-27 |
2017-12-06 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
5−アザインダゾール化合物及び使用方法
|
KR20150030744A
(ko)
|
2012-06-27 |
2015-03-20 |
에프. 호프만-라 로슈 아게 |
표적에 특이적으로 결합하는 하나 이상의 결합 단위를 포함하는 항체 Fc-영역 접합체의 제조 방법 및 그의 용도
|
MX354862B
(es)
|
2012-06-27 |
2018-03-23 |
Hoffmann La Roche |
Método para la producción de entidades dirigidas altamente selectivas hechas a la medida y biespecíficas que contienen dos entidades de unión diferentes.
|
CA2877441A1
(en)
|
2012-07-02 |
2014-01-09 |
Medizinische Universitat Wien |
Complement split product c4d for the treatment of inflammatory conditions
|
CA2878478A1
(en)
|
2012-07-06 |
2014-01-09 |
Genentech, Inc. |
N-substituted benzamides and methods of use thereof
|
EP2687225A1
(en)
|
2012-07-19 |
2014-01-22 |
Alfact Innovation |
HIP/PAP protein and derivatives thereof for use in treating cancer
|
IN2015DN00847A
(ja)
|
2012-07-25 |
2015-06-12 |
Sarcode Bioscience Inc |
|
JP2015525781A
(ja)
|
2012-07-31 |
2015-09-07 |
ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドThe Brigham and Women’s Hospital, Inc. |
免疫応答の調節
|
US8603470B1
(en)
|
2012-08-07 |
2013-12-10 |
National Cheng Kung University |
Use of IL-20 antagonists for treating liver diseases
|
WO2014025813A1
(en)
|
2012-08-07 |
2014-02-13 |
Genentech, Inc. |
Combination therapy for the treatment of glioblastoma
|
EP2695950A1
(en)
|
2012-08-10 |
2014-02-12 |
Blackfield AG |
Markers for responsiveness to an inhibitor of the fibroblast growth factor receptor
|
SG10201701165TA
(en)
|
2012-08-14 |
2017-03-30 |
Univ Nanyang Tech |
Angiopoietin-like 4 antibody and a method of its use in cancer treatment
|
WO2014031498A1
(en)
|
2012-08-18 |
2014-02-27 |
Academia Sinica |
Cell-permeable probes for identification and imaging of sialidases
|
EP2888238A4
(en)
|
2012-08-21 |
2016-01-27 |
Academia Sinica |
BENZOCYCLO-OCTYNE COMPOUNDS AND USES THEREOF
|
EP2887942A4
(en)
|
2012-08-21 |
2016-08-31 |
Genesys Res Inst |
COMPOSITIONS AND METHODS FOR TREATMENT OR PREVENTION OF ANTHRACYCLIN-INDUCED CARDIOTOXICITY
|
CA2879496C
(en)
|
2012-08-29 |
2024-01-09 |
F. Hoffmann-La Roche Ag |
Blood brain barrier shuttle
|
EP2890720B1
(en)
|
2012-08-30 |
2019-07-17 |
The General Hospital Corporation |
Compositions and methods for treating cancer
|
CN104583215B
(zh)
|
2012-08-30 |
2016-12-07 |
霍夫曼-拉罗奇有限公司 |
二噁烯并-和噁嗪-[2,3-d]嘧啶pi3k抑制剂化合物及使用方法
|
KR102158467B1
(ko)
|
2012-09-07 |
2020-09-25 |
제넨테크, 인크. |
Ii형 항-cd20 항체와 선택적 bcl-2 억제제와의 병용 치료요법
|
TWI660972B
(zh)
|
2012-09-10 |
2019-06-01 |
愛爾蘭商尼歐托普生物科學公司 |
抗mcam抗體及相關使用方法
|
PT3835310T
(pt)
|
2012-09-13 |
2024-05-20 |
Bristol Myers Squibb Co |
Proteínas de domínio de estrutura à base de fibronectina que ligam à miostatina
|
US9309235B2
(en)
|
2012-09-18 |
2016-04-12 |
Ironwood Pharmaceuticals, Inc. |
SGC stimulators
|
CA2885645A1
(en)
|
2012-09-19 |
2014-03-27 |
Ironwood Pharmaceuticals, Inc. |
Sgc stimulators
|
KR102281288B1
(ko)
|
2012-09-26 |
2021-07-26 |
에프. 호프만-라 로슈 아게 |
환형 에터 피라졸-4-일-헤테로사이클릴-카복사마이드 화합물 및 이의 사용 방법
|
EP2900642B1
(en)
|
2012-09-27 |
2018-02-28 |
F. Hoffmann-La Roche AG |
Substituted sulfonamide compounds
|
ES2660027T3
(es)
|
2012-10-01 |
2018-03-20 |
Adaptive Biotechnologies Corporation |
Evaluación de la inmunocompetencia por la diversidad de los receptores de inmunidad adaptativa y caracterización de la clonalidad
|
KR101947702B1
(ko)
|
2012-10-04 |
2019-02-14 |
다나-파버 캔서 인스티튜트 인크. |
인간 단클론 항-pd-l1 항체 및 사용 방법
|
PL2903691T3
(pl)
|
2012-10-05 |
2019-10-31 |
Hoffmann La Roche |
Sposoby diagnozowania i leczenia nieswoistego zapalenia jelit
|
EP2903692B1
(en)
|
2012-10-08 |
2019-12-25 |
St. Jude Children's Research Hospital |
Therapies based on control of regulatory t cell stability and function via a neuropilin-1:semaphorin axis
|
BR112015008118A2
(pt)
|
2012-10-12 |
2017-12-05 |
Brigham & Womens Hospital Inc |
reforço da resposta imune
|
US9309318B2
(en)
|
2012-10-17 |
2016-04-12 |
Amgen, Inc. |
Compositions relating to anti-IL-21 receptor antibodies
|
PT2908865T
(pt)
|
2012-10-17 |
2019-01-11 |
Vascular Biogenics Ltd |
Adenovírus que expressa uma quimera de fas e sua utilização em métodos de tratamento de cancro
|
WO2015160439A2
(en)
|
2014-04-17 |
2015-10-22 |
Adaptive Biotechnologies Corporation |
Quantification of adaptive immune cell genomes in a complex mixture of cells
|
AU2013334790A1
(en)
|
2012-10-23 |
2015-04-30 |
Oncomed Pharmaceuticals, Inc. |
Methods of treating neuroendocrine tumors using Wnt pathway-binding agents
|
JP6348115B2
(ja)
|
2012-10-26 |
2018-06-27 |
ザ ユニバーシティー オブ クイーンズランド |
がん療法のためのエンドサイトーシス阻害剤および抗体の使用
|
KR101911438B1
(ko)
|
2012-10-31 |
2018-10-24 |
삼성전자주식회사 |
이중 특이 항원 결합 단백질 복합체 및 이중 특이 항체의 제조 방법
|
CA2889638A1
(en)
|
2012-10-31 |
2014-05-08 |
Oncomed Pharmaceuticals, Inc. |
Methods and monitoring of treatment with a dll4 antagonist
|
EP2914621B1
(en)
|
2012-11-05 |
2023-06-07 |
Foundation Medicine, Inc. |
Novel ntrk1 fusion molecules and uses thereof
|
WO2014073292A1
(ja)
|
2012-11-09 |
2014-05-15 |
ジーンフロンティア株式会社 |
癌治療のための抗adam28抗体
|
UY35148A
(es)
|
2012-11-21 |
2014-05-30 |
Amgen Inc |
Immunoglobulinas heterodiméricas
|
CA2889298C
(en)
|
2012-11-30 |
2024-01-02 |
Anton Belousov |
Identification of patients in need of pd-l1 inhibitor cotherapy
|
EP3725807A1
(en)
|
2012-12-03 |
2020-10-21 |
NovImmune SA |
Anti-cd47 antibodies and methods of use thereof
|
BR112015013196A2
(pt)
|
2012-12-07 |
2018-02-06 |
Massachusetts Gen Hospital |
combinações de um composto inibidor de pi3k/akt com um composto inibidor de her3/egfr e métodos de uso
|
TW201425336A
(zh)
|
2012-12-07 |
2014-07-01 |
Amgen Inc |
Bcma抗原結合蛋白質
|
EP2931292B1
(en)
|
2012-12-13 |
2018-06-13 |
Warsaw Orthopedic, Inc. |
Compositions and methods comprising polyethylene glycol and magnesium for treatment of neuronal injury
|
JP6326066B2
(ja)
|
2012-12-20 |
2018-05-16 |
メディミューン,エルエルシー |
凝集プロファイルが改善されている液状抗体製剤
|
GB201223053D0
(en)
|
2012-12-20 |
2013-02-06 |
Medical Res Council |
Receptor
|
US10968276B2
(en)
|
2013-03-12 |
2021-04-06 |
Xencor, Inc. |
Optimized anti-CD3 variable regions
|
US9605084B2
(en)
|
2013-03-15 |
2017-03-28 |
Xencor, Inc. |
Heterodimeric proteins
|
US10487155B2
(en)
|
2013-01-14 |
2019-11-26 |
Xencor, Inc. |
Heterodimeric proteins
|
US10131710B2
(en)
|
2013-01-14 |
2018-11-20 |
Xencor, Inc. |
Optimized antibody variable regions
|
US11053316B2
(en)
|
2013-01-14 |
2021-07-06 |
Xencor, Inc. |
Optimized antibody variable regions
|
US9701759B2
(en)
|
2013-01-14 |
2017-07-11 |
Xencor, Inc. |
Heterodimeric proteins
|
CA3211863A1
(en)
|
2013-01-14 |
2014-07-17 |
Xencor, Inc. |
Novel heterodimeric proteins
|
EP2945969A1
(en)
|
2013-01-15 |
2015-11-25 |
Xencor, Inc. |
Rapid clearance of antigen complexes using novel antibodies
|
BR112015016395A2
(pt)
|
2013-01-18 |
2017-07-11 |
Hoffmann La Roche |
pirazóis 3-substituídos e uso como inibidores de dlk
|
US10980804B2
(en)
|
2013-01-18 |
2021-04-20 |
Foundation Medicine, Inc. |
Methods of treating cholangiocarcinoma
|
WO2014114649A1
(en)
|
2013-01-22 |
2014-07-31 |
Technische Universität Graz |
Lipase inhibitors
|
WO2014116749A1
(en)
|
2013-01-23 |
2014-07-31 |
Genentech, Inc. |
Anti-hcv antibodies and methods of using thereof
|
EP2948478B1
(en)
|
2013-01-25 |
2019-04-03 |
Amgen Inc. |
Antibodies targeting cdh19 for melanoma
|
JO3519B1
(ar)
|
2013-01-25 |
2020-07-05 |
Amgen Inc |
تركيبات أجسام مضادة لأجل cdh19 و cd3
|
AU2014212014A1
(en)
|
2013-02-01 |
2015-08-27 |
Amgen Inc. |
Administration of an anti-activin-A compound to a subject
|
WO2014120891A2
(en)
|
2013-02-01 |
2014-08-07 |
Bristol-Myers Squibb Company |
Fibronectin based scaffold proteins
|
CN105101997B
(zh)
|
2013-02-06 |
2018-11-09 |
印希彼有限合伙公司 |
不减少血小板和不减少血红细胞的cd47抗体及其使用方法
|
PL2953634T3
(pl)
|
2013-02-07 |
2021-11-22 |
The General Hospital Corporation |
Sposoby namnażania lub zubożania limfocytów t-regulatorowych
|
JP6494527B2
(ja)
|
2013-02-07 |
2019-04-03 |
ザ チルドレンズ メディカル センター コーポレーション |
肺炎球菌のコロニー形成および/または疾患からの保護を提供するタンパク質抗原
|
EP3718557A3
(en)
|
2013-02-25 |
2020-10-21 |
Bausch Health Ireland Limited |
Guanylate cyclase receptor agonist sp-333 for use in colonic cleansing
|
US20150366890A1
(en)
|
2013-02-25 |
2015-12-24 |
Trustees Of Boston University |
Compositions and methods for treating fungal infections
|
MX369175B
(es)
|
2013-02-25 |
2019-10-30 |
Genentech Inc |
Métodos para detectar mutantes de akt resistentes a fármacos.
|
US20140255413A1
(en)
|
2013-03-07 |
2014-09-11 |
Boehringer Ingelheim International Gmbh |
Combination therapy for neoplasia treatment
|
US11338036B2
(en)
|
2013-03-08 |
2022-05-24 |
The Curators Of The University Of Missouri |
Methods and compositions for the treatment and/or prevention of type 1 diabetes
|
WO2014165264A1
(en)
|
2013-03-12 |
2014-10-09 |
Micell Technologies, Inc. |
Bioabsorbable biomedical implants
|
US9458246B2
(en)
|
2013-03-13 |
2016-10-04 |
Amgen Inc. |
Proteins specific for BAFF and B7RP1
|
WO2014165093A2
(en)
|
2013-03-13 |
2014-10-09 |
Bristol-Myers Squibb Company |
Fibronectin based scaffold domains linked to serum albumin or a moiety binding thereto
|
JOP20140087B1
(ar)
|
2013-03-13 |
2021-08-17 |
Amgen Inc |
بروتينات مخصصة ل baff و b7rp1 وإستخداماتها
|
SG11201507477XA
(en)
|
2013-03-14 |
2015-10-29 |
Genentech Inc |
Combinations of a mek inhibitor compound with an her3/egfr inhibitor compound and methods of use
|
AU2014244444A1
(en)
|
2013-03-14 |
2015-09-24 |
Amgen Inc. |
CHRDL-1 antigen binding proteins and methods of treatment
|
US9580486B2
(en)
|
2013-03-14 |
2017-02-28 |
Amgen Inc. |
Interleukin-2 muteins for the expansion of T-regulatory cells
|
US9717583B2
(en)
|
2014-03-13 |
2017-08-01 |
Cell and Molecular Tissue Engineering, LLC |
Sensors, cannulas, collars and coated surgical mesh, and corresponding systems and methods
|
WO2014139885A2
(en)
|
2013-03-14 |
2014-09-18 |
Galapagos Nv |
Molecular targets and compounds, and methods to identify the same, useful in the treatment of diseases associated with epithelial mesenchymal transition
|
RU2015143906A
(ru)
|
2013-03-14 |
2017-04-18 |
Дженентек, Инк. |
Замещенные триазолопиридины и способы их применения
|
EP2972322B1
(en)
|
2013-03-14 |
2019-03-06 |
Galapagos NV |
Molecular targets and compounds, and methods to identify the same, useful in the treatment of fibrotic diseases
|
US9952202B2
(en)
|
2013-03-14 |
2018-04-24 |
Galapagos Nv |
Methods of identifying compounds for the treatment of fibrosis by using S1PR5
|
US9850297B2
(en)
|
2013-03-15 |
2017-12-26 |
Amgen Inc. |
Secreted frizzle-related protein 5 (SFRP5) binding proteins
|
JP2016516071A
(ja)
|
2013-03-15 |
2016-06-02 |
ユベンタス セラピューティクス,インコーポレイテッド |
瘢痕形成を軽減するためのsdf−1の使用
|
CA2904357C
(en)
|
2013-03-15 |
2020-09-22 |
Intrinsic Lifesciences Llc |
Anti-hepcidin antibodies and uses thereof
|
US9708367B2
(en)
|
2013-03-15 |
2017-07-18 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase and their uses
|
PT2970243T
(pt)
|
2013-03-15 |
2020-03-05 |
Cyclerion Therapeutics Inc |
Estimuladores de sgc
|
US10544187B2
(en)
|
2013-03-15 |
2020-01-28 |
Xencor, Inc. |
Targeting regulatory T cells with heterodimeric proteins
|
AU2014236867A1
(en)
|
2013-03-15 |
2015-09-24 |
Amgen Inc. |
Methods and compositions relating to anti-CCR7 antigen binding proteins
|
WO2014151200A2
(en)
|
2013-03-15 |
2014-09-25 |
Synergy Pharmaceuticals Inc. |
Compositions useful for the treatment of gastrointestinal disorders
|
WO2014145654A1
(en)
|
2013-03-15 |
2014-09-18 |
The Trustees Of The University Of Pennsylvania |
Method for the site-specific covalent cross-linking of antibodies to surfaces
|
SI2970449T1
(sl)
|
2013-03-15 |
2019-11-29 |
Amgen Res Munich Gmbh |
Enoverižne vezavne molekule, ki vsebujejo N-terminalni ABP
|
US10858417B2
(en)
|
2013-03-15 |
2020-12-08 |
Xencor, Inc. |
Heterodimeric proteins
|
WO2014145314A2
(en)
|
2013-03-15 |
2014-09-18 |
Cancer Research Technology, Llc |
Methods and compositions for gamma-glutamyl cycle modulation
|
US10035859B2
(en)
|
2013-03-15 |
2018-07-31 |
Biogen Ma Inc. |
Anti-alpha V beta 6 antibodies and uses thereof
|
ES2743216T3
(es)
|
2013-03-15 |
2020-02-18 |
Xencor Inc |
Proteínas heterodiméricas
|
US10106624B2
(en)
|
2013-03-15 |
2018-10-23 |
Xencor, Inc. |
Heterodimeric proteins
|
US9872899B2
(en)
|
2013-03-15 |
2018-01-23 |
Biological Mimetics, Inc. |
Immunogenic human rhinovirus (HRV) compositions
|
US9587235B2
(en)
|
2013-03-15 |
2017-03-07 |
Atyr Pharma, Inc. |
Histidyl-tRNA synthetase-Fc conjugates
|
EP2970446A1
(en)
|
2013-03-15 |
2016-01-20 |
Amgen Research (Munich) GmbH |
Antibody constructs for influenza m2 and cd3
|
EP3683237A1
(en)
|
2013-03-15 |
2020-07-22 |
Amgen Inc. |
Human pac1 antibodies
|
IL292121B2
(en)
|
2013-03-15 |
2024-02-01 |
Takeda Pharmaceuticals Co |
Anti-plasma kallikrein antibodies
|
TR201809571T4
(tr)
|
2013-03-15 |
2018-07-23 |
Hoffmann La Roche |
Ll-22 polipeptidleri ile ıl-22 fc füzyon proteinleri ve kullanım yöntemleri.
|
US10519242B2
(en)
|
2013-03-15 |
2019-12-31 |
Xencor, Inc. |
Targeting regulatory T cells with heterodimeric proteins
|
NZ712300A
(en)
|
2013-03-15 |
2020-07-31 |
Sutter West Bay Hospitals |
Falz for use as a target for therapies to treat cancer
|
US11376329B2
(en)
|
2013-03-15 |
2022-07-05 |
Trustees Of Tufts College |
Low molecular weight silk compositions and stabilizing silk compositions
|
US10035860B2
(en)
|
2013-03-15 |
2018-07-31 |
Biogen Ma Inc. |
Anti-alpha V beta 6 antibodies and uses thereof
|
JP6457482B2
(ja)
|
2013-03-15 |
2019-01-23 |
トラスティーズ オブ タフツ カレッジ |
低分子量絹組成物および絹組成物の安定化
|
CN105705165B
(zh)
|
2013-03-15 |
2020-04-24 |
纪念斯隆-凯特琳癌症中心 |
高亲和力抗gd2抗体
|
US9822166B2
(en)
|
2013-03-15 |
2017-11-21 |
Dana-Farber Cancer Institute, Inc. |
Flavivirus neutralizing antibodies and methods of use thereof
|
US9708375B2
(en)
|
2013-03-15 |
2017-07-18 |
Amgen Inc. |
Inhibitory polypeptides specific to WNT inhibitors
|
JP6434485B2
(ja)
|
2013-03-15 |
2018-12-05 |
アムジエン・インコーポレーテツド |
Pla2g12aポリペプチド及びpla2g12a変異ポリペプチドを使用して代謝障害を治療する方法
|
US9802888B2
(en)
|
2013-03-22 |
2017-10-31 |
University Of Hawaii |
STAT3 inhibitors
|
US9937231B2
(en)
|
2013-03-27 |
2018-04-10 |
The General Hospital Corporation |
Methods and agents for treating Alzheimer's disease
|
EP3495814A3
(en)
|
2013-03-27 |
2019-07-17 |
F. Hoffmann-La Roche AG |
Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7 integrin antagonists
|
EP2983681B1
(en)
|
2013-04-05 |
2020-07-15 |
Manuka Health New Zealand Limited |
Therapeutic compositions and uses thereof
|
TW201517901A
(zh)
|
2013-04-05 |
2015-05-16 |
Manuka Health New Zealand Ltd |
治療組合物及其用途
|
ITTO20130284A1
(it)
*
|
2013-04-09 |
2014-10-10 |
Fond Istituto Italiano Di Tecnologia |
Procedimento per la produzione di microparticelle polimeriche sagomate
|
BR112015027381A8
(pt)
|
2013-05-01 |
2018-01-30 |
Hoffmann La Roche |
pirimidinas substituídas por heterocicloalquila ligadas ao c e seus usos
|
WO2014177060A1
(en)
|
2013-05-01 |
2014-11-06 |
F.Hoffmann-La Roche Ag |
Biheteroaryl compounds and uses thereof
|
US11293064B2
(en)
|
2013-05-02 |
2022-04-05 |
Thomas Jefferson University |
Human miRNAs for use in diagnosis, prognosis, and therapy of human conditions and diseases
|
KR20160005749A
(ko)
|
2013-05-07 |
2016-01-15 |
리나트 뉴로사이언스 코프. |
항-글루카곤 수용체 항체 및 이의 사용 방법
|
AU2014265460B2
(en)
|
2013-05-15 |
2018-10-18 |
Micell Technologies, Inc. |
Bioabsorbable biomedical implants
|
MX2015015970A
(es)
|
2013-05-20 |
2016-09-08 |
Genentech Inc |
Anticuerpos receptores de antitransferina y metodos de uso.
|
EP2805730A1
(en)
|
2013-05-21 |
2014-11-26 |
Bergen Teknologioverforing AS |
Nitric oxide donor for the treatment of chronic fatigue syndrome
|
EP3461909A1
(en)
|
2013-05-21 |
2019-04-03 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Isoforms of gata6 and nkx2-1 as markers for diagnosis and therapy of cancer and as targets for anti-cancer therapy
|
CA2927309A1
(en)
|
2013-05-24 |
2014-11-27 |
Promis Neurosciences Inc. |
Fasr antibodies for diagnostic and therapeutic use
|
WO2014193800A2
(en)
|
2013-05-28 |
2014-12-04 |
The Johns Hopkins University |
Aptamers for the treatment of sickle cell disease
|
EP3971212B1
(en)
|
2013-05-30 |
2023-12-27 |
Kiniksa Pharmaceuticals, Ltd. |
Oncostatin m receptor antigen binding proteins
|
US9884126B2
(en)
|
2013-05-31 |
2018-02-06 |
Genentech, Inc. |
Anti-wall teichoic antibodies and conjugates
|
CA2910029A1
(en)
|
2013-05-31 |
2014-12-04 |
Genentech, Inc. |
Anti-wall teichoic antibodies and conjugates
|
US9517276B2
(en)
|
2013-06-04 |
2016-12-13 |
Cytomx Therapeutics, Inc. |
Compositions and methods for conjugating activatable antibodies
|
EP2810648A1
(en)
|
2013-06-04 |
2014-12-10 |
Daniel Rauh |
Targeting domain-domain interaction for the identification of kinase modulators
|
SG10201708143QA
(en)
|
2013-06-06 |
2017-11-29 |
Pierre Fabre Médicament |
Anti-c10orf54 antibodies and uses thereof
|
KR102523912B1
(ko)
|
2013-06-11 |
2023-04-21 |
프레지던트 앤드 펠로우즈 오브 하바드 칼리지 |
SC-β 세포 및 조성물 그리고 그 생성 방법
|
JP6442404B2
(ja)
|
2013-06-11 |
2018-12-19 |
国立研究開発法人国立精神・神経医療研究センター |
再発寛解型多発性硬化症(rrms)患者の治療予後予測方法、及び新規治療適応判断方法
|
JP6869720B2
(ja)
|
2013-06-13 |
2021-05-12 |
アンチセンス セラピューティクス リミテッド |
併用療法
|
EP2835135A3
(en)
|
2013-06-19 |
2015-06-24 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Berlin |
Means and methods for treating pseudomonas infection
|
EP3013365B1
(en)
|
2013-06-26 |
2019-06-05 |
Academia Sinica |
Rm2 antigens and use thereof
|
WO2014210564A1
(en)
|
2013-06-27 |
2014-12-31 |
Academia Sinica |
Glycan conjugates and use thereof
|
WO2014207213A1
(en)
|
2013-06-28 |
2014-12-31 |
Medizinische Universität Innsbruck |
Novel inhibitors of protein kinase c epsilon signaling
|
WO2014209384A1
(en)
|
2013-06-28 |
2014-12-31 |
Amgen Inc. |
Methods for treating homozygous familial hypercholesterolema
|
US9708657B2
(en)
|
2013-07-01 |
2017-07-18 |
Adaptive Biotechnologies Corp. |
Method for generating clonotype profiles using sequence tags
|
BR112015029972A2
(pt)
|
2013-07-03 |
2017-07-25 |
Hoffmann La Roche |
composto, composição farmacêutica, processo para a preparação de uma composição farmacêutica, método para o tratamento de uma doença, conjunto e utilização de um composto
|
US20170319709A1
(en)
|
2013-07-05 |
2017-11-09 |
Formation Biologics Inc. |
Egfr antibody conjugates
|
EP3019595A4
(en)
|
2013-07-09 |
2016-11-30 |
|
THERAPEUTIC USES OF A GENERIC CHANGE WITH CRISPR / CAS SYSTEMS
|
PT3019533T
(pt)
|
2013-07-11 |
2020-04-17 |
Scripps Research Inst |
Proteínas de fusão de imunoglobulinas de hélices super-enroladas e composições das mesmas
|
WO2015017146A2
(en)
|
2013-07-18 |
2015-02-05 |
Fabrus, Inc. |
Antibodies with ultralong complementarity determining regions
|
JP6687520B2
(ja)
|
2013-07-18 |
2020-04-22 |
トーラス バイオサイエンシズ リミテッド ライアビリティ カンパニー |
極めて長い相補性決定領域を有するヒト化抗体
|
CA2918795A1
(en)
|
2013-07-25 |
2015-01-29 |
Cytomx Therapeutics, Inc. |
Multispecific antibodies, multispecific activatable antibodies and methods of using the same
|
UY35686A
(es)
|
2013-07-31 |
2015-01-30 |
Amgen Inc |
Construcciones del factor de diferenciación de crecimiento 15 (gdf-15)
|
BR112016002008B1
(pt)
|
2013-08-02 |
2021-06-22 |
Pfizer Inc. |
Anticorpos anti-cxcr4, seu uso, conjugado anticorpo-fármaco e composição farmacêutica
|
EP2835136A1
(en)
|
2013-08-07 |
2015-02-11 |
PregLem S.A. |
Somatostatin Receptor Modulator for the treatment of infertility
|
WO2015022326A1
(en)
|
2013-08-12 |
2015-02-19 |
Xiber Science Gmbh |
Peptides as active agents for treating primary graft dysfunction
|
KR20160042438A
(ko)
|
2013-08-12 |
2016-04-19 |
제넨테크, 인크. |
보체-연관 상태의 치료를 위한 조성물 및 방법
|
WO2015023851A1
(en)
|
2013-08-14 |
2015-02-19 |
The Governing Council Of The University Of Toronto |
Antibodies against frizzled proteins and methods of use thereof
|
EP3036226B1
(en)
|
2013-08-22 |
2020-01-08 |
The General Hospital Corporation |
Inhibitors of human 12/15-lipoxygenase
|
US11382883B2
(en)
|
2013-08-29 |
2022-07-12 |
Trustees Of Boston University |
Intermediate metabolism products to potentiate aminoglycoside antibiotics in bacterial infections
|
US10617755B2
(en)
|
2013-08-30 |
2020-04-14 |
Genentech, Inc. |
Combination therapy for the treatment of glioblastoma
|
US10456470B2
(en)
|
2013-08-30 |
2019-10-29 |
Genentech, Inc. |
Diagnostic methods and compositions for treatment of glioblastoma
|
TW201605896A
(zh)
|
2013-08-30 |
2016-02-16 |
安美基股份有限公司 |
Gitr抗原結合蛋白
|
CA2923145A1
(en)
|
2013-09-05 |
2015-03-12 |
Amgen Inc. |
Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles
|
JP6486368B2
(ja)
|
2013-09-06 |
2019-03-20 |
アカデミア シニカAcademia Sinica |
改変されたグリコシル基を含む糖脂質を用いたヒトiNKT細胞の活性化
|
EP3043790B1
(en)
|
2013-09-11 |
2021-05-26 |
The Administrators of the Tulane Educational Fund |
Novel anthranilic amides and the use thereof
|
CA2924109A1
(en)
|
2013-09-13 |
2015-03-19 |
The California Institute For Biomedical Research |
Modified therapeutic agents and compositions thereof
|
TWI688401B
(zh)
|
2013-09-13 |
2020-03-21 |
美商安進公司 |
用於治療骨髓性白血病的表觀遺傳因子與靶向cd33及cd3之雙特異性化合物的組合
|
PL2808338T3
(pl)
|
2013-09-16 |
2016-09-30 |
|
Zmutowana kalretikulina do rozpoznawania złośliwych nowotworów szpiku kostnego
|
EP3047857A4
(en)
|
2013-09-20 |
2017-08-09 |
Chugai Seiyaku Kabushiki Kaisha |
Treatment for hemorrhagic diseases by anti-protein-c antibody
|
CN104436157A
(zh)
|
2013-09-23 |
2015-03-25 |
恩金生物有限公司 |
流感疫苗和治疗
|
CN118146306A
(zh)
|
2013-09-25 |
2024-06-07 |
西托姆克斯治疗公司 |
基质金属蛋白酶底物和其它可切割部分及其使用方法
|
WO2015048331A1
(en)
|
2013-09-25 |
2015-04-02 |
Cornell University |
Compounds for inducing anti-tumor immunity and methods thereof
|
US20150087649A1
(en)
|
2013-09-26 |
2015-03-26 |
Atterocor, Inc. |
Treating disorders associated with aberrant adrenocortical cell behavior
|
JP6946000B2
(ja)
|
2013-10-04 |
2021-10-06 |
アプトース バイオサイエンシーズ, インコーポレイテッド |
がんの治療用組成物及び方法
|
AU2014331704A1
(en)
|
2013-10-10 |
2016-04-28 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase useful for the treatment of opioid induced dysfunctions
|
ES2968371T3
(es)
|
2013-10-10 |
2024-05-09 |
Eastern Virginia Medical School |
Derivados de 4-((2-hidroxi-3-metoxibencil)amino) bencenosulfonamida como inhibidores de la 12-lipoxigenasa
|
AU2014331909B2
(en)
|
2013-10-10 |
2020-03-12 |
Beth Israel Deaconess Medical Center, Inc. |
TM4SF1 binding proteins and methods of using same
|
WO2015052264A1
(en)
|
2013-10-11 |
2015-04-16 |
F. Hoffmann-La Roche Ag |
Substituted heterocyclic sulfonamide compounds useful as trpa1 modulators
|
WO2015056808A1
(en)
|
2013-10-15 |
2015-04-23 |
Genefrontier Corporation |
Human antibody against aggrecanase-type adamts species for therapeutics of aggrecanase-related diseases
|
ES2741308T3
(es)
|
2013-10-15 |
2020-02-10 |
Scripps Research Inst |
Interruptores de células T con receptores de antígenos quiméricos y usos de los mismos
|
WO2015057834A1
(en)
|
2013-10-15 |
2015-04-23 |
The California Institute For Biomedical Research |
Peptidic chimeric antigen receptor t cell switches and uses thereof
|
WO2015057908A1
(en)
|
2013-10-18 |
2015-04-23 |
Novartis Ag |
Methods of treating diabetes and related disorders
|
US10780070B2
(en)
|
2013-10-18 |
2020-09-22 |
The Schepens Eye Research Institute, Inc. |
Alpha-aminoadipate for treatment of vision loss and restoring sight
|
WO2015058197A1
(en)
|
2013-10-18 |
2015-04-23 |
The Schepens Eye Research Institute, Inc. |
Alpha-aminoadipate for treatment of vision loss and restoring sight
|
US9540440B2
(en)
|
2013-10-30 |
2017-01-10 |
Cytomx Therapeutics, Inc. |
Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
|
CN106170491B
(zh)
|
2013-10-30 |
2020-07-24 |
阿尔杰妮卡治疗学有限公司 |
神经保护肽
|
DK3063275T3
(da)
|
2013-10-31 |
2019-11-25 |
Resolve Therapeutics Llc |
Terapeutiske nuklease-albumin-fusioner og fremgangsmåder
|
CN105813637A
(zh)
|
2013-11-01 |
2016-07-27 |
卑尔根技术转移公司 |
用于治疗慢性疲劳综合征的可溶性鸟苷酸环化酶的激活剂或刺激剂
|
GB201319374D0
(en)
|
2013-11-01 |
2013-12-18 |
Univ Nottingham |
Glycans as functional cancer targets abd antibodies thereto
|
EP3663763B1
(en)
|
2013-11-26 |
2022-02-16 |
The Brigham and Women's Hospital, Inc. |
Compositions and methods for modulating an immune response
|
WO2015082583A1
(en)
|
2013-12-05 |
2015-06-11 |
F. Hoffmann-La Roche Ag |
Heteroaryl pyridone and aza-pyridone compounds with electrophilic functionality
|
EP3083684A1
(en)
|
2013-12-06 |
2016-10-26 |
NovImmune SA |
Anti-tlr4 antibodies and methods of use thereof
|
WO2015087187A1
(en)
|
2013-12-10 |
2015-06-18 |
Rinat Neuroscience Corp. |
Anti-sclerostin antibodies
|
US20160311826A1
(en)
|
2013-12-11 |
2016-10-27 |
Ironwood Pharmaceuticals, Inc. |
Sgc stimulators
|
US20160333063A1
(en)
|
2013-12-13 |
2016-11-17 |
The General Hospital Corporation |
Soluble high molecular weight (hmw) tau species and applications thereof
|
WO2015095406A1
(en)
|
2013-12-18 |
2015-06-25 |
The California Institute For Biomedical Research |
Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof
|
CA2931113C
(en)
|
2013-12-20 |
2023-07-11 |
Genentech, Inc. |
Antibodies comprising an antigen-binding site that specifically binds to two different epitopes and methods of making them
|
MX2016008110A
(es)
|
2013-12-20 |
2016-08-19 |
Hoffmann La Roche |
Derivados de pirazol como inhibidores de la cinasa de cremallera de leucina dual (dlk) y usos de los mismos.
|
EP3083672A1
(en)
|
2013-12-20 |
2016-10-26 |
Yissum Research Development Company of The Hebrew University of Jerusalem Ltd. |
Pro-angiogenic peptides and peptide conjugates
|
CN103965357B
(zh)
|
2013-12-31 |
2016-08-17 |
嘉和生物药业有限公司 |
一种抗人rankl抗体
|
WO2015106268A1
(en)
|
2014-01-13 |
2015-07-16 |
Ironwood Pharmaceuticals, Inc. |
USE OF sGC STIMULATORS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS
|
WO2016114819A1
(en)
|
2015-01-16 |
2016-07-21 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
US10150818B2
(en)
|
2014-01-16 |
2018-12-11 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
AU2015206370A1
(en)
|
2014-01-16 |
2016-07-07 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
WO2015110930A1
(en)
|
2014-01-24 |
2015-07-30 |
Pfizer Inc. |
Modified interleukin 21 receptor proteins
|
JP6835586B2
(ja)
|
2014-01-31 |
2021-02-24 |
シトムクス セラピューティクス,インコーポレイティド |
マトリプターゼ及びu‐プラスミノーゲン活性化因子の基質及び他の切断可能部分、並びにその使用方法
|
WO2015116902A1
(en)
|
2014-01-31 |
2015-08-06 |
Genentech, Inc. |
G-protein coupled receptors in hedgehog signaling
|
DK3102197T3
(en)
|
2014-02-04 |
2018-11-19 |
Genentech Inc |
Smoothened mutant and methods for its use
|
WO2015120187A1
(en)
|
2014-02-05 |
2015-08-13 |
The University Of Chicago |
Chimeric antigen receptors recognizing cancer-spevific tn glycopeptide variants
|
US10532083B2
(en)
|
2014-02-13 |
2020-01-14 |
Technische Universität München |
Methods for inducing differentiation or conversion of white adipocytes and/or preadipocytes to brown adipocites using FGF8
|
JP2017506640A
(ja)
|
2014-02-14 |
2017-03-09 |
セントローズ, エルエルシー |
細胞外標的化薬物共役体
|
AU2015218903B2
(en)
|
2014-02-20 |
2020-10-15 |
Allergan, Inc. |
Complement component C5 antibodies
|
EP3110974A4
(en)
|
2014-02-24 |
2018-01-24 |
Celgene Corporation |
Methods of using an activator of cereblon for neural cell expansion and the treatment of central nervous system disorders
|
AU2015223056B2
(en)
|
2014-02-27 |
2020-10-01 |
Allergan, Inc. |
Complement Factor Bb antibodies
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
AU2015227054A1
(en)
|
2014-03-05 |
2016-09-22 |
Adaptive Biotechnologies Corporation |
Methods using randomer-containing synthetic molecules
|
US20170029366A1
(en)
|
2014-03-07 |
2017-02-02 |
The Johns Hopkins University |
Inhibitors of histone lysine specific demethylase (lsd1) and histone deacetylases (hdacs)
|
US20150252434A1
(en)
|
2014-03-07 |
2015-09-10 |
University Health Network |
Methods and compositions for detection of targets involved in cancer metastasis
|
JP6554480B2
(ja)
|
2014-03-18 |
2019-07-31 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
オキセパン−2−イル−ピラゾール−4−イル−ヘテロシクリル−カルボキサミド化合物と使用方法
|
US20170174751A1
(en)
|
2014-03-19 |
2017-06-22 |
Dana-Farber Cancer Institute, Inc. |
Immunogenetic restriction on elicitation of antibodies
|
MX371403B
(es)
|
2014-03-20 |
2020-01-29 |
Bristol Myers Squibb Co |
Moleculas de andamiaje a base de fibronectina estabilizada.
|
WO2015143343A2
(en)
|
2014-03-21 |
2015-09-24 |
The Brigham And Women's Hospital, Inc. |
Methods and compositions for treatment of immune-related diseases or disorders and/or therapy monitoring
|
KR102274964B1
(ko)
|
2014-03-21 |
2021-07-09 |
테바 파마슈티컬스 인터내셔널 게엠베하 |
칼시토닌 유전자-관련 펩티드에 대한 길항제 항체 및 그의 사용 방법
|
KR102397324B1
(ko)
|
2014-03-27 |
2022-05-13 |
제넨테크, 인크. |
염증성 장 질환의 진단 및 치료 방법
|
TWI797430B
(zh)
|
2014-03-27 |
2023-04-01 |
中央研究院 |
反應性標記化合物及其用途
|
AP2016009475A0
(en)
|
2014-03-28 |
2016-09-30 |
Xencor Inc |
Bispecific antibodies that bind to cd38 and cd3
|
US10066265B2
(en)
|
2014-04-01 |
2018-09-04 |
Adaptive Biotechnologies Corp. |
Determining antigen-specific t-cells
|
ES2871029T3
(es)
|
2014-04-04 |
2021-10-28 |
Harvard College |
Dispositivos de liberación de fármacos recargables y procedimientos de uso de los mismos
|
US10507227B2
(en)
|
2014-04-15 |
2019-12-17 |
The Hospital For Sick Children |
Cationic antimicrobial peptides
|
AU2015249666A1
(en)
|
2014-04-25 |
2016-11-17 |
The Brigham And Women's Hospital, Inc. |
Compositions and methods for treating subjects with immune-mediated diseases
|
WO2015164865A1
(en)
|
2014-04-25 |
2015-10-29 |
Dana-Farber Cancer Institute, Inc. |
Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof
|
EP3148567A4
(en)
|
2014-04-25 |
2018-01-10 |
The Brigham and Women's Hospital, Inc. |
Methods to manipulate alpha-fetoprotein (afp)
|
SG10201809628SA
(en)
|
2014-04-30 |
2018-11-29 |
Pfizer |
Anti-ptk7 antibody-drug conjugates
|
EP3139955B1
(en)
|
2014-04-30 |
2024-03-20 |
President and Fellows of Harvard College |
Fusion proteins for treating cancer and related methods
|
CN107073090A
(zh)
|
2014-04-30 |
2017-08-18 |
哈佛学院董事会 |
结合的疫苗装置和杀死癌细胞的方法
|
CN106536561A
(zh)
|
2014-05-01 |
2017-03-22 |
豪夫迈·罗氏有限公司 |
抗‑因子d抗体变体及其用途
|
HRP20231139T1
(hr)
|
2014-05-06 |
2024-01-05 |
F. Hoffmann - La Roche Ag |
Proizvodnja heteromultimernih proteina upotrebom stanica sisavaca
|
EP3143143A1
(en)
|
2014-05-15 |
2017-03-22 |
CeMM - Forschungszentrum für Molekulare Medizin GmbH |
Antagonists of slc38a9 and their use in therapy
|
US10392438B2
(en)
|
2014-05-16 |
2019-08-27 |
Pfizer Inc. |
Bispecific antibodies
|
WO2015179415A1
(en)
|
2014-05-19 |
2015-11-26 |
Novartis Ag |
Methods of treating anorexia
|
EP2947460A1
(en)
|
2014-05-22 |
2015-11-25 |
Medizinische Universität Wien |
Personalized therapy of inflammation-associated cancer using methods of assessing the susceptibility of a subject to the treatment with EGFR inhibitors/antagonists
|
EA028614B1
(ru)
|
2014-05-22 |
2017-12-29 |
Общество С Ограниченной Ответственностью "Русские Фармацевтические Технологии" |
Селективные ингибиторы, нарушающие взаимодействие рецептора фактора роста фибробластов и frs2, для профилактики и лечения рака
|
US10118969B2
(en)
|
2014-05-27 |
2018-11-06 |
Academia Sinica |
Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
|
JP2017518989A
(ja)
|
2014-05-27 |
2017-07-13 |
アカデミア シニカAcademia Sinica |
抗cd20糖操作抗体群およびその使用
|
CN107074945B
(zh)
|
2014-05-27 |
2021-08-24 |
中央研究院 |
增进抗体功效的通用糖型的组合物及方法
|
TWI679020B
(zh)
|
2014-05-27 |
2019-12-11 |
中央研究院 |
抗her2醣抗體及其用途
|
TWI732738B
(zh)
|
2014-05-28 |
2021-07-11 |
中央研究院 |
抗TNF-α醣抗體及其用途
|
KR102366644B1
(ko)
|
2014-05-30 |
2022-02-22 |
상하이 헨리우스 바이오테크, 인크. |
항-표피 성장 인자 수용체 (egfr) 항체
|
WO2015184260A2
(en)
|
2014-05-30 |
2015-12-03 |
The Johns Hopkins University |
Methods for treating mendelian disorders of the epigenetic machinery
|
CN106456763B
(zh)
|
2014-06-03 |
2018-03-13 |
埃克斯生物科技公司 |
用于治疗和预防金黄色葡萄球菌感染的组合物和方法
|
AU2015275128C1
(en)
|
2014-06-09 |
2020-02-13 |
Kyowa Kirin Co., Ltd. |
The effective and efficient control of serum phosphate for optimal bone formation
|
EP3155016A1
(en)
|
2014-06-11 |
2017-04-19 |
Gilead Sciences, Inc. |
Methods for treating cardiovascular diseases
|
KR20170035891A
(ko)
|
2014-06-13 |
2017-03-31 |
산타 마리아 바이오테라퓨틱스, 인코포레이티드 |
제형화된 수용체 폴리펩타이드 및 관련 방법
|
TWI695011B
(zh)
|
2014-06-18 |
2020-06-01 |
美商梅爾莎納醫療公司 |
抗her2表位之單株抗體及其使用之方法
|
US10562946B2
(en)
|
2014-06-20 |
2020-02-18 |
Genentech, Inc. |
Chagasin-based scaffold compositions, methods, and uses
|
TW201625299A
(zh)
|
2014-06-20 |
2016-07-16 |
Chugai Pharmaceutical Co Ltd |
用於因第viii凝血因子及/或活化的第viii凝血因子的活性降低或欠缺而發病及/或進展的疾病之預防及/或治療之醫藥組成物
|
US9840553B2
(en)
|
2014-06-28 |
2017-12-12 |
Kodiak Sciences Inc. |
Dual PDGF/VEGF antagonists
|
EP3166939B1
(en)
|
2014-07-07 |
2019-06-05 |
Genentech, Inc. |
Therapeutic compounds and methods of use thereof
|
US10166304B2
(en)
|
2014-07-11 |
2019-01-01 |
Regents Of The University Of Minnesota |
Antibody fragments for detecting cancer and methods of use
|
EP2966085A1
(en)
|
2014-07-11 |
2016-01-13 |
Boehringer Ingelheim International GmbH |
Antibody IgG1 with a modified heavy chain constant region
|
EP3309174B1
(en)
|
2014-07-11 |
2022-05-11 |
Ventana Medical Systems, Inc. |
Anti-pd-l1 antibodies and diagnostic uses thereof
|
EP3169801A1
(en)
|
2014-07-14 |
2017-05-24 |
F. Hoffmann-La Roche AG |
Diagnostic methods and compositions for treatment of glioblastoma
|
EP2977758A1
(en)
|
2014-07-24 |
2016-01-27 |
Université De Nice Sophia Antipolis |
Methods and kits for monitoring membranous nephropathy
|
CA2955947A1
(en)
|
2014-07-25 |
2016-01-28 |
Cytomx Therapeutics, Inc. |
Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
|
TW201609812A
(zh)
|
2014-07-31 |
2016-03-16 |
安美基研究(慕尼黑)公司 |
最佳化之跨物種特異性雙特異性單鏈抗體構築體
|
AR101669A1
(es)
|
2014-07-31 |
2017-01-04 |
Amgen Res (Munich) Gmbh |
Constructos de anticuerpos para cdh19 y cd3
|
WO2016020799A1
(en)
|
2014-08-06 |
2016-02-11 |
Rinat Neuroscience Corp. |
Methods for reducing ldl-cholesterol
|
JP2017523980A
(ja)
|
2014-08-06 |
2017-08-24 |
ライナット ニューロサイエンス コーポレイション |
Ldl−コレステロールを低下させるための方法
|
US20170216403A1
(en)
|
2014-08-12 |
2017-08-03 |
Massachusetts Institute Of Technology |
Synergistic tumor treatment with il-2, a therapeutic antibody, and an immune checkpoint blocker
|
EP3646879B1
(en)
|
2014-08-12 |
2024-04-03 |
Massachusetts Institute Of Technology |
Synergistic tumor treatment with integrin-binding-fc-fusion protein and an immune checkpoint inhibitor
|
US11111284B2
(en)
|
2014-08-21 |
2021-09-07 |
The General Hospital Corporation |
Tumor necrosis factor superfamily and TNF-like ligand muteins and methods of preparing
|
EA201790434A1
(ru)
|
2014-08-22 |
2017-07-31 |
Окленд Юнисервисиз Лимитед |
Модуляторы каналов
|
EP3186378A1
(en)
|
2014-08-27 |
2017-07-05 |
Peptimed, Inc. |
Anti-tumor compositions and methods
|
AU2015312098B2
(en)
|
2014-09-01 |
2018-08-02 |
Academia Sinica; |
Animal model of longevity and related methods for increasing longevity and inhibiting tumorigenesis
|
WO2016034968A1
(en)
|
2014-09-02 |
2016-03-10 |
Pfizer Inc. |
Therapeutic antibody
|
US9879042B2
(en)
|
2014-09-08 |
2018-01-30 |
Academia Sinica |
Human iNKT cell activation using glycolipids
|
WO2016040767A2
(en)
|
2014-09-12 |
2016-03-17 |
Amgen Inc. |
Chrdl-1 epitopes and antibodies
|
AR101875A1
(es)
|
2014-09-15 |
2017-01-18 |
Amgen Inc |
Proteína de unión a antígenos, bi-específicos del receptor anti-cgrp / receptor pac1 y usos de las mismas
|
US20170298055A1
(en)
|
2014-09-17 |
2017-10-19 |
Ironwood Pharmaceuticals, Inc. |
sGC STIMULATORS
|
JP6624616B2
(ja)
|
2014-09-17 |
2019-12-25 |
サイクレリオン・セラピューティクス,インコーポレーテッド |
sGC刺激剤
|
AU2015317823A1
(en)
|
2014-09-17 |
2017-03-23 |
Ironwood Pharmaceuticals, Inc. |
sGC stimulators
|
JP7095990B2
(ja)
|
2014-09-18 |
2022-07-05 |
シーダーズ-サイナイ メディカル センター |
線維症を治療するための組成物及び方法
|
NZ730186A
(en)
|
2014-09-22 |
2020-04-24 |
Intrinsic Lifesciences Llc |
Humanized anti-hepcidin antibodies and uses thereof
|
EP3197492A1
(en)
|
2014-09-23 |
2017-08-02 |
Pfizer Inc |
Treatment with anti-pcsk9 antibodies
|
EP3000814A1
(en)
|
2014-09-26 |
2016-03-30 |
Domain Therapeutics |
Substituted pyrazoloquinazolinones and pyrroloquinazolinones as allosteric modulators of group II metabotropic glutamate receptors
|
US9889085B1
(en)
|
2014-09-30 |
2018-02-13 |
Intarcia Therapeutics, Inc. |
Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
|
CN106922146B
(zh)
|
2014-10-02 |
2020-05-26 |
豪夫迈·罗氏有限公司 |
用于治疗由布鲁顿酪氨酸激酶(btk)介导的疾病的吡唑甲酰胺化合物
|
JP2017531427A
(ja)
|
2014-10-03 |
2017-10-26 |
デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド |
グルココルチコイド誘導腫瘍壊死因子受容体(gitr)抗体およびその使用法
|
CN107250160B
(zh)
|
2014-10-06 |
2022-01-11 |
达纳-法伯癌症研究所公司 |
人源化cc趋化因子受体4 (ccr4)抗体及其使用方法
|
US10463716B2
(en)
|
2014-10-13 |
2019-11-05 |
University Of Maryland, Baltimore |
Methods for treating cardiovascular dysfunction and improving fluid homeostasis with Elabela peptide hormone
|
CA2962451C
(en)
|
2014-10-21 |
2023-01-17 |
Sciclone Pharmaceuticals, Inc. |
Treatment of cancer with immune stimulators
|
JP6702962B2
(ja)
|
2014-10-24 |
2020-06-03 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
改変fgf−21ポリペプチドおよびその使用
|
ES2784343T3
(es)
|
2014-10-29 |
2020-09-24 |
Adaptive Biotechnologies Corp |
Detección simultánea altamente multiplexada de ácidos nucleicos que codifican heterodímeros de receptores inmunes adaptativos emparejados de muchas muestras
|
WO2016069889A1
(en)
|
2014-10-31 |
2016-05-06 |
Resolve Therapeutics, Llc |
Therapeutic nuclease-transferrin fusions and methods
|
DK3212233T3
(da)
|
2014-10-31 |
2020-07-27 |
Oncomed Pharm Inc |
Kombinationsterapi til behandling af sygdom
|
WO2016077083A1
(en)
|
2014-11-05 |
2016-05-19 |
University Of The Sciences In Philadelphia |
A high molecular weight biodegradable gelatin-doxorubicin conjugate
|
CN107108740B
(zh)
|
2014-11-05 |
2021-09-17 |
豪夫迈·罗氏有限公司 |
抗fgfr2/3抗体及其使用方法
|
CN107109494B
(zh)
|
2014-11-10 |
2023-10-27 |
豪夫迈·罗氏有限公司 |
Il-33介导型疾病的治疗方法和诊断方法
|
US10246701B2
(en)
|
2014-11-14 |
2019-04-02 |
Adaptive Biotechnologies Corp. |
Multiplexed digital quantitation of rearranged lymphoid receptors in a complex mixture
|
BR112017010303A2
(pt)
|
2014-11-18 |
2018-05-15 |
Janssen Pharmaceutica Nv |
anticorpos anti-cd47, métodos e usos
|
US11008403B2
(en)
|
2014-11-19 |
2021-05-18 |
Genentech, Inc. |
Anti-transferrin receptor / anti-BACE1 multispecific antibodies and methods of use
|
JP6779876B2
(ja)
|
2014-11-19 |
2020-11-04 |
ジェネンテック, インコーポレイテッド |
抗トランスフェリン受容体抗体及びその使用方法
|
WO2016079321A1
(en)
|
2014-11-20 |
2016-05-26 |
Cemm Forschungszentrum Für Molekulare Medizin Gmbh |
Antagonists of setdb2 for use in the therapy of infectious diseases
|
EA037590B1
(ru)
|
2014-11-25 |
2021-04-19 |
Бристол-Майерс Сквибб Компани |
Связывающиеся с pd-l1 полипептиды на основе 10fn3 домена для визуализации
|
CA2969145A1
(en)
|
2014-11-26 |
2016-06-02 |
The Regents Of The University Of California |
Therapeutic compositions comprising transcription factors and methods of making and using the same
|
US20160176969A1
(en)
|
2014-11-26 |
2016-06-23 |
Xencor, Inc. |
Heterodimeric antibodies including binding to cd8
|
ES2886523T3
(es)
|
2014-11-26 |
2021-12-20 |
Xencor Inc |
Anticuerpos heterodiméricos que se unen a CD3 y CD20
|
AU2015353416C1
(en)
|
2014-11-26 |
2022-01-27 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and CD38
|
US10259887B2
(en)
|
2014-11-26 |
2019-04-16 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and tumor antigens
|
BR112017011478A2
(pt)
|
2014-12-03 |
2018-02-27 |
Genentech, Inc. |
composto de conjugado anticorpo-antibiótico, conjugado anticorpo-antibiótico, composição farmacêutica, métodos de tratamento de uma infecção bacteriana e para exterminar staph aureus, processo para a preparação do composto, kit e intermediário antibiótico-ligante
|
MX2017007055A
(es)
|
2014-12-03 |
2017-11-08 |
Genentech Inc |
Conjugados de anticuerpo rifamicina anti-staphylococcus aureus y usos de estos.
|
JP6721590B2
(ja)
|
2014-12-03 |
2020-07-15 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
多重特異性抗体
|
WO2016090317A1
(en)
|
2014-12-05 |
2016-06-09 |
Aquinnah Pharmaceuticals, Inc. |
Sulfonamide derivatives, compositions and methods of use in the treatment of neurodegenerative diseases
|
WO2016090313A1
(en)
|
2014-12-05 |
2016-06-09 |
Aquinnah Pharmaceuticals, Inc. |
Compounds, compositions and methods of use
|
TWI595006B
(zh)
|
2014-12-09 |
2017-08-11 |
禮納特神經系統科學公司 |
抗pd-1抗體類和使用彼等之方法
|
WO2016094566A2
(en)
|
2014-12-10 |
2016-06-16 |
Genentech, Inc. |
Blood brain barrier receptor antibodies and methods of use
|
KR20170087500A
(ko)
|
2014-12-11 |
2017-07-28 |
피에르 파브르 메디카먼트 |
항-c10orf54 항체들 및 그들의 용도들
|
TW201702218A
(zh)
|
2014-12-12 |
2017-01-16 |
美國杰克森實驗室 |
關於治療癌症、自體免疫疾病及神經退化性疾病之組合物及方法
|
CN107108611B
(zh)
|
2014-12-18 |
2020-09-25 |
豪夫迈·罗氏有限公司 |
四氢-吡啶并[3,4-b]吲哚雌激素受体调节剂及其用途
|
WO2016105450A2
(en)
|
2014-12-22 |
2016-06-30 |
Xencor, Inc. |
Trispecific antibodies
|
EP3237638B1
(en)
|
2014-12-24 |
2020-01-15 |
F.Hoffmann-La Roche Ag |
Therapeutic, diagnostic and prognostic methods for cancer of the bladder
|
EP3085709B1
(en)
|
2014-12-28 |
2019-08-21 |
Genor Biopharma Co., Ltd |
Humanized anti-human rankl antibody, pharmaceutical composition and use thereof
|
SG10201906471PA
(en)
|
2015-01-14 |
2019-09-27 |
Brigham & Womens Hospital Inc |
Treatment of cancer with anti-lap monoclonal antibodies
|
US10495645B2
(en)
|
2015-01-16 |
2019-12-03 |
Academia Sinica |
Cancer markers and methods of use thereof
|
US9975965B2
(en)
|
2015-01-16 |
2018-05-22 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
MA41374A
(fr)
|
2015-01-20 |
2017-11-28 |
Cytomx Therapeutics Inc |
Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci
|
CA2974369A1
(en)
|
2015-01-20 |
2016-07-28 |
The Children's Medical Center Corporation |
Anti-net compounds for treating and preventing fibrosis and for facilitating wound healing
|
KR102630294B1
(ko)
|
2015-01-24 |
2024-01-26 |
아카데미아 시니카 |
암 마커 및 이를 사용하는 방법
|
EP3789766A1
(en)
|
2015-01-24 |
2021-03-10 |
Academia Sinica |
Novel glycan conjugates and methods of use thereof
|
CN107683289B
(zh)
|
2015-01-26 |
2021-08-06 |
芝加哥大学 |
IL13Rα2结合剂和其在癌症治疗中的用途
|
EP3250611B1
(en)
|
2015-01-26 |
2021-04-21 |
The University of Chicago |
Car t-cells recognizing cancer-specific il 13r-alpha2
|
CN107407677B
(zh)
|
2015-01-28 |
2020-07-17 |
豪夫迈·罗氏有限公司 |
多发性硬化的基因表达标志和治疗
|
CN107614521B
(zh)
|
2015-01-30 |
2022-02-08 |
台湾地区“中央研究院” |
增进抗体功效的通用糖型组合物及方法
|
WO2016123573A1
(en)
|
2015-01-30 |
2016-08-04 |
President And Fellows Of Harvard College |
Peritumoral and intratumoral materials for cancer therapy
|
WO2016126972A1
(en)
|
2015-02-04 |
2016-08-11 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
US10383945B2
(en)
|
2015-02-18 |
2019-08-20 |
The United States of America as Represented by the Department of Verterans Affairs |
Methods for DNA-dependent targeting of a cell permeant antibody
|
AU2016219835B2
(en)
|
2015-02-19 |
2020-12-03 |
Compugen Ltd. |
Anti-PVRIG antibodies and methods of use
|
US10550173B2
(en)
|
2015-02-19 |
2020-02-04 |
Compugen, Ltd. |
PVRIG polypeptides and methods of treatment
|
WO2016135138A1
(en)
|
2015-02-23 |
2016-09-01 |
Cemm - Forschungszentrum Für Molekulare Medizin Gmbh |
Oxoquinoline derivatives as mth1 inhibitors for the therapy of cancer
|
WO2016135139A1
(en)
|
2015-02-23 |
2016-09-01 |
Cemm - Forschungszentrum Für Molekulare Medizin Gmbh |
2,3-dihydrocyclopenta[b]quinoline derivatives as mth1 inhibitors for the therapy of cancer
|
WO2016135140A1
(en)
|
2015-02-23 |
2016-09-01 |
Cemm - Forschungszentrum Für Molekulare Medizin Gmbh |
4-aminoquinazoline derivatives as mth1 inhibitors for the therapy of cancer
|
US10906948B2
(en)
|
2015-02-23 |
2021-02-02 |
Seagull Therapeutics Sas |
Non-natural Semaphorins 3 and their medical use
|
WO2016135137A1
(en)
|
2015-02-23 |
2016-09-01 |
Cemm - Forschungszentrum Für Molekulare Medizin Gmbh |
Substituted 4-(phenylamino)quinoline derivatives as mth1 inhibitors for the therapy of cancer
|
EP3262035A1
(en)
|
2015-02-25 |
2018-01-03 |
F. Hoffmann-La Roche AG |
Alkynyl alcohols and methods of use
|
CA2972099A1
(en)
|
2015-02-26 |
2016-09-01 |
Genentech, Inc. |
Integrin beta7 antagonists and methods of treating crohn's disease
|
MA41599A
(fr)
|
2015-02-26 |
2018-01-02 |
Array Biopharma Inc |
Formes cristallines d'un composé pyrrolopyridine
|
AU2016224409B2
(en)
|
2015-02-27 |
2021-01-28 |
Chugai Seiyaku Kabushiki Kaisha |
Composition for treating IL-6-related diseases
|
CN108064169B
(zh)
|
2015-03-03 |
2022-02-11 |
科马布有限公司 |
抗体、用途和方法
|
MA41629A
(fr)
|
2015-03-04 |
2018-01-09 |
Center For Human Reproduction |
Compositions et méthodes d'utilisation de l'hormone anti-müllérienne pour le traitement de l'infertilité
|
US10227411B2
(en)
|
2015-03-05 |
2019-03-12 |
Xencor, Inc. |
Modulation of T cells with bispecific antibodies and FC fusions
|
WO2016144860A1
(en)
|
2015-03-06 |
2016-09-15 |
Ironwood Pharmaceuticals, Inc. |
Faah inhibitors for the treatment or prevention of nausea
|
EP3268373B1
(en)
|
2015-03-09 |
2022-04-27 |
F. Hoffmann-La Roche AG |
Tricyclic dlk inhibitors and uses thereof
|
IL292449B2
(en)
|
2015-03-13 |
2024-02-01 |
Cytomx Therapeutics Inc |
Nucleic acids encoding antibodies against PDL1 and methods for their preparation
|
WO2016149368A1
(en)
|
2015-03-17 |
2016-09-22 |
Memorial Sloan Kettering Cancer Center |
Anti-muc16 antibodies and uses thereof
|
AR104068A1
(es)
|
2015-03-26 |
2017-06-21 |
Hoffmann La Roche |
Combinaciones de un compuesto inhibidor de fosfoinosítido 3-cinasa y un compuesto inhibidor de cdk4/6 para el tratamiento del cáncer
|
WO2016154621A1
(en)
|
2015-03-26 |
2016-09-29 |
The California Institute For Biomedical Research |
SWITCHABLE NON-scFv CHIMERIC RECEPTORS, SWITCHES, AND USES THEREOF
|
CA2979732A1
(en)
|
2015-04-03 |
2016-10-06 |
Eureka Therapeutics, Inc. |
Constructs targeting afp peptide/mhc complexes and uses thereof
|
US9758575B2
(en)
|
2015-04-06 |
2017-09-12 |
Yung Shin Pharmaceutical Industrial Co. Ltd. |
Antibodies which specifically bind to canine vascular endothelial growth factor and uses thereof
|
WO2016164476A2
(en)
|
2015-04-06 |
2016-10-13 |
Millendo Therapeutics, Inc. |
Combination therapy for treating disorders associated with excess cortisol production
|
WO2016164480A1
(en)
|
2015-04-07 |
2016-10-13 |
Genentech, Inc. |
Antigen binding complex having agonistic activity and methods of use
|
WO2016164835A1
(en)
|
2015-04-08 |
2016-10-13 |
Dana-Farber Cancer Institute, Inc. |
Humanized influenza monoclonal antibodies and methods of use thereof
|
MY188430A
(en)
|
2015-04-10 |
2021-12-08 |
Amgen Inc |
Interleukin-2 muteins for the expansion of t-regulatory cells
|
WO2016164705A1
(en)
|
2015-04-10 |
2016-10-13 |
Omar Abdel-Rahman Ali |
Immune cell trapping devices and methods for making and using the same
|
AU2016248946B2
(en)
|
2015-04-13 |
2022-03-10 |
Pfizer Inc. |
Therapeutic antibodies and their uses
|
EP3283113A4
(en)
|
2015-04-15 |
2018-12-05 |
The California Institute for Biomedical Research |
Optimized pne-based chimeric receptor t cell switches and uses thereof
|
JP6907124B2
(ja)
|
2015-04-17 |
2021-07-21 |
アムゲン リサーチ (ミュンヘン) ゲーエムベーハーAMGEN Research(Munich)GmbH |
Cdh3及びcd3に対する二重特異性抗体構築物
|
EP3285795B1
(en)
|
2015-04-22 |
2022-11-16 |
Cedars-Sinai Medical Center |
Enterically delivered bitter oligopeptides for the treatment for type 2 diabetes and obesity
|
EP3085366A1
(en)
|
2015-04-22 |
2016-10-26 |
Institut du Cerveau et de la Moelle Epiniere-ICM |
Nmda antagonists for the treatment of mental disorders with occurrence of aggressive and/or impulsive behavior
|
EP3285753A1
(en)
|
2015-04-22 |
2018-02-28 |
CeMM - Forschungszentrum für Molekulare Medizin GmbH |
Combination of an antiandrogen with a vitamin k antagonist or with a gamma -glutamyl carboxylase inhibitor for the therapy of androgen receptor positive cancer
|
SG11201708441RA
(en)
|
2015-04-24 |
2017-11-29 |
Viiv Healthcare Uk (No 5) Ltd |
Polypeptides targeting hiv fusion
|
JP6952605B2
(ja)
|
2015-04-24 |
2021-10-20 |
ジェネンテック, インコーポレイテッド |
多特異性抗原結合タンパク質
|
CN107847446A
(zh)
|
2015-05-01 |
2018-03-27 |
因库博实验室有限责任公司 |
药物组合物和用于制备包含多肽和/或蛋白质的固体块的方法
|
US10233244B2
(en)
|
2015-05-04 |
2019-03-19 |
Cytomx Therapeutics, Inc. |
Anti-ITGA3 antibodies, activatable anti-ITGA3 antibodies, and methods of use thereof
|
IL292798A
(en)
|
2015-05-04 |
2022-07-01 |
Cytomx Therapeutics Inc |
Anti-cd166 antibodies, activatable anti-cd166 antibodies, preparations containing them and their uses
|
TWI726879B
(zh)
|
2015-05-04 |
2021-05-11 |
美商Cytomx生物製藥公司 |
抗cd71抗體類、可活化之抗cd71抗體類及使用彼等之方法
|
JP6694446B2
(ja)
|
2015-05-08 |
2020-05-13 |
ゼンコー・インコーポレイテッドXencor、 Inc. |
Cd3および腫瘍抗原に結合するヘテロ二量体抗体
|
EP3294770B2
(en)
|
2015-05-12 |
2024-03-20 |
F. Hoffmann-La Roche AG |
Therapeutic and diagnostic methods for cancer
|
US20180146703A1
(en)
*
|
2015-05-15 |
2018-05-31 |
The Johns Hopkins University |
Novel fluoride prenatal dietary supplement
|
MX2017014715A
(es)
|
2015-05-22 |
2018-03-16 |
Genentech Inc |
Benzamidas sustituidas y metodos para utilizarlas.
|
AU2016270625B2
(en)
|
2015-05-29 |
2022-10-06 |
Genentech, Inc. |
Therapeutic and diagnostic methods for cancer
|
AU2016271142A1
(en)
|
2015-05-29 |
2017-11-23 |
Genentech, Inc. |
PD-L1 promoter methylation in cancer
|
WO2016196664A1
(en)
|
2015-06-01 |
2016-12-08 |
Cedars-Sinai Medical Center |
Methods and use of compounds that bind to rela of nf-kb
|
JP6993235B2
(ja)
|
2015-06-03 |
2022-01-13 |
インターシア セラピューティクス,インコーポレイティド |
インプラントの設置及び撤去システム
|
MX367312B
(es)
|
2015-06-04 |
2019-08-14 |
Ospedale San Raffaele Srl |
Inhibidor del eje igrbp3/tmem219 y diabetes.
|
EP3302520B1
(en)
|
2015-06-04 |
2020-08-05 |
Ospedale San Raffaele S.r.l. |
Igfbp3 and uses thereof
|
US20160361380A1
(en)
|
2015-06-12 |
2016-12-15 |
Nymox Corporation |
Combination compositions for treating disorders requiring removal or destruction of unwanted cellular proliferations
|
EP3310376A4
(en)
|
2015-06-17 |
2019-01-23 |
The California Institute for Biomedical Research |
MODIFIED THERAPEUTIC AGENTS AND COMPOSITIONS THEREOF
|
HUE057952T2
(hu)
|
2015-06-24 |
2022-06-28 |
Hoffmann La Roche |
Anti-transzferrin receptor antitestek testreszabott affinitással
|
EP3598134A1
(en)
|
2015-06-29 |
2020-01-22 |
F. Hoffmann-La Roche AG |
Methods of treatment with taselisib
|
US9643980B2
(en)
|
2015-07-02 |
2017-05-09 |
Genentech, Inc. |
Benzoxazepin oxazolidinone compounds and methods of use
|
EP3778607B1
(en)
|
2015-07-02 |
2023-08-30 |
F. Hoffmann-La Roche AG |
Benzoxazepin oxazolidinone compounds and methods of use
|
WO2017007955A1
(en)
|
2015-07-07 |
2017-01-12 |
The Research Foundation For The State University Of New York |
Use of amine carboxyboranes as therapeutic delivery of carbon monoxide and as general drug delivery system in the presence of reactive oxygen species
|
WO2017007846A1
(en)
|
2015-07-07 |
2017-01-12 |
Genentech, Inc. |
Combination therapy with an anti-her2 antibody-drug conjugate and a bcl-2 inhibitor
|
KR20180040138A
(ko)
|
2015-07-13 |
2018-04-19 |
싸이톰스 테라퓨틱스, 인크. |
항pd-1 항체, 활성화 가능한 항pd-1 항체, 및 이들의 사용 방법
|
EP3322733B1
(en)
|
2015-07-13 |
2021-09-15 |
Compugen Ltd. |
Hide1 compositions and methods
|
US10913802B2
(en)
|
2015-07-21 |
2021-02-09 |
Dyax Corp. |
Monoclonal antibody inhibitor of factor XIIA
|
EP3328856A2
(en)
|
2015-07-28 |
2018-06-06 |
Vyome Biosciences Pvt. Ltd. |
Antibacterial therapeutics and prophylactics
|
BR112018001900A2
(pt)
|
2015-07-28 |
2018-09-18 |
Otonomy, Inc. |
composições agonistas de trkb ou trkc e métodos para o tratamento de condições óticas
|
US10842763B2
(en)
|
2015-07-31 |
2020-11-24 |
The Johns Hopkins University |
Methods for cancer and immunotherapy using prodrugs of glutamine analogs
|
TWI829617B
(zh)
|
2015-07-31 |
2024-01-21 |
德商安美基研究(慕尼黑)公司 |
Flt3及cd3抗體構築體
|
TWI717375B
(zh)
|
2015-07-31 |
2021-02-01 |
德商安美基研究(慕尼黑)公司 |
Cd70及cd3抗體構築體
|
TWI796283B
(zh)
|
2015-07-31 |
2023-03-21 |
德商安美基研究(慕尼黑)公司 |
Msln及cd3抗體構築體
|
TW202346349A
(zh)
|
2015-07-31 |
2023-12-01 |
德商安美基研究(慕尼黑)公司 |
Dll3及cd3抗體構築體
|
TWI744242B
(zh)
|
2015-07-31 |
2021-11-01 |
德商安美基研究(慕尼黑)公司 |
Egfrviii及cd3抗體構築體
|
EA034571B1
(ru)
|
2015-07-31 |
2020-02-21 |
Дзе Джонс Хопкинс Юниверсити |
Пролекарства аналогов глутамина
|
EP3328376A4
(en)
|
2015-07-31 |
2019-03-13 |
The Johns Hopkins University |
METHODS AND COMPOSITIONS FOR THE TREATMENT OF METABOLIC REPROGRAMMING DISORDERS
|
EP3328374A4
(en)
|
2015-07-31 |
2019-03-13 |
The Johns Hopkins University |
GLUTAMINANTAGONISTS FOR THE TREATMENT OF COGNITIVE DEFICITES
|
JO3620B1
(ar)
|
2015-08-05 |
2020-08-27 |
Amgen Res Munich Gmbh |
مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم
|
BR102016018074A2
(pt)
|
2015-08-07 |
2021-11-16 |
ALX Oncology Inc. |
Construção variante de sirp-alfa, seu método de preparação e seus usos, molécula de ácido nucleico, vetor, célula hospedeira, e composição farmacêutica
|
GEP20227447B
(en)
|
2015-08-07 |
2022-12-12 |
Alx Oncology Inc |
Constructs having sirp-alpha domain or variant thereof
|
CN105384825B
(zh)
|
2015-08-11 |
2018-06-01 |
南京传奇生物科技有限公司 |
一种基于单域抗体的双特异性嵌合抗原受体及其应用
|
CN108137477A
(zh)
|
2015-08-27 |
2018-06-08 |
基因泰克公司 |
治疗化合物及其使用方法
|
JP2018532990A
(ja)
|
2015-09-04 |
2018-11-08 |
オービーアイ ファーマ,インコーポレイテッド |
グリカンアレイおよび使用の方法
|
WO2017041001A2
(en)
|
2015-09-04 |
2017-03-09 |
The California Institute For Biomedical Research |
Insulin immunoglobulin fusion proteins
|
KR102596852B1
(ko)
|
2015-09-15 |
2023-11-02 |
스칼러 락, 인크. |
항-프로/잠재성-미오스타틴 항체 및 그의 용도
|
WO2017049004A1
(en)
|
2015-09-15 |
2017-03-23 |
Amgen Inc. |
Tetravalent bispecific and tetraspecific antigen binding proteins and uses thereof
|
CA2999160A1
(en)
|
2015-09-23 |
2017-03-30 |
Oncomed Pharmaceuticals, Inc. |
Methods and compositions for treatment of cancer
|
KR20180057657A
(ko)
|
2015-09-23 |
2018-05-30 |
브리스톨-마이어스 스큅 컴퍼니 |
글리피칸-3-결합 피브로넥틴 기반 스캐폴드 분자
|
EP3355909B1
(en)
|
2015-09-28 |
2023-06-07 |
Children's Hospital Los Angeles |
Methods for treating diseases mediated by erbb4-positive pro-inflammatory macrophages
|
WO2017055966A1
(en)
|
2015-10-01 |
2017-04-06 |
Pfizer Inc. |
Low viscosity antibody compositions
|
CA3000697A1
(en)
|
2015-10-01 |
2017-04-06 |
Amgen Inc. |
Treatment of bile acid disorders
|
AR106189A1
(es)
|
2015-10-02 |
2017-12-20 |
Hoffmann La Roche |
ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
|
JP6657392B2
(ja)
|
2015-10-02 |
2020-03-04 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
二重特異性抗ヒトcd20/ヒトトランスフェリン受容体抗体及び使用方法
|
JP2018529747A
(ja)
|
2015-10-06 |
2018-10-11 |
ジェネンテック, インコーポレイテッド |
多発性硬化症を治療するための方法
|
US20190255107A1
(en)
|
2015-10-09 |
2019-08-22 |
The Brigham And Women's Hospital, Inc. |
Modulation of novel immune checkpoint targets
|
CA3001857A1
(en)
|
2015-10-14 |
2017-04-20 |
Aquinnah Pharmaceuticals, Inc. |
Compounds, compositions and methods of use against stress granules
|
WO2017066714A1
(en)
|
2015-10-16 |
2017-04-20 |
Compugen Ltd. |
Anti-vsig1 antibodies and drug conjugates
|
US10780171B2
(en)
|
2015-10-26 |
2020-09-22 |
President And Fellows Of Harvard College |
Reduced and oxidized polysaccharides and methods of use thereof
|
WO2017075037A1
(en)
|
2015-10-27 |
2017-05-04 |
Scholar Rock, Inc. |
Primed growth factors and uses thereof
|
JP2018534930A
(ja)
|
2015-10-30 |
2018-11-29 |
ジェネンテック, インコーポレイテッド |
抗d因子抗体及びコンジュゲート
|
BR112018007703A2
(pt)
|
2015-10-30 |
2018-11-06 |
Genentech Inc |
anticorpos, ácido nucleico isolado, métodos de produção de um anticorpo e de tratamento de um distúrbio, composição farmacêutica, terapia de combinação e uso do anticorpo
|
WO2017075252A1
(en)
|
2015-10-30 |
2017-05-04 |
Genentech, Inc. |
Anti-factor d antibody variant conjugates and uses thereof
|
JP2019503985A
(ja)
|
2015-11-03 |
2019-02-14 |
グリコミメティクス, インコーポレイテッド |
モノクローナル抗体、造血幹細胞の産生のための方法および組成物、ならびにそれらを使用する方法
|
SG10201913746RA
(en)
|
2015-11-03 |
2020-03-30 |
Ambrx Inc |
Anti-cd3-folate conjugates and their uses
|
AU2016354661B2
(en)
|
2015-11-13 |
2020-12-10 |
Domain Therapeutics |
Substituted tricyclic 1,4-benzodiazepinone derivatives as allosteric modulators of group II metabotropic glutamate receptors
|
ES2824120T3
(es)
|
2015-11-19 |
2021-05-11 |
Hoffmann La Roche |
Procedimientos de tratamiento del cáncer usando inhibidores de b-raf e inhibidores de los puntos de control inmunitario
|
CN108495851A
(zh)
|
2015-11-25 |
2018-09-04 |
基因泰克公司 |
取代的苯甲酰胺及其使用方法
|
TWI727380B
(zh)
|
2015-11-30 |
2021-05-11 |
美商輝瑞股份有限公司 |
位點專一性her2抗體藥物共軛體
|
TWI812873B
(zh)
|
2015-11-30 |
2023-08-21 |
美商輝瑞股份有限公司 |
用於部位專一性接合之抗體和抗體片段
|
EP3383497A4
(en)
|
2015-12-04 |
2019-06-12 |
The Regents of The University of California |
NEW ANTIBODIES FOR THE TREATMENT OF CANCERS
|
WO2017096262A1
(en)
|
2015-12-04 |
2017-06-08 |
Jomoco, Corp. |
Compositions and methods to mitigate or prevent an immune response to an immunogenic therapeutic molecule in non-human primates
|
US10227410B2
(en)
|
2015-12-07 |
2019-03-12 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and PSMA
|
DK3387019T3
(da)
|
2015-12-09 |
2022-01-10 |
Scripps Research Inst |
Relaxin-immunoglobulinfusionsproteiner og anvendelsesfremgangsmåder
|
CA3004630A1
(en)
|
2015-12-09 |
2017-06-15 |
Medizinische Universitat Wien |
Monomaleimide-functionalized platinum compounds for cancer therapy
|
WO2017106175A2
(en)
|
2015-12-14 |
2017-06-22 |
Ironwood Pharmaceuticals, Inc. |
USE OF sGC STIMULATORS FOR THE TREATMENT OF GASTROINTESTINAL SPHINCTER DYSFUNCTION
|
WO2017106578A1
(en)
|
2015-12-15 |
2017-06-22 |
Amgen Inc. |
Pacap antibodies and uses thereof
|
CN108778320A
(zh)
|
2015-12-18 |
2018-11-09 |
泰伦基国际有限公司 |
一种预防和治疗心血管病的新方法
|
EA201891323A1
(ru)
|
2015-12-23 |
2019-02-28 |
Амген Инк. |
Способ лечения или облегчения метаболических нарушений с использованием белков, связывающих рецептор желудочного ингибиторного пептида (gipr), в комбинации с агонистами glp-1
|
EP3395835B1
(en)
|
2015-12-25 |
2021-02-03 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody having enhanced activity, and method for modifying same
|
KR20180104635A
(ko)
|
2015-12-30 |
2018-09-21 |
코디악 사이언시스 인코포레이티드 |
항체 및 이의 접합체
|
MX2018008369A
(es)
|
2016-01-08 |
2019-05-15 |
Scholar Rock Inc |
Anticuerpos de anti-miostatina pro/latente y metodo de uso de los mismos.
|
JP2019506383A
(ja)
|
2016-01-11 |
2019-03-07 |
シナジー ファーマシューティカルズ インコーポレイテッド |
潰瘍性大腸炎を治療するための製剤および方法
|
AU2017207867A1
(en)
|
2016-01-15 |
2018-08-09 |
Universität Hamburg |
Flavonoide-type compounds bearing an O-rhamnosyl residue
|
TWI797073B
(zh)
|
2016-01-25 |
2023-04-01 |
德商安美基研究(慕尼黑)公司 |
包含雙特異性抗體建構物之醫藥組合物
|
UA126657C2
(uk)
|
2016-02-03 |
2023-01-11 |
Емджен Рісерч (Мюнік) Ґмбг |
ОДНОЛАНЦЮГОВА КОНСТРУКЦІЯ АНТИТІЛА ДО BCMA І CD3<font face="Symbol">e</font>
|
DK3411404T3
(da)
|
2016-02-03 |
2023-01-30 |
Amgen Res Munich Gmbh |
Psma- og cd3-bispecifikke t-celleinddragende antistofkonstruktioner
|
EA039859B1
(ru)
|
2016-02-03 |
2022-03-21 |
Эмджен Рисерч (Мюник) Гмбх |
Биспецифические конструкты антител, связывающие egfrviii и cd3
|
CN109071625A
(zh)
|
2016-02-04 |
2018-12-21 |
柯瑞斯公司 |
平滑化突变体和其使用方法
|
US10098909B2
(en)
|
2016-02-05 |
2018-10-16 |
University Of South Florida |
Ionic cocrystal of lithium, lispro, for the treatment of fragile X syndrome
|
CN115487351A
(zh)
|
2016-02-06 |
2022-12-20 |
哈佛学院校长同事会 |
重塑造血巢以重建免疫
|
ES2970828T3
(es)
|
2016-02-10 |
2024-05-30 |
Univ Rutgers |
Nuevos anticuerpos anti-lam
|
US10519442B2
(en)
|
2016-02-11 |
2019-12-31 |
City Of Hope |
Twist signaling inhibitor compositions and methods of using the same
|
WO2017140728A1
(en)
|
2016-02-15 |
2017-08-24 |
Cemm - Forschungszentrum Für Molekulare Medizin Gmbh |
Taf1 inhibitors for the therapy of cancer
|
CN114395624A
(zh)
|
2016-02-29 |
2022-04-26 |
基因泰克公司 |
用于癌症的治疗和诊断方法
|
WO2017148880A1
(en)
|
2016-03-01 |
2017-09-08 |
F. Hoffmann-La Roche Ag |
Obinutuzumab variants having altered cell death induction
|
EP3216458A1
(en)
|
2016-03-07 |
2017-09-13 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Modified vascular endothelial growth factor a (vegf-a) and its medical use
|
JP2019515876A
(ja)
|
2016-03-08 |
2019-06-13 |
アカデミア シニカAcademia Sinica |
N−グリカンおよびそのアレイのモジュール合成のための方法
|
DK3365368T3
(da)
|
2016-03-11 |
2023-06-26 |
Scholar Rock Inc |
Tgfbeta1-bindende immunoglobuliner og anvendelse deraf
|
MX2018011204A
(es)
|
2016-03-15 |
2019-03-07 |
Mersana Therapeutics Inc |
Conjugados de anticuerpo-farmaco dirigidos a napi2b y sus metodos de uso.
|
JP7066627B2
(ja)
|
2016-03-28 |
2022-05-13 |
シニュークス インターナショナル(タイワン)コーポレイション |
タンニン酸を含有する組成物及びその使用
|
US10980894B2
(en)
|
2016-03-29 |
2021-04-20 |
Obi Pharma, Inc. |
Antibodies, pharmaceutical compositions and methods
|
CA3019560A1
(en)
|
2016-03-29 |
2017-10-05 |
Obi Pharma, Inc. |
Antibodies, pharmaceutical compositions and methods
|
US10766858B2
(en)
|
2016-03-30 |
2020-09-08 |
Genentech, Inc. |
Substituted benzamides and methods of use thereof
|
CN109563130A
(zh)
|
2016-04-07 |
2019-04-02 |
卡斯西部储备大学 |
用于治疗神经退行性疾病的tdp-43线粒体定位抑制剂
|
EP3443120A2
(en)
|
2016-04-15 |
2019-02-20 |
H. Hoffnabb-La Roche Ag |
Methods for monitoring and treating cancer
|
KR20190003958A
(ko)
|
2016-04-15 |
2019-01-10 |
제넨테크, 인크. |
암의 치료 및 모니터링 방법
|
US20190111069A1
(en)
|
2016-04-15 |
2019-04-18 |
Oxford University Innovation Limited |
Adenosine Receptor Modulators for the Treatment of Circadian Rhythm Disorders
|
SG11201809024UA
(en)
|
2016-04-22 |
2018-11-29 |
Obi Pharma Inc |
Cancer immunotherapy by immune activation or immune modulation via globo series antigens
|
JP7422480B2
(ja)
|
2016-05-04 |
2024-01-26 |
アムジエン・インコーポレーテツド |
制御性t細胞の増殖のためのインターロイキン-2変異タンパク質
|
BR112018073133A2
(pt)
|
2016-05-10 |
2019-04-30 |
Genentech Inc |
métodos de diminuição das ligações trissulfeto durante a produção recombinante de polipeptídeos
|
EP3458084B1
(en)
|
2016-05-16 |
2020-04-01 |
Intarcia Therapeutics, Inc |
Glucagon-receptor selective polypeptides and methods of use thereof
|
US20190282588A1
(en)
*
|
2016-05-16 |
2019-09-19 |
Amag Pharmaceuticals, Inc. |
Polymeric extended release compositions of hydroxyprogesterone caproate and methods of using same
|
USD840030S1
(en)
|
2016-06-02 |
2019-02-05 |
Intarcia Therapeutics, Inc. |
Implant placement guide
|
USD860451S1
(en)
|
2016-06-02 |
2019-09-17 |
Intarcia Therapeutics, Inc. |
Implant removal tool
|
EP3468997B1
(en)
|
2016-06-08 |
2023-09-13 |
Xencor, Inc. |
Treatment of igg4-related diseases with anti-cd19 antibodies crossbinding to cd32b
|
US11779657B2
(en)
|
2016-06-10 |
2023-10-10 |
City Of Hope |
Compositions and methods for mitochondrial genome editing
|
WO2017218707A2
(en)
|
2016-06-14 |
2017-12-21 |
Xencor, Inc. |
Bispecific checkpoint inhibitor antibodies
|
JP7018026B2
(ja)
|
2016-06-16 |
2022-02-09 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
ヘテロアリールエストロゲン受容体モジュレーター及びその使用
|
EP3472159A1
(en)
|
2016-06-16 |
2019-04-24 |
F. Hoffmann-La Roche AG |
TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF
|
US10183058B2
(en)
|
2016-06-17 |
2019-01-22 |
Nymox Corporation |
Method of preventing or reducing the progression of prostate cancer
|
WO2018005706A1
(en)
|
2016-06-28 |
2018-01-04 |
Xencor, Inc. |
Heterodimeric antibodies that bind somatostatin receptor 2
|
EP3478269A4
(en)
|
2016-06-29 |
2020-04-08 |
Otonomy, Inc. |
OTIC FORMULATIONS BASED ON TRIGLYCERIDES AND THEIR USES
|
WO2018005954A2
(en)
|
2016-07-01 |
2018-01-04 |
Resolve Therapeutics, Llc |
Optimized binuclease fusions and methods
|
US11124805B2
(en)
|
2016-07-13 |
2021-09-21 |
Vertex Pharmaceuticals Incorporated |
Methods, compositions and kits for increasing genome editing efficiency
|
CN115404196A
(zh)
|
2016-07-13 |
2022-11-29 |
哈佛学院院长等 |
抗原呈递细胞模拟支架及其制备和使用方法
|
WO2018013924A1
(en)
|
2016-07-15 |
2018-01-18 |
Massachusetts Institute Of Technology |
Synthetic nanoparticles for delivery of immunomodulatory compounds
|
AU2017296236A1
(en)
|
2016-07-15 |
2019-01-03 |
Poseida Therapeutics, Inc. |
Chimeric antigen receptors and methods for use
|
RU2019104075A
(ru)
|
2016-07-15 |
2020-08-17 |
Посейда Терапьютикс, Инк. |
Химерные рецепторы антигенов (car), специфические для muc1, и способы их применения
|
JP7316930B2
(ja)
|
2016-07-15 |
2023-07-28 |
武田薬品工業株式会社 |
形質芽細胞及び形質細胞枯渇療法に対する応答を評価するための方法及び材料
|
EP3487849A1
(en)
|
2016-07-20 |
2019-05-29 |
H. Hoffnabb-La Roche Ag |
Sulfonylcycloalkyl carboxamide compounds as trpa1 modulators
|
CN109476640B
(zh)
|
2016-07-20 |
2022-02-25 |
豪夫迈·罗氏有限公司 |
双环脯氨酸化合物
|
WO2018014260A1
(en)
|
2016-07-20 |
2018-01-25 |
Nanjing Legend Biotech Co., Ltd. |
Multispecific antigen binding proteins and methods of use thereof
|
CA3030996A1
(en)
|
2016-07-21 |
2018-01-25 |
The University Of North Carolina At Chapel Hill |
Inhibitors of microbial beta-glucuronidase enzymes and uses thereof
|
WO2018015466A1
(en)
|
2016-07-22 |
2018-01-25 |
Ecole Polytechnique Federale De Lausanne (Epfl) |
Virucidal metallic nanoparticles and uses thereof
|
KR102534568B1
(ko)
|
2016-07-22 |
2023-05-18 |
다나-파버 캔서 인스티튜트 인크. |
글루코코르티코이드-유도된 종양 괴사 인자 수용체 (gitr) 항체 및 이의 이용 방법
|
BR112019001131A2
(pt)
|
2016-07-22 |
2019-04-30 |
Ecole Polytechnique Federale De Lausanne (Epfl) |
composto virucida, composição farmacêutica, método de desinfecção e/ou esterilização, dispositivo e uso dos compostos virucidas
|
CA3032049C
(en)
|
2016-07-27 |
2023-11-07 |
Obi Pharma, Inc. |
Immunogenic/therapeutic glycan compositions and uses thereof
|
US10172910B2
(en)
|
2016-07-28 |
2019-01-08 |
Nymox Corporation |
Method of preventing or reducing the incidence of acute urinary retention
|
TWI786054B
(zh)
|
2016-07-29 |
2022-12-11 |
台灣浩鼎生技股份有限公司 |
人類抗體、醫藥組合物、及其方法
|
WO2018024654A1
(en)
|
2016-08-02 |
2018-02-08 |
Friedrich-Alexander-Universität Erlangen-Nürnberg |
Heterocyclic diamidines
|
CN109963871A
(zh)
|
2016-08-05 |
2019-07-02 |
豪夫迈·罗氏有限公司 |
具有激动活性的多价及多表位抗体以及使用方法
|
KR20190037261A
(ko)
|
2016-08-08 |
2019-04-05 |
암젠 인크 |
항-스클레로스틴 항체를 사용한 결합 조직 부착 개선 방법
|
JP7071959B2
(ja)
|
2016-08-12 |
2022-05-19 |
エフ.ホフマン-ラ ロシュ アーゲー |
スルホニルピリジルtrp阻害剤
|
CA3034057A1
(en)
|
2016-08-22 |
2018-03-01 |
CHO Pharma Inc. |
Antibodies, binding fragments, and methods of use
|
CA3034259A1
(en)
|
2016-08-23 |
2018-03-01 |
Genentech, Inc. |
Combination therapy for the treatment of pancreatic cancer
|
EP3504192B1
(en)
|
2016-08-24 |
2022-04-06 |
F. Hoffmann-La Roche AG |
2-azabicyclo[3.1.0]hexan-3-one derivatives and methods of use
|
WO2018037059A1
(en)
|
2016-08-24 |
2018-03-01 |
F. Hoffmann-La Roche Ag |
2-azabicyclo[3.1.0]hexan-3-one derivatives and methods of use
|
US10793632B2
(en)
|
2016-08-30 |
2020-10-06 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
DK3506921T3
(da)
|
2016-08-31 |
2023-07-31 |
Mapi Pharma Ltd |
Depotsystemer, der omfatter glatirameracetat
|
WO2018044970A1
(en)
|
2016-08-31 |
2018-03-08 |
University Of Rochester |
Human monoclonal antibodies to human endogenous retrovirus k envelope (herv-k) and uses thereof
|
RS62256B1
(sr)
|
2016-09-02 |
2021-09-30 |
Cyclerion Therapeutics Inc |
Fuzionisani biciklični sgc stimulatori
|
CN109661241A
(zh)
|
2016-09-06 |
2019-04-19 |
中外制药株式会社 |
使用识别凝血因子ix和/或活化凝血因子ix以及凝血因子x和/或活化凝血因子x的双特异性抗体的方法
|
US10532081B2
(en)
|
2016-09-07 |
2020-01-14 |
Nymox Corporation |
Method of ameliorating or preventing the worsening or the progression of symptoms of BPH
|
CN110198729A
(zh)
|
2016-09-09 |
2019-09-03 |
豪夫迈·罗氏有限公司 |
卷曲蛋白的选择性肽抑制剂
|
CA3036829A1
(en)
|
2016-09-14 |
2018-03-22 |
The Trustees Of The University Of Pennsylvania |
Proximity-based sortase-mediated protein purification and ligation
|
AU2017327828B2
(en)
|
2016-09-16 |
2023-11-16 |
Shanghai Henlius Biotech, Inc. |
Anti-PD-1 antibodies
|
CA3032046A1
(en)
|
2016-09-16 |
2018-03-22 |
Research Triangle Institute |
Tetrahydroisoquinoline kappa opioid antagonists
|
SG10201913032TA
(en)
|
2016-09-23 |
2020-02-27 |
Teva Pharmaceuticals Int Gmbh |
Treating refractory migraine
|
EA201990548A1
(ru)
|
2016-09-23 |
2019-09-30 |
Тева Фармасьютикалз Интернэшнл Гмбх |
Лечение кластерной головной боли
|
CN110418851A
(zh)
|
2016-10-06 |
2019-11-05 |
基因泰克公司 |
癌症的治疗和诊断方法
|
US20200016202A1
(en)
|
2016-10-07 |
2020-01-16 |
The Brigham And Women's Hospital, Inc. |
Modulation of novel immune checkpoint targets
|
WO2018068201A1
(en)
|
2016-10-11 |
2018-04-19 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies and variants thereof against ctla-4
|
EP3526241A1
(en)
|
2016-10-14 |
2019-08-21 |
Xencor, Inc. |
Il15/il15r heterodimeric fc-fusion proteins
|
CN109843886B
(zh)
|
2016-10-17 |
2022-04-19 |
豪夫迈·罗氏有限公司 |
二环吡啶酮内酰胺及其使用方法
|
US10738338B2
(en)
|
2016-10-18 |
2020-08-11 |
The Research Foundation for the State University |
Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate
|
KR102613430B1
(ko)
|
2016-10-19 |
2023-12-18 |
더 스크립스 리서치 인스티튜트 |
인간화된 표적화 모이어티 및/또는 최적화된 키메라 항원 수용체-상호작용 도메인을 갖는 키메라 항원 수용체 효과기 세포 스위치 및 이의 용도
|
WO2018078031A1
(en)
|
2016-10-28 |
2018-05-03 |
Ecole Polytechnique Federale De Lausanne (Epfl) |
Methods of derivation and/or propagation of epithelial cells
|
US11779604B2
(en)
|
2016-11-03 |
2023-10-10 |
Kymab Limited |
Antibodies, combinations comprising antibodies, biomarkers, uses and methods
|
KR20230141941A
(ko)
|
2016-11-03 |
2023-10-10 |
브리스톨-마이어스 스큅 컴퍼니 |
활성화가능한 항-ctla-4 항체 및 그의 용도
|
CA3040812A1
(en)
|
2016-11-04 |
2018-05-11 |
Novimmune Sa |
Anti-cd19 antibodies and methods of use thereof
|
SG10202104876SA
(en)
|
2016-11-08 |
2021-06-29 |
Cyclerion Therapeutics Inc |
Sgc stimulators
|
EA201991147A1
(ru)
|
2016-11-08 |
2019-11-29 |
|
ЛЕЧЕНИЕ ЗАБОЛЕВАНИЙ ЦЕНТРАЛЬНОЙ НЕРВНОЙ СИСТЕМЫ С ПОМОЩЬЮ СТИМУЛЯТОРОВ sGC
|
EP3538549A1
(en)
|
2016-11-10 |
2019-09-18 |
iOmx Therapeutics AG |
Or10h1 antigen binding proteins and uses thereof
|
AU2017359288A1
(en)
|
2016-11-14 |
2019-05-30 |
Cemm - Forschungszentrum Für Molekulare Medizin Gmbh |
Combination of a BRD4 inhibitor and an antifolate for the therapy of cancer
|
WO2018090052A1
(en)
|
2016-11-14 |
2018-05-17 |
Amgen Inc. |
Bispecific or biparatopic antigen binding proteins and uses thereof
|
US10646540B2
(en)
|
2016-11-18 |
2020-05-12 |
City Of Hope |
Peptide inhibitors of twist
|
AU2017361549B2
(en)
|
2016-11-21 |
2023-12-21 |
Obi Pharma, Inc. |
Conjugated biological molecules, pharmaceutical compositions and methods
|
JP7126500B2
(ja)
|
2016-11-22 |
2022-08-26 |
エフ.ホフマン-ラ ロシュ アーゲー |
抗体薬物コンジュゲート
|
WO2018096159A1
(en)
|
2016-11-28 |
2018-05-31 |
F. Hoffmann-La Roche Ag |
Oxadiazolones as transient receptor potential channel inhibitors
|
US11091490B2
(en)
|
2016-11-30 |
2021-08-17 |
Medizinische Universität Innsbruck |
3-amino-1,5-dihydro-pyrazolo[3,4-d]pyrimidin-4-ones as cyclin dependent kinase inhibitors
|
WO2018100070A1
(en)
|
2016-12-02 |
2018-06-07 |
F. Hoffmann-La Roche Ag |
Bicyclic amide compounds and methods of use thereof
|
US20190381039A1
(en)
|
2016-12-13 |
2019-12-19 |
Cyclerion Therapeutics, Inc. |
USE OF sGC STIMULATORS FOR THE TREATMENT OF ESOPHAGEAL MOTILITY DISORDERS
|
TW201834690A
(zh)
|
2016-12-14 |
2018-10-01 |
美商寶珍那提公司 |
以免疫抑制劑治療胃腸道疾病
|
WO2018112235A1
(en)
|
2016-12-14 |
2018-06-21 |
Progenity Inc. |
Treatment of a disease of the gastrointestinal tract with a smad7 inhibitor
|
MX2019006821A
(es)
|
2016-12-14 |
2019-10-21 |
Progenity Inc |
Tratamiento de una enfermedad del tracto gastrointestinal con un inhibidor de cinasa de janus (jak) y dispositivos.
|
WO2018112264A1
(en)
|
2016-12-14 |
2018-06-21 |
Progenity Inc. |
Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor
|
JP7237834B2
(ja)
|
2016-12-14 |
2023-03-13 |
ビオラ・セラピューティクス・インコーポレイテッド |
消化管疾病のil-12/il-23阻害薬による治療
|
MX2019006864A
(es)
|
2016-12-14 |
2019-10-15 |
Progenity Inc |
Tratamiento de una enfermedad del tracto gastrointestinal con un inhibidor de factor de necrosis tumoral (tnf).
|
CA3046019A1
(en)
|
2016-12-14 |
2018-06-21 |
Progenity Inc. |
Treatment of a disease of the gastrointestinal tract with a tlr modulator
|
WO2018112237A1
(en)
|
2016-12-14 |
2018-06-21 |
Progenity Inc. |
Treatment of a disease of the gastrointestinal tract with an il-6r inhibitor
|
EP3554539B9
(en)
|
2016-12-14 |
2023-10-04 |
Biora Therapeutics, Inc. |
Treatment of a disease of the gastrointestinal tract with an integrin inhibitor
|
WO2018112256A1
(en)
|
2016-12-14 |
2018-06-21 |
Progenity Inc. |
Treatment of a disease of the gastrointestinal tract with an il-1 inhibitor
|
CN110402150A
(zh)
|
2016-12-15 |
2019-11-01 |
泰伦基国际有限公司 |
一种预防和治疗骨质疏松的药物及其用途
|
CA3047170A1
(en)
|
2016-12-15 |
2018-06-21 |
Talengen International Limited |
Method for preventing and treating drug-induced renal injury
|
EP3556380A4
(en)
|
2016-12-15 |
2020-05-13 |
Talengen International Limited |
METHOD FOR PREVENTING AND TREATING FABRIC OF TISSUE AND ORGAN
|
CA3047168A1
(en)
|
2016-12-15 |
2018-06-21 |
Talengen International Limited |
Method for treating coronary atherosclerosis and complications thereof
|
JP7171572B2
(ja)
|
2016-12-15 |
2022-11-15 |
タレンゲン インターナショナル リミテッド |
糖尿病を治療するための新しい方法
|
CN110114079A
(zh)
|
2016-12-15 |
2019-08-09 |
泰伦基国际有限公司 |
一种预防和治疗肥胖症的方法和药物
|
TWI677348B
(zh)
|
2016-12-15 |
2019-11-21 |
大陸商深圳瑞健生命科學研究院有限公司 |
一種改善心臟病變的方法
|
US11072607B2
(en)
|
2016-12-16 |
2021-07-27 |
Genentech, Inc. |
Inhibitors of RIP1 kinase and methods of use thereof
|
MD3555064T2
(ro)
|
2016-12-16 |
2023-08-31 |
Pfizer |
Agoniști ai receptorului GLP-1 și utilizările acestora
|
EP3557998B1
(en)
|
2016-12-23 |
2023-08-16 |
Aquinnah Pharmaceuticals Inc. |
Compouns, compositions and methods of use
|
KR20190104039A
(ko)
|
2017-01-03 |
2019-09-05 |
인타르시아 세라퓨틱스 인코포레이티드 |
Glp-1 수용체 효능제의 연속적인 투여 및 약물의 동시-투여를 포함하는 방법
|
WO2018128454A1
(ko)
|
2017-01-06 |
2018-07-12 |
에이비엘바이오 주식회사 |
항 α-SYN 항체 및 그 용도
|
AU2018205231A1
(en)
|
2017-01-06 |
2019-07-18 |
Scholar Rock, Inc. |
Isoform-specific, context-permissive TGFβ1 inhibitors and use thereof
|
RS64159B1
(sr)
|
2017-01-06 |
2023-05-31 |
Scholar Rock Inc |
Tretiranje metaboličkih bolesti inhibiranjem aktivacije miostatina
|
PT3565592T
(pt)
|
2017-01-06 |
2023-05-31 |
Scholar Rock Inc |
Tratamento de doenças metabólicas através da inibição da ativação da miostatina
|
WO2018129470A1
(en)
|
2017-01-09 |
2018-07-12 |
The Board Of Trustees Of The Leland Stanford Junior University |
Reversing deficient hedgehog signaling restores deficient skeletal regeneration
|
US11111305B2
(en)
|
2017-01-09 |
2021-09-07 |
Torch Therapeutics |
Method of using a bispecific antibody to conditionally inhibit a receptor signaling complex
|
WO2018130554A1
(en)
|
2017-01-11 |
2018-07-19 |
Paracelsus Medizinische Privatuniversität Salzburg - Privatstiftung |
Mesenchymal stem cell-derived extracellular vesicles and their medical use
|
US11274157B2
(en)
|
2017-01-12 |
2022-03-15 |
Eureka Therapeutics, Inc. |
Constructs targeting histone H3 peptide/MHC complexes and uses thereof
|
JOP20190177A1
(ar)
|
2017-01-17 |
2019-07-16 |
Amgen Inc |
طريقة لعلاج أو تحسين اضطرابات أيضية باستخدام مساعدات مستقبل glp-1 مقترنة بمناهضات لمستقبل ببتيد مثبط معوي (gipr)
|
US11299480B2
(en)
|
2017-01-23 |
2022-04-12 |
University Of Hawaii |
2-arylsulfonamido-N-arylacetamide derivatized STAT3 inhibitors
|
US11377492B2
(en)
|
2017-01-24 |
2022-07-05 |
Innate Pharma |
NKp46 binding agents
|
CA3051484A1
(en)
|
2017-01-27 |
2018-08-02 |
Memorial Sloan Kettering Cancer Center |
Bispecific her2 and cd3 binding molecules
|
CA3052095A1
(en)
|
2017-01-30 |
2018-08-02 |
Janssen Biotech, Inc. |
Anti-tnf antibodies, compositions, and methods for the treatment of active psoriatic arthritis
|
JOP20190189A1
(ar)
|
2017-02-02 |
2019-08-01 |
Amgen Res Munich Gmbh |
تركيبة صيدلانية ذات درجة حموضة منخفضة تتضمن بنيات جسم مضاد يستهدف الخلية t
|
KR20240038148A
(ko)
|
2017-02-07 |
2024-03-22 |
얀센 바이오테크 인코포레이티드 |
활성 강직성 척추염의 치료를 위한 항-tnf 항체, 조성물, 및 방법
|
MY193457A
(en)
|
2017-02-08 |
2022-10-14 |
Bristol Myers Squibb Co |
Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
|
JP7200138B2
(ja)
|
2017-02-16 |
2023-01-06 |
ソネット バイオセラピューティクス,インコーポレイテッド |
アルブミン結合ドメイン融合タンパク質
|
WO2018152496A1
(en)
|
2017-02-17 |
2018-08-23 |
The Usa, As Represented By The Secretary, Dept. Of Health And Human Services |
Compositions and methods for the diagnosis and treatment of zika virus infection
|
WO2018160538A1
(en)
|
2017-02-28 |
2018-09-07 |
Mersana Therapeutics, Inc. |
Combination therapies of her2-targeted antibody-drug conjugates
|
US10335453B2
(en)
|
2017-03-01 |
2019-07-02 |
Nymox Corporation |
Compositions and methods for improving sexual function
|
ES2953595T3
(es)
|
2017-03-01 |
2023-11-14 |
Hoffmann La Roche |
Procedimientos diagnósticos y terapéuticos para el cáncer
|
US11021529B2
(en)
|
2017-03-03 |
2021-06-01 |
Massachusetts Institute Of Technology |
Antimicrobial constructs and uses thereof
|
AU2018226646A1
(en)
|
2017-03-03 |
2019-09-19 |
Rinat Neuroscience Corp. |
Anti-GITR antibodies and methods of use thereof
|
EP3592739A1
(en)
|
2017-03-07 |
2020-01-15 |
H. Hoffnabb-La Roche Ag |
Oxadiazole transient receptor potential channel inhibitors
|
BR112019018541A2
(pt)
|
2017-03-09 |
2020-04-14 |
Cytomx Therapeutics Inc |
anticorpos cd147, anticorpos cd147 ativáveis e métodos de produção e uso dos mesmos
|
US10421968B2
(en)
|
2017-03-15 |
2019-09-24 |
Versitech Limited |
Amphiphilic dendrimers complexed with siRNA for treatment of cancer
|
CN110546148A
(zh)
|
2017-03-24 |
2019-12-06 |
基因泰克公司 |
作为钠通道抑制剂的4-哌啶-n-(嘧啶-4-基)色满-7-磺酰胺衍生物
|
BR112019017724A2
(pt)
|
2017-03-26 |
2020-03-31 |
Mapi Pharma Ltd. |
Sistemas depot de glatiramer para tratar formas progressivas de esclerose múltipla
|
JP7442439B2
(ja)
|
2017-03-30 |
2024-03-04 |
アルベルト-ルートヴィヒ-ユニバーシティー フライブルク |
Kdm4阻害剤
|
AU2018244935A1
(en)
|
2017-03-30 |
2019-08-15 |
F. Hoffmann-La Roche Ag |
Naphthyridines as inhibitors of HPK1
|
CA3054632A1
(en)
|
2017-03-30 |
2018-10-04 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
|
EP3600249A1
(en)
|
2017-03-30 |
2020-02-05 |
Progenity Inc. |
Treatment of a disease of the gastrointestinal tract with a chst15 inhibitor
|
CN110709392B
(zh)
|
2017-03-30 |
2023-09-29 |
豪夫迈·罗氏有限公司 |
作为hpk1抑制剂的异喹啉
|
WO2018183931A1
(en)
|
2017-03-30 |
2018-10-04 |
Progenity Inc. |
Treatment of a disease of the gastrointestinal tract with il-10 or an il-10 agonist
|
WO2018183932A1
(en)
|
2017-03-30 |
2018-10-04 |
Progenity Inc. |
Treatment of a disease of the gastrointestinal tract with a il-13 inhibitor
|
US20210401895A1
(en)
|
2017-03-30 |
2021-12-30 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with live biotherapeutics
|
MY200973A
(en)
|
2017-04-11 |
2024-01-26 |
Inhibrx Inc |
Multispecific Polypeptide Constructs Having Constrained Cd3 Binding And Methods Of Using The Same
|
EP3609915A1
(en)
|
2017-04-12 |
2020-02-19 |
Pfizer Inc |
Antibodies having conditional affinity and methods of use thereof
|
EP4230649A3
(en)
|
2017-04-25 |
2023-10-25 |
The U.S.A. As Represented By The Secretary, Department Of Health And Human Services |
Antibodies and methods for the diagnosis and treatment of epstein barr virus infection
|
KR20240067275A
(ko)
|
2017-04-26 |
2024-05-16 |
유레카 쎄라퓨틱스, 인코포레이티드 |
글리피칸 3을 특이적으로 인식하는 구축물 및 그의 용도
|
WO2018203545A1
(ja)
|
2017-05-02 |
2018-11-08 |
国立研究開発法人国立精神・神経医療研究センター |
Il-6及び好中球の関連する疾患の治療効果の予測及び判定方法
|
US20200071372A1
(en)
|
2017-05-04 |
2020-03-05 |
Helsingin Yliopisto |
C-terminal CDNF and MANF fragments, pharmaceutical compositions comprising same and uses thereof
|
EP3618864A1
(en)
|
2017-05-05 |
2020-03-11 |
Amgen Inc. |
Pharmaceutical composition comprising bispecific antibody constructs for improved storage and administration
|
EP3634403A1
(en)
|
2017-05-12 |
2020-04-15 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Phenyl-heterocycle-phenyl derivatives for use in the treatment or prevention of melanoma
|
CN110769830A
(zh)
|
2017-05-12 |
2020-02-07 |
马瓦隆治疗有限公司 |
作为ii组代谢型谷氨酸受体的别构调节剂的取代的杂环化合物
|
CA3065008A1
(en)
|
2017-05-26 |
2018-11-29 |
Novimmune Sa |
Anti-cd47 x anti-mesothelin antibodies and methods of use thereof
|
JOP20190259A1
(ar)
|
2017-05-31 |
2019-10-31 |
Amgen Inc |
بروتينات ربط مولد ضد مضادة لـ jagged1
|
JP2020522486A
(ja)
|
2017-06-01 |
2020-07-30 |
サイトメックス セラピューティクス インコーポレイテッド |
活性化可能抗pdl1抗体、およびその使用方法
|
UY37753A
(es)
|
2017-06-02 |
2018-11-30 |
Amgen Inc |
Antagonistas de péptido pac1
|
CN111344004A
(zh)
|
2017-06-19 |
2020-06-26 |
泰伦基国际有限公司 |
一种调控glp-1/glp-1r 的方法和药物
|
US20190062428A1
(en)
|
2017-06-19 |
2019-02-28 |
Surface Oncology, Inc. |
Combination of anti-cd47 antibodies and cell death-inducing agents, and uses thereof
|
AU2018288854A1
(en)
|
2017-06-20 |
2019-11-21 |
Amgen Inc. |
Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (GIPR) in combination with GLP-1 agonists
|
WO2019000223A1
(en)
|
2017-06-27 |
2019-01-03 |
Nanjing Legend Biotech Co., Ltd. |
ENABLERS OF IMMUNE EFFECTOR CELLS OF CHIMERIC ANTIBODIES AND METHODS OF USE THEREOF
|
CA3067603A1
(en)
|
2017-06-30 |
2019-01-03 |
Xencor, Inc. |
Targeted heterodimeric fc fusion proteins containing il-15/il-15ra and antigen binding domains
|
WO2019014328A2
(en)
|
2017-07-11 |
2019-01-17 |
Compass Therapeutics Llc |
AGONISTIC ANTIBODIES THAT BIND HUMAN CD137 AND USES THEREOF
|
CA3069179A1
(en)
|
2017-07-13 |
2019-01-17 |
Massachusetts Institute Of Technology |
Targeting the hdac2-sp3 complex to enhance synaptic function
|
RS65308B1
(sr)
|
2017-07-14 |
2024-04-30 |
Hoffmann La Roche |
Biciklična ketonska jedinjenja i postupci za njihovu upotrebu
|
US11344603B2
(en)
|
2017-07-19 |
2022-05-31 |
Auckland Uniservices Limited |
Cytokine modulation
|
EP3655430A1
(en)
|
2017-07-19 |
2020-05-27 |
The U.S.A. as represented by the Secretary, Department of Health and Human Services |
Antibodies and methods for the diagnosis and treatment of hepatitis b virus infection
|
WO2019016784A1
(en)
|
2017-07-21 |
2019-01-24 |
Universidade De Coimbra |
ANTI-NUCLEOLIN ANTIBODIES
|
EP3655034A1
(en)
|
2017-07-21 |
2020-05-27 |
Genentech, Inc. |
Therapeutic and diagnostic methods for cancer
|
CN110891608A
(zh)
|
2017-07-26 |
2020-03-17 |
豪夫迈·罗氏有限公司 |
用BET抑制剂和Bcl-2抑制剂进行的组合疗法
|
CN110869391A
(zh)
|
2017-07-26 |
2020-03-06 |
豪夫迈·罗氏有限公司 |
用BET抑制剂,Bcl-2抑制剂和抗CD20抗体的组合疗法
|
EP3658583A1
(en)
|
2017-07-28 |
2020-06-03 |
Scholar Rock, Inc. |
Ltbp complex-specific inhibitors of tgf-beta 1 and uses thereof
|
JP2020530453A
(ja)
|
2017-08-09 |
2020-10-22 |
マサチューセッツ インスティテュート オブ テクノロジー |
アルブミン結合ペプチド結合体及びその方法
|
US20200306516A1
(en)
|
2017-08-14 |
2020-10-01 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with glatiramer or a pharmaceutically acceptable salt thereof
|
US11485781B2
(en)
|
2017-08-17 |
2022-11-01 |
Massachusetts Institute Of Technology |
Multiple specificity binders of CXC chemokines
|
SG11202001311VA
(en)
|
2017-08-22 |
2020-03-30 |
Sanabio Llc |
Soluble interferon receptors and uses thereof
|
CN111212853A
(zh)
|
2017-08-30 |
2020-05-29 |
西托姆克斯治疗公司 |
可活化的抗cd166抗体及其使用方法
|
JP2020535128A
(ja)
|
2017-09-19 |
2020-12-03 |
マサチューセッツ インスティテュート オブ テクノロジー |
キメラ抗原受容体t細胞治療のための組成物およびその使用
|
US11364303B2
(en)
|
2017-09-29 |
2022-06-21 |
Pfizer Inc. |
Cysteine engineered antibody drug conjugates
|
AU2018346151A1
(en)
|
2017-10-04 |
2020-04-02 |
Amgen Inc. |
Transthyretin immunoglobulin fusions
|
PE20211246A1
(es)
|
2017-10-11 |
2021-07-13 |
Hoffmann La Roche |
Compuestos biciclicos para su uso como inhibidores de rip1 quinasa
|
CA3185107A1
(en)
|
2017-10-12 |
2019-04-18 |
Immunowake Inc. |
Vegfr-antibody light chain fusion protein
|
EP3694885A1
(en)
|
2017-10-14 |
2020-08-19 |
CytomX Therapeutics, Inc. |
Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof
|
US10336724B2
(en)
|
2017-10-18 |
2019-07-02 |
Syneurx International (Taiwan) Corp. |
D-amino acid oxidase inhibitors and therapeutic uses thereof
|
WO2019078344A1
(ja)
|
2017-10-20 |
2019-04-25 |
学校法人兵庫医科大学 |
抗il-6受容体抗体を含有する術後の癒着を抑制するための医薬組成物
|
EP3700567A4
(en)
|
2017-10-26 |
2021-09-29 |
The Regents of The University of California |
INHIBITION OF OXIDATION SPECIFIC EPITOPES FOR TREATMENT OF ISCHEMIC REPERFUSION DAMAGE
|
MX2020004381A
(es)
|
2017-10-27 |
2020-08-20 |
Pfizer |
Anticuerpos y conjugados de anticuerpo-farmaco especificos para cd123 y usos de los mismos.
|
EP3704132A4
(en)
|
2017-10-30 |
2021-07-28 |
Enterin, Inc. |
NEW SOLID FORMS OF SQUALAMINE AND PROCESSES FOR PRODUCING THEM
|
CA3078676A1
(en)
|
2017-10-30 |
2019-05-09 |
F. Hoffmann-La Roche Ag |
Method for in vivo generation of multispecific antibodies from monospecific antibodies
|
US11718679B2
(en)
|
2017-10-31 |
2023-08-08 |
Compass Therapeutics Llc |
CD137 antibodies and PD-1 antagonists and uses thereof
|
EP3704097B1
(en)
|
2017-10-31 |
2023-10-25 |
F. Hoffmann-La Roche AG |
Bicyclic sulfones and sulfoxides and methods of use thereof
|
TW201923089A
(zh)
|
2017-11-06 |
2019-06-16 |
美商建南德克公司 |
癌症之診斷及治療方法
|
US10981992B2
(en)
|
2017-11-08 |
2021-04-20 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
EP3706793A1
(en)
|
2017-11-08 |
2020-09-16 |
Xencor, Inc. |
Bispecific and monospecific antibodies using novel anti-pd-1 sequences
|
GB2568526A
(en)
*
|
2017-11-20 |
2019-05-22 |
Rebio Tech Oy |
Composition
|
WO2019100052A2
(en)
|
2017-11-20 |
2019-05-23 |
Compass Therapeutics Llc |
Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof
|
WO2019104214A1
(en)
|
2017-11-22 |
2019-05-31 |
Dauntless 2, Inc. |
Membrane emulsification device for microsphere creation
|
WO2019104225A1
(en)
|
2017-11-22 |
2019-05-31 |
Dauntless 2, Inc. |
Therapeutic compound formulations
|
US20210179591A1
(en)
|
2017-12-05 |
2021-06-17 |
Eth Zurich |
New compounds for use as a therapeutically active substance and in particular for use in the treatment of tumors
|
MX2020006007A
(es)
|
2017-12-11 |
2020-08-17 |
Amgen Inc |
Procedimiento de fabricacion continuo para productos de anticuerpos biespecificos.
|
BR112020013714A2
(pt)
|
2017-12-15 |
2020-12-01 |
The Australian National University |
compostos para tratamento e prevenção de patologias mediadas por histona extracelular
|
CA3123318A1
(en)
|
2017-12-15 |
2019-06-20 |
Talengen International Limited |
Method and drug for preventing or treating osteoarthritis
|
JP2021507717A
(ja)
|
2017-12-18 |
2021-02-25 |
ビーブ、ヘルスケア、ユーケー、(ナンバー5)、リミテッドViiv Healthcare Uk (No.5) Limited |
抗原結合性ポリペプチド
|
EP3728302A1
(en)
|
2017-12-19 |
2020-10-28 |
Xencor, Inc. |
Engineered il-2 fc fusion proteins
|
JP2021506851A
(ja)
|
2017-12-19 |
2021-02-22 |
マサチューセッツ インスティテュート オブ テクノロジー |
抗原−アジュバントカップリング試薬および使用の方法
|
MX2020006689A
(es)
|
2017-12-20 |
2020-11-06 |
Poseida Therapeutics Inc |
Composiciones de vcar y metodos de uso.
|
CA3078849A1
(en)
|
2017-12-28 |
2019-07-04 |
Nanjing Legend Biotech Co., Ltd. |
Antibodies and variants thereof against pd-l1
|
JP7369127B2
(ja)
|
2017-12-28 |
2023-10-25 |
ナンジン レジェンド バイオテック カンパニー,リミテッド |
Tigitに対する単一ドメイン抗体及びその変異体
|
UY38041A
(es)
|
2017-12-29 |
2019-06-28 |
Amgen Inc |
Construcción de anticuerpo biespecífico dirigida a muc17 y cd3
|
BR112020013621A2
(pt)
|
2018-01-12 |
2020-12-01 |
Amgen Inc. |
anticorpos contra pac1 e usos dos mesmos
|
SG11202004233UA
(en)
|
2018-01-15 |
2020-06-29 |
Nanjing Legend Biotech Co Ltd |
Single-domain antibodies and variants thereof against pd-1
|
AU2019209292B2
(en)
|
2018-01-17 |
2023-10-05 |
Vertex Pharmaceuticals Incorporated |
Quinoxalinone compounds, compositions, methods, and kits for increasing genome editing efficiency
|
JP7391854B2
(ja)
|
2018-01-17 |
2023-12-05 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
Dna-pk阻害剤
|
WO2019147779A1
(en)
|
2018-01-24 |
2019-08-01 |
Genentech, Inc. |
Diagnostic and therapeutic methods for the treatment of rheumatoid arthritis (ra)
|
US20210031012A1
(en)
|
2018-01-26 |
2021-02-04 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with a pde4 inhibitor
|
BR112020015016A2
(pt)
|
2018-01-26 |
2020-12-29 |
Genentech, Inc. |
Composições farmacêuticas, métodos de tratamento da doença inflamatória intestinal, de inibição da infecção microbiana no intestino e de aceleração ou melhora da cicatrização de feridas
|
MA51676A
(fr)
|
2018-01-26 |
2021-05-05 |
Hoffmann La Roche |
Protéines de fusion il-22 fc et procédés d'utilisation
|
JP7458790B2
(ja)
|
2018-01-31 |
2024-04-01 |
元一 加藤 |
Il-6阻害剤を含有する喘息の治療剤
|
PE20211116A1
(es)
|
2018-02-08 |
2021-06-23 |
Genentech Inc |
Moleculas biespecificas de union al antigeno y metodos de uso
|
MX2020008193A
(es)
|
2018-02-09 |
2020-11-24 |
Nestle Skin Health Sa |
Nemolizumab en el tratamiento de dermatitis atópica con excoriación moderada a severa.
|
CA3088557C
(en)
|
2018-02-09 |
2024-02-27 |
Genentech, Inc. |
Therapeutic and diagnostic methods for mast cell-mediated inflammatory diseases
|
WO2019164778A1
(en)
|
2018-02-20 |
2019-08-29 |
Genentech, Inc. |
Process for preparing 1-arylsulfonyl-pyrrolidine-2-carboxamide transient receptor potential channel antagonist compounds and crystalline forms thereof
|
KR20200123118A
(ko)
|
2018-02-21 |
2020-10-28 |
제넨테크, 인크. |
IL-22 Fc 융합 단백질로 치료를 위한 투약
|
TW202000651A
(zh)
|
2018-02-26 |
2020-01-01 |
美商建南德克公司 |
治療性組成物及其使用方法
|
SG11202007518RA
(en)
|
2018-02-28 |
2020-09-29 |
Pfizer |
Il-15 variants and uses thereof
|
WO2019173771A1
(en)
|
2018-03-09 |
2019-09-12 |
Cytomx Therapeutics, Inc. |
Activatable cd147 antibodies and methods of making and use thereof
|
CA3093330A1
(en)
|
2018-03-14 |
2019-09-19 |
Novimmune Sa |
Anti-cd3 epsilon antibodies and methods of use thereof
|
AU2019235842B2
(en)
|
2018-03-14 |
2022-02-03 |
Surface Oncology, Inc. |
Antibodies that bind CD39 and uses thereof
|
US10710994B2
(en)
|
2018-03-19 |
2020-07-14 |
Genentech, Inc. |
Oxadiazole transient receptor potential channel inhibitors
|
MA52094A
(fr)
|
2018-03-22 |
2021-01-27 |
Adimab Llc |
Anticorps anti-il-27 et leurs utilisations
|
RU2020131433A
(ru)
|
2018-03-29 |
2022-05-04 |
Хельсингин Илиописто |
C-концевые фрагменты cdnf, фармацевтические композиции, содержащие указанные фрагменты, и применения указанных фрагментов и композиций
|
CN112166120A
(zh)
|
2018-03-30 |
2021-01-01 |
安姆根有限公司 |
C末端抗体变体
|
US10947251B2
(en)
|
2018-03-30 |
2021-03-16 |
Genentech, Inc. |
Therapeutic compounds and methods of use thereof
|
JP7346790B2
(ja)
|
2018-03-30 |
2023-09-20 |
ナンジン レジェンド バイオテック カンパニー,リミテッド |
Lag‐3に対する単一ドメイン抗体およびその使用
|
WO2019195623A2
(en)
|
2018-04-04 |
2019-10-10 |
Xencor, Inc. |
Heterodimeric antibodies that bind fibroblast activation protein
|
WO2019193161A1
(en)
|
2018-04-06 |
2019-10-10 |
Universität Wien |
Bumetanide derivatives for the therapy of stroke and other neurological diseases/disorders involving nkccs
|
CN112334485A
(zh)
|
2018-04-06 |
2021-02-05 |
百进生物科技公司 |
抗-四次穿膜蛋白33药剂及其组合物以及制备和使用方法
|
AU2019247641A1
(en)
|
2018-04-06 |
2020-11-12 |
Zilentin AG |
Bumetanide derivatives for the therapy of hyperhidrosis
|
AU2019253462A1
(en)
|
2018-04-09 |
2020-11-26 |
Amgen Inc. |
Growth differentiation factor 15 fusion proteins
|
MX2020010638A
(es)
|
2018-04-11 |
2021-01-08 |
Inhibrx Inc |
Constructos de polipeptidos multiespecificos que tienen union a cd3 restringida y metodos y usos relacionados.
|
WO2019200357A1
(en)
|
2018-04-12 |
2019-10-17 |
Surface Oncology, Inc. |
Biomarker for cd47 targeting therapeutics and uses therefor
|
US20210115156A1
(en)
|
2018-04-13 |
2021-04-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Fc-engineered anti-human ige antibodies and methods of use
|
AU2019256529A1
(en)
|
2018-04-18 |
2020-11-26 |
Xencor, Inc. |
TIM-3 targeted heterodimeric fusion proteins containing IL-15/IL-15Ra Fc-fusion proteins and TIM-3 antigen binding domains
|
WO2019201882A1
(en)
|
2018-04-18 |
2019-10-24 |
F. Hoffmann-La Roche Ag |
Combination therapy with a bet inhibitor and a proteasome inhibitor
|
CN112867734A
(zh)
|
2018-04-18 |
2021-05-28 |
Xencor股份有限公司 |
包含IL-15/IL-15Ra Fc融合蛋白和PD-1抗原结合结构域的靶向PD-1的异源二聚体融合蛋白及其用途
|
AU2019255370B2
(en)
|
2018-04-19 |
2023-11-02 |
Checkmate Pharmaceuticals, Inc. |
Synthetic RIG-I-like receptor agonists
|
WO2019204537A1
(en)
|
2018-04-20 |
2019-10-24 |
Genentech, Inc. |
N-[4-oxo-2,3-dihydro-1,5-benzoxazepin-3-yl]-5,6-dihydro-4h-pyrrolo[1,2-b]pyrazol e-2-carboxamide derivatives and related compounds as rip1 kinase inhibitors for treating e.g. irritable bowel syndrome (ibs)
|
WO2019207051A1
(en)
|
2018-04-25 |
2019-10-31 |
Università Degli Studi Di Torino |
Medical use of combinations of non-natural semaphorins 3 and antimetabolites
|
WO2019213444A1
(en)
|
2018-05-02 |
2019-11-07 |
Cytomx Therapeutics, Inc. |
Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof
|
WO2019213416A1
(en)
|
2018-05-02 |
2019-11-07 |
The Usa, As Represented By The Secretary, Dept. Of Health And Human Services |
Antibodies and methods for the diagnosis, prevention, and treatment of epstein barr virus infection
|
US11155638B2
(en)
|
2018-05-08 |
2021-10-26 |
Rhode Island Hospital |
Anti-CHI3L1 antibodies for the detection and/or treatment of nonalcoholic fattly liver disease/nonalcoholic steatonhepatitis and subsequent complications
|
US20190345245A1
(en)
|
2018-05-11 |
2019-11-14 |
Janssen Biotech, Inc. |
Methods of Treating Crohn's Disease with Anti-IL23 Specific Antibody
|
WO2019226617A1
(en)
|
2018-05-21 |
2019-11-28 |
Compass Therapeutics Llc |
Compositions and methods for enhancing the killing of target cells by nk cells
|
WO2019226658A1
(en)
|
2018-05-21 |
2019-11-28 |
Compass Therapeutics Llc |
Multispecific antigen-binding compositions and methods of use
|
TW202003490A
(zh)
|
2018-05-22 |
2020-01-16 |
瑞士商赫孚孟拉羅股份公司 |
治療性化合物及其使用方法
|
EP3796983A2
(en)
|
2018-05-23 |
2021-03-31 |
Pfizer Inc. |
Antibodies specific for gucy2c and uses thereof
|
EP3797121B1
(en)
|
2018-05-23 |
2024-06-19 |
Pfizer Inc. |
Antibodies specific for cd3 and uses thereof
|
WO2019225787A1
(ko)
|
2018-05-24 |
2019-11-28 |
에이비엘바이오 주식회사 |
항-b7-h3 항체 및 그 용도
|
CN110540590B
(zh)
|
2018-05-29 |
2023-08-18 |
康诺亚生物医药科技(成都)有限公司 |
一种自免疫抑制物的开发和应用
|
US20210196823A1
(en)
|
2018-06-08 |
2021-07-01 |
Pfizer Inc. |
Methods of Treating Metabolic Disease
|
CN110577597B
(zh)
|
2018-06-11 |
2021-10-22 |
康诺亚生物医药科技(成都)有限公司 |
一种阻断CD47和SIRPα相互作用的抗体
|
US10934279B2
(en)
|
2018-06-13 |
2021-03-02 |
Pfizer Inc. |
GLP-1 receptor agonists and uses thereof
|
AU2019285570B2
(en)
|
2018-06-15 |
2022-03-24 |
Pfizer Inc. |
GLP-1 receptor agonists and uses thereof
|
CA3103936A1
(en)
|
2018-06-18 |
2019-12-26 |
Eureka Therapeutics, Inc. |
Constructs targeting prostate-specific membrane antigen (psma) and uses thereof
|
US20210363233A1
(en)
|
2018-06-20 |
2021-11-25 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with an il-12/il-23 inhibitor
|
EP3810094A1
(en)
|
2018-06-20 |
2021-04-28 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with a jak or other kinase inhibitor
|
US20230041197A1
(en)
|
2018-06-20 |
2023-02-09 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with an immunomodulator
|
US20230009902A1
(en)
|
2018-06-20 |
2023-01-12 |
Progenity, Inc. |
Treatment of a disease or condition in a tissue orginating from the endoderm
|
US20230033021A1
(en)
|
2018-06-20 |
2023-02-02 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with an integrin inhibitor
|
US20230312700A1
(en)
|
2018-06-20 |
2023-10-05 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with a tnf inhibitor
|
WO2020005842A1
(en)
|
2018-06-25 |
2020-01-02 |
Dauntless 2, Inc. |
Membrane emulsification device with impeller for microsphere creation
|
US11203645B2
(en)
|
2018-06-27 |
2021-12-21 |
Obi Pharma, Inc. |
Glycosynthase variants for glycoprotein engineering and methods of use
|
CR20210047A
(es)
|
2018-07-02 |
2021-05-21 |
Amgen Inc |
Proteína de unión al antígeno anti-steap1
|
TWI709562B
(zh)
|
2018-07-06 |
2020-11-11 |
美商輝瑞股份有限公司 |
吡咯并〔2,3-d〕嘧啶化合物的製造方法與中間產物及其用途
|
WO2020011938A1
(en)
|
2018-07-11 |
2020-01-16 |
Medizinische Universität Wien |
Glucocorticoids for the topical treatment of autoimmune gastritis
|
EP3820508A1
(en)
|
2018-07-11 |
2021-05-19 |
Scholar Rock, Inc. |
High-affinity, isoform-selective tgf?1 inhibitors and use thereof
|
HRP20212034T1
(hr)
|
2018-07-11 |
2022-04-01 |
Scholar Rock, Inc. |
Izoformno selektivni inhibitori tgfbeta1 i njihove uporabe
|
TW202019957A
(zh)
|
2018-07-11 |
2020-06-01 |
美商供石公司 |
TGFβ1抑制劑及其用途
|
WO2020018715A1
(en)
|
2018-07-17 |
2020-01-23 |
Massachusetts Institute Of Technology |
Soluble multimeric immunoglobulin-scaffold based fusion proteins and uses thereof
|
AU2019306165A1
(en)
|
2018-07-20 |
2021-02-25 |
Pierre Fabre Medicament |
Receptor for vista
|
JP7386841B2
(ja)
|
2018-07-24 |
2023-11-27 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
イソキノリン化合物及びその使用
|
TW202012405A
(zh)
|
2018-07-24 |
2020-04-01 |
瑞士商赫孚孟拉羅股份公司 |
萘啶化合物及其用途
|
CN112789294A
(zh)
|
2018-07-24 |
2021-05-11 |
印希比股份有限公司 |
含有受限cd3结合结构域和受体结合区的多特异性多肽构建体及其使用方法
|
WO2020033925A2
(en)
|
2018-08-09 |
2020-02-13 |
Compass Therapeutics Llc |
Antibodies that bind cd277 and uses thereof
|
WO2020033923A1
(en)
|
2018-08-09 |
2020-02-13 |
Compass Therapeutics Llc |
Antigen binding agents that bind cd277 and uses thereof
|
US20210309746A1
(en)
|
2018-08-09 |
2021-10-07 |
Compass Therapeutics Llc |
Antibodies that bind cd277 and uses thereof
|
AU2019320072A1
(en)
|
2018-08-10 |
2021-02-25 |
Vertex Pharmaceuticals Incorporated |
Stem cell derived islet differentiation
|
CA3109090A1
(en)
|
2018-08-17 |
2020-02-20 |
F. Hoffmann-La Roche Ag |
Diagnostic and therapeutic methods for the treatment of breast cancer
|
US20210317213A1
(en)
|
2018-08-28 |
2021-10-14 |
Ambrx, Inc. |
Anti-CD3 Antibody Folate Bioconjugates and Their Uses
|
UY38349A
(es)
|
2018-08-30 |
2020-03-31 |
Array Biopharma Inc |
Compuestos de pirazolo[3,4-b]piridina como inhibidores de cinasas tam y met
|
CN112805267B
(zh)
|
2018-09-03 |
2024-03-08 |
豪夫迈·罗氏有限公司 |
用作tead调节剂的甲酰胺和磺酰胺衍生物
|
US20210322568A1
(en)
|
2018-09-04 |
2021-10-21 |
Ecole Polytechnique Federale De Lausanne (Epfl) |
Virucidal Nanoparticles And Use Thereof Against Influenza Virus
|
CN116948006A
(zh)
|
2018-09-11 |
2023-10-27 |
北京泰德制药股份有限公司 |
白介素-2多肽偶联物及其用途
|
WO2020053808A1
(en)
|
2018-09-12 |
2020-03-19 |
Georg Dewald |
Method of diagnosing vasoregulatory disorders
|
JP7098826B2
(ja)
|
2018-09-12 |
2022-07-11 |
ジェネンテック, インコーポレイテッド |
ピリミジニル-ヘテロアリールオキシ-ナフチル化合物および使用方法
|
TWI831829B
(zh)
|
2018-09-12 |
2024-02-11 |
美商建南德克公司 |
苯氧基-吡啶基-嘧啶化合物及使用方法
|
EP3852752A1
(en)
|
2018-09-19 |
2021-07-28 |
F. Hoffmann-La Roche AG |
Spirocyclic 2,3-dihydro-7-azaindole compounds and uses thereof
|
MX2021003214A
(es)
|
2018-09-19 |
2021-05-12 |
Genentech Inc |
Metodos terapeuticos y de diagnostico para el cancer de vejiga.
|
US20210353715A1
(en)
|
2018-09-20 |
2021-11-18 |
Mandalmed, Inc. |
Methods and compositions for preventing, treating, and reversing liver fibrosis
|
CN113365697A
(zh)
|
2018-09-25 |
2021-09-07 |
百进生物科技公司 |
抗tlr9药剂和组合物及其制备方法和使用方法
|
JP2022503961A
(ja)
|
2018-09-28 |
2022-01-12 |
リビジェン バイオファーマ カンパニー リミテッド |
操作されたFcドメインを有する抗CD40結合分子およびその治療用途
|
SG11202100935TA
(en)
|
2018-09-28 |
2021-02-25 |
Massachusetts Inst Technology |
Collagen-localized immunomodulatory molecules and methods thereof
|
CN113454070A
(zh)
|
2018-09-30 |
2021-09-28 |
豪夫迈·罗氏有限公司 |
噌啉化合物及用于hpk1依赖性疾患诸如癌症的治疗
|
TW202024053A
(zh)
|
2018-10-02 |
2020-07-01 |
美商建南德克公司 |
異喹啉化合物及其用途
|
TW202023558A
(zh)
|
2018-10-03 |
2020-07-01 |
美商建南德克公司 |
8-胺基異喹啉化合物及其用途
|
JP2022503959A
(ja)
|
2018-10-03 |
2022-01-12 |
ゼンコア インコーポレイテッド |
Il-12ヘテロ二量体fc-融合タンパク質
|
WO2020070333A1
(en)
|
2018-10-05 |
2020-04-09 |
Fondazione Telethon |
Ezrin inhibitors and uses thereof
|
KR20210074341A
(ko)
|
2018-10-10 |
2021-06-21 |
베링거 인겔하임 인터내셔날 게엠베하 |
고밀도 생물 반응기 배양에서 막 기체 전달을 위한 방법
|
CA3114802A1
(en)
|
2018-10-11 |
2020-04-16 |
Amgen Inc. |
Downstream processing of bispecific antibody constructs
|
US11427591B2
(en)
|
2018-10-17 |
2022-08-30 |
Insilico Medicine Ip Limited |
Kinase inhibitors
|
KR20210079311A
(ko)
|
2018-10-18 |
2021-06-29 |
제넨테크, 인크. |
육종성 신장암에 대한 진단과 치료 방법
|
AU2019361206A1
(en)
|
2018-10-19 |
2021-06-03 |
Ambrx, Inc. |
Interleukin-10 polypeptide conjugates, dimers thereof, and their uses
|
WO2020086736A1
(en)
|
2018-10-23 |
2020-04-30 |
Scholar Rock, Inc. |
Rgmc-selective inhibitors and use thereof
|
KR20210098989A
(ko)
|
2018-11-02 |
2021-08-11 |
싸이톰스 테라퓨틱스, 인크. |
활성화 가능한 항-cd166 항체 및 이의 사용 방법
|
MX2021004819A
(es)
|
2018-11-02 |
2021-06-08 |
Annexon Inc |
Composiciones y metodos para tratar lesiones cerebrales.
|
MX2021005594A
(es)
|
2018-11-13 |
2021-10-22 |
Compass Therapeutics Llc |
Constructos multiespecificos de union contra moleculas de puntos de control y usos de los mismos.
|
BR112021009373A2
(pt)
|
2018-11-16 |
2021-08-17 |
Memorial Sloan Kettering Cancer Center |
anticorpos para mucina-16 e métodos de uso dos mesmos
|
WO2020103815A1
(en)
|
2018-11-22 |
2020-05-28 |
Qilu Regor Therapeutics Inc. |
Glp-1r agonists and uses thereof
|
US20200377602A1
(en)
|
2018-12-06 |
2020-12-03 |
Cytomx Therapeutics, Inc. |
Matrix metalloprotease-cleavable and serine or cysteine protease-cleavable substrates and methods of use thereof
|
AU2019398214C1
(en)
|
2018-12-11 |
2024-03-28 |
Q32 Bio Inc. |
Fusion protein constructs for complement associated disease
|
WO2020127200A1
(en)
|
2018-12-17 |
2020-06-25 |
Tolremo Therapeutics Ag |
Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment, amelioration or prevention of cancer
|
WO2020132230A2
(en)
|
2018-12-20 |
2020-06-25 |
Genentech, Inc. |
Modified antibody fcs and methods of use
|
CA3124103A1
(en)
|
2018-12-20 |
2020-06-25 |
Poseida Therapeutics, Inc. |
Nanotransposon compositions and methods of use
|
US11352445B2
(en)
|
2018-12-31 |
2022-06-07 |
Jecho Laboratories Inc. |
Method for preparing recombinant protein from bacterium and composition containing the same
|
TWI748317B
(zh)
|
2019-01-03 |
2021-12-01 |
美商建南德克公司 |
吡啶并-嘧啶酮與喋啶酮化合物及使用方法
|
BR112021013096A2
(pt)
|
2019-01-04 |
2022-04-19 |
Resolve Therapeutics, Llc |
Tratamento de doença de sjögren com proteínas de fusão de nuclease
|
CN113614102A
(zh)
|
2019-01-07 |
2021-11-05 |
鸿绪生物医药科技(北京)有限公司 |
新型多肽及其治疗用途
|
CN111499747B
(zh)
|
2019-01-11 |
2022-03-18 |
康诺亚生物医药科技(成都)有限公司 |
一种抗cd73单克隆抗体及其应用
|
WO2020146615A1
(en)
|
2019-01-11 |
2020-07-16 |
Genentech, Inc. |
Bicyclic pyrrolotriazolr ketone compounds and methods of use thereof
|
JP2022518208A
(ja)
|
2019-01-15 |
2022-03-14 |
ヤンセン バイオテツク,インコーポレーテツド |
若年性特発性関節炎の治療のための抗tnf抗体、組成物、及び方法
|
US11680105B2
(en)
|
2019-01-17 |
2023-06-20 |
Regents Of The University Of Minnesota |
Antibody fragments for detecting cancer and methods of use
|
WO2020154374A1
(en)
|
2019-01-22 |
2020-07-30 |
Massachusetts Institute Of Technology |
In vitro human blood brain barrier
|
WO2020154032A1
(en)
|
2019-01-23 |
2020-07-30 |
Massachusetts Institute Of Technology |
Combination immunotherapy dosing regimen for immune checkpoint blockade
|
CA3127748A1
(en)
|
2019-01-23 |
2020-07-30 |
Janssen Biotech, Inc. |
Anti-tnf antibody compositions for use in methods for the treatment of psoriatic arthritis
|
JP2020117502A
(ja)
|
2019-01-28 |
2020-08-06 |
ファイザー・インク |
変形性関節症の徴候および症状を処置する方法
|
US11236157B2
(en)
|
2019-01-28 |
2022-02-01 |
Galderma Holding SA |
Treatment of skin lesions and pruritus in prurigo nodularis patients
|
PE20220279A1
(es)
|
2019-01-30 |
2022-02-25 |
Scholar Rock Inc |
Inhibidores especificos del complejo de ltbp de tgf beta y usos de los mismos
|
GB201901305D0
(en)
|
2019-01-30 |
2019-03-20 |
Immunocore Ltd |
Specific binding molecules
|
KR20210136014A
(ko)
|
2019-02-12 |
2021-11-16 |
암브룩스, 인코포레이티드 |
항체-tlr 작용제 콘쥬게이트를 함유하는 조성물, 방법 및 이의 용도
|
WO2020165788A1
(en)
|
2019-02-15 |
2020-08-20 |
Pfizer Inc. |
Crystalline pyrimidinyl-3,8-diazabicyclo[3.2.1]octanylmethanone compound and use thereof
|
EP3927433A1
(en)
|
2019-02-18 |
2021-12-29 |
Genentech, Inc. |
Pyrido-pyrimidinyl compounds and methods of use
|
US20220135663A1
(en)
|
2019-02-18 |
2022-05-05 |
Pfizer Inc. |
Method of treatment of Chronic Low Back Pain
|
CN113874394B
(zh)
|
2019-02-20 |
2024-01-19 |
和铂抗体有限公司 |
抗体
|
US11739078B2
(en)
|
2019-02-22 |
2023-08-29 |
Insilico Medicine Ip Limited |
Methods of inhibiting kinases
|
CN113677372A
(zh)
|
2019-02-26 |
2021-11-19 |
西托姆克斯治疗公司 |
可活化免疫检查点抑制剂和经缀合可活化抗体的组合疗法
|
CA3132185A1
(en)
|
2019-03-01 |
2020-09-10 |
Xencor, Inc. |
Heterodimeric antibodies that bind enpp3 and cd3
|
CN113966221A
(zh)
|
2019-03-08 |
2022-01-21 |
麻省理工学院 |
合成溶瘤lnp复制子rna和用于癌症免疫治疗的用途
|
KR20210141998A
(ko)
|
2019-03-14 |
2021-11-23 |
얀센 바이오테크 인코포레이티드 |
항-tnf 항체 조성물의 제조 방법
|
MA55283A
(fr)
|
2019-03-14 |
2022-01-19 |
Janssen Biotech Inc |
Procédés de production de compositions d'anticorps anti-tnf
|
EP3938390A1
(en)
|
2019-03-14 |
2022-01-19 |
Janssen Biotech, Inc. |
Manufacturing methods for producing anti-tnf antibody compositions
|
JP2022525781A
(ja)
|
2019-03-20 |
2022-05-19 |
マサチューセッツ インスティテュート オブ テクノロジー |
免疫細胞療法における両親媒性物質の使用およびそのための組成物
|
WO2020197400A1
(en)
|
2019-03-27 |
2020-10-01 |
Umc Utrecht Holding B.V. |
Engineered iga antibodies and methods of use
|
CA3133610A1
(en)
|
2019-03-29 |
2020-10-08 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-il-6 receptor antibody-containing inhibitor for inhibiting deterioration of bbb function
|
EP3946457A1
(en)
|
2019-04-01 |
2022-02-09 |
Genentech, Inc. |
Compositions and methods for stabilizing protein-containing formulations
|
CA3135555C
(en)
|
2019-04-02 |
2023-09-19 |
Array Biopharma Inc. |
Protein tyrosine phosphatase inhibitors
|
WO2020213665A1
(ja)
|
2019-04-17 |
2020-10-22 |
国立大学法人広島大学 |
Il-6阻害剤及びccr2阻害剤を組み合わせて投与することを特徴とする泌尿器がんの治療剤
|
US20220218799A1
(en)
|
2019-05-10 |
2022-07-14 |
Talengen International Limited |
Method and medicine for treating amyotrophic lateral sclerosis
|
WO2020236985A1
(en)
|
2019-05-21 |
2020-11-26 |
President And Fellows Of Harvard College |
Endocrine differentiation-inducing molecule
|
WO2020234445A1
(en)
|
2019-05-23 |
2020-11-26 |
F. Hoffmann-La Roche Ag |
Combination therapy with a bet inhibitor and a bcl-2 inhibitor
|
CA3138241A1
(en)
|
2019-05-23 |
2020-11-26 |
Janssen Biotech, Inc. |
Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha
|
JP2022534212A
(ja)
|
2019-05-31 |
2022-07-28 |
エーエルエックス オンコロジー インコーポレイテッド |
免疫チェックポイント阻害剤と組み合わせてsirpアルファfc融合によりがんを治療する方法
|
CN113924119A
(zh)
|
2019-05-31 |
2022-01-11 |
国立大学法人大阪大学 |
新型的消化器官癌治疗剂及其筛选方法
|
JP2022536279A
(ja)
|
2019-06-03 |
2022-08-15 |
ヤンセン バイオテツク,インコーポレーテツド |
乾癬性関節炎を治療するための抗tnf抗体組成物及び方法
|
WO2020245677A1
(en)
|
2019-06-03 |
2020-12-10 |
Janssen Biotech, Inc. |
Anti-tnf antibodies, compositions, and methods for the treatment of active ankylosing spondylitis
|
JP2022536655A
(ja)
|
2019-06-11 |
2022-08-18 |
ジェネンテック, インコーポレイテッド |
キナゾリニル化合物及び使用方法
|
EP3983520A1
(en)
|
2019-06-13 |
2022-04-20 |
Amgen, Inc |
Automated biomass-based perfusion control in the manufacturing of biologics
|
WO2020257525A1
(en)
|
2019-06-20 |
2020-12-24 |
Cspc Dophen Corporation |
Modified il-2 proteins, peg conjugates, and uses thereof
|
US11642409B2
(en)
|
2019-06-26 |
2023-05-09 |
Massachusetts Insttute of Technology |
Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof
|
TW202115086A
(zh)
|
2019-06-28 |
2021-04-16 |
美商輝瑞大藥廠 |
Bckdk抑制劑
|
US20220363770A1
(en)
|
2019-06-28 |
2022-11-17 |
Amgen Inc. |
Anti-cgrp receptor/anti-pac1 receptor bispecific antigen binding proteins
|
EP3990452A1
(en)
|
2019-06-28 |
2022-05-04 |
Pfizer Inc. |
5-(thiophen-2-yl)-1h-tetrazole derivatives as bckdk inhibitors useful for treating various diseases
|
US20220324924A1
(en)
|
2019-07-08 |
2022-10-13 |
Amgen Inc. |
Multispecific transthyretin immunoglobulin fusions
|
WO2021016128A1
(en)
|
2019-07-19 |
2021-01-28 |
Oncoresponse, Inc. |
Immunomodulatory antibodies and methods of use thereof
|
WO2021021676A1
(en)
|
2019-07-26 |
2021-02-04 |
Amgen Inc. |
Anti-il13 antigen binding proteins
|
CN112300279A
(zh)
|
2019-07-26 |
2021-02-02 |
上海复宏汉霖生物技术股份有限公司 |
针对抗cd73抗体和变体的方法和组合物
|
GB201910900D0
(en)
|
2019-07-31 |
2019-09-11 |
Scancell Ltd |
Modified fc-regions to enhance functional affinity of antibodies and antigen binding fragments thereof
|
GB201910899D0
(en)
|
2019-07-31 |
2019-09-11 |
Scancell Ltd |
Binding members
|
CA3149494A1
(en)
|
2019-08-12 |
2021-02-18 |
Purinomia Biotech, Inc. |
Methods and compositions for promoting and potentiating t-cell mediated immune responses through adcc targeting of cd39 expressing cells
|
PE20220706A1
(es)
|
2019-08-13 |
2022-05-04 |
Amgen Inc |
Muteinas de interleucina-2 para la expansion de celulas t reguladoras
|
WO2021028752A1
(en)
|
2019-08-15 |
2021-02-18 |
Janssen Biotech, Inc. |
Anti-tfn antibodies for treating type i diabetes
|
CN114980901A
(zh)
|
2019-08-30 |
2022-08-30 |
挪威西部创新股份有限公司 |
使用针对浆细胞的抑制剂或细胞毒性剂治疗慢性疲劳综合征的方法
|
GB201912657D0
(en)
|
2019-09-03 |
2019-10-16 |
Scancell Ltd |
Binding members
|
JP2022547866A
(ja)
|
2019-09-05 |
2022-11-16 |
ポセイダ セラピューティクス,インコーポレイティド |
同種異系細胞組成物と使用方法
|
GB201912882D0
(en)
|
2019-09-06 |
2019-10-23 |
Scancell Ltd |
Ssea-4 binding members
|
US11655303B2
(en)
|
2019-09-16 |
2023-05-23 |
Surface Oncology, Inc. |
Anti-CD39 antibody compositions and methods
|
CR20220149A
(es)
|
2019-09-20 |
2022-05-23 |
Genentech Inc |
Dosis para anticuerpos anti-triptasa
|
JP2022548310A
(ja)
|
2019-09-23 |
2022-11-17 |
シートムエックス セラピューティクス,インコーポレイテッド |
抗cd47抗体、活性化可能抗cd47抗体、およびその使用方法
|
WO2021062244A1
(en)
|
2019-09-25 |
2021-04-01 |
Surface Oncology, Inc. |
Anti-il-27 antibodies and uses thereof
|
WO2021062096A1
(en)
|
2019-09-26 |
2021-04-01 |
Massachusetts Institute Of Technology |
Microrna-based logic gates and uses thereof
|
US11834659B2
(en)
|
2019-09-26 |
2023-12-05 |
Massachusetts Institute Of Technology |
Trans-activated functional RNA by strand displacement and uses thereof
|
WO2021064141A1
(en)
|
2019-10-02 |
2021-04-08 |
Tolremo Therapeutics Ag |
Inhibitors of dual specificity tyrosine phosphorylation regulated kinase 1b
|
JP7395723B2
(ja)
|
2019-10-02 |
2023-12-11 |
トルレモ・セラピューティクス・アクチェンゲゼルシャフト |
複素環式誘導体、医薬組成物および癌の処置または寛解におけるそれらの使用
|
TWI771766B
(zh)
|
2019-10-04 |
2022-07-21 |
美商輝瑞股份有限公司 |
二醯基甘油醯基轉移酶2 抑制劑
|
US20240050529A1
(en)
|
2019-10-07 |
2024-02-15 |
University Of Virginia Patent Foundation |
Modulating lymphatic vessels in neurological disease
|
CA3157509A1
(en)
|
2019-10-10 |
2021-04-15 |
Kodiak Sciences Inc. |
Methods of treating an eye disorder
|
WO2021072244A1
(en)
|
2019-10-11 |
2021-04-15 |
Beth Israel Deaconess Medical Center, Inc. |
Anti-tn antibodies and uses thereof
|
TWI745114B
(zh)
|
2019-10-11 |
2021-11-01 |
日商中外製藥股份有限公司 |
用於後天性血友病a之預防及/或治療之醫藥組成物、及包含該醫藥組成物之製品
|
WO2021074418A1
(en)
|
2019-10-16 |
2021-04-22 |
Cemm - Forschungszentrum Für Molekulare Medizin Gmbh |
Carbazole-type cullin ring ubiquitin ligase compounds and uses thereof
|
EP4045142A1
(en)
|
2019-10-16 |
2022-08-24 |
CeMM - Forschungszentrum für Molekulare Medizin GmbH |
Oxazole and thioazole-type cullin ring ubiquitin ligase compounds and uses thereof
|
CA3155202A1
(en)
|
2019-10-23 |
2021-04-29 |
Arthur M. Krieg |
Synthetic rig-i-like receptor agonists
|
US20220380487A1
(en)
|
2019-10-24 |
2022-12-01 |
Minotaur Therapeutics, Inc. |
Chimeric cytokine modified antibodies and methods of use thereof
|
WO2021080682A1
(en)
|
2019-10-24 |
2021-04-29 |
Massachusetts Institute Of Technology |
Monoclonal antibodies that bind human cd161 and uses thereof
|
CR20220207A
(es)
|
2019-11-13 |
2022-06-06 |
Genentech Inc |
Compuestos terapéuticos y métodos de uso
|
EP4058485A1
(en)
|
2019-11-13 |
2022-09-21 |
Amgen Inc. |
Method for reduced aggregate formation in downstream processing of bispecific antigen-binding molecules
|
WO2021099518A1
(en)
|
2019-11-19 |
2021-05-27 |
Modag Gmbh |
Novel compounds for the diagnosis, treatment and prevention of diseases associated with the aggregation of alpha-synuclein
|
EP3831843A1
(en)
|
2019-12-08 |
2021-06-09 |
Royal College Of Surgeons In Ireland |
A hemostatic agent and uses thereof
|
US20230045419A1
(en)
|
2019-12-10 |
2023-02-09 |
Pfizer Inc. |
Solid Forms of 2-((4-((S)-2-(5-Chloropyridin-2-yl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((S)-oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid, 1,3-Dihydroxy-2-(hydroxymethyl)propan-2-amine Salt
|
US20230040604A1
(en)
|
2019-12-17 |
2023-02-09 |
Amgen Inc. |
Interleukin-2 in combination with tnf receptor family members for the expansion of t-regulatory cells
|
EP3838912A1
(en)
|
2019-12-20 |
2021-06-23 |
Herantis Pharma Oyj |
Retro-inverso peptides
|
JP2023510121A
(ja)
|
2019-12-20 |
2023-03-13 |
ポセイダ セラピューティクス,インコーポレイティド |
抗Muc1組成物及び使用方法
|
EP3838345A1
(en)
|
2019-12-20 |
2021-06-23 |
Herantis Pharma Oyj |
Macrocyclic peptides
|
MX2022008341A
(es)
|
2020-01-06 |
2022-08-10 |
Vaccinex Inc |
Anticuerpos anti-ccr8 y usos de estos.
|
IL294650A
(en)
|
2020-01-11 |
2022-09-01 |
Scholar Rock Inc |
Inhibitors of tgf in the cell and their use
|
US20230050148A1
(en)
|
2020-01-11 |
2023-02-16 |
Scholar Rock, Inc. |
Tgf-beta inhibitors and use thereof
|
EP4090681A1
(en)
|
2020-01-17 |
2022-11-23 |
Biolegend, Inc. |
Anti-tlr7 agents and compositions and methods for making and using the same
|
US20230066726A1
(en)
|
2020-01-17 |
2023-03-02 |
Talengen International Limited |
Method for treatment of nerve injury and related disease
|
EP4093426A1
(en)
|
2020-01-24 |
2022-11-30 |
University of Virginia Patent Foundation |
Modulating lymphatic vessels in neurological disease
|
CN115427066A
(zh)
|
2020-02-06 |
2022-12-02 |
泰伦基国际有限公司 |
一种预防和治疗多发性硬化症的方法和药物
|
CA3167593A1
(en)
|
2020-02-11 |
2021-08-19 |
Jinan Li |
Method and drug for treating viral pneumonia
|
JP2022058085A
(ja)
|
2020-02-24 |
2022-04-11 |
ファイザー・インク |
ジアシルグリセロールアシルトランスフェラーゼ2阻害剤とアセチル-CoAカルボキシラーゼ阻害剤との組合せ
|
KR20220143913A
(ko)
|
2020-02-26 |
2022-10-25 |
탈렌젠 인터내셔널 리미티드 |
혈압 이상 병증의 예방 및 치료 방법과 약물
|
WO2021173889A1
(en)
|
2020-02-26 |
2021-09-02 |
Ambrx, Inc. |
Uses of anti-cd3 antibody folate bioconjugates
|
AU2021230361A1
(en)
|
2020-03-04 |
2022-09-08 |
Poseida Therapeutics, Inc. |
Compositions and methods for the treatment of Metabolic Liver Disorders
|
WO2021181233A2
(en)
|
2020-03-09 |
2021-09-16 |
Pfizer Inc. |
Fusion proteins and uses thereof
|
CA3169827A1
(en)
|
2020-03-10 |
2021-09-16 |
Kunwar Shailubhai |
Compositions of il-6/il-6r antibodies and methods of use thereof
|
WO2021183795A1
(en)
|
2020-03-11 |
2021-09-16 |
Poseida Therapeutics, Inc. |
Chimeric stimulatory receptors and methods of use in t cell activation and differentiation
|
AU2021233909A1
(en)
|
2020-03-11 |
2022-09-29 |
Ambrx, Inc. |
Interleukin-2 polypeptide conjugates and methods of use thereof
|
GB202003632D0
(en)
|
2020-03-12 |
2020-04-29 |
Harbour Antibodies Bv |
SARS-Cov-2 (SARS2, COVID-19) antibodies
|
CA3175275A1
(en)
|
2020-03-19 |
2021-09-23 |
Amgen Inc. |
Antibodies against mucin 17 and uses thereof
|
CN115867577A
(zh)
|
2020-03-23 |
2023-03-28 |
基因泰克公司 |
用于预测covid-19肺炎中对il-6拮抗剂反应的生物标志物
|
WO2021194865A1
(en)
|
2020-03-23 |
2021-09-30 |
Genentech, Inc. |
Method for treating pneumonia, including covid-19 pneumonia, with an il6 antagonist
|
EP4107186A1
(en)
|
2020-03-23 |
2022-12-28 |
Genentech, Inc. |
Tocilizumab and remdesivir combination therapy for covid-19 pneumonia
|
TW202144000A
(zh)
|
2020-03-24 |
2021-12-01 |
大陸商深圳瑞健生命科學研究院有限公司 |
一種治療帕金森氏症的方法和藥物
|
US20230141921A1
(en)
|
2020-03-24 |
2023-05-11 |
Talengen International Limited |
Method and medicine for treating huntington's disease
|
EP4122488A4
(en)
|
2020-03-24 |
2023-04-05 |
Talengen International Limited |
METHODS AND MEDICATIONS FOR TREATMENT OF ALZHEIMER'S DISEASE
|
KR20220156934A
(ko)
|
2020-03-24 |
2022-11-28 |
탈렌젠 인터내셔널 리미티드 |
잘못 접힌 단백질 및 이의 응집체 분해의 촉진 방법 및 약물
|
BR112022017578A2
(pt)
|
2020-03-27 |
2022-10-18 |
Pfizer |
Tratamento do diabetes tipo 2 ou obesidade ou sobrepeso com ácido 2-[(4-{6-[(4-ciano-2-fluorobenzil)óxi]piridin-2-il}piperidin-1-il)metil]-1-[(2s)-oxetan-2-ilmetil]-1h-benzimidazol-6-carboxílico ou um sal farmacêutico do mesmo
|
KR20220159997A
(ko)
|
2020-03-30 |
2022-12-05 |
에꼴 뽈리떼끄닉 뻬데랄 드 로잔느 (으뻬에프엘) |
살바이러스 조성물 및 이의 용도
|
CN115698717A
(zh)
|
2020-04-03 |
2023-02-03 |
基因泰克公司 |
癌症的治疗和诊断方法
|
US20230159539A1
(en)
|
2020-04-08 |
2023-05-25 |
Pfizer Inc. |
Crystalline forms of 3-cyano-1-[4-[6-(1-methyl-1h-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]-1h-pyrazol-1-yl]cyclobutaneacetonitrile, and use thereof
|
WO2021207662A1
(en)
|
2020-04-10 |
2021-10-14 |
Genentech, Inc. |
Use of il-22fc for the treatment or prevention of pneumonia, acute respiratory distress syndrome, or cytokine release syndrome
|
AU2021255869A1
(en)
|
2020-04-14 |
2022-10-27 |
Poseida Therapeutics, Inc. |
Compositions and methods for use in the treatment of cancer
|
JP2023106635A
(ja)
|
2020-04-17 |
2023-08-02 |
中外製薬株式会社 |
二重特異性抗原結合分子ならびに、それに関連する組成物、組成物の製造のための使用、キット、および方法
|
WO2021216572A1
(en)
|
2020-04-20 |
2021-10-28 |
Massachusetts Institute Of Technology |
Lipid compositions for delivery of sting agonist compounds and uses thereof
|
WO2021216488A1
(en)
|
2020-04-21 |
2021-10-28 |
Regeneron Pharmaceuticals, Inc. |
Il-2 variants with reduced binding to il-2 receptor alpha and uses thereof
|
WO2021214587A1
(en)
|
2020-04-21 |
2021-10-28 |
Janssen Biotech, Inc. |
Anti-tnf alpha agent for treating viral infections
|
WO2021214588A1
(en)
|
2020-04-21 |
2021-10-28 |
Janssen Biotech, Inc. |
Anti-tnf alpha agent for treating coronavirus infections
|
AU2021262744A1
(en)
|
2020-04-27 |
2022-10-06 |
The Regents Of The University Of California |
Isoform-independent antibodies to lipoprotein(a)
|
WO2021221783A1
(en)
|
2020-05-01 |
2021-11-04 |
Massachusetts Institute Of Technology |
Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof
|
WO2021221782A1
(en)
|
2020-05-01 |
2021-11-04 |
Massachusetts Institute Of Technology |
Chimeric antigen receptor-targeting ligands and uses thereof
|
EP4146688A1
(en)
|
2020-05-06 |
2023-03-15 |
CRISPR Therapeutics AG |
Mask peptides and masked anti-ptk7 antibodies comprising such
|
US20230181699A1
(en)
|
2020-05-11 |
2023-06-15 |
Talengen International Limited |
Method and drug for treating spinal muscular atrophy
|
WO2021231976A1
(en)
|
2020-05-14 |
2021-11-18 |
Xencor, Inc. |
Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
|
TW202210473A
(zh)
|
2020-05-27 |
2022-03-16 |
大陸商上海齊魯銳格醫藥研發有限公司 |
Glp-1r促效劑之鹽和晶型及其用途
|
WO2021238886A1
(en)
|
2020-05-27 |
2021-12-02 |
Staidson (Beijing) Biopharmaceuticals Co., Ltd. |
Antibodies specifically recognizing nerve growth factor and uses thereof
|
EP4161520A1
(en)
|
2020-06-05 |
2023-04-12 |
The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone |
Acvr1 (alk2) receptor inhibition to treat neurological diseases
|
GB202101299D0
(en)
|
2020-06-09 |
2021-03-17 |
Avacta Life Sciences Ltd |
Diagnostic polypetides and methods
|
BR112022024527A2
(pt)
|
2020-06-09 |
2022-12-27 |
Pfizer |
Compostos de espiro como antagonistas do receptor de melanocortina 4 e usos dos mesmos
|
CA3183808A1
(en)
|
2020-06-11 |
2021-12-16 |
Genentech, Inc. |
Nanolipoprotein-polypeptide conjugates and compositions, systems, and methods using same
|
EP4168537A1
(en)
|
2020-06-17 |
2023-04-26 |
Tiziana Life Sciences PLC |
Compositions and methods for augmenting chimeric antigen receptor (car) t cell therapies
|
WO2021259227A1
(zh)
|
2020-06-23 |
2021-12-30 |
江苏康缘药业股份有限公司 |
抗cd38抗体及其用途
|
MX2022016497A
(es)
|
2020-06-25 |
2023-01-30 |
Tolremo Therapeutics Ag |
Derivados heterociclicos, composiciones farmaceuticas y su uso en el tratamiento, mejora o prevencion de la enfermedad fibrotica.
|
KR20230025898A
(ko)
|
2020-06-26 |
2023-02-23 |
화이자 인코포레이티드 |
Tl1a 항체를 사용하여 염증성 장 질환을 치료하는 방법
|
WO2022006153A1
(en)
|
2020-06-29 |
2022-01-06 |
Resolve Therapeutics, Llc |
Treatment of sjogren's syndrome with nuclease fusion proteins
|
WO2022006562A1
(en)
|
2020-07-03 |
2022-01-06 |
Dana-Farber Cancer Institute, Inc. |
Multispecific coronavirus antibodies
|
CA3185229A1
(en)
|
2020-07-06 |
2022-01-13 |
Jie Han |
Novel polypeptide and therapeutic use thereof
|
EP3939578A1
(en)
|
2020-07-13 |
2022-01-19 |
Novaremed Ltd. |
Compounds for treatment or prevention of an infection resulting from a coronavirus and/or a coronavirus-induced disease
|
CN116323668A
(zh)
|
2020-07-17 |
2023-06-23 |
辉瑞公司 |
治疗性抗体及其用途
|
US11787775B2
(en)
|
2020-07-24 |
2023-10-17 |
Genentech, Inc. |
Therapeutic compounds and methods of use
|
WO2022020811A1
(en)
|
2020-07-24 |
2022-01-27 |
Strand Therapeutics, Inc. |
Lipidnanoparticle comprising modified nucleotides
|
WO2022023335A1
(en)
|
2020-07-30 |
2022-02-03 |
Ecole Polytechnique Federale De Lausanne (Epfl) |
Virucidal compositions and use thereof
|
WO2022023292A2
(en)
|
2020-07-31 |
2022-02-03 |
Friedrich-Alexander-Universität Erlangen-Nürnberg |
Corona virus spike protein-targeting antibodies and use thereof
|
WO2022031994A1
(en)
|
2020-08-06 |
2022-02-10 |
Qilu Regor Therapeutics Inc. |
Glp-1r agonists and uses thereof
|
AU2021324842A1
(en)
|
2020-08-14 |
2023-03-02 |
F. Hoffmann-La Roche Ag |
Methods for treating multiple sclerosis with ocrelizumab
|
AU2021327396A1
(en)
|
2020-08-20 |
2023-03-23 |
Ambrx, Inc. |
Antibody-TLR agonist conjugates, methods and uses thereof
|
EP4190911A4
(en)
|
2020-08-20 |
2024-03-13 |
Talengen Int Ltd |
METHOD AND DRUGS FOR TUMOR TREATMENT
|
WO2022043400A1
(en)
|
2020-08-26 |
2022-03-03 |
Scancell Limited |
Nucleic acids encoding a polypeptide comprising a modified fc region of a human igg1 and at least one heterologous antigen
|
EP3964497A1
(en)
|
2020-09-04 |
2022-03-09 |
Friedrich-Alexander-Universität Erlangen-Nürnberg |
Substituted vicinal diamine compounds and their use in the treatment, amelioration or prevention of pain
|
WO2022060412A1
(en)
|
2020-09-17 |
2022-03-24 |
Genentech, Inc. |
Results of empacta: a randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of tocilizumab in hospitalized patients with covid-19 pneumonia
|
CN116744933A
(zh)
|
2020-10-02 |
2023-09-12 |
基因泰克公司 |
用于制备双杂芳基化合物及其晶型的方法
|
MX2023003997A
(es)
|
2020-10-06 |
2023-06-15 |
Xencor Inc |
Biomarcadores, métodos y composiciones para el tratamiento de la enfermedad autoinmunitaria, que incluye el lupus eritematoso sistémico (les).
|
TW202227421A
(zh)
|
2020-10-14 |
2022-07-16 |
大陸商上海齊魯銳格醫藥研發有限公司 |
Glp-1r促效劑的晶型及其用途
|
EP4229081A1
(en)
|
2020-10-15 |
2023-08-23 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Antibody specific for sars-cov-2 receptor binding domain and therapeutic methods
|
CA3194868A1
(en)
|
2020-10-16 |
2022-04-21 |
Georg Winter |
Heterocyclic cullin ring ubiquitin ligase compounds and uses thereof
|
WO2022087274A1
(en)
|
2020-10-21 |
2022-04-28 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Antibodies that neutralize type-i interferon (ifn) activity
|
WO2022093641A1
(en)
|
2020-10-30 |
2022-05-05 |
BioLegend, Inc. |
Anti-nkg2a agents and compositions and methods for making and using the same
|
WO2022093640A1
(en)
|
2020-10-30 |
2022-05-05 |
BioLegend, Inc. |
Anti-nkg2c agents and compositions and methods for making and using the same
|
MX2023005322A
(es)
|
2020-11-06 |
2023-08-29 |
Amgen Inc |
Moleculas de union a antigeno biespecificas con multiples dianas de selectividad aumentada.
|
CN116490200A
(zh)
|
2020-11-17 |
2023-07-25 |
泰伦基国际有限公司 |
一种提高ngf水平的方法和药物
|
CA3198988A1
(en)
|
2020-11-17 |
2022-05-27 |
Talengen International Limited |
Method and drug for increasing bdnf level
|
WO2022140797A1
(en)
|
2020-12-23 |
2022-06-30 |
Immunowake Inc. |
Immunocytokines and uses thereof
|
JP2024503000A
(ja)
|
2021-01-08 |
2024-01-24 |
ストランド セラピューティクス インコーポレイテッド |
発現構築物およびその使用
|
WO2022159349A1
(en)
|
2021-01-20 |
2022-07-28 |
Oncoresponse, Inc. |
Immunomodulatory antibodies and uses thereof
|
EP4288428A1
(en)
|
2021-02-03 |
2023-12-13 |
Genentech, Inc. |
Amides as cbl-b inhibitors
|
WO2022173678A1
(en)
|
2021-02-09 |
2022-08-18 |
Genentech, Inc. |
Tetracyclic oxazepine compounds and uses thereof
|
AU2022224636A1
(en)
|
2021-02-19 |
2023-09-07 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Single domain antibodies that neutralize sars-cov-2
|
EP4298205A1
(en)
|
2021-02-23 |
2024-01-03 |
Poseida Therapeutics, Inc. |
Genetically modified induced pluripotent stem cells and methods of use thereof
|
WO2022179528A1
(en)
|
2021-02-24 |
2022-09-01 |
Insilico Medicine Ip Limited |
Analogs for the treatment of disease
|
WO2022187671A1
(en)
|
2021-03-04 |
2022-09-09 |
Poseida Therapeutics, Inc. |
Compositions and methods for the treatment of hemophilia
|
EP4305067A1
(en)
|
2021-03-09 |
2024-01-17 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and cldn6
|
EP4305065A1
(en)
|
2021-03-10 |
2024-01-17 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and gpc3
|
CA3211581A1
(en)
|
2021-03-10 |
2022-09-15 |
Ellen WU |
Immunomodulatory molecules and uses thereof
|
MX2023010491A
(es)
|
2021-03-12 |
2023-09-18 |
Chugai Pharmaceutical Co Ltd |
Composicion farmaceutica para el tratamiento o la prevencion de la miastenia gravis.
|
WO2022195504A1
(en)
|
2021-03-19 |
2022-09-22 |
Pfizer Inc. |
Method of treating osteoarthritis pain with an anti ngf antibody
|
JP2024512574A
(ja)
|
2021-03-22 |
2024-03-19 |
ノビミューン エスアー |
Cd47およびpd-l1を標的とする二重特異性抗体ならびにその使用方法
|
WO2022200389A1
(en)
|
2021-03-22 |
2022-09-29 |
Novimmune S.A. |
Bispecific antibodies targeting cd47 and pd-l1 and methods of use thereof
|
WO2022204581A2
(en)
|
2021-03-26 |
2022-09-29 |
Scholar Rock, Inc. |
Tgf-beta inhibitors and use thereof
|
KR20240004342A
(ko)
|
2021-04-03 |
2024-01-11 |
암브룩스, 인코포레이티드 |
항-her2 항체-약물 접합체 및 이의 용도
|
TW202304882A
(zh)
|
2021-04-07 |
2023-02-01 |
瑞士商妥瑞莫醫療公司 |
雜環衍生物、醫藥組成物及彼等於治療或改善癌症之用途
|
TW202304510A
(zh)
|
2021-04-07 |
2023-02-01 |
瑞士商葛德瑪控股公司 |
結節性癢疹之治療
|
WO2022216762A1
(en)
|
2021-04-08 |
2022-10-13 |
Genentech, Inc. |
Oxazepine compounds and uses thereof in the treatment of cancer
|
EP4323497A1
(en)
|
2021-04-11 |
2024-02-21 |
President and Fellows of Harvard College |
Cardiomyocytes and compositions and methods for producing the same
|
WO2022223544A1
(en)
|
2021-04-19 |
2022-10-27 |
Centre National De La Recherche Scientifique (Cnrs) |
COMBINATION THERAPY OF NUCANT AND mTOR INHIBITORS FOR TREATING CANCER
|
EP4329887A1
(en)
|
2021-04-28 |
2024-03-06 |
Minotaur Therapeutics, Inc. |
Humanized chimeric bovine antibodies and methods of use
|
EP4334354A1
(en)
|
2021-05-06 |
2024-03-13 |
Dana-Farber Cancer Institute, Inc. |
Antibodies against alk and methods of use thereof
|
MX2023012931A
(es)
|
2021-05-06 |
2023-11-13 |
Amgen Res Munich Gmbh |
Moleculas de union a antigeno dirigidas a cd20 y cd22 para su uso en enfermedades proliferativas.
|
MX2023013149A
(es)
|
2021-05-07 |
2023-11-28 |
Surface Oncology Llc |
Anticuerpos anti-il-27 y usos de estos.
|
KR20240035394A
(ko)
|
2021-05-14 |
2024-03-15 |
클라리스 바이오쎄라퓨틱스, 인코포레이티드 |
안질환 치료를 위한 성장 인자 조성물
|
WO2022245859A1
(en)
|
2021-05-17 |
2022-11-24 |
Curia Ip Holdings, Llc |
Sars-cov-2 spike protein antibodies
|
WO2022245877A1
(en)
|
2021-05-17 |
2022-11-24 |
Curia Ip Holdings, Llc |
Sars-cov-2 spike protein antibodies
|
WO2022256723A2
(en)
|
2021-06-03 |
2022-12-08 |
Scholar Rock, Inc. |
Tgf-beta inhibitors and therapeutic use thereof
|
WO2022256688A1
(en)
|
2021-06-04 |
2022-12-08 |
Sonnet BioTherapeutics, Inc. |
Methods of treating age-related frailty with interleukin-6
|
CN117980333A
(zh)
|
2021-06-11 |
2024-05-03 |
基因泰克公司 |
用st2拮抗剂治疗慢性阻塞性肺疾病的方法
|
WO2022265984A1
(en)
|
2021-06-14 |
2022-12-22 |
Curtails Llc |
Use of nep inhibitors for the treatment of gastrointestinal sphincter disorders
|
IL309078A
(en)
|
2021-06-23 |
2024-02-01 |
Scholar Rock Inc |
A myostatin pathway inhibitor in combination with a GLP-1 pathway activator for use in the treatment of metabolic disorders
|
CN118103397A
(zh)
|
2021-07-08 |
2024-05-28 |
舒泰神(加州)生物科技有限公司 |
特异性识别tnfr2的抗体及其用途
|
IL309996A
(en)
|
2021-07-09 |
2024-03-01 |
Janssen Biotech Inc |
Production methods for the production of anti-TNF antibody compositions
|
WO2023281462A1
(en)
|
2021-07-09 |
2023-01-12 |
Janssen Biotech, Inc. |
Manufacturing methods for producing anti-tnf antibody compositions
|
WO2023288277A1
(en)
|
2021-07-14 |
2023-01-19 |
Scholar Rock, Inc. |
Ltbp complex-specific inhibitors of tgfb1 and uses thereof
|
CN115812082A
(zh)
|
2021-07-14 |
2023-03-17 |
舒泰神(北京)生物制药股份有限公司 |
特异性识别cd40的抗体及其应用
|
EP4370107A1
(en)
|
2021-07-15 |
2024-05-22 |
Allspim |
Compositions and methods for preventing and/or treating disease associated with il-23 expression
|
CN117693355A
(zh)
|
2021-07-20 |
2024-03-12 |
瑞泽恩制药公司 |
用于治疗炎性病症的嗜乳脂蛋白样2
|
WO2023007374A1
(en)
|
2021-07-27 |
2023-02-02 |
Pfizer Inc. |
Method of treatment of cancer pain with tanezumab
|
WO2023018795A1
(en)
|
2021-08-11 |
2023-02-16 |
Curtails Llc |
Nep inhibitors for the treatment of laminitis
|
EP4384553A1
(en)
|
2021-08-13 |
2024-06-19 |
Genentech, Inc. |
Dosing for anti-tryptase antibodies
|
WO2023028077A1
(en)
|
2021-08-24 |
2023-03-02 |
Genentech, Inc. |
Sodium channel inhibitors and methods of designing same
|
WO2023028056A1
(en)
|
2021-08-24 |
2023-03-02 |
Genentech, Inc. |
3-amino piperidyl sodium channel inhibitors
|
CA3229982A1
(en)
|
2021-08-30 |
2023-03-09 |
Galderma Holding SA |
Treatments for atopic dermatitis
|
CA3230347A1
(en)
|
2021-08-31 |
2023-03-09 |
Pfizer Inc. |
Solid forms of 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[(2s)-oxetan-2-ylmethyl]-1h-benzimidazole-6-carboxylic acid, 1,3-dihydroxy-2-(hydroxymethyl)propan-2-amine salt
|
WO2023034901A1
(en)
|
2021-09-01 |
2023-03-09 |
The Broad Institute, Inc. |
Tumor avatar vaccine compositions and uses thereof
|
TW202323276A
(zh)
|
2021-09-03 |
2023-06-16 |
瑞士伯恩大學 |
用於治療長qt症候群之組成物及方法
|
GB202112935D0
(en)
|
2021-09-10 |
2021-10-27 |
Harbour Antibodies Bv |
Sars-cov-2 (sars2, covid-19) heavy chain only antibodies
|
WO2023036982A1
(en)
|
2021-09-10 |
2023-03-16 |
Harbour Antibodies Bv |
Anti-sars2-s antibodies
|
WO2023039276A1
(en)
|
2021-09-13 |
2023-03-16 |
Curtails Llc |
Use of ibat inhibitors and antimicrobials for the treatment of diseases
|
WO2023056368A1
(en)
|
2021-09-30 |
2023-04-06 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Cyclic peptides as non-hormonal male contraceptive agents and methods of use thereof
|
IL311782A
(en)
|
2021-10-04 |
2024-05-01 |
Poseida Therapeutics Inc |
Transposases and their uses
|
CA3233506A1
(en)
|
2021-10-04 |
2023-04-13 |
Joseph S. LUCAS |
Transposon compositions and methods of use thereof
|
CA3234693A1
(en)
|
2021-10-15 |
2023-04-20 |
Tango Therapeutics, Inc. |
Novel modulators of ehmt1 and ehmt2 and therapeutic use thereof
|
CA3237018A1
(en)
|
2021-11-03 |
2023-05-11 |
Joachim Koch |
Bispecific cd16a binders
|
CA3233696A1
(en)
|
2021-11-03 |
2023-05-11 |
Joachim Koch |
Bispecific cd16a binders
|
AU2022383057A1
(en)
|
2021-11-05 |
2024-05-16 |
Abviro Llc |
Human broadly crossreactive influenza monoclonal antibodies and methods of use thereof
|
CA3237467A1
(en)
|
2021-11-05 |
2023-05-11 |
Genentech, Inc. |
Lactams as cbl-b inhibitors selective over c-cbl
|
CA3236294A1
(en)
|
2021-11-19 |
2023-05-25 |
Mirobio Limited |
Engineered pd-1 antibodies and uses thereof
|
US20230203062A1
(en)
|
2021-11-24 |
2023-06-29 |
Genentech, Inc. |
Therapeutic compounds and methods of use
|
US20230202984A1
(en)
|
2021-11-24 |
2023-06-29 |
Genentech, Inc. |
Therapeutic compounds and methods of use
|
CA3238936A1
(en)
|
2021-11-24 |
2023-06-01 |
Wayne A. Marasco |
Antibodies against ctla-4 and methods of use thereof
|
WO2023100061A1
(en)
|
2021-12-01 |
2023-06-08 |
Pfizer Inc. |
3-phenyl-1-benzothiophene-2-carboxylic acid derivatives as branched-chain alpha keto acid dehydrogenase kinase inhibitors for the treatment of diabetes, kidney diseases, nash and heart failure
|
US20230174501A1
(en)
|
2021-12-03 |
2023-06-08 |
Tango Therapeutics, Inc. |
Novel hdac inhibitors and therapeutic use thereof
|
WO2023105387A1
(en)
|
2021-12-06 |
2023-06-15 |
Pfizer Inc. |
Melanocortin 4 receptor antagonists and uses thereof
|
WO2023105371A1
(en)
|
2021-12-08 |
2023-06-15 |
Array Biopharma Inc. |
Crystalline form of n-(2-chloro-3-((5-chloro-3-methyl-4-oxo-3,4-dihydroquinazolin-6-yl)amino)-4-fluorophenyl)-3-fluoroazetidine-1-sulfonamide
|
WO2023114544A1
(en)
|
2021-12-17 |
2023-06-22 |
Dana-Farber Cancer Institute, Inc. |
Antibodies and uses thereof
|
WO2023111817A1
(en)
|
2021-12-17 |
2023-06-22 |
Pfizer Inc. |
Crystalline forms of [(1r,5s,6r)-3-{2-[(2s)-2-methylazetidin-1-yl]-6-(trifluoromethyl) pyrimidin-4-yl}-3-azabicyclo[3.1.0]hex-6-yl]acetic acid
|
WO2023114543A2
(en)
|
2021-12-17 |
2023-06-22 |
Dana-Farber Cancer Institute, Inc. |
Platform for antibody discovery
|
WO2023118150A1
(en)
|
2021-12-22 |
2023-06-29 |
Royal College Of Surgeons In Ireland |
A conjugate for use in localising a molecule to the vascular endothelium.
|
WO2023150552A1
(en)
|
2022-02-04 |
2023-08-10 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for treatment of neurological disorders
|
WO2023164573A1
(en)
|
2022-02-23 |
2023-08-31 |
Poseida Therapeutics, Inc. |
Genetically modified cells and methods of use thereof
|
WO2023178357A1
(en)
|
2022-03-18 |
2023-09-21 |
Evolveimmune Therapeutics, Inc. |
Bispecific antibody fusion molecules and methods of use thereof
|
US20230416361A1
(en)
|
2022-04-06 |
2023-12-28 |
Mirobio Limited |
Engineered cd200r antibodies and uses thereof
|
WO2023203378A1
(en)
|
2022-04-19 |
2023-10-26 |
Garth Cooper |
Treatment of brain copper disorders
|
WO2023203172A1
(en)
|
2022-04-20 |
2023-10-26 |
Proxygen Gmbh |
Heterocyclic cullin ring ubiquitin ligase compounds and uses thereof
|
WO2023212618A1
(en)
|
2022-04-26 |
2023-11-02 |
Strand Therapeutics Inc. |
Lipid nanoparticles comprising venezuelan equine encephalitis (vee) replicon and uses thereof
|
TW202346368A
(zh)
|
2022-05-12 |
2023-12-01 |
德商安美基研究(慕尼黑)公司 |
具有增加的選擇性的多鏈多靶向性雙特異性抗原結合分子
|
WO2023225302A1
(en)
|
2022-05-19 |
2023-11-23 |
Genentech, Inc. |
Aza-tetracyclic oxazepine compounds and uses thereof
|
WO2023228023A1
(en)
|
2022-05-23 |
2023-11-30 |
Pfizer Inc. |
Treatment of type 2 diabetes or weight management control with 2-((4-((s)-2-(5-chloropyridin-2-yl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-benzo[d]imidazole-6-carboxylic acid or a pharmaceutically salt thereof
|
US20240025987A1
(en)
|
2022-05-25 |
2024-01-25 |
Surface Oncology, Inc. |
Use of anti-il-27 antibodies
|
US20240026001A1
(en)
|
2022-05-25 |
2024-01-25 |
Surface Oncology, Inc. |
Use of anti-il-27 antibodies
|
WO2023235852A1
(en)
|
2022-06-03 |
2023-12-07 |
Zenas Biopharma, Inc. |
Methods and compositions for treating igg4- related diseases
|
WO2024020407A1
(en)
|
2022-07-19 |
2024-01-25 |
Staidson Biopharma Inc. |
Antibodies specifically recognizing b- and t-lymphocyte attenuator (btla) and uses thereof
|
WO2024020051A1
(en)
|
2022-07-19 |
2024-01-25 |
BioLegend, Inc. |
Anti-cd157 antibodies, antigen-binding fragments thereof and compositions and methods for making and using the same
|
WO2024020564A1
(en)
|
2022-07-22 |
2024-01-25 |
Genentech, Inc. |
Anti-steap1 antigen-binding molecules and uses thereof
|
WO2024036273A1
(en)
|
2022-08-11 |
2024-02-15 |
Poseida Therapeutics, Inc. |
Chimeric cd8-alpha co-receptor compositions and methods of use
|
WO2024039672A2
(en)
|
2022-08-15 |
2024-02-22 |
Dana-Farber Cancer Institute, Inc. |
Antibodies against msln and methods of use thereof
|
WO2024039670A1
(en)
|
2022-08-15 |
2024-02-22 |
Dana-Farber Cancer Institute, Inc. |
Antibodies against cldn4 and methods of use thereof
|
WO2024040114A2
(en)
|
2022-08-18 |
2024-02-22 |
BioLegend, Inc. |
Anti-axl antibodies, antigen-binding fragments thereof and methods for making and using the same
|
WO2024050526A1
(en)
|
2022-09-02 |
2024-03-07 |
Biomarin Pharmaceutical Inc. |
Compositions and methods for treating long qt syndrome
|
US20240141050A1
(en)
|
2022-09-02 |
2024-05-02 |
Galderma Holding S.A. |
Treatments for prurigo nodularis
|
WO2024059675A2
(en)
|
2022-09-14 |
2024-03-21 |
Amgen Inc. |
Bispecific molecule stabilizing composition
|
WO2024076995A1
(en)
|
2022-10-03 |
2024-04-11 |
Insigna Inc. |
Compositions for non-surgical prevention of boar taint and aggressive behavior
|
WO2024075051A1
(en)
|
2022-10-07 |
2024-04-11 |
Pfizer Inc. |
Hsd17b13 inhibitors and/or degraders
|
US20240182468A1
(en)
|
2022-10-18 |
2024-06-06 |
Pfizer Inc. |
Compounds for the activation of ampk
|
WO2024084363A1
(en)
|
2022-10-18 |
2024-04-25 |
Pfizer Inc. |
Use of patatin-like phospholipase domain-containing protein 3 compounds
|
WO2024084360A1
(en)
|
2022-10-18 |
2024-04-25 |
Pfizer Inc. |
Patatin-like phospholipase domain-containing protein 3 (pnpla3) modifiers
|
WO2024083168A1
(en)
|
2022-10-19 |
2024-04-25 |
Genentech, Inc. |
Oxazepine compounds comprising a 6-aza moiety and uses thereof
|
WO2024084052A1
(en)
|
2022-10-21 |
2024-04-25 |
Novimmune Sa |
Pd-l1xcd28 bispecific antibodies for immune checkpoint-dependent t cell activation
|
WO2024097767A1
(en)
|
2022-11-02 |
2024-05-10 |
Sonnet BioTherapeutics, Inc. |
Recombinant il-12 albumin binding domain fusion proteins for use in methods for the treatment of cancer
|
WO2024121796A1
(en)
|
2022-12-07 |
2024-06-13 |
Fondazione Matilde Tettamanti E Menotti De Marchi Onlus |
Methods for generating genetically modified cytokine induced killer (cik) cells
|